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On the subjects of this thesis:
On Medicine: We rationalise, we dissimulate, we pretend: we pretend that modern
medicine is a rational science, all facts, no nonsense and just what it seems. But we
have only to tap its glossy veneer for it to split wide open and reveal to us its roots and
foundations, its old dark heart of metaphysics, mysticism, magic and myth. Medicine is
the oldest of arts and the oldest of sciences: would one not expect it to spring forth from
the deepest knowledge and feelings we have? - Oliver Sacks, Awakenings, (1982).
On Mathematics: Mathematics is not a book conﬁned within a cover and bound be-
tween brazen clasps, whose contents it need only patience to ransack; it is not a mine,
whose treasures may take long to reduce to possessions, but which ﬁll only a limited num-
ber of veins and lodes; it is not a soil, whose fertility can be exhausted by the yield of
successive harvests; it is not a continent or an ocean, whose area can be mapped out and
its contour deﬁned: it is limitless as the space which it ﬁnds too narrow for its aspirations;
its possibilities are as inﬁnite as the worlds which are forever crowding in and multiplying
upon the astronomer's gaze; it is as incapable of being restricted within assigned bound-
aries or being reduced to deﬁnitions of permanent validity, as the consciousness, the life,
which seems to slumber in each monad, in every atom of matter, in each leaf and bud
and cell, and is forever ready to burst forth into new forms of vegetable and animal exis-
tence. - James Joseph Sylvester, Speech made on Commemoration Day at John Hopkins
University, (1877).
On Computing: For it is unworthy of excellent men to lose hours like slaves in the
labour of calculation, which could be safely relegated to anyone else if the machine were
used. - Gottfried Leibniz, Machina arithmetica in qua non aditio tantum et subtractio sed
et multiplicatio nullo, divisio vero paene nullo animi labore peragantur, (1685).
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Abstract
In this thesis we consider the application of network theoretic tools in the anal-
ysis of genome wide gene-expression data describing complex diseases, displaying
defects in diﬀerentiation. After considering the literature, we motivate the con-
struction of entropy based network rewiring methodologies, postulating that such
an approach may provide a systems level correlate of the diﬀerentiation potential
of a cellular sample, and may prove informative in the analysis of pathology. We
construct, analytically investigate and validate three such network theoretic tools:
Network Transfer Entropy, Signalling Entropy and Interactome Sparsiﬁcation and
Rewiring (InSpiRe). By considering over 1000 genome wide gene expression samples
corresponding to healthy cells at diﬀerent levels of diﬀerentiation, we demonstrate
that signalling entropy is a strong correlate of cell potency conﬁrming our initial pos-
tulate. The remainder of the thesis applies our network theoretic tools to two ends
of the developmental pathology spectrum. Firstly we consider cancer, in which the
power of cell diﬀerentiation is hijacked, to develop a malicious new tissue. Secondly,
we consider muscular dystrophy, in which cell diﬀerentiation is inhibited, resulting
in the poor development of muscle tissue. In the case of cancer we demonstrate
that signalling entropy is a measure of tumour anaplasia and intra-tumour hetero-
geneity, which displays distinct values in diﬀerent cancer subtypes. Moreover, we
ﬁnd signalling entropy to be a powerful prognostic indicator in epithelial cancer,
outperforming conventional gene expression based assays. In the case of muscular
dystrophy we focus on the most prevalent: facioscapulohumeral muscular dystrophy
(FSHD). We demonstrate that muscle diﬀerentiation is perturbed in FSHD and that
signalling entropy is elevated in myoblasts over-expressing the primary FSHD can-
didate gene DUX4. We subsequently utilise InSpiRe, performing a meta-analysis of
FSHD muscle biopsy gene-expression data, uncovering a network of DUX4 driven
rewired interactions in the pathology, and a novel therapeutic target which we vali-
date experimentally.
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Overview
`In medicine - as in life - some problems are more complex than others and, science being
the art of the soluble, it is only sensible to leave the apparently intractable aside, hoping
perhaps that at some time in the future something will happen to open the doors to their
resolution.' (James Le Fanu, The Rise and Fall of Modern Medicine [1]). Regardless of
sensibilities, it is clear that patients with complex pathology cannot wait for some unde-
ﬁned future time. Moreover, since these words were written the age of multidisciplinary
science has caused `complexity' to take on an altogether diﬀerent meaning. The vision of
a complex biomedical problem as intractable has been usurped, in its place we have a per-
turbation to a large and sophisticated system. Understanding such a perturbation requires
a twofold investigation. First: the generation of high throughput data describing the de-
tailed interplay of interacting components, and second: the development and application
of mathematical models intended to convert such data into a mechanistic understanding
of the pathology. Given the abundance of publicly available high-throughput data, in
this thesis we will dominantly focus on the development and application of mathematical
models for the understanding of complex disease. Pathology-wise our key interests will
be cancer and facioscapulohumeral muscular dystrophy (FSHD), for the latter pathology
we will validate some of our computational ﬁndings experimentally.
Following introduction, we, in the second chapter, describe the development of three
network theoretic tools for investigating genome wide gene expression data. The ﬁrst,
Network Transfer Entropy (NTE) proposes a model of signal transduction, which can
be represented as a stochastic matrix, describing the interaction probability of network
vertices. The model is theoretically examined from a metric space perspective, and a
measure is constructed for comparing dynamics on two weighted networks. The measure
is then reﬁned to compute the information transferred between any two vertices in a
weighted biochemical network and its validity is demonstrated by application to a phos-
phorylation network. The second methodology, signalling entropy, further considers the
signal transduction model applied for the development of NTE, exploring the entropy
rate of the stochastic matrix as a global measure of network robustness. It is analyti-
cally demonstrated that signalling entropy is a population level correlate of intra-sample
heterogeneity and that it is driven by the activity of highly connected vertices. The ﬁ-
nal methodology Interactome Sparsiﬁcation and Rewiring (InSpiRe), considers the signal
transduction model again on a local scale, to construct an algorithm for identifying net-
work rewiring between two biological phenotypes.
After construction, the second are third network theoretic tools are applied in a number
of settings. As development is frequently altered in complex pathology, in the third chap-
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ter, we ﬁrst motivate and demonstrate that signalling entropy is a robust and powerful
measure of the diﬀerentiation potential of a single cellular sample. Through the consider-
ation of over 1000 genome wide gene expression assays we reveal that signalling entropy
systematically decreases during diﬀerentiation. Moreover, we ﬁnd that the local entropy
measure utilised in InSpiRe is capable of identifying genes critical to the diﬀerentiation
process. We also consider signalling entropy in the context of pathological development,
conﬁrming ﬁndings that our measure is elevated in cancerous compared to healthy tissue,
and demonstrate that it is elevated in cancer stem cells compared to the tumour bulk.
In the fourth chapter we investigate the relationship between signalling entropy and can-
cer in more detail. We demonstrate that our measure correlates with many quantiﬁers of
tumour stemness across multiple malignancies. Following this, we reveal that signalling
entropy is strongly prognostic in both breast and lung cancer, by considering over 5000
bulk tumour samples. We also reveal a number of intriguing associations between sig-
nalling entropy and cancer clinical variables, including that signalling entropy is elevated
in lung cancer patients with a history of smoking, and in luminal B beast cancer patients
despite the low expression of stem cell genes. These results suggest a diﬀerential role for
intra-tumour heterogeneity and stemness in certain cancer subtypes. We further demon-
strate that the prognostic power of signalling entropy is superior to other gene expression
based indicators, and that it is driven by genes involved in cancer stem cells and treat-
ment resistance.
Finally, in the ﬁfth chapter, we consider FSHD as a pathology of cellular diﬀerentiation,
independent to cancer. We investigate the primary FSHD candidate gene DUX4 and
reveal that signalling entropy is elevated in mouse myoblasts over-expressing this gene.
This result is indicative of inhibited diﬀerentiation driving this pathology. We subse-
quently consider a human myoblast model of FSHD and demonstrate that DUX4 is over
expressed at low levels, leading to an inhibited muscle diﬀerentiation programme. To
further investigate the molecular mechanisms driving FSHD we utilise the InSpiRe algo-
rithm. By performing a meta-analysis of publicly available muscle biopsy gene expression
data sets, we reveal a detailed network of rewired interactions in FSHD. We show that
the expression of genes in this network are modiﬁed by DUX4 expression conﬁrming
this candidate as driver of FSHD pathomechanisms. Interrogation of this network by
betweenness centrality reveals β-catenin signalling as critical to pathomechanisms. We
subsequently validate experimentally that β-catenin is activated by DUX4 expression.
Page 6
Network Theoretic Tools in the Analysis of Complex Diseases C. R. S. Banerji
Facilities
1. Centre of Mathematics and Physics in the Life Sciences and Experimental Biology,
University College London, London WC1E 6BT, UK.
2. Department of Computer Science, University College London, London WC1E 6BT,
UK.
3. Statistical Cancer Genomics, Paul O'Gorman Building, UCL Cancer Institute, Uni-
versity College London, London WC1E 6BT, UK.
4. Randall Division of Cell and Molecular Biophysics, New Hunt's House, King's Col-
lege London, Guy's Campus, London SE1 1UL, UK.
Page 7
Network Theoretic Tools in the Analysis of Complex Diseases C. R. S. Banerji
Publications
Much of the work described in this thesis has been published in peer-reviewed academic
journals, with some work still in preparation. The adapted contents of the following
publications feature in this thesis (* denotes corresponding author):
1. C. R. S. Banerji*, S. Severini and A. E. Teschendorﬀ, Network transfer entropy and
metric space for causality inference, Phys. Rev. E, 87:052814 (2013),
(pdf:arXiv:1303.0231).
2. C. R. S. Banerji, D. Miranda-Saavedra, S. Severini, M. Widschwendter, T. Enver,
J. X. Zhou, A. E. Teschendorﬀ*, Cellular network entropy as the energy potential
in Waddington's diﬀerentiation landscape, Scientiﬁc Reports, 3:3039, (2013).
3. C. R. S. Banerji*, S. Severini, C. Caldas and A. E. Teschendorﬀ*, Intra-Tumour
Signalling Entropy Determines Clinical Outcome in Breast and Lung Cancer. PLoS
Comput Biol, 11(3):e1004115, (2015).
4. A. E. Teschendorﬀ*, C. R. S. Banerji, S. Severini, Reimer Kuehn and Peter Sollich,
Increased signaling entropy in cancer requires the scale-free property of protein
interaction network, Scientiﬁc Reports, in press (2015), (pdf: arxiv:1504.00120).
5. C. R. S. Banerji*, P. Knopp, L. Moyle, S. Severini, R. Orrell, A. E. Teschendorﬀ, P.
S. Zammit*, β-catenin is central to DUX4 driven network rewiring in facioscapulo-
humeral muscular dystrophy, Journal of The Royal Society Interface,
12(102):20140797, (2015).
6. P. Knopp, C. R.S. Banerji, L. Moyle, J. Davies and P. S. Zammit*, DUX4 inhibits
satellite cell myogenesis and maintains a stem cell phenotype, in preperation
The author also contributed to the following publications which feature less prominently
in the thesis:
7. C. R. S. Banerji, T. Mansour, and S. Severini*, A notion of graph likelihood and
an inﬁnite monkey theorem, Journal of Physics A: Mathematical and Theoretical,
47(3),035101, (2014) (pdf: arXiv:1304.3600).
8. M.-L. Lin, H. Patel, J. Remenyi, C. R. S. Banerji, M. Pariyasamy, C.-F. Lai, S.
Ottaviani, P. R. Quinlan, C. A. Purdie, L. B. Jordan, A. M. Thompson, R. C.
Coombes, F. V. Fuller-Pace, A. E. Teschendorﬀ, L. Buluwela, S. Ali*, Gene Ex-
pression Proﬁling of Nuclear Receptors as Diagnostic and Therapeutic Targets in
Breast Cancer, Oncotarget, in press,(2015).
Page 8
Network Theoretic Tools in the Analysis of Complex Diseases C. R. S. Banerji
Acknowledgements
I would like to thank my supervisors Simone Severini, Andrew Teschendorﬀ and Peter
Zammit, for their incredible support, expert guidance and huge enthusiasm throughout
the work on this thesis, as well as for the great intellectual freedom they permitted me in
my research.
In addition, I would like to thank my collaborators and co-authors: Richard Orrell, Louise
Moyle, Paul Knopp, Nico Figac, Congshan Sun, Pedro Quiroga, Robert Knight, James
West, Touﬁk Mansour, Carlos Caldas, Diego Miranda-Saavedra, Martin Widschwendter,
Tariq Enver, Joseph Zhou, Simak Ali, Meng-Lay Lin, Reimer Kuehn and Peter Sollich.
Their diverse expertise, ranging from the clinical and experimental to the physical and
mathematical sciences has been invaluable, and contributed greatly to the work presented
in this thesis.
I must also thank my funders the Engineering and Physical Sciences Research Council
(EPSRC), the British Heart Foundation (BHF) and the FSH Society, without the support
of whom this work would not have have been possible.
Lastly I must thank family and friends, in particular, my parents Kathy and Ranjan, my
sister Christina, and my girlfriend Catherine, for their interest, patience and encourage-
ment and for dragging me from the ivory tower before cabin fever set in.
Page 9
Network Theoretic Tools in the Analysis of Complex Diseases C. R. S. Banerji
Contents
List of Figures 17
1 Introduction 20
1.1 The development of network theoretic tools . . . . . . . . . . . . . . . . . 21
1.1.1 Uncovering the Structure of Biological Networks . . . . . . . . . . 23
1.1.2 Single Phenotype Networks . . . . . . . . . . . . . . . . . . . . . . 27
1.1.3 Network Rewiring: a shift in methodology . . . . . . . . . . . . . . 31
1.1.4 Perspectives: Relevance for our research . . . . . . . . . . . . . . . 35
1.2 Mathematical approaches to understanding cell diﬀerentiation . . . . . . . 36
1.2.1 Experimental approaches to quantifying cell potency: some limita-
tions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
1.2.2 Systems biology of cell diﬀerentiation . . . . . . . . . . . . . . . . 40
1.2.2.1 Waddington's Landscape . . . . . . . . . . . . . . . . . . 40
1.2.2.2 Small regulatory networks and binary decisions . . . . . . 42
1.2.2.3 Stochasticity and cell fate . . . . . . . . . . . . . . . . . . 44
1.2.2.4 Quantifying randomness in stem cell gene expression . . . 44
1.2.3 Perspectives: Relevance for our research . . . . . . . . . . . . . . . 45
1.3 The pathophysiology of breast cancer . . . . . . . . . . . . . . . . . . . . . 46
1.3.1 Breast cancer diagnosis: imaging to biopsy . . . . . . . . . . . . . 47
1.3.2 Histology: subtyping on cellular composition . . . . . . . . . . . . 49
1.3.3 Molecular subtyping: Hormone receptors and HER2 . . . . . . . . 51
1.3.4 Further molecular sub-typing: Genome-wide gene expression . . . 55
1.3.4.1 Luminal A . . . . . . . . . . . . . . . . . . . . . . . . . . 57
1.3.4.2 Luminal B . . . . . . . . . . . . . . . . . . . . . . . . . . 57
1.3.4.3 HER2 positive . . . . . . . . . . . . . . . . . . . . . . . . 58
1.3.4.4 Basal-like . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
1.3.4.5 Claudin-low . . . . . . . . . . . . . . . . . . . . . . . . . 60
1.3.4.6 Deeper molecular subtyping . . . . . . . . . . . . . . . . 61
1.3.4.7 Gene expression proﬁling for prognostic evaluation . . . . 61
1.3.5 Oncogenesis and cancer stem cells . . . . . . . . . . . . . . . . . . 62
1.3.5.1 Tumour origins . . . . . . . . . . . . . . . . . . . . . . . . 62
1.3.5.2 Tumour development . . . . . . . . . . . . . . . . . . . . 63
1.3.5.3 Evidence for breast CSCs . . . . . . . . . . . . . . . . . . 65
1.3.6 Perspectives: Relevance for our research . . . . . . . . . . . . . . . 66
1.4 The pathophysiology of FSHD . . . . . . . . . . . . . . . . . . . . . . . . 67
Page 10
Network Theoretic Tools in the Analysis of Complex Diseases C. R. S. Banerji
1.4.1 History of clinical presentation and heredity . . . . . . . . . . . . . 70
1.4.2 The identiﬁcation of FSHD candidate genes and the rise of DUX4 74
1.4.3 DUX4, necessary but not suﬃcient? An emerging role for telomeres 76
1.4.4 FSHD transcriptional dysregulation . . . . . . . . . . . . . . . . . 77
1.4.5 Perspectives: Relevance for our research . . . . . . . . . . . . . . . 78
1.5 Overview of introductory sections . . . . . . . . . . . . . . . . . . . . . . . 79
2 Entropic Network Theoretic Tools: Concept and Theory 80
2.1 A Random Walk Model of Network Traﬃc . . . . . . . . . . . . . . . . . . 82
2.2 Network Transfer Entropy and Metric Space . . . . . . . . . . . . . . . . . 84
2.2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
2.2.2 Information transfer on weighted networks and metric space . . . . 85
2.2.2.1 A closed form expression of P [Xin| ~X0] . . . . . . . . . . . 85
2.2.2.2 Metric Space . . . . . . . . . . . . . . . . . . . . . . . . . 87
2.2.2.3 Convergence Principle . . . . . . . . . . . . . . . . . . . . 88
2.2.3 Network Transfer Entropy . . . . . . . . . . . . . . . . . . . . . . . 92
2.2.4 Simple examples . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94
2.2.5 NTE on a biological network . . . . . . . . . . . . . . . . . . . . . 96
2.2.6 Conclusions and Possible Further Work . . . . . . . . . . . . . . . 98
2.3 Signalling Entropy: Theoretical Investigations . . . . . . . . . . . . . . . . 102
2.3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
2.3.2 Signalling entropy and high degree vertices . . . . . . . . . . . . . 104
2.3.2.1 Motivation . . . . . . . . . . . . . . . . . . . . . . . . . . 104
2.3.2.2 Proof of Proposition 1 . . . . . . . . . . . . . . . . . . . . 105
2.3.2.3 Empirical Validation . . . . . . . . . . . . . . . . . . . . . 108
2.3.2.4 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
2.3.3 Signalling Entropy and heterogeneity . . . . . . . . . . . . . . . . . 111
2.3.3.1 Motivation . . . . . . . . . . . . . . . . . . . . . . . . . . 111
2.3.3.2 Super-additivity implies signalling entropy is elevated in
a mixed sample on average . . . . . . . . . . . . . . . . . 111
2.3.3.3 A suﬃcient condition for signalling entropy to be super-
additive . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
2.3.3.4 Empirical validation of super-additivity of signalling en-
tropy on Ω . . . . . . . . . . . . . . . . . . . . . . . . . . 116
2.3.3.5 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . 116
2.3.4 Conclusions and Future Directions . . . . . . . . . . . . . . . . . . 121
2.4 Interactome Sparsiﬁcation and Rewiring . . . . . . . . . . . . . . . . . . . 122
Page 11
Network Theoretic Tools in the Analysis of Complex Diseases C. R. S. Banerji
2.4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 122
2.4.2 The three steps of the InSpiRe algorithm . . . . . . . . . . . . . . 123
2.4.2.1 Step 1: Integration of mRNA expression data with the PIN123
2.4.2.2 Step 2: Detecting Rewiring Hotspots - Local Entropy and
Kullback-Leibler divergence . . . . . . . . . . . . . . . . . 125
2.4.2.3 Step 3: Sparsiﬁcation of Relevant Subset of PIN . . . . . 126
2.4.2.4 Statistical signiﬁcance determined via the jackknife . . . 127
2.4.3 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127
2.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127
2.6 Materials and Methods, Chapter 2 . . . . . . . . . . . . . . . . . . . . . . 129
2.6.1 Estimating NTE . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129
2.6.2 Assigning an ISD to the biological network . . . . . . . . . . . . . 130
2.6.3 mRNA Expression data . . . . . . . . . . . . . . . . . . . . . . . . 133
2.6.4 Protein Expression data . . . . . . . . . . . . . . . . . . . . . . . . 133
2.6.5 Protein Interaction Network . . . . . . . . . . . . . . . . . . . . . . 134
2.6.6 Integration of the PIN with gene expression data . . . . . . . . . . 135
2.6.7 Signalling Entropy . . . . . . . . . . . . . . . . . . . . . . . . . . . 135
3 Signalling Entropy as the energy potential of Waddington's Landscape136
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 136
3.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137
3.2.1 Rationale of signalling entropy as a measure of diﬀerentiation po-
tential . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137
3.2.2 Signalling entropy is raised in pluripotent stem cells . . . . . . . . 138
3.2.3 Signalling entropy is raised in adult stem cells . . . . . . . . . . . . 141
3.2.4 Signalling entropy dynamically decreases during diﬀerentiation time
courses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 142
3.2.5 Signalling entropy discriminates cancer stem cells from the tumour
bulk . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 145
3.2.6 Dynamic changes in local entropy identiﬁes key diﬀerentiation genes
and pathways . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 145
3.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 148
3.4 Materials and Methods, Chapter 3 . . . . . . . . . . . . . . . . . . . . . . 154
3.4.1 Signalling Entropy . . . . . . . . . . . . . . . . . . . . . . . . . . . 154
3.4.2 Simulation analysis of signalling entropy as a measure of pathway
promiscuity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 154
3.4.3 Gene expression data . . . . . . . . . . . . . . . . . . . . . . . . . . 155
Page 12
Network Theoretic Tools in the Analysis of Complex Diseases C. R. S. Banerji
3.4.3.1 The stem cell matrix (SCM and SCM2) compendia . . . 155
3.4.3.2 Further ES cell, MSC and iPSC data sets . . . . . . . . . 155
3.4.3.3 Expression data describing the diﬀerentiation of MSCs
into osteoblasts and chondrocytes . . . . . . . . . . . . . 156
3.4.3.4 Combined haematological data set . . . . . . . . . . . . . 156
3.4.3.5 Time course de-diﬀerentiation and re-diﬀerentiation ex-
periment of RPE cells . . . . . . . . . . . . . . . . . . . . 156
3.4.3.6 Time course HL60 neutrophil expression data . . . . . . . 157
3.4.3.7 Time course pancreatic β-cell diﬀerentiation . . . . . . . 157
3.4.3.8 Cancer stem cell and parental cancer cell data set . . . . 157
3.4.4 Protein Expression data . . . . . . . . . . . . . . . . . . . . . . . . 158
3.4.5 Gene expression based pluripotency signatures . . . . . . . . . . . 158
3.4.6 Protein Interaction Network . . . . . . . . . . . . . . . . . . . . . . 158
3.4.7 Integration of PIN with gene expression data . . . . . . . . . . . . 158
3.4.8 GSEA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159
4 Signalling Entropy Correlates with Clinical Outcome in Epithelial Can-
cer 159
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159
4.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 161
4.2.1 Rationale of signalling entropy as a prognostic measure . . . . . . 161
4.2.2 Signalling entropy correlates with tumour stemness . . . . . . . . . 162
4.2.2.1 Signalling entropy correlates with measures of tumour stem-
ness in breast cancer . . . . . . . . . . . . . . . . . . . . . 163
4.2.2.2 Signalling Entropy correlates with levels of tumour stem-
ness in lung adenocarinoma, and is elevated in squamous-
cell carcinoma . . . . . . . . . . . . . . . . . . . . . . . . 163
4.2.2.3 Signalling Entropy associates with measures of tumour
stemness in prostate cancer and glioma . . . . . . . . . . 167
4.2.3 Signalling Entropy associates with key clinical variables in breast
and lung cancer: novel insights into pathology . . . . . . . . . . . 167
4.2.3.1 Luminal B breast cancer displays the highest signalling
entropy, yet a low tumour stemness, suggesting high intra-
tumour heterogeneity . . . . . . . . . . . . . . . . . . . . 167
4.2.3.2 Signalling Entropy associates with smoking history in NSCLC172
4.2.4 Signalling Entropy correlates with clinical outcome in breast cancer
and lung adenocarcinoma . . . . . . . . . . . . . . . . . . . . . . . 174
Page 13
Network Theoretic Tools in the Analysis of Complex Diseases C. R. S. Banerji
4.2.4.1 Signalling entropy is prognostic in the major subtypes of
breast cancer . . . . . . . . . . . . . . . . . . . . . . . . . 174
4.2.4.2 Signalling entropy is prognostic in stage I lung adenocar-
cinoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . 179
4.2.5 Signalling entropy's prognostic power in breast cancer can be rep-
resented by a small number of genes . . . . . . . . . . . . . . . . . 183
4.2.6 A signalling entropy based prognostic score for lung adenocarci-
noma outperforms CADM1 expression . . . . . . . . . . . . . . . . 183
4.2.7 The prognostic impact of signalling entropy is associated with genes
involved in CSCs and treatment resistance . . . . . . . . . . . . . . 185
4.2.8 Signalling entropy diﬀerences between healthy and cancerous tissue
correlates with tissue speciﬁc cancer mortality . . . . . . . . . . . 187
4.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 187
4.4 Materials and Methods, Chapter 4 . . . . . . . . . . . . . . . . . . . . . . 190
4.4.1 Expression Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . 190
4.4.2 Protein Expression data . . . . . . . . . . . . . . . . . . . . . . . . 191
4.4.3 Construction of the PIN . . . . . . . . . . . . . . . . . . . . . . . . 191
4.4.4 Signalling Entropy . . . . . . . . . . . . . . . . . . . . . . . . . . . 191
4.4.5 GSEA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 191
4.4.6 Transcriptomic tumour stemness signatures . . . . . . . . . . . . . 191
4.4.7 The SE Score in Breast Cancer . . . . . . . . . . . . . . . . . . . . 192
4.4.8 The SE Score in Lung Adenocarcinoma . . . . . . . . . . . . . . . 193
4.4.9 MammaPrint and CADM1 expression . . . . . . . . . . . . . . . . 193
4.4.10 OncotypeDX and Kratz et al. score approximations . . . . . . . . 194
4.4.11 Meta-analysis of prognostic scores . . . . . . . . . . . . . . . . . . 194
4.4.12 Evaluation of random gene expression signatures . . . . . . . . . . 194
4.4.13 Mortality rate data . . . . . . . . . . . . . . . . . . . . . . . . . . . 195
5 Network Rewiring in Facioscapulohumeral Muscular Dystrophy 195
5.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 195
5.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 197
5.2.1 Over-expression of DUX4 increases signalling entropy . . . . . . . 197
5.2.1.1 Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . 197
5.2.1.2 DUX4 is a transcriptional activator . . . . . . . . . . . . 198
5.2.1.3 DUX4, but not DUX4c, induces genes associated with
apoptosis and reduced cell proliferation . . . . . . . . . . 202
Page 14
Network Theoretic Tools in the Analysis of Complex Diseases C. R. S. Banerji
5.2.1.4 A DUX4 expression signature validates in multiple data
sets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 204
5.2.1.5 DUX4 expression increases signalling entropy . . . . . . . 204
5.2.2 FSHD cell lines show an inhibition of diﬀerentiation . . . . . . . . 206
5.2.2.1 Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . 206
5.2.2.2 Pathological immortalised myoblast cell line 54-12 over
expresses DUX4 . . . . . . . . . . . . . . . . . . . . . . . 208
5.2.2.3 FSHD cell lines demonstrate a proliferation defect . . . . 208
5.2.2.4 FSHD cell line 54-12 demonstrates a sensitivity to oxida-
tive stress . . . . . . . . . . . . . . . . . . . . . . . . . . . 208
5.2.2.5 FSHD cell line 54-12 displays an atrophic myotube phe-
notype . . . . . . . . . . . . . . . . . . . . . . . . . . . . 212
5.2.2.6 Immortalised cell lines 54-6 and 54-12 fuse at diﬀerent rates212
5.2.3 Network Rewiring in FSHD reveals β-catenin as central to DUX4
driven pathomechanisms . . . . . . . . . . . . . . . . . . . . . . . . 214
5.2.3.1 Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . 214
5.2.3.2 Meta-analysis of FSHD data sets using InSpiRe . . . . . 214
5.2.3.3 Gene expression changes speciﬁc to FSHD . . . . . . . . 216
5.2.3.4 The FSHD network . . . . . . . . . . . . . . . . . . . . . 216
5.2.3.5 DUX4 -driven gene expression mirrors FSHD . . . . . . . 217
5.2.3.6 Dysregulation of β-catenin signalling is central to rewiring
in FSHD . . . . . . . . . . . . . . . . . . . . . . . . . . . 217
5.2.3.7 HIF1-α Signalling . . . . . . . . . . . . . . . . . . . . . . 218
5.2.3.8 TNF-α over-activation of reactive oxygen species induced
JNK cell death pathways . . . . . . . . . . . . . . . . . . 218
5.2.3.9 PerturbedWnt/β-catenin signalling inDUX4 -infected satel-
lite cell-derived myoblasts . . . . . . . . . . . . . . . . . . 218
5.2.3.10 Comparison of InSpiRe to other methodologies . . . . . . 225
5.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 226
5.4 Materials and Methods, Chapter 5 . . . . . . . . . . . . . . . . . . . . . . 230
5.4.1 Cell Culture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 230
5.4.2 Immunocytochemistry . . . . . . . . . . . . . . . . . . . . . . . . . 230
5.4.3 5-Ethynyl-2'-deoxyuridine (EdU) incorporation . . . . . . . . . . . 231
5.4.4 Oxidative Stress Sensitivity . . . . . . . . . . . . . . . . . . . . . . 231
5.4.5 Cell Diﬀerentiation . . . . . . . . . . . . . . . . . . . . . . . . . . . 231
5.4.6 Time course imaging . . . . . . . . . . . . . . . . . . . . . . . . . . 231
Page 15
Network Theoretic Tools in the Analysis of Complex Diseases C. R. S. Banerji
5.4.7 Image analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 232
5.4.8 Harvesting cells for RNA . . . . . . . . . . . . . . . . . . . . . . . 234
5.4.9 Signalling Entropy . . . . . . . . . . . . . . . . . . . . . . . . . . . 234
5.4.10 Expression Data sets . . . . . . . . . . . . . . . . . . . . . . . . . . 234
5.4.11 Construction of the PIN . . . . . . . . . . . . . . . . . . . . . . . . 235
5.4.12 The InSpiRe Algorithm . . . . . . . . . . . . . . . . . . . . . . . . 236
5.4.13 Comparing Possible Transformed Pearson Correlations in Step 1 of
InSpiRe . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 236
5.4.14 Comparing methodologies . . . . . . . . . . . . . . . . . . . . . . . 237
5.4.14.1 Diﬀerential expression analysis . . . . . . . . . . . . . . . 237
5.4.14.2 NetWalk analysis . . . . . . . . . . . . . . . . . . . . . . 237
5.4.14.3 Functional annotation for InSpiRe implicated genes . . . 237
5.4.14.4 Comparison . . . . . . . . . . . . . . . . . . . . . . . . . . 238
5.4.15 Re-sampling procedure to assess concordance between microarray
and the the FSHD network . . . . . . . . . . . . . . . . . . . . . . 238
5.4.16 qPCR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 239
6 Overview, Discussion and Philosophy 239
6.1 On our philosophy of approach . . . . . . . . . . . . . . . . . . . . . . . . 239
6.2 An overview of our work . . . . . . . . . . . . . . . . . . . . . . . . . . . . 241
6.3 Future Directions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 243
7 Abbreviations 245
8 References 246
Page 16
Network Theoretic Tools in the Analysis of Complex Diseases C. R. S. Banerji
List of Figures
1.1 Network topologies. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
1.2 Network Rewiring. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
1.3 Waddington's Landscape. . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
1.4 Small regulatory circuits for binary decisions. . . . . . . . . . . . . . . . . 43
1.5 Breast cancer subtype proportions. . . . . . . . . . . . . . . . . . . . . . . 52
1.6 The CSC hypothesis and clonal evolution. . . . . . . . . . . . . . . . . . . 64
1.7 The structure of skeletal muscle. . . . . . . . . . . . . . . . . . . . . . . . 69
1.8 FSHD aﬀected muscle groups. . . . . . . . . . . . . . . . . . . . . . . . . . 71
1.9 The Genetics of FSHD. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
2.1 NTE Example 1: Deterministic Path. . . . . . . . . . . . . . . . . . . . . 95
2.2 NTE example 2: Directed Feedback. . . . . . . . . . . . . . . . . . . . . . 97
2.3 ISDs, edge-weights and NTE computations on the biological network. . . 99
2.4 NTE computed over two perturbations of a biological network. . . . . . . 100
2.5 Signalling entropy is driven by the expression of high degree vertices. . . . 110
2.6 Analysis of the expression sign(1−1/b+2/a)+sign(1−a+2b) for a range
of biologically plausible values: a, b ∈ [0.01, 20]. . . . . . . . . . . . . . . . 117
2.7 Demonstration that the claim of super-additivity
SR
(
x+y
2
)
> SR(x)2 +
SR(y)
2 is correct for all pairwise combinations of sam-
ples in GSE2361. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118
2.8 Signalling entropy of homogeneous and mixed tissues. . . . . . . . . . . . 119
2.9 Demonstration that the proposition∫
Ω
∫
Ω
(
SR
(
x+y
2
)− SR(x)) dxdy > 0 is correct for samples in GSE2361. . 120
2.10 An overview of the InSpiRe algorithm. . . . . . . . . . . . . . . . . . . . . 124
2.11 NTE dependence on the ISD. . . . . . . . . . . . . . . . . . . . . . . . . . 132
3.1 Signalling entropy as the height in Waddington's Landscape. . . . . . . . 139
3.2 Signalling entropy correlates with the diﬀerentiation potential of a sample. 140
3.3 Signalling entropy is similar in ES cells and iPSCs. . . . . . . . . . . . . . 141
3.4 Signalling entropy is not driven by cell cycle genes. . . . . . . . . . . . . . 142
3.5 Signalling entropy associates with the diﬀerentiation hierarchy within mul-
tiple lineages. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 143
3.6 Comparison of signalling entropy across major blood cell types in the
hematopoietic system. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 144
3.7 Signalling entropy exhibits dynamic changes during the diﬀerentiation pro-
cess. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 146
3.8 Signalling entropy is higher in cancerous tissue and in CSCs. . . . . . . . 147
Page 17
Network Theoretic Tools in the Analysis of Complex Diseases C. R. S. Banerji
3.9 Local entropy identiﬁes rewiring ofNotch pathway mediators in non-plutipotent
cells. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 149
3.10 Local entropy decreases in criticalNotch pathway mediators in non-plutipotent
cells. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150
3.11 JAK -STAT signalling is signiﬁcantly enriched among genes which decrease
their local entropy during HL60 diﬀerentiation into neutrophils. . . . . . . 151
3.12 Local entropy detects the rewiring of JAK2 's interaction distribution into
an active state during neutrophil diﬀerentiation. . . . . . . . . . . . . . . 152
4.1 Rationale behind signalling entropy as a prognostic factor in cancer. . . . 162
4.2 Signalling entropy is correlated with measures of tumour stemness in breast
cancer. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 164
4.3 Signalling entropy is correlated with measures of tumour stemness in lung
adenocarcinoma. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 166
4.4 Signalling entropy is correlated with measures of tumour stemness in prostate
cancer and glioma. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 168
4.5 Association between signalling entropy and the Ben-Porath et al. ES cell
signature and intrinsic subtypes in the METABRIC dataset. . . . . . . . . 170
4.6 Association between signalling entropy and histological subtypes in the
discovery and validation sets of METABRIC. . . . . . . . . . . . . . . . . 171
4.7 Signalling entropy is elevated in NSCLC patients with a history of smoking.173
4.8 Meta-analysis of prognostic implications of signalling entropy in breast cancer176
4.9 Signalling entropy out-performs MammaPrint over ER negative samples . 177
4.10 Meta-analysis comparison of signalling entropy with OncotypeDX. . . . . 178
4.11 Meta-analysis of prognostic implications of signalling entropy in lung ade-
nocarcinoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 181
4.12 Signalling entropy outperforms tumour size staging expression across stage
I samples. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 182
4.13 Meta-analysis comparison of the breast cancer SE score with MammaPrint. 184
4.14 Meta-analysis comparison of the lung cancer SE score with the expression
of CADM1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 186
4.15 Signalling entropy increase during oncogenesis correlates with tissue spe-
ciﬁc cancer mortality. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 188
5.1 The DUX4 retroviral constructs introduced to murine myoblasts before
transcriptomic analysis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 198
5.2 Clustering of the DUX4 construct infected myoblast samples. . . . . . . . 200
Page 18
Network Theoretic Tools in the Analysis of Complex Diseases C. R. S. Banerji
5.3 Relationship between transcriptional perturbations induced by the DUX4
constructs. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 201
5.4 Flowchart describing the selection of DUX4 and DUX4c expressed genes. 203
5.5 A DUX4 expression signature validates in multiple datasets. . . . . . . . 205
5.6 DUX4 expression increases signalling entropy. . . . . . . . . . . . . . . . . 207
5.7 DUX4 is over expressed in pathological cell line 54-12. . . . . . . . . . . . 209
5.8 Pathological cell line 54-12 displays a defect in proliferation. . . . . . . . . 210
5.9 Pathological cell line 54-12 displays a sensitivity to oxidative stress. . . . . 211
5.10 Pathological cell line 54-12 displays an atrophic myotube phenotype. . . . 213
5.11 Pathological cell line 54-12 aligns and fuses more slowly than control line
54-6. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215
5.12 The neighbourhood of CTNNB1 in the FSHD network. . . . . . . . . . . 219
5.13 The Wnt pathway in the FSHD network. . . . . . . . . . . . . . . . . . . . 220
5.14 The neighbourhood of HIF1A in the FSHD network. . . . . . . . . . . . . 221
5.15 The neighbourhood of MAP4K5 in the FSHD network. . . . . . . . . . . 222
5.16 The neighbourhood of PARP2 in the FSHD network. . . . . . . . . . . . 223
5.17 The neighbourhood of JUNB in the FSHD network. . . . . . . . . . . . . 224
5.18 DUX4 perturbs Wnt/β-catenin signalling. . . . . . . . . . . . . . . . . . . 225
5.19 Comparing InSpiRe to NetWalk and GSEA on diﬀerentially expressed genes.226
5.20 Automated image analysis of immunocytochemistry. . . . . . . . . . . . . 233
Page 19
Network Theoretic Tools in the Analysis of Complex Diseases C. R. S. Banerji
1 Introduction
Our ﬁeld of study is multifaceted, interdisciplinary and fast paced, thus a review of all
topics relevant to our work will almost surely be incomplete. However, I hope that in this
introduction we can provide suﬃcient background to motivate our research. Following
this introduction, the body of the thesis will consist of 4 chapters:
2. Entropic Network Theoretic Tools: Concept and Theory.
3. Signalling Entropy as the energy potential of Waddington's Landscape.
4. Signalling Entropy correlates with Clinical Outcome in Epithelial Cancer.
5. Network Rewiring in Facioscapulohumeral Muscular Dystrophy.
In the second chapter we describe a general model for dynamics on a weighted biological
network, which can be derived from genome wide gene expression data. From this model
we derive three network theoretic tools for investigating and understanding genes and
pathways perturbed in complex pathology: Network Transfer Entropy (NTE), Signalling
Entropy and Interactome Sparsiﬁcation and Rewiring (InSpiRe). We investigate these
tools analytically and demonstrate some general properties.
In the third chapter we consider cellular diﬀerentiation, a highly sophisticated process crit-
ical to multicellular organism development, which is perturbed in many complex patholo-
gies. We demonstrate that one of our network theoretic tools, signalling entropy, is a
powerful measure of the progression of diﬀerentiation and motivate the use of the measure
in the understanding of diseases of development. In an oncogenic context we demonstrate
signalling entropy is elevated in cancer stem cells as compared to the tumour bulk.
In the fourth chapter we investigate signalling entropy in more detail in the context of
epithelial cancer. We reveal our measure to be correlated with tumour stemness and other
clinical variables across multiple malignancies and strongly prognostic in both breast and
lung cancer.
Finally, in the ﬁfth chapter we investigate network rewiring in facoiscapulohumeral mus-
cular dystrophy (FSHD), a complex disease of development. We ﬁrst reveal the sig-
nalling entropy is raised in samples over-expressing the primary FSHD candidate gene
DUX4. Subsequently, we experimentally demonstrate that DUX4 is over-expressed in
human muscle precursor cells from FSHD patients, and that such cells exhibit clear de-
fects in muscle regeneration, such as ineﬃcient alignment and fusion, leading to atrophic
myotubes. To investigate in more detail which genes and pathways are driving FSHD
pathomechanisms, we employ InSpiRe, our more local network theoretic algorithm, in a
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meta-analysis of FSHD muscle biopsy gene expression data sets. We uncover a network
of rewired protein interactions in FSHD, which can be attributed to DUX4 expression.
Betweenness centrality indicates that β-catenin is the most critical bottleneck to FSHD
signalling. We subsequently validate that over-expression of DUX4 induces dysregulation
of a number of β-catenin downstream targets.
Given these topics of interest, we will focus our introduction on the following areas:
1. The development of network theoretic tools.
2. Mathematical approaches to understanding cell diﬀerentiation
3. The pathophysiology of breast cancer.
4. The pathophysiology of FSHD.
At the end of each introductory review we will consider the lessons learned from the
literature and explain the relevance of the information to guiding our research.
1.1 The development of network theoretic tools
Genes do not act in isolation [2]. This is a simply stated fact but the ramiﬁcations are
profound; for the complex and detailed interplay between intracellular components forms
the basis of the most sophisticated and enigmatic biological processes, and the perfect
hiding place for elusive mechanisms of incurable disease.
Unmasking these elaborate molecular mechanisms in healthy and diseased biological pro-
cesses has thus become a rich sub-discipline of systems biology. The complexity of this
ﬁeld is embodied by its demand for strong inter-disciplinary, with the deepest insights
requiring a powerful combination of well-designed, high throughput experimental biology,
with the computational and mathematical sciences to analyse and interpret the resulting
data.
Large-scale ventures in the study of the molecular mechanisms of the cell often focus on
the representation and analysis of biological pathways as large graphs, referred to as net-
works, in which vertices represent interacting biological components connected by ﬁxed
edges [3]. Many algorithms have been designed and reﬁned for the purpose of reverse
engineering these networks from genome wide gene expression data [4]. Early approaches
focused on utilising hierarchical clustering or co-expression to postulate gene interdepen-
dencies. These were largely succeeded by more sophisticated methodologies, drawing on
the concepts of information theory [5], Bayesian networks [6] and dynamical systems [7].
Debate still persists on the superiority of these more recent approaches, and it seems
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likely that the optimal choice of network inference algorithm is dependent on a num-
ber of variables [4]. In addition, many large, online, manually curated data bases exist,
detailing experimentally veriﬁed interactions for the empirical construction of networks
[8, 9, 10, 11, 12] and many investigators prefer to work with these more high conﬁdence
interaction maps, to overcome the insuﬃciencies of inference algorithms.
Subsequent analysis of these networks relied heavily on the classical ﬁeld of graph theory
[13]. Topological measures of graph centrality became a popular approach to the inter-
rogation of structural properties of interacting biological systems, frequently providing
insight into genes which are well placed to drive malicious phenotypes [3]. More recently
some exciting approaches in the analysis of network structure have arisen from the con-
sideration of geometric graphs and the statistical embedding of a biological network into
a metric space [14].
Further insights on the nature of genetic interactions have been achieved by the inte-
gration of genome wide expression data with biological networks to generate weighted
graphs [15, 16, 17]. Methodologies to analyse these richer structures often draw insight
from stochastic analysis, most notably from random walk theory, to construct more infor-
mative network centrality measures and to interrogate dysregulated dynamics in disease
[15, 18, 19].
Recently, the study of large scale molecular interactions has undergone a paradigm shift,
following the discovery that the structure of the complex cellular machinery can be en-
tirely re-organised in response to environmental perturbation, disease or even naturally
during development [20, 21, 22]. This insight, dubbed network rewiring, has led to the
construction of a new set of mathematical and computational tools which have been de-
signed to investigate experimental data from this more informative viewpoint.
These more recent methodologies have generally focused on the comparison of two or
more weighted networks, describing diﬀerent phenotypes or conditions. Among the most
successful approaches are random walk based algorithms, which have led to signiﬁcant
advances in our understanding of sophisticated biological processes, revealing novel mech-
anisms for complex diseases and elucidating drug responses [16, 17, 23].
In what follows we will review popular methodologies employed for the analysis of health
and disease from the perspective of complex networks. We will progress systematically,
ﬁrst considering how one constructs a network of biological interactions by experimental
approaches and via statistical methodologies for gene network inference from expression
data. We then progress to explain the analysis of such networks from a single phenotype
perspective. Subsequently, we consider diﬀerential networks and chart the rise of the pow-
erful concept of network rewiring, describing the recent methodologies developed around
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this notion and the new insights gained. We close with some perspectives, explaining the
relevance of the reviewed literature to our research goals and examining the ﬂavour of
methodology that given insights from our ﬁndings would be useful to develop.
1.1.1 Uncovering the Structure of Biological Networks
In order to understand and interrogate the structural and dynamical properties of biologi-
cal networks, one must ﬁrst have a reasonable knowledge of at least a representative subset
of bio-molecular interactions. Many biochemical assays exist to identify such interactions
with a high sensitivity and speciﬁcity. The most utilised of these are the immunologi-
cal methods such as co-immunoprecipitation (Co-IP) and chromatin immunoprecipitation
(ChIP). Co-IP utilises antibodies against speciﬁc proteins to investigate putative interac-
tions, and can even be used to identify unknown interaction partners for a speciﬁed protein
[24], whilst ChIP precipitates DNA fragments to which a protein of interest binds, to iden-
tify genetic regulatory interactions. Whilst accurate, these methodologies are reasonably
small scale and can only investigate the interaction partners of few proteins at a time,
and under speciﬁc laboratory conditions. More high-throughput experimental techniques
for interaction identiﬁcation exist, such as Yeast 2 Hybrid (Y2H), which utilises a coupled
reporter gene system in yeast to identify gene pair interactions [25]. Whilst useful, Y2H
is renowned for false positives, likely caused by the natural separation of two proteins
in the organism of interest (by organelles etc.) which is not recapitulated in the experi-
mental setting. Though this is an issue, annotations describing intra-cellular localisations
for many proteins exist [26] and can be used to reﬁne Y2H identiﬁed interactions and
remove false positives. Collectively, the results of these sophisticated molecular biological
techniques have been compiled into a number of evidence based interaction data bases,
such as Pathway Commons, BioGrid, IntAct and KEGG [8, 9, 10, 11, 12], which serve as
high conﬁdence resources for network data.
In addition to the use of targeted assays, the large scale identiﬁcation of molecular inter-
actions has been achieved by reverse engineering genome wide gene expression data into
genetic networks, using a multitude of diﬀerent mathematical approaches [4, 5, 6, 27, 28].
Underlying all these algorithms is the principle that if a gene x is perturbed, resulting in
the modiﬁcation of the expression of another gene y, then x and y must either directly or
indirectly (through some mediators) interact. Thus if one is given an expression data set
comprising global gene expression proﬁles for an organism, under a large number of known
perturbations, theoretically one will be able to uncover causal interdependencies between
genes, with the caveat that certain relations will be indirect. In reality such a perfect
data set does not exist [27]. Rather gene expression data generally consists of either a
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number, M , of observations of the expression of many, n, genes either in steady state, or
ordered as a time course. Perturbations between the observations are generally unknown
and may derive from genetic variation between samples in the case of the steady state
observations [4]. Consequentially, causal interdependencies between genes are diﬃcult to
infer as interactions cannot generally be traced from a causal perturbation. However, this
does not mean that network inference is impossible [29], rather interactions must be iden-
tiﬁed through measures designed to infer dependencies between the expression proﬁles of
gene pairs from the M samples [4, 27].
A popular methodology for inferring genetic networks from expression data is Algorithm
for the Reconstruction of Accurate Cellular Networks (ARACNe), which employs an
information-theoretic approach [5]. ARACNe treats the expression of each gene as a
random variable and utilises mutual information, between data estimated gene expres-
sion probability density functions, to assess interdependencies between gene pairs. The
mutual information between two random variables X and Y can be deﬁned in terms of
entropies
I(X,Y ) := S(X) + S(Y )− S(X,Y ),
where S(X) := −∑x PX(x) logPX(x) is the entropy of X,
S(X,Y ) = −∑x,y PX,Y (x, y) logPX,Y (x, y) is the joint entropy of X and Y and PX(x)
and PX,Y (X,Y ) are the probability mass function (pmf) of X and the joint pmf of X and
Y respectively. I(X,Y ) is a symmetric, model free measure of the interdependency of X
and Y , in particular if X and Y are independent variables, i.e., PX,Y (x, y) = PX(x)PY (y),
then I(X,Y ) = 0. ARACNe uses a Gaussian Kernel estimator [30] to approximate
the joint probability distribution of the expression of all gene pairs described by the
expression data, from which the univariate distributions are computable as the marginals.
The mutual information between every gene pair is thus computed and a randomisation
procedure is utilised on the expression data to identify a mutual information threshold
above which gene interdependency is statistically signiﬁcant. ARACNe also employs the
Data Processing Inequality (DPI) to eliminate potentially non-causal interactions. The
DPI states that for three genes in a network X, Y and Z, if the edges (X,Y ) and (Y,Z)
exist in the true network but (X,Z) does not, then it follows that
I(X,Z) ≤ min[I(X,Y ); I(Y, Z)].
It should be noted that this is a necessary but not suﬃcient condition and that by em-
ploying the DPI, ARACNe may be deleting a number of real interactions [4].
ARACNe, has been shown to be successful in inference of networks from in silico data
[4, 5], most notably in the case of small data sets of steady state expression proﬁles, where
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it out performs many other popular methodologies. In order for the mutual information
to be well deﬁned, however, ARACNe requires the input expression data assays to be
mutually independent measurements; consequentially ARACNe has demonstrated poor
performance on short spaced, time series data where this assumption fails [4]. Moreover,
as mutual information is a symmetric measure, ARACNe can only ever produce undi-
rected networks. Despite these limitations the methodology has provided strong insights
into biological networks. Notably, in an analysis of expression data from 336 perturbations
of human B cells, ARACNe identiﬁed a large number of targets of the proto-oncogene
MYC, including many which had not been previously documented [31]. By performing
ChIP, the authors of this study validated many of these putative targets, conﬁrming the
ability of the methodology to predict true biological interactions. Moreover, many of the
downstream targets of MYC were found to be highly connected in the ARACNe inferred
network, suggesting a hierarchical nature to genetic regulation [28].
Another class of reverse engineering algorithms include methodologies such as Bayesian
Network Inference with Java Objects (BANJO) [6], which utilise Bayesian networks to
infer probabilistic relationships between genes. In a Bayesian network interdependen-
cies between a set of random variables X1, ..., Xn are assumed to be in the form of a
directed acyclic graph G = (V,E), where V := {X1, ..., Xn} is a set of vertices and
E ⊂ {(i, j) : i, j ∈ V } is a set of directed edges. A Markovian assumption is also em-
ployed, stating that a variable Xk is dependent only on its immediate inputs in G, also
known as the parental variables of Xk. This assumption, via Bayes theorem, can be
represented by a probability distribution P (X1..., Xn) satisfying
P (X1..., Xn) =
n∏
i=1
P (Xi|{Xj : (j, i) ∈ E}.
In the reverse engineering of gene networks, each variable Xk can be considered the
expression of a gene, and theM repeated measurements of gene expression at steady state
represent a sample of these variables, which we will denote by Y . The task of Bayesian
network algorithms is thus to infer the optimal G for the data set Y , generally using
a maximum likelihood approach. This amounts to ﬁnding G which maximises P (G|Y ),
which can be represented via Bayes rule as
P (G|Y ) = P (Y |G)P (G)
P (Y )
,
where P (G) may encode some prior on the expected graphical structure (possibly guided
by literature curated networks [32]). Finding the precise G which maximises P (G|Y ), will
likely lead to over-ﬁtting due to the large parameter space represented by G however, thus
Bayesian Scoring metrics, with complexity penalizations are generally employed. Due to
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the huge state space of possible networks G, it is impractical to test every possibility
to identify the structure that maximises the score. Consequentially, a variety of search
algorithms have been utilised to sample the parameter space in a manner which permits
an approximation of the optimal network structure. Popular examples of these algorithms
include greedy search, simulated annealing and genetic algorithms. It was demonstrated
that in the BANJO algorithm setting, all three search algorithms gave similar results on
simulated data, however the greedy search provided the most rapid convergence [6].
The Bayesian network algorithm BANJO was directly compared to ARACNe in terms of
sensitivity and speciﬁcity of networks inferred from simulated data [4]. This revealed that
BANJO is very powerful for the inference of smaller networks (< 1000 vertices) when
there is a large amount of data available (> 10 samples). However, the complexity of
BANJO prevented it from converging on larger networks, and in the cases when datasets
were small, ARACNe was a clear winner, with BANJO performing no better than random.
Despite this limitation, Bayesian network approaches to the reverse engineering of genetic
interactions have provided many important results [32], particularly through the use of
the prior P (G) to encode additional information to the expression data, guiding the
construction of more accurate networks. For example, Jensen et al. [33] utilised ChIP
binding data to inform the prior and improve network inference in a reverse engineering
of a gene regulatory network from expression data in yeast.
In addition to Baysean networks and information theoretic approaches, a third class of
reverse engineering algorithms takes its origins from the ﬁeld of dynamical systems. In
these algorithms, the expression and interactions between a set of genes X1, ..., Xn are
modelled by a deterministic set of ordinary diﬀerential equations (ODEs)
dXk
dt
= f(X1, ..., Xn, θ),
where f is a continuous function and θ is a vector of parameters which speciﬁes the net-
work. The expression data is then utilised to estimate θ, either by setting dXkdt = 0 in
the case of steady state data, or estimating the time derivative in the case of time course
data. The choice of f is clearly critical to this approach, with non-linearity providing
more realism at the cost of higher computational complexity. Despite this trade oﬀ, it
appears that a linear model may be suﬃciently powerful for reliable inference and many
popular algorithms such as Network Inference by Reverse-engineering (NIR) [7], utilise
such a linear model and regression techniques to successfully engineer networks from ex-
pression data. The deterministic nature of these ordinary diﬀerential equation (ODE)
approaches, however, mean that they are better suited to data sets where noise is low [4].
Thus a combination of experimental and computational techniques can be employed to
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identify large scale genetic interactions within the cell, and map out molecular networks
for detailed interrogation. There is a vast array of algorithms available for the reverse
engineering of interaction networks from expression data, each with their own strengths
and weaknesses that depend critically on the data set being employed for inference. In
this work we will aim to develop general methodologies that are useful regardless of data
set structures. Hence we will not restrict ourselves to a given network inference algo-
rithm which may provide diﬀering results on independent data sets describing the same
phenotype. Instead we will utilise the experimentally compiled networks, described by
the integrated results of the many online manually curated interaction data-bases. As
explored above the reliance of these data bases on Y2H experiments may lead to false
positives due to poor localisation restrictions, hence we will utilise protein intra-cellular
localisation annotations to reﬁne our network. It should be noted that an advantage of
gene network inference is that its derivation from data provides a sample speciﬁc context
to the interaction patterns. We will thus only consider our experimentally derived net-
works as weighted graphs, where edge weights are derived from gene expression data and
provide a sample speciﬁc context to the known interactions. In this way we create sample
speciﬁcity without introducing/removing interactions in a manner which may over ﬁt the
network to the data set.
Once the network structure is decided upon, the next stage of analysis requires the devel-
opment and implementation of methodologies to interrogate the global and local nature
of biological networks, with the aim of identifying critical mediators of healthy and patho-
logical processes. Early approaches to this investigation began via the evaluation of the
topological properties of biological networks, describing either general biological interac-
tions or interactions attributable to a single biological phenotype.
1.1.2 Single Phenotype Networks
Once a biological network was elucidated describing a single phenotype, either via ex-
perimental or algorithmic means, the challenge became to understand how the structure
of the network could inform us about the system it described. Early characterisation of
inferred and experimentally veriﬁed networks focused on centrality measures of the static
network topology and famously suggested a scale free structure [31, 34, 35]. In scale free
networks the degree distribution typically follows an inverse power law, resulting in a net-
work in which highly connected vertices or hubs are rare and poorly connected vertices
predominate (Fig 1.1). Scale free networks became highly studied and were found to be
robust, in terms of connectivity, to the deletion of random vertices, but particularly sus-
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Random Network Scale Free Network Hierarchical (Modular) Network
A) B) C)
Figure 1.1: Network topologies. (A) Random networks have normally distributed de-
gree distributions. (B) Scale free networks have power-law degree distributions, resulting
in a low number of high degree vertices. (C) Hierarchical networks are scale-free and
yield a modular structure, with high degree vertices displaying higher clustering coeﬃ-
cients (forming more triangles via their edges). Biological networks have been posited to
display concordance with a hierarchical network structure.
ceptible to the targeted deletion of highly connected vertices [36]. The biological relevance
of this theory was subsequently demonstrated in yeast, where it was shown that knock
outs of genes corresponding to hubs in the protein interaction network, were far more
likely to convey lethality than poorly connected genes [37]. However, our understanding
of biological interactions is constantly evolving and, for the present at least, we only ever
have knowledge of a subset of all true biological interactions. This is concerning as it was
recently demonstrated that subsets of scale free networks are not likely to be scale free
[38]. Moreover, more current studies of static networks compiled from publicly available
data bases have revealed a troubling inconsistency with previously established scale free
structure [39, 40].
Further insights into biological network structure came from the identiﬁcation of mod-
ularity, deriving from the initial observation, in yeast, that genes with similar functional
annotations were more likely to cluster together in protein-protein interaction networks
[41] (Fig 1.1). This revealed modularity of biological networks has motivated more local
analysis of topology, and led to methodologies permitting the decomposition of networks
Page 28
Network Theoretic Tools in the Analysis of Complex Diseases C. R. S. Banerji
into pathways and subsystems for detailed functional analysis [42]. Modularity has also
led to the use of a diﬀerent class of centrality measures, aimed at identifying inter-modular
hubs, which may not be highly connected but are clear bottlenecks for information ﬂow
between discrete modules in the network. Among these measures is the well-studied
betweenness centrality, which quantiﬁes the number of shortest paths between any two
vertices in the network which pass through a given vertex. It was demonstrated that
this measure is computable through the consideration of the stationary distribution of a
walker moving randomly through a network [43]. These inter-modular hubs were found
to be mutated in breast cancer far more frequently than intra-modular hubs [44], demon-
strating the importance of communication between functional network subsets for the
maintenance of healthy homoeostasis.
The analysis of single phenotype biological network structure has also diverged from the
consideration of local centrality measures to understand more global properties. It was
recently observed that complex networks display self-similarity, particularly with respect
to degree-threshold re-normalisation (considering the ensemble of complex networks gen-
erated by sequentially thresholding the degree of vertices) [45]. The main topological
characteristics of the networks in the ensemble generated by this procedure (e.g. degree
distribution, clustering coeﬃcient) are found to be self-similar, a property not observed
in randomised networks. It was subsequently demonstrated that if one considers a graph
generated by uniformly distributing vertices in a metric space, and then connecting ver-
tices with a probability inversely proportional to their separation, then one can generate
from this assumption networks which demonstrate such self-similarity. By employing a
maximum likelihood approach, Serrano et al. [14] embedded the topologies of metabolic
networks into a hyperbolic geometry and found that reactants with functional similarity
tended to be more proximal in this underlying metric space, implying a hidden modular-
ity is encoded in the structure of these networks.
The study of single phenotype networks advanced further from the consideration of
weighted network topologies. This permitted the use of methodologies based on the
notion of random walks on weighted graphs, which provided insight into disease path-
omechanisms. Among these methodologies is NetRank, a modiﬁcation of the Google
PageRank algorithm, which was able to identify novel, robust, network based biomarkers
for survival time in various cancers [18, 19]. The methodology integrates gene expression
data, survival data and interaction data describing a single cancer phenotype to generate
a weighted network. Brieﬂy, each vertex in a biological network is matched to a gene
in the expression data and then weighted with the correlation between gene expression
and survival time. The algorithm then considers the motion of a random walker on the
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weighted biological network, at each time point the walker can move to a neighbouring
vertex with probability d, with the choice of neighbour uniform, or to a random vertex
in the network with probability (1− d) with the choice of random vertex proportional to
the vertex weight (correlation of expression with survival time). In this way the walker
is biased towards the neighbourhood of genes which are over-expressed in patients with
a better clinical outcome and away from the neighbourhood of genes which are under-
expressed. This process is iterated until convergence to obtain a ranking for the vertices
in terms of visitation probability of the random walker. To compute this ﬁnal ranking
an iterative approach is adopted by noticing that the ranking rkj of the j
th vertex in the
network after the kth evolution of the random walker satisﬁes
rkj = (1− d)cj + d
V∑
i=1
aijr
k−1
i
deg(i)
,
where aij is the adjacency matrix of the network, cj is the correlation of the expression
of the gene corresponding to vertex j with survival time, V is the number of vertices
in the network and deg(i) is the degree of vertex i in the network. Consequentially, at
convergence the ranking satisﬁes
(I − dATD−1)~r = (1− d)~c,
where I is the identity matrix, A is the adjacency matrix of the network, D is a diago-
nal matrix of vertex degrees and ~r and ~c are the vectors of rankings and correlations of
expression with survival time respectively. The top ranked features are then utilised to
train a classiﬁer for predicting survival time in various cancers. Estimating the optimal
d for NetRank has been achieved by Monte Carlo cross validation, in which the classiﬁer
training data set is split randomly into a test and training set and various values of d
are utilised to train and test a classiﬁer, with the optimal value of d then chosen as that
which leads to the classiﬁcation with the highest accuracy.
Thus the analysis of single phenotype biological networks, through the consideration of
topology and random walks has led to many insights on how form may inﬂuence function
in interacting biological systems. However, these methodologies ignore a potential dy-
namism between diﬀerent biological phenotypes; a network rewiring which may provide
deeper insights into the diﬀerences across biological phenotypes and how to ameliorate
them.
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1.1.3 Network Rewiring: a shift in methodology
Whilst the analysis of single phenotype biological networks has proved insightful in the
identiﬁcation of critical disease genes, recent studies have revealed that the true topol-
ogy of biological networks is far from static; rather it is constantly rewiring in response
to environmental and genetic perturbations [46]. Such a revelation suggests that net-
works underlying biological phenotypes must be considered in a case-control setting, and
that the rewired diﬀerences between networks describing phenotypes are of more criti-
cal importance than the phenotype speciﬁc network topologies. The concept of network
rewiring in response to external stimulus was most convincingly demonstrated in the work
of Bandyopadhyay et al. [20]. The authors of this study used a new technique dubbed
diﬀerential epistatic mini-array proﬁling, to identify the remodelling of all pairwise genetic
interactions, between 418 genes in yeast, following exposure to the DNA damaging agent
methanesulfonate (MMS). Brieﬂy, the methodology involved generating a large number
of pairwise gene knockouts (or hypomorphic alleles for essential genes), one for each gene
pair assessed. Each pairwise interaction was then scored, in each condition (exposure or
non-exposure to MMS), with a measure of cell viability. The authors thus generated two
weighted networks, one describing genetic, cell viability modifying interactions in stan-
dard laboratory conditions and the other describing interactions under exposure to MMS.
The two networks showed large diﬀerences, though intriguingly the MMS treated network
was not enriched for interactions between DNA damage response genes. However, when
the untreated network was subtracted from the MMS treated network, signiﬁcant enrich-
ment of DNA damage response was revealed. This discovery emphasised that it is in the
diﬀerential interactions between two conditions that the biological response can be found,
rather than in the static network of the responding organism (Fig 1.2). This ﬁnding has
contributed to a rapid growth in the study of diﬀerential networks, and to the prominence
of the concept of network rewiring [47].
Understanding of genetic disease has beneﬁted from the consideration of network
rewiring, where a causal genetic aberration leads to a restructuring of intra-cellular in-
teractions from the healthy state. Many early studies considered a gene mutation as the
deletion of a vertex in a static network with no further rewiring. Such an approach is lim-
ited, however, as it cannot explain how multiple diverse diseases may arise from mutations
in the same gene. It was subsequently demonstrated that many mutations corresponding
to Mendelian diseases, may in fact be better represented by deletion or remodelling of
network interactions [22]. In this model mutations in a single gene could naturally lead
to many diverse diseases, through subtle modiﬁcation of interaction preferences.
A focus on the concept of network rewiring has led to advances in the study of patholo-
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Figure 1.2: Network Rewiring. Protein interaction networks dynamically rewire in
response to treatment with DNA damaging agents. The static protein interactions within
treated and untreated cells are not enriched for treatment response, however the diﬀer-
ential interactions are strongly enriched.
gies from the consideration of diﬀerential co-expression networks [27]. In such studies
gene expression data proﬁling healthy and diseased tissue is used to reverse engineer a
weighted network for each phenotype utilising ARACNe or BANJO. Topological metrics
or clustering techniques are then utilised to identify genes and interactions which are sub-
stantially remodelled in disease. This strategy has been successfully utilised to identify
gene sets activated and repressed during mouse mammary tumour gland formation [48].
In addition, diﬀerential co-expression networks have been able to identify oncogenic tran-
scriptional regulators, to which conventional diﬀerential expression techniques are blind
[49].
Random walk theory has also been employed in the development of diﬀerential network
methodologies, such as NetWalk [16], which investigate network dynamics. This method-
ology is similar to the single phenotype NetRank but investigates the behaviour of the
random walker in a diﬀerential setting. NetWalk ﬁrst integrates gene expression data
with a compiled network of all known biological interactions referred to as the Knowl-
edgebase (with adjacency matrix (aij)
V
ij=1, where V denotes the number of vertices), by
utilising a general vertex weighting. Every vertex i in the network is assigned a value
wi, which may correspond to any number of data derived quantities such as the diﬀeren-
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tial expression of the gene corresponding to vertex i between two phenotypes of interest.
As in NetRank, the vertex weightings are then utilised to construct a stochastic matrix
(pij)
V
ij=1, describing the transition probabilities of a random walker biased by the vertex
weights (wi)
V
i=1:
pij = (1− q) aijwj∑
k∈Ni wk
+
qwj∑V
k=1 wk
,
where Ni is the neighbourhood of vertex i in the network and q ∈ (0, 1). By the Perron
Frobenius theorem, the left eigenvector of this transition probability matrix corresponds
to the stationary distribution, (ri)
V
i=1, of the walker. In addition to computing (ri)
V
i=1,
NetWalk also considers an edge ﬂux, eij , which is the probability of the walker (initiated
from its stationary distribution) traversing an edge (i, j) in the network, simply evaluated
as:
eij = ripij .
By computing edge ﬂuxes, NetWalk can be utilised to postulate not only genes which are
associated with a given phenotype, but also interactions, permitting this methodology
a strong insight into the eﬀects of network rewiring between two diﬀerent conditions.
Indeed the methodology was employed to investigate network rewiring in MCF7 breast
cancer cells in response to various doses of the chemotherapeutic drug doxorubicin and
revealed a switching behaviour in the p53 network controlling apoptosis and cell cycle
arrest [16].
Other random walk based approaches include Expression Quantitative trait loci Electrical
Diagrams (eQED), a methodology developed in [50] and applied in [15] to identify path-
ways dysregulated in brain cancer. The methodology integrates both expression data and
SNP data with an experimentally veriﬁed network of biological interactions. The authors
ﬁrst identify a set of genes, which are diﬀerentially expressed in patients with the brain
cancer Glioblastoma multiforme compared to healthy controls, deﬁning this set of genes
as the phenotypic layer of the network. Genes identiﬁed by SNP assays as holding ge-
nomic aberrations driving this cancer phenotype are also identiﬁed and are referred to as
the causal layer of the network. The algorithm proceeds by utilising a random walk based
analogy between signal transfer through a biological network and the ﬂow of current in
an electrical circuit. Edges in the network are assigned a conductance, based upon the
expression correlation between the vertices they connect and the genes in the phenotypic
layer of the network. The methodology then proceeds to investigate signal transfer in the
network from the causal layer to the phenotypic layer by computing the currents along
edges and the voltages at vertices, which can be found from considerations of Ohm's and
Kirchoﬀ's Laws. This methodology was thus capable of tracing paths of dysregulated
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signalling which were driving the cancer phenotype and thus may represent relevant ther-
apeutic targets, however, the daunting size of the causal layer made prioritisation of these
pathways diﬃcult.
In addition to methodologies like NetWalk and eQED, which focus on the local level of
individual genes and pathways, network rewiring methodologies based on random walkers
have also beneﬁted from a more global, systems perspective. Methodologies of this ﬂavour
include the network entropy analysis introduced in [17] and explored in greater detail in
[23] to identify systems properties of biological signalling in cancer. This methodology
integrates gene expression data with an experimentally veriﬁed network of protein-protein
interactions by weighing each edge (i, j) in the network with the correlation in gene ex-
pression between the genes i and j, across samples corresponding to a given phenotype.
This edge weighting corresponds to a sparsiﬁed correlation matrix for each phenotype,
which is then row normalised to create a stochastic matrix for each phenotype (one for
healthy and one for cancerous tissue). This stochastic matrix: P = (pij)
V
ij=1 (where V is
the number of vertices in the network), describes the transition probabilities of a random
walker in the network. Rather than investigate the stationary distribution of this walker,
like NetWalk and NetRank, however, the next stage of this methodology considers the
rows of the stochastic matrix P . The ith row of P describes the probabilities that a
walker starting at vertex i will transition to a given neighbouring vertex in the network.
By considering the entropy of the ith row of P , given by
Si = − 1
log deg(i)
∑
k∈Ni
pik log pik,
one is able to determine the promiscuity of signalling from vertex i. If i has no preference
in which of its neighbours it will send the walker to, then Si will be 1, if i deterministically
sends the walker to a given vertex then Si will be zero.
This methodology was employed to compare metastatic and non-metastatic breast cancer
[17]. By integrating the two cancer phenotypes separately with a protein interaction net-
work and computing a vector of entropies for each, it was found that genes in metastatic
breast cancer have signiﬁcantly higher entropies than non-metastatic breast cancer. More-
over, by considering expression data from a large number of cancerous and healthy tissue
samples, it was demonstrated that the average entropy of genes in cancerous tissue was
higher than healthy tissue, implying that network entropy increases as cancer progresses
[23]. Intriguingly, the entropy of oncogenes was lower in cancerous tissue versus healthy
tissue and the reverse was true of tumour suppressors. This demonstrated that a rewiring
from a high entropy state to a lower state, is indicative of activation of a gene in a path-
way and revealed the power of the entropy based methodology in pinpointing critical
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coordinators of a phenotype.
The experimental demonstration that biological networks were rewiring thus led to the
birth of many new methodologies centred on comparing network structure and dynamics.
Many powerful diﬀerential network algorithms are based on random walks on weighted
networks, which represents a powerful framework for the integration of gene expression
data with interaction data for the inference of phenotype level diﬀerences. Methodologies
such as NetWalk and eQED provide a glimpse into diﬀerences between intracellular inter-
actions between phenotypes, but the general principles and dynamic nature of network
rewiring are still unclear. Network entropy, a measure of pathway promiscuity appears
to show a clear directed increased as healthy tissue became cancerous and subsequently
metastatic, indicating that disorder is a global property of protein interaction signalling
that dynamically increases in cancer. This result is important as it suggests that systems
properties may underlie network rewiring in pathology, permitting us to posit rules and
laws regarding signalling changes that may provide the basis of a strong mechanistic un-
derstanding of complex pathology.
1.1.4 Perspectives: Relevance for our research
Our work focuses on the development of network theoretic tools for the analysis of com-
plex disease with the ultimate goal being the identiﬁcation and validation of novel drug
targets.
It is clear that a critical ﬁrst consideration is the selection of the most suitable interac-
tion network. The work in this thesis will consider heterogeneous pathologies, described
by both time course and steady state gene expression data sets of varying sample size
and our aim is to develop methodologies which are relevant to all these scenarios. We
have seen, however, that the main classes of network inference algorithm are highly data
dependent and would likely provide very diﬀerent results on diﬀerent data sets. We thus
will opt to use manually curated, experimentally veriﬁed interaction networks. We will
use gene expression data to weigh our interactome and thus impose sample speciﬁcity.
In addition, we will use Gene Ontology (GO) annotations to delete spurious interactions
between proteins which are unlikely to co-localise, thus deleting false positives introduced
by Y2H protocols.
The next important consideration for the the development of network theoretic tools is
whether to consider single phenotype or diﬀerential networks. We have seen that both
approaches have proved informative but that the diﬀerential network approach is likely
to capture more biologically relevant information. Of such network rewiring approaches,
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it is clear that random walk theory and stochastic analysis are powerful tools for mod-
elling network traﬃc, with methodologies such as NetWalk and eQED elucidating novel
diﬀerential interactions between phenotypes.
It is evident that many methodologies are emerging in this ﬁeld, yet it is unclear which
are superior for given applications. It seems that a reason for this may be that most cur-
rent methodologies are based upon the identiﬁcation of local network alterations, which
are not scalable to a global property, e.g., visitation frequency of a vertex in a weighted
random walk [16]. To me this represents a problem; it is clear from experimental evidence
that network rewiring is a global phenomenon, with thousands of genes and interactions
modiﬁed by a single perturbation (e.g., administration of MMS to yeast [20]). More-
over, biological networks are highly sophisticated dynamical systems, which have evolved
to orchestrate tightly co-ordinated responses. It does not seem unlikely therefore, that
there may be global properties underlying network rewiring, i.e., only certain trajectories
in network rewiring state space may be admissible. Moreover, one may ﬁnd that global
properties of network rewiring provide an ordering for the evolution of network traﬃc and
topology during descent into pathology, the progression of a complex healthy biological
process (such as cell diﬀerentiation), or following multi-drug administration.
Were such global properties to be uncovered a natural next stage would be the devel-
opment of local analogues, to identify key features (e.g., genes or pathways), which are
driving the global shift. These may represent the most sensible targets for modifying a
biological network, as their modiﬁcation will have the greatest potential to aﬀect global
network rewiring.
We will thus focus on the development of random walk based network rewiring methodolo-
gies, which aim to characterise biologically relevant global properties of network rewiring
that are scalable to local properties, for the subsequent identiﬁcation of drug targets.
1.2 Mathematical approaches to understanding cell diﬀerentia-
tion
In the previous section we explored the realisation that global genetic interactions are
highly dynamic, shifting enigmatically as a cell responds to perturbation to maintain
homeostasis. This has raised the question: is there a regularity to this restructuring?
More speciﬁcally, are there certain important, natural dynamical biological process in
which network rewiring, as assessed by some global systems property, proceeds in a re-
producible and regular fashion? Were this the case, not only would the systems properties
of the biological process in question be elucidated, but one would have a metric of network
rewiring with a solid biological interpretation. Assessing such a global systems measure
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of network rewiring in pathological cells would provide a proxy for the progression of an
important biological process in the disease state, providing novel insights into what may
be driving the pathology. The choice of biological process to investigate in this case must
be made carefully to ensure the relevance to disease.
Arguably a suitable natural biological processes is cell diﬀerentiation. Representing the
concerted orchestration of the expression of a vast number of genes, cell diﬀerentiation
results in the temporally ordered convergence of form and function as a pluripotent cell
moulds its way towards a terminal cell fate. Such dynamic modiﬁcation suggests that this
process is an excellent candidate for the identiﬁcation of a systems property of network
rewiring. Moreover, cell diﬀerentiation is frequently altered in complex diseases, most no-
tably cancer [51] and developmental diseases such as FSHD [52], making it an informative
process to measure from the perspective of subsequent analysis of pathomechanims.
Following a stem cell on its journey through the mysterious landscape of diﬀerentiation,
and the precise measurement of cell potency, are problems that have plagued systems
biology for more than 50 years [53]. Over time, however, general principles of what char-
acterises a stem cell and how these alter over a diﬀerentiation trajectory have emerged.
In what follows we review the history of this ﬁeld. First we examine the experimental
approaches to understanding the molecular circuitry governing cell fate committal, before
exploring the more theoretical, systems approaches to assessing pluripotency, culminating
with the most recent statistical mechanical concepts of MacArthur and Lemischka [54].
We close as above with some perspectives of relevance to our research goals. Most notably
we express the notion that a network rewiring methodology may be developed on entropic
principles to assess the validity of the statistical mechanical approach to cell pluripotency.
This approach may form the basis of a methodology of the ﬂavour we outlined above,
namely one which aims at identifying global properties of network rewiring which may be
scaled to more local ones to identify driver features.
1.2.1 Experimental approaches to quantifying cell potency: some limitations
During development pluripotent stem cells are stimulated to undergo complex and tem-
porally ordered transcriptional programmes, resulting in unidirectional functional and
morphological changes and culminating in the generation of a plethora of diverse ter-
minally diﬀerentiated cells, each specialised for a given role within the organism. Un-
derstanding and control of this process is an exciting and active area of research, which
may prove critical to the understanding and treatment of developmental pathology with
disease modelling [55] and regenerative medicine [56]. Moreover, cell diﬀerentiation is
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altered and possibly reversed in cancer and elucidation of the principles governing the
directionality of the process may shed light on oncogenesis [57].
A critical question in stem cell biology, and one that has profound implications for the
clinical applications of the discipline is: How do we measure cell potency accurately
enough to track a cell through a diﬀerentiation programme?
A pluripotent stem cell is currently most rigorously deﬁned by its ability to form a ter-
atoma containing all three germ layers in immune-deﬁcient mice [58]. However, this
qualitative, binary deﬁnition does not provide us with a metric with which to track cell
potency. Without such a quantitative measure, the translation of stem cell medicine to
the clinic must overcome some daunting hurdles [59].
Stem cell therapies typically initially require the isolation and propagation of stem cells.
Following isolation, these cells may either be coerced to diﬀerentiate into a particular cell
lineage required for therapy, via the use of growth factors, before transplantation [60], or
simply introduced into the tissue to be repaired, where microenvironmental cues deter-
mine cell fate [61]. Pluripotent stem cells, such as embryonic stem (ES) cells, however,
in addition to having the ability to generate all three germ layers also have a high pro-
liferative capacity and are potentially tumorigenic [62]. We currently lack understanding
of how a stem cell may diﬀerentiate into a tumour, or be safely guided towards a given
tissue to be repaired. This represents a large barrier to the clinical applications of re-
generative medicine [51]. The construction of an intuitive measure which can reliably
distinguish pluripotent cells, cancerous tissue and healthy terminally diﬀerentiated cells
would thus represent a critical step towards the development of strategies for regenera-
tive medicine, which may avoid oncogenic complications. In addition, such a measure, if
based on theoretical principles, would provide a conceptual step in the understanding of
de-diﬀerentiation leading to oncogenesis, and would be able to empirically assess recent
hypotheses regarding cancer stem cells (CSCs) and tumour cell plasticity [63, 64].
Stem cell therapy has long been plagued by the issue of immune rejection of transplanted
ES cells. Whilst strategies to induce tolerance have been suggested [65], the most ex-
citing potential solution is the use of induced pluripotent stem cells (iPSCs) which were
ﬁrst generated by Takahashi and Yamanaka in 2006 [66]. The two authors demonstrated
that by the induction of just four factors, Oct3/4, Sox2, c-Myc, and Klf4, mouse ﬁbrob-
lasts could be converted into pluripotent cells capable of generating all three germ layers.
This study had great implications for the overcoming of immune rejection of transplanted
cells for regenerative medicine, as iPSCs can be derived from the skin cells of the patient
to be treated, and thus are a perfect genetic match. However, whilst certain studies
have demonstrated successful acceptance of transplanted iPSCs and derived cells in mice
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[67], this ﬁnding is not universal and controversies over immune rejection of these cells
is widespread [68]. Moreover, clear molecular diﬀerences between iPSCs and ES cells
have been documented, and functional diﬀerences regarding their in vitro diﬀerentiation
capacity currently limit clinical applications of iPSCs [69]. The molecular underpinnings
of these functional diﬀerences are poorly understood, however, and a true understanding
would require the ability to track cell potency as iPSCs and ES cells diﬀerentiate into
a speciﬁed lineage, for direct comparison. Despite these diﬃculties iPSCs have found a
powerful application in the modelling of complex diseases, providing a potentially limitless
source of (often diﬃcult to biopsy) cells for in vitro studies and the screening of thera-
peutics [55, 70, 71]. Such disease models often require the carefully guided diﬀerentiation
of pluripotent stem cells into the pathological tissue of interest, however, without a met-
ric for cell potency, deciding that a cell has reached a particular fate relies on qualitative
assessment of phenotype [55]. Such a subjective and non-quantitative measure for obtain-
ing disease model cells may result in large diﬀerences on the molecular level, between the
iPSC derived cell and the true cell. This has the potential to render conclusions derived
from pluripotent stem cell models inapplicable in a clinical setting, and emphasises the
need for a more quantitative measure of cell potency, derived from a global understanding
of the mechanisms of cell diﬀerentiation.
Constructing a quantitative deﬁnition of pluripotency which can follow a cell through any
lineage, however, appears to be a highly non-trivial pursuit. It was initially proposed that
stem cells expressed a unique set of molecular markers which would allow their robust iden-
tiﬁcation from committed cells. Consequentially, several microarray studies attempted to
extract a molecular signature of `stemness' [72, 73]. However, the signatures identiﬁed in
these early studies were refuted, and a reproducible microarray assessed gene expression
based classiﬁer for identifying pluripotent stem cells remained elusive [74, 75]. Genetic
studies proved more useful in the identiﬁcation of genes essential for the establishment
and maintenance of pluripotency, such as Oct4 and Nanog [76]; however the expression
of even these key genes appeared to be highly variable among pluripotent cell popula-
tions [54]. Functional studies were able to demonstrate the ability of certain pluripotency
factors to determine the early stages of diﬀerentiation, such as bimodality in Nanog ex-
pression dictating either the asymmetric or symmetric division of pluripotent cells [77].
In addition considerable eﬀorts have been made in identifying the regulatory networks es-
sential for the maintenance of pluripotency. These include the work of Wang et al. [78], in
which mass spectrometry was used to quantitatively asses the protein-protein interactions
with Nanog in ES cells to identify regulatory modules required for the maintenance of
pluripotency. In addition Muller et al. published two extensive microarray studies [59, 79]
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proﬁling gene expression in a considerable number of pluripotent and multipotent stem
cell lines. In their ﬁrst paper Muller and co-authors utilised graph theoretic techniques
to derive a putative network of interactions required for pluripotency, which they named
PluriNet [79]. In their second study the authors utilised a machine learning algorithm to
classify microarray samples as pluripotent or not [59]. Their resulting bioinformatic as-
say, dubbed PluriTest, was intended to be a quantitative, standardised alternative to the
teratoma assay and displayed a high sensitivity and speciﬁcity. However, beyond these
early stages of loss of pluripotency, commitment to diﬀerent cell lineages requires such
a highly diverse set of pathway activation and gene expression programmes, depending
on terminal fate, that consideration of the expression of speciﬁed gene sets is unlikely to
provide a measure of potency that is robust across all lineages. Rather, to derive such
a measure one must consider not which genes are expressed, but how the genes are ex-
pressed in concert; one must therefore consider the systems biology of cell diﬀerentiation.
1.2.2 Systems biology of cell diﬀerentiation
1.2.2.1 Waddington's Landscape The study of the systems biology of cell diﬀer-
entiation has a rich history, of the early approaches the most successful was doubtless
the epigenetic landscape concept introduced by C. H. Waddington [53] (Fig 1.3). Within
this framework, the cell is represented by a ball on a sloping landscape, pluripotent stem
cells occupy high positions, capable of rolling down branching paths to eventually rest
in one of multiple valleys, each representing a diﬀerentiated cell fate. The structure of
the landscape was postulated to be governed by interactions between genes and proteins,
though the precise relationship was not elaborated upon. However, by dictating a po-
tential gradient from stem cell to committed cell, and hills separating terminal valleys,
Waddington incorporated a low probability of de/trans-diﬀerentiation directly into his
model. However, the structure of the landscape did not disallow de/trans-diﬀerentiation,
it simply suggested that such phenomena would require large perturbations to overcome
the potential wells of committed cells. Indeed this concept was validated by the genera-
tion of iPSCs, in which the perturbation of the cell by the introduction of pluripotency
factors was suﬃcient to induce de-diﬀerentiation.
Though it was intended as a qualitative description, Waddington's landscape became
an intuitive framework for a more quantitative dynamical systems analysis of cell diﬀer-
entiation, where it was seen as the gene expression phase space [80]. Under a dynamical
systems model, interactions between genes can be represented as systems of diﬀerential
equations, the nullclines of which can be used to construct a phase space describing the
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Figure 1.3: Waddington's Landscape. (A) Waddington's original sketch of the diﬀer-
entiation landscape, stem cells occupy positions of high potential energy, and diﬀerentiate
by losing this potential. (B) A later sketch by Waddington hypothesises that the structure
of the landscape is underpinned by genetic interactions. Adapted from [53].
evolution of a gene expression trajectory emanating from any starting state [81]. The
valleys representing terminally diﬀerentiated cells ﬁnd a natural interpretation as attrac-
tors of the system, whilst meta-stable states, from which a trajectory may escape given
a suﬃcient perturbation and converge to a stable attractor, can be interpreted as stem
cell states [82]. This notion of high dimensional gene expression phase space attractors
representing committed cell fates, dubbed the attractor hypothesis, has been supported
by direct experimental evidence. Huang et al. [83] generated microarray time courses of
two independent stimulations of human HL60 promyelocytic progenitor cells diﬀerentiat-
ing into neutrophils. One time course represented diﬀerentiation stimulated by all-trans
retinoic acid (ATRA) and the other by dimethylsulphoxide (DMSO). Utilising principal
component analysis, the authors demonstrated that whilst the gene expression trajecto-
ries of the two stimulations initially diverged (representing diﬀerent perturbations from
the progenitor cell state) they subsequently converged to the same stable terminal state
rather than exploring the state space. This is the same behaviour as trajectories in a
dynamical system converging to an attractor in phase space. Whilst this result is con-
vincing, alternatives to the attractor hypothesis have been suggested, such as the work
of Mar and Quackenbush [84], which considered cell diﬀerentiation as a superposition of
transient and core processes. In addition, a new model has recently been proposed for cell
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fate committal in an attempt to adjust Waddington's theory to account for feasibility of
de/trans-diﬀerentiation now possible in vitro. Dubbed the epigenetic disc [85], this new
model discards the potential slope of Waddington in favour of ﬂat landscape, which may
be tilted by the introduction of various factors to induce trajectories from one cell fate
to another. In the context of this new model, the clinically important question of how to
measure cell potency, i.e., measuring the height in Waddington's landscape, is replaced
by measuring the gradient of the disc during transition between cell states.
1.2.2.2 Small regulatory networks and binary decisions Given the huge com-
plexity of genetic interactions, many dynamical systems studies aiming for high resolu-
tion of the molecular mechanisms of cell diﬀerentiation have focused on small regulatory
circuits. Of these perhaps the most well studied is a mutually repressive pair of auto-
activating transcription factors [86, 87]. This simple genetic circuit, common in the speci-
ﬁcation of cell fate, admits a dynamical systems model with a phase space which is highly
intuitive under the attractor hypothesis (Fig 1.4). The system has two stable attractors,
each corresponding to high expression of one transcription factor and no expression of the
other, in addition, there is a meta-stable state corresponding to the moderate expression
of both transcription factors. Clearly a small perturbation from the meta-stable state,
in which the quantity of one transcription factor is increased above the other, initiates a
convergent trajectory towards the attractor state in which only the perturbed factor is
present. Such a regulatory circuit provides an elegant means for binary decision making,
as a cell which over-expresses one factor commits to a given cell fate whilst over-expression
of the other factor initiates a diﬀerent, mutually exclusive cell fate. The most well stud-
ied example of this regulatory circuit in the determination of cell fate, is the case of
GATA1 and PU.1 in the speciﬁcation of erythroid and myelomonocytic lineages [88]. In
progenitor cells both GATA1 and PU.1 are expressed at low levels, however, following
introduction of a stimuli which perturbs the levels of these factors, the cell will either con-
verge to an erythroid state, in which GATA1 >> PU.1 or a myelomonocytic state where
PU.1 >> GATA1. This notion of expression reversal in dictating cell fate was explored in
greater detail in a recent study by Heinaniemi et al. [89], where the authors investigated
gene expression data from 166 cell types to identify gene pairs which displayed opposite
expression levels between lineages. This exploratory data analysis identiﬁed a number of
candidate circuits involved in the control of cell fate and pluripotency that exhibited a
similar structure to the classic GATA1 -PU.1 circuit.
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Figure 1.4: Small regulatory circuits for binary decisions. A pair of auto-activating
mutually repressive transcription factors such as GATA1 and PU.1 are shown, alongside
a phase space evaluated by Wang et al. [90]. We see that the circuit results in a meta-
stable state, which can be easily perturbed to one of two stable states corresponding to
high expression of only one of the transcription factors. This small circuit can thus be
used to make binary decisions. Adapted from [90].
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1.2.2.3 Stochasticity and cell fate It is well known that gene expression is an in-
herently noisy process [91], with the expression levels of genes and proteins subject to
high degrees of variability, in a manner which depends upon a number of factors, includ-
ing, crucially, the network architecture of genetic interactions, which can act to supress
or enhance stochastic ﬂuctuations [92, 93]. Given that cell diﬀerentiation can proceed
along independent lineages as the result of small perturbations in the levels of certain
transcription factors, it was suggested that stochasticity may play an important role in
the determination of cell fate [21, 94]. Indeed it has been proposed that noise is essential
in the selection of cell lineage [95], for example in Drosophila melanogaster where neural
precursors arise consequential of stochastic ﬂuctuations in protein levels in a homogeneous
population of cells [96]. Rather intriguingly, it has also been demonstrated that stem cells
display a considerable, dynamic variability in their expression levels. This variability has
been interpreted as noise driven single cell transitions between multiple meta-stable at-
tractor states corresponding to the same stem cell, but with diﬀerent biases for lineage
committal [97]. This variability of single stem cells, is counteracted by a robustness at the
population level for the proportions of cells assigned to each meta-stable sub-state, which
appears tightly regulated [21]. The ability of stem cells to exhibit such noisy dynamic
variability in their expression proﬁles, allows them to maintain the option of committing
to a multitude of cell fates. This is in stark contrast to committed cells which must main-
tain robust activation of many pathways to prevent de/trans-diﬀerentiation and ensure
functionality. Thus we have stumbled upon a hint as to a systems property underlying cell
potency which may be utilised to construct a global measure of diﬀerentiation potential:
gene expression in stem cells is highly variable and noisy and this variability decreases as
cells diﬀerentiate [58].
1.2.2.4 Quantifying randomness in stem cell gene expression Recently, several
attempts have been made to quantify the observation that stem cells exhibit a more vari-
able and dynamic expression proﬁle and construct a measure of pluripotency based upon
global analysis of stem cell and diﬀerentiating cell molecular proﬁles. To date, however,
these works have remained largely hypothesis driven and theoretical, with little attempt
to apply the measures to experimental data. These hypotheses include the dynamical
systems based approach of Furusawa and Kaneko [98], in which the authors postulated,
based on the observation of stem cell heterogeneity, that pluripotent stem cells would ex-
hibit a highly chaotic gene expression dynamic. This chaotic attractor of stem cells was
postulated to be meta-stable, with stochastic ﬂuctuations in gene expression permitting
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divergence to new attractor states representing more diﬀerentiated cells, which would be
less irregular, though still chaotic. This process was postulated to continue until a stable
attractor was eventually reached, representing the terminally diﬀerentiated cell. The au-
thors provided a proof of principle of their hypothesis via the use of genetic algorithms to
construct gene regulatory networks evolved under a ﬁtness function aimed to maximise
cell type heterogeneity (number of distinct terminal states to the expression dynamic).
These simulations demonstrated that the proposed sequence of chaotic attractors was the
most likely outcome of the genetic algorithm. While this result is not without interest, in
that it aims to quantify cell potency through the `chaocity' of expression dynamics, the
immediacy of application to measuring cell potency experimentally is not clear, though
an approach based on ﬂuorescence-activated cell sorting (FACS) was proposed.
A second hypothesis was suggested very recently by MacArthur and Lemischka [54] and
was based upon statistical mechanics, postulating the concept that entropic measures
may be suitable to quantify the uncertainty in gene expression in pluripotent stem cells.
The authors suggested that if one could construct a probability mass function, describing
gene expression in a given cell population, then one could measure pluripotency as the
entropy of this distribution. The logic behind this theory being that stem cells have highly
variable gene expression proﬁles and thus will display a more uniform probability distri-
bution of gene expression than committed cells. Whilst this theory is elegant and would
indeed provide a quantitative measure of cell potency, the authors deliberately avoid any
suggestion as to how to estimate the probability mass function essential for computation
of the entropy, making application elusive.
1.2.3 Perspectives: Relevance for our research
The aim of our research is to develop and apply network theoretic tools for the analysis of
complex diseases, with the objective of postulating and validating novel drug targets. In
the ﬁrst review in this section, on network biology, we identiﬁed a gap in the literature for
a methodology which utilises scalable global measures to characterise systems properties
of biological network rewiring and identify key drivers of these global alterations.
Developing such a methodology requires careful consideration. Primarily one needs a
hypothesis pertaining to a global systems property of network rewiring during an easily
measurable dynamical biological process. Moreover, this hypothesis needs to be express-
ible in mathematical terms, as a global network measure, which can be scaled to a local
measure. Given these criteria one must then use experimental data to test the validity
of the hypothesis. Only if the hypothesis is conﬁrmed can we proceed to develop our
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network rewiring methodology in a manner that is biologically realistic.
Given the pathologies we are investigating in this thesis (namely cancer and FSHD) dis-
play defects in cell diﬀerentiation, we believe this natural biological process to be highly
suitable, as a measurable phenomenon which may be quantiﬁed by a property of global
network rewiring. Recent ﬁndings in stem cell biology have led to the postulate that
gene expression uncertainty is high in stem cells and decreases throughout diﬀerentia-
tion. We have also seen that pluripotent cells have the possibility to activate of a large
number of pathways to commit to various lineages, whilst committed cells must maintain
ﬁxed activation of pathways speciﬁc to their fate (e.g., the GATA1 -PU.1 regulatory cir-
cuit in hematopoietic cells). These observations leads us to postulate that intra-cellular
networks are rewiring during diﬀerentiation from a highly promiscuous, non-preferential,
meta-stable state in stem cells to a more deterministic state in committed cells. The
promiscuity of network signalling can be measured by adapting the network entropy mea-
sure constructed in [17] and explored in the ﬁrst introductory section.
Thus in this section we have explored cell diﬀerentiation as a complex biological process
of great relevance to our complex diseases of interest. We have seen how pluripotency
may be considered as a state of highly disordered promiscuous signalling, and proposed
entropy as a measure which may associate with diﬀerentiation potential. Elegantly this
measure can be applied both globally and locally, precisely as required for a methodology
of the ﬂavour described in the ﬁrst introduction. We will thus explore in this thesis a
form of network entropy in the context of a measure of cell potency.
1.3 The pathophysiology of breast cancer
In this thesis we aim to investigate complex pathologies, in which cell diﬀerentiation and
development play a critical part. Of such pathologies, cancer is arguably the most well
know and exalts the most severe emotional response. Though we will touch on a range of
epithelial cancers, our main focus will be breast cancer. A complete introduction to all
tissue speciﬁc malignancies considered is thus beyond the scope of this work. Hence in
this introductory section we will focus solely on neoplasms of the breast, as a representa-
tive member of the class of oncogenic pathologies we will work on.
Breast cancer is a highly complex pathology, requiring the involvement of a diverse set on
intra and extracellular interactions, which conspire to drive the progression of neoplastic
malignancy. The condition is characterised by a considerable heterogeneity in clinical
presentation, morphology (as assessed by histology) and in molecular mechanisms, which
diﬀer vastly between patients. In addition to being a highly sophisticated condition, breast
cancer is also the most common cancer among women (30.7% of female cancer cases in
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the UK in 2011; ONS Cancer Registration Statistics [99]), and deaths from breast cancer
represent the second most common cause of death among women in the UK (15% of all
female deaths from cancer). These statistics highlight the importance of the development
of treatments and therapies for this highly complex condition.
A key aim of our thesis is the application of network theoretic tools to understand breast
cancer molecular mechanisms. To this end it is important to consider a number of factors.
A ﬁrst consideration is how the condition is diagnosed and the nature of the sample one
can obtain from patients for investigation. A second consideration is the sub-classiﬁcation
of the pathology into phenotypically distinct subtypes, and whether the understanding
of diﬀerences between subtypes can be improved by the application of network theoretic
tools. Given our interest in cell diﬀerentiation and our postulate that entropic measures
may prove powerful metrics of cell potency, we should also consider the notion of stemness
in malignancy, generating hypotheses around how an entropic measure of diﬀerentiation
potential may prove useful in understanding this concept.
In what follows, therefore, we review the pathobiology of human breast cancer, beginning
brieﬂy with diagnosis via imaging and histology, and moving on to subtype classiﬁcation,
initially by a handful of molecular markers and subsequently by genome wide expression
proﬁling. We then explore the cancer stem cell (CSC) hypothesis, noting potential ap-
plications of a cell diﬀerentiation based network rewiring approach. We close, as usual,
with some perspectives of the relevance of this review to the work pursued in our the-
sis. In particular we note how an entropic approach, explored at the end of the previous
introductory section on stem cell biology, may prove useful in the identiﬁcation of drug
targets for certain breast cancer phenotypes.
1.3.1 Breast cancer diagnosis: imaging to biopsy
In the data driven analysis of any pathology, it is important to ﬁrst consider where one's
data comes from. Typically, data is acquired following the completion of diagnostic testing
and the limitations and epidemiological non-uniformity of such testing may introduce bias
to one's sample. To this end we here consider breast cancer diagnosis via imaging. Many
countries run national breast cancer screening programmes for woman at increased risk
of developing the condition; one third of breast cancer patients are diagnosed following
such screens [100]. There has been much debate over the costs and beneﬁts of screening
programs. The major beneﬁt of screening is believed to be in the early detection of breast
cancer, which permits therapeutic intervention at a stage where the cancer is most treat-
able. Costs of screening are generally attributed to over-diagnosis, in which cancers are
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detected which would otherwise not be noticed during the lifetime of the patient, resulting
in unnecessary surgery as well as detrimental psychological eﬀects. A recent independent
study analysing the costs and beneﬁts of breast cancer screening in the UK, based upon
a meta-analysis of 11 randomised control trials following patients aged between 50 and
70 for at least 13 years, concluded that patients invited to undergo screening beneﬁted
from a 20% reduction in breast cancer mortality [101]. Though the authors of the study
commented that the assessment of over diagnosis was somewhat subjective, and that no
20 year follow up study into its adverse eﬀects existed, they concluded that the beneﬁts
of screening outweighed the costs.
It must be noted, however, that the beneﬁts of screening are highly age dependant. In-
deed the reduction in mortality rate due to screening among women aged 40-49 years
(15%) is nearly 5 times less than for women aged 60-69 years [102].
Mammography is considered the gold standard method for breast cancer screening and
diagnostic imaging, and employs low energy X-rays to image the breast for subsequent
determination of tumour masses [103]. Though this low dosage of radiation is unlikely to
be carcinogenic in post-menopausal women, it was demonstrated that in women younger
than 40 the beneﬁcial eﬀect of biennial mammography from early detection and treat-
ment of breast cancer, was oﬀset by the oncogenic eﬀect of exposure to radiation [104].
In addition to the increased risk from radiation exposure, conventional screen ﬁlm mam-
mography images are often diﬃcult to interpret and it is estimated that radiologists fail
to detect between 10% and 30% of tumours, with this error rate rising in dense breast
tissue [105], where the risk of developing malignancy is four to six times higher [106].
Despite these limitations, imaging is a critical part of the breast cancer treatment path-
way. Providing the essential initial insights required for preliminary diagnosis, as well as
a powerful guide for surgical intervention to remove tumour masses.
Once a tumour is diagnosed via imaging, it is biopsied to conﬁrm. This biopsy can be
investigated via a number of means, including histologically and molecularly, to provide
clinical information which can subtype the tumour and guide a suitable treatment course,
often beginning with surgical excision. We will, in this thesis, consider gene or protein
expression data from bulk tumours. The data we will consider typically corresponds to
the biopsy or surgery stage in progression. Whilst this is likely to provide a representative
subset of most patients, it must be made clear that the nature of image based diagnosis
will somewhat skew our sample. We will likely not detect dense breast tumours at as early
a stage as tumours that arise in less dense breast. Similarly, we will likely detect tumours
earlier in post-menopausal women, and women with certain genetic dispositions to breast
cancer who undergo regular mammography screening. Women who are not screened as
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regularly will likely present at a later stage. It is important to be aware of these biases
before considering the data.
1.3.2 Histology: subtyping on cellular composition
As mentioned, after detection by imaging of the breast, an abnormality is generally biop-
sied whereupon the tumour sample is examined and classiﬁed. This classiﬁcation allows
us to consider breast cancer as an array of pathologies, each with their own rates of pro-
gression and responses to therapy. Understanding this subtyping will allow us to tailor
our methodologies and investigations to these distinct sub-diseases.
The vast heterogeneity of breast cancer means that classiﬁcation is a complex procedure.
The ﬁrst stage is generally histological classiﬁcation, the consideration of tumour cell
morphology to divide tumours into distinct groups. Brieﬂy, biopsied tumours are sliced
in a cruciate manner, in the fresh state (not frozen) immediately after resection and ﬁxed
in 10% phosphate buﬀered formalin. Sections suﬃciently thin for the elucidation of nu-
clear detail (4-6µm) are then cut and stained with haematoxylin and eosin (H&E) and
analysed by microscopy [107].
The two most important histological classiﬁcations from a prognostic perspective are
histological grade and histological type [108]. Histological grade is a measure of cell
anaplasia (level of de-diﬀerentiation) and is assessed by the combined scoring of three
features: tubule formation, nuclear pleomorphism and mitotic counts [107]. Assessment
of these three features is generally performed via a slightly modiﬁed Nottingham grading
method [109]. Brieﬂy, nuclear pleomorphism is assessed on a scale from 1 to 3, with low
scoring samples displaying small, low variability sized nuclei, with inconspicuous or no
visible nucleoli; high scoring tumours in contrast have large variable sized nuclei, which
are often vesicular and irregularly shaped. Tubule formation is again scored from 1 to
3, with low scoring tumours having > 75% of the sample comprising tubular structures;
high scoring tumours are dominated by vacuolated cells and solid sheets of cells. Mitotic
counts are again scored from 1 to 3 with high scoring samples having a large number of
mitotic cells per sample area. These three scores are then combined to provide a grade
from 1 to 3 for each sample. It has been demonstrated that low grade tumours have a
signiﬁcantly more favourable outcome than high grade tumours and thus the assessment
of histological grade is an important stage in clinical diagnosis of breast cancer [107].
Histological type is a classiﬁcation of tumour samples based upon the similarity of tu-
mour cells to common diﬀerentiated cell types. All breast cancer tumours which arise
from the mammary epithelium are by deﬁnition, based on tissue of origin, adenocarci-
nomas [110]. Among observed neoplasms of the breast histologists have identiﬁed one
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common type and 17 special types [111], which are characterised by certain morphologies
and which comprise about 25% of all breast tumours [108]. The 75% of common breast
tumours are classiﬁed as invasive ductal carcinomas of no special type (IDC-NST) [108].
Given that their deﬁnition is simply that over 50% of their observed morphology is not
of a special type [108], IDC-NST tumours exhibit a great variability in their morphology,
displaying diversity in nuclear pleomorphy, cell dispersal and glandular formation [112].
Consequentially the World Health Organisation (WHO) sub-classiﬁed IDC-NST tumours
into 4 distinct subtypes based on observed features: pleomorphic carcniomas, carcino-
mas with osteoclast-like giant cells, carcinomas with choriocarcinomatous features and
carcinomas with melanotic features [111]. The proportions of the diﬀerent histological
subtypes found in a large breast cancer data sets are displayed in Fig 1.5A.
A tumour is said to be of pure special type if >90% of its morphology matches that of
the considered type, if the tumour is a 50-90% match, it is referred to as a mixed type.
Mixed types have been reported at a higher prevalence than pure special types (25.3%
vs. 18.3%) [113].
Of the special histological types of breast cancer the most common are invasive lobular
carcinomas which comprise 5-15% of all breast cancers [111]. Invasive lobular carcinomas
are characterised by their migration pattern as single cells or in single ﬁle lines, often
making diagnosis diﬃcult as they do not always present as a lump [108]. Morpholog-
ically the cells of invasive lobular carcinomas are generally regular, small, round and
with little cytoplasm [112]. Heterogeneity among invasive lobular carcinomas has led to
their sub-classiﬁcation into 4 distinct groups: classic, alveolar, solid and tubulolobular
[113]. Alveolar lobular carcinoma presents with small aggregates of 20 or more cells [112].
Solid lobular carcinomas invade the surrounding stroma in sheets rather than single ﬁle
lines [112], whilst tubulolobular carcinoma invades the stroma in cords which occasionally
form small tubules [112]. Lobular carcinomas as a global group have a similar progno-
sis to IDC-NST tumours, however tubulolobular carcinoma holds a survival advantage
over IDC-NST, whilst solid lobular carcinoma has the worst prognosis of the group [112].
Lobular tumours are also characterised by an increased tendency to metastasise to the
gastrointestinal tract and gynaecological organs [108] and are less responsive to adju-
vant chemotherapy than other breast cancer types [114]. It should be emphasised that
although it was initially hypothesised that ductal and lobular carcinomas derived from
ductal and lobular epithelium respectively, this hypothesis is poorly supported [112, 108].
Among the other special types, tubular and medullary tumours are the most common
[108]. Tubular tumours are characterised by presence of inﬁltrative tubules extending
into connective and adipose tissue and hold a survival advantage over IDC-NST [112].
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Medullary tumours are characterised by interconnecting sheets of pleomorphic cells, lym-
phocyte inﬁltration and sharp borders. Medullary tumours also convey a survival ad-
vantage over IDC-NST of matching grade (generally grade 3) [112]. It should be noted
that the fact that tumours of diﬀerent histological type but of the same histological grade
have diﬀerent prognoses testiﬁes to the orthogonality of prognostic implications for these
two classiﬁcations. The remaining special types are considerably rarer and thus less is
known concretely about associated survival, however as a group these rare special types
also display superior prognosis to IDC-NST [112].
Thus histological classiﬁcation has provided a tumour subtyping of prognostic relevance
which in some cases can predict the eﬃcacy of given treatments. These classiﬁcations
however, whilst useful in this sense, do not provide any information as to the reason why
certain tumours are more aggressive than others. Obtaining this information is key to the
development of therapies tailored to combat the most aggressive forms of breast cancer
and requires the consideration of molecular mechanisms.
1.3.3 Molecular subtyping: Hormone receptors and HER2
Whilst histological classiﬁcation is routine and provides essential prognostic information
about breast neoplasms it is performed by eye and hence is subjective. Moreover, it pro-
vides limited information as to molecular mechanisms underpinning the aggressive nature
of certain subtypes. An understanding of such mechanisms can inform the development
of targeted therapies. For our purposes, it is thus important to appraise the ﬁeld of
molecular subtyping of breast cancer.
Understanding possible molecular mechanisms of breast cancer has focused for many years
on hormone receptors (HRs), of which the most important appear to the oestrogen re-
ceptor (ER) and the progesterone receptor (PR). Elucidating the involvement of HRs in
breast cancer has been a long and diﬃcult process and one which has not yet approached
its conclusion. The ﬁrst indication of their involvement came from a paper published in
1869 by G.T. Beatson [115]. In this article Beatson explained his ovarian theory of breast
cancer which was based on observations of fat accumulation in the lactating breasts of
rabbits following oophorectomy. Beatson also reported a case in which surgical removal
of the ovarian tubes and ovaries coupled with thyroid tablets led to remission of breast
cancer in a case that was considered inoperable. This ﬁnding was the ﬁrst hint that
endocrine therapy may be a suitable course of action in the treatment of certain breast
cancers. However, it was clear that not all breast carcinomas responded well to such
therapy. It was not until the characterisation of the ER and the development of sensitive
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Figure 1.5: Breast cancer subtype proportions. Analysis of the METABRIC data
set of 1980 breast cancers shows the proportions of (A) histological subtypes, (B) HR and
HER2 expression and (C) molecular subtypes.
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assays to measure its concentration in tumours in the 1970s (most notably the dextran-
coated charcoal assay [116]) that a rational understanding of which patients to treat using
endocrine therapy was gained. The 1980s saw the development of monoclonal antibodies
for the ER, which permitted the assessment of ER status by immunological techniques
[117]. Reﬁnement of these protocols and antibodies led to immunohistochemical assays,
permitting the coupled assessment of ER status and cell morphology, which remains the
gold standard assessment today.
Approximately two thirds of all breast cancers are assessed as ER positive [118]. ER is
a member of the nuclear receptor family of ligand activated transcriptional modulators.
Upon activation of ER by the binding of oestrogens, the protein is translocated to the
nucleus where it is carefully directed by epigenetic mechanisms and cofactors to bind to
target gene promoters and regulate transcript expression [119, 120]. ER orchestrates the
expression of numerous genes involved in cell proliferation, angiogenesis, metastasis and
inhibition of apoptosis [103]. Consequentially, inhibition of ER activity via various means
has proved a successful endocrine therapy for many breast cancer patients. Among such
therapies the most well-known and successful is tamoxifen [121], which antagonises the
binding of oestrogens to ER and thus inhibit its activity. Aromatase inhibitors, which
block oestrogen synthesis have also proved successful [119]. These therapies are essential
to the treatment of breast cancer and it is estimated that approximately 400,000 women
are alive today as a direct consequence of tamoxifen therapy [122]. However, it should
be noted that the conventional 10 years of tamoxifen treatment is associated with an
increased risk of endometrial cancer and pulmonary embolism [118].
Despite these advances, one third of breast cancers are ER negative and thus show no
response to anti-oestrogen therapies. Moreover one third of ER positive cancers treated
with tamoxifen will relapse within 15 years [123], implying that such cancers have an
innate or acquired resistance to endocrine therapy. Consequently, further biomarkers and
sub-classiﬁcations were required to improve targeted breast cancer therapies.
Many biomarkers were subsequently proposed, among them the most informative for clin-
ical treatment were the PR and the HER2 membrane receptor.
PR, like ER is a nuclear receptor and is found in the majority of breast cancers [124]
but rarely seen outside of ER positive cases [103]. Progesterone (the PR agonist) is also
known as the pregnancy hormone due to its increased expression and critical role in preg-
nancy. Moreover, it was demonstrated that the risk of developing PR positive breast
cancer is substantially lower in individuals who have carried full-term pregnancies early
in life [124]. Much like with ER positive cancers, antagonists were developed for the PR
as a potential therapy for PR positive cancers. However, unlike tamoxifen these interven-
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tions resulted in severe side eﬀects, such as liver toxicity, and thus failed to succeed as
therapies [124]. The prognostic implications of PR expression are debated [103], however
it has been suggested that PR expression in ER positive breast cancer results in a better
prognosis and a stronger response to tamoxifen therapy [125, 126].
The HER2 membrane receptor is a member of the receptor tyrosine kinase family of epi-
dermal growth factor (EGF) receptors. These receptors initiate the activation of signalling
pathways that culminate in the up-regulation of gene sets involved in cell proliferation
and which are anti-apoptotic [127]. The HER2 gene was ﬁrst identiﬁed as an oncogene
through studies into chemically induced neuroblastoma in rat cell lines. It was demon-
strated that genomic DNA isolated from such cells could induce oncogenic transformation
when introduced into healthy mouse ﬁbroblasts, and that this isolated DNA encoded the
HER2 gene [128]. Support for the oncogenic nature of HER2 also came from studies into
tumour viruses, where it was discovered that the avian erythroblastosis virus encoded a
copy of a HER2 related gene, which it retro-transposed into host cells to induce oncoge-
nesis [110]. Subsequently it was found that many tumour-virus derived oncogenes were
present in increased copy numbers in certain non-viral cancers, and notably the HER2
amplicon was found ampliﬁed (almost exclusively [127]) in a subset of breast cancer sam-
ples [110]. It was then demonstrated that breast tumours displaying HER2 ampliﬁcation
were of signiﬁcantly worse prognosis than HER2 negative tumours, and that the absence
of this biomarker may in fact be more a powerful indicator of survival than HR status
[129]. The HER2 membrane receptor holds a constitutively active conformation, and
its abundance due to over expression in HER2 positive breast cancer is believed to lead
to oncogenic pathway over-activation through dimerization with other EGR membrane
receptors, most notably HER3 [130].
About half of HER2 positive tumours express either ER or PR, however, the levels of ex-
pression of the hormone receptors are considerably lower in HER2 positive breast cancer
than in HER2 negative, resulting in a decreased eﬃcacy of tamoxifen therapy in HER2
positive ER positive breast cancers [127]. Thus in addition to being more aggressive,
HER2 positive breast cancers are also resistant to anti-oestrogen therapy. Consequen-
tially new therapeutic strategies were required to tackle this breast cancer subtype.
Trastuzumab (also know as herceptin) is a monoclonal antibody directed against the ex-
tracellular domain of the HER2 membrane receptor and is currently used as an eﬀective
treatment for HER2 positive breast cancer [131]. Trastuzumab has also been reported
to potentiate the eﬀects of chemotherapy, making synergistic treatment a possible strong
option [127]. The precise mechanism by which Trastuzumab combats HER2 positive dis-
ease is not currently well understood, however it is believed that a number of modes of
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action may dominate, such as antibody induced cytotoxicity, cleavage of the extracellular
domain of HER2 and blocking of ligand independent receptor dimerization, among others
[130].
Despite the power of Trastuzumab in improving survival for women with HER2 positive
breast cancers, a subset of such women do appear resistant to the treatment [127, 101].
Many hypotheses have been put forward as to why resistance may arise and of these,
the possible compensatory signalling via EGFR in response to HER2 inhibition has war-
ranted further investigation [127]. Approximately 30% of HER2 positive breast cancers
are also EGFR positive, thus it seems plausible that inhibition of both HER2 and EGFR
may prove a more powerful therapy than HER2 inhibition alone. Consequentially, a
dual small molecule inhibitor lapatinib was developed to target both HER2 and EGFR
simultaneously [132]. Lapatinib is now FDA approved and has been shown to induce a
clinically relevant beneﬁt in patients who are resistant to Trastuzumab [130, 131].
Even with the advances in the treatment of HER2 positive and HR positive breast can-
cers, a signiﬁcant proportion of such cancers remain resistant to therapy. Moreover, there
remain between 10 and 20% of breast cancers which show no expression of ER, PR or
HER2 ; these tumours are referred to as triple negative breast cancers [133]. These triple
negative neoplasms have a very poor prognosis and due to the absence of key therapeutic
targets are diﬃcult to treat with eﬃcacy [134]. Consequentially, it is essential to probe
the molecular mechanisms of breast cancers in further detail, to attempt to elucidate
possible causes of treatment resistance in HR positive and HER2 positive breast cancers
and to identify novel biomarkers and therapeutic targets for the elusive triple negative
cancers. The proportions of the diﬀerent molecular markers found in a large breast cancer
data sets are displayed in Fig 1.5B.
1.3.4 Further molecular sub-typing: Genome-wide gene expression
The elucidation of the role of HRs and the HER2 membrane receptor in breast cancer
pathobiology led to great advancements in targeted therapies. However, many patients
develop resistance to such interventions and there is still a sizeable subset of individuals
for whom no targeted therapy exists. To address this issue many groups have employed
high-throughput expression proﬁling technologies to probe the molecular mechanisms of
breast cancer in more detail. Molecular proﬁling has been conventionally performed at the
transcript level by microarrays, though RNA-sequencing (RNA-seq) is increasingly being
used due to its larger dynamic range and the ability to investigate alternative splicing.
Brieﬂy, these assays ﬁrst require the isolation of RNA (often by spin column techniques
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[135]), from a given tumour sample. Following isolation the RNA is reverse transcribed
into cDNA. Subsequently the cDNA may be hybridised to a DNA microarray, a chip
containing DNA spots in which a large number of sequence speciﬁc, ﬂuorescence tagged
probes measurably alter their ﬂuorescence when bound to the isolated cDNA, allowing
one to quantify the amount of RNA in the sample. Alternatively one may perform RNA-
seq, in which the reverse transcribed cDNA is directly quantiﬁed by Next Generation
Sequencing techniques. Thus these assays give a snapshot of genome wide gene expres-
sion in the tumour sample.
By considering the expression of thousands of genes simultaneously, genome wide molec-
ular proﬁling has led to a more detailed sub-classiﬁcation of breast cancer than was ever
possible by the investigation of a small handful of biomarkers. Their use has provided
deeper insights into treatment resistance and diﬀerential survival prospects among pa-
tients. Moreover, such assays provide the means to investigate which genes drive the
worse prognosis subtypes, thus revealing novel targeted treatments .
The ﬁrst study investigating molecular proﬁling of breast cancer with the aim of identi-
fying prognostic subtypes was that of Perou et al. [136]. In this paper the authors used
microarray proﬁling of 36 IDC-NST and 2 lobular carcinomas to identify 4 molecularly
distinct subtypes: luminal, basal-like, HER2 positive and normal breast like. The authors
also suggested a set of 496 genes (involved in specifying endothelial cells, adipose tissue,
B and T lymphocytes and macrophages) which displayed intra-subtype homogeneity and
yet great variability between subtypes, as a robust classiﬁer of tumour samples into the
four groups.
Following this work a larger study was published, which revealed that the luminal breast
cancers could be further subdivided into luminal A and luminal B [137]. This discov-
ery pushed molecular subtyping of breast cancer into the limelight of clinical relevance,
as it was robustly demonstrated that luminal B breast cancers have signiﬁcantly worse
prognosis than luminal A. In addition to prognostic signiﬁcance, the subtyping of luminal
breast cancer also predicted patient response to treatment. Luminal breast cancers are
generally ER positive, and it was demonstrated that the worse prognosis of luminal B
breast cancer persisted following tamoxifen treatment, however, it was also found that
this subtype responded better to neoadjuvant chemotherapy than luminal A tumours,
greatly impacting the treatment of this breast cancer subtype [138]. The proportions of
these diﬀerent molecular subtypes found in a large breast cancer data sets are displayed
in Fig 1.5C.
Subsequently, from the consideration of the overlap between human breast carcinoma
gene expression and that of mouse models for the disease, the same group of researchers
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identiﬁed a sixth subtype, similar to basal breast cancer, which was named claudin low
[139] and which also had clinical and prognostic signiﬁcance. As it is of signiﬁcant rele-
vance to our work on understanding breast cancer at the molecular level, we now explain
the hallmarks of each of these subtypes in detail, examining molecular mechanisms and
diﬀerential responses to therapy.
1.3.4.1 Luminal A Luminal A is the most common subtype of breast cancer, com-
prising about 35-60% of all cases [138]. Histologically luminal A tumours are generally of
low grade, type wise they are reasonably diverse, comprising mostly IDC-NST but also
lobular, cribriform, mucinous and tubular carcinomas [118, 111]. This subtype is typi-
cally ER and PR positive and HER2 negative and is also characterised by the expression
of genes expressed in the luminal epithelium, as well as BCL2 and CK8/18 [138, 137].
Genetically these tumours show a high rate of PI3K mutation (49%) and a low rate of
TP53 mutation (12%) [103]. Luminal A tumours also have a low proliferation rate and
attempts have been made to characterise this subtype via low expression of the prolif-
eration protein KI67, however, this approach has revealed a great deal of inter-observer
variability [118].
Luminal A breast cancer has the most favourable prognosis of any breast cancer molecular
subtype, with a relapse rate of only 27.8% [138]. This subtype also exhibits a characteris-
tic pattern of metastasis, invading the bone more than any other tissue [138]. Treatment
generally involves tamoxifen or aromatase inhibitors (in post-menopausal women), and
patients are generally spared chemotherapy, due to the low risk of relapse observed with-
out such treatment [118, 138, 140]. In fact it has been demonstrated that luminal A
patients respond less well to chemotherapy than do other breast cancer subtypes [141].
An understanding of this poor response to chemotherapy in luminal A breast cancer has
been gained from the consideration of the mitogen activated protein kinase stress response
pathway. It was demonstrated that over expression of MKP-1, a suppressor of c-Jun N-
terminal kinase (JNK) signalling, led to chemoresistance in breast cancer cell lines [142].
Subsequently it was shown by next generation sequencing studies, that luminal A can-
cers have more frequent loss of function mutations in MAP3K1 or MAP2K4, which are
essential for JNK signalling [118].
1.3.4.2 Luminal B Luminal B breast cancers comprise between 10 and 25% of all
cases [103, 138]. Histologically this subtype is of high grade and of similar type to luminal
A. Expression-wise, like luminal A cancers, the luminal B subtype are ER positive, and
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express genes associated with the luminal epithelium, however, they tend to be PR neg-
ative and may be HER2 positive as well, they are also often positive for EGFR (making
them potentially susceptible to treatment with lapatinib) [103, 138]. Luminal B tumours
also have a high proliferation rate, and overexpress KI67 [138]. Genetically these tu-
mours often have mutations in PIK3CA (32%) and in TP53 (29%), in addition they also
frequently have MDM2 ampliﬁcation (22%) [103, 118]. MDM2 acts to repress TP53 and
thus its ampliﬁcation has similar eﬀects to TP53 loss of function mutation.
Luminal B breast cancer displays a far worse prognosis than luminal A, with a higher
probability of relapse and a shorter life expectancy following relapse (1.6 years) [138].
Like luminal A, luminal B tumours are most likely to metastasise to the bone (30%),
but they also show a tendency to metastasise to the liver (13.8%) [138]. These cancers
also often display resistance to anti-oestrogen therapies despite being ER positive [138]
and this resistance can be acquired during the course of treatment. Many strategies to
overcome this acquired resistance, such as staggering treatment and dosage and combin-
ing multiple forms of therapy have unfortunately proven unsuccessful [118]. Though, as
mentioned earlier, luminal B tumours show a better response to chemotherapy than the
resistant luminal A tumours (17% vs. 7%), this response is still lower than for other breast
cancer subtypes (such as HER2 positive) [138]. An understanding of the molecular mech-
anisms underlying treatment resistance in luminal B has been gained from considering
the molecular proﬁle of this subtype. It was demonstrated by next generation sequencing
that inactivation of TP53 by MDM2 ampliﬁcation in luminal B, may contribute to en-
docrine therapy resistance [143]. Thus inhibition of MDM2 may prove a powerful option
in inducing treatment sensitivity in these cancers [118]. The high rate of mutation in
PI3KCA has led to further postulation that luminal B tumours may beneﬁt from treat-
ment with inhibitors of the PI3K/AKT/mTOR pathway, and such therapy is currently
in clinical trials [103].
Lastly, it has been shown that in luminal breast cancers, following surgery, there still ex-
ists residual disease in the form of circulating tumour cells (CTCs) [118]. Interestingly, it
was demonstrated that the self-renewal of these CTCs is dependent on HER2 expression,
even in luminal tumours where HER2 is not ampliﬁed [144]. This suggests a role for
anti-HER2 therapy in preventing disease recurrence following local treatment of luminal
breast cancer.
1.3.4.3 HER2 positive HER2 positive breast cancers were discussed to some extent
earlier and comprise 12-20% of all breast cancers [138]. Though the majority of HER2
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positive tumours display HER2 ampliﬁcation and high HER2 expression, a signiﬁcant
proportion (30-40%) do not. These tumours are classiﬁed as HER2 positive due to the
expression of a similar gene expression proﬁle to that found in HER2 expressing cancers
[103, 130, 138]. This ﬁnding is intriguing as it suggests that the HER2 proﬁle may not
be solely driven by HER2 expression and may be induced by other means, having pro-
found implications for anti-HER2 therapy and resistance. Histologically HER2 positive
tumours are typically high grade [103]; they are also characterised by poor prognosis and
a high proliferative index, though they generally respond well to chemotherapy [103, 130].
HER2 breast cancers have been further sub-divided into three distinct subtypes, based
on gene expression, of which one is of signiﬁcantly worse prognosis to the others. This
poor prognosis subtype is typically ER negative but over-expresses steroid response genes
[145]. Though HER2 positive breast cancer generally responds to trastuzumab, resistant
cases exist, moreover, the drug itself is cardiotoxic and thus cannot be administered to
certain patients and requires careful cardiac monitoring [130].
Mechanisms of trastuzumab resistance have been investigated and include compensatory
activation of the pathways downstream of HER2 such as the PI3K/AKT pathway, either
by alternative membrane receptor signalling (e.g., EGFR) or by mutation of downstream
components [130]. Over 40% of HER2 positive breast cancers display such mutations
in TP53 or PIK3CA [103, 138]. Whilst lapatinib (a dual blocker of HER2 and EGFR
mentioned earlier) is able to improve survival in trastuzumab resistant cases where EGFR
signalling is involved, this drug is poor at treating cancers with PIK3CA mutations [130].
Rather intriguingly it was demonstrated that over-exposure to lapatinib may also lead to
treatment resistance by the upregulation of FOXO3, which in turn upregulates ER [146].
This ﬁnding has interesting implications, suggesting that we may supress treatment re-
sistance to lapatinib by combining it with anti-oestrogen therapies.
1.3.4.4 Basal-like Basal-like breast cancer comprises between 10 and 20% of all
breast cancer cases [103]. Though these cancers have recently been described via their
gene expression proﬁle, the term basal breast cancer has a long history, being originally
deﬁned by Moll et al. due to histological appearance and the expression of certain cytok-
eratins [147]. Though there is considerable overlap between basal and basal-like breast
cancer it is important to note that they are distinct classiﬁcations [148, 149].
Histologically, Basal-like tumours tend to be of high grade and often display lympho-
cytic inﬁltrates [149]. These cancers also have a higher tendency to be of metaplastic or
medullary histological type [149]. In fact, these breast cancers morphologically resemble
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human papilloma virus (HPV) related squamous cell carcinomas. This comparison led
to the identiﬁcation of RB under-expression and CDKN2A over-expression in basal-like
breast cancer, a combination which is associated with TP53 inactivation [150]. Basal-like
breast cancer is named after its tendency to express high molecular weight cytokeratins
CK5 and CK17, which are typically expressed in the basal myoepithelial cells of the
breast [138], though it has to be emphasised that this is not indicative of cell of origin
[148]. Basal-like breast cancers also typically express EGFR and genes involved in cell
proliferation. Genetically TP53 and BRCA1 mutations are also common in this breast
cancer subtype [149, 151].
The high rate of BRCA1 mutations leads to an inherited component to this breast cancer
subtype, making it common among African American and Ashkenazi Jewish women. In
such patients the cancer presents at a young age and typically at a larger size, with a
higher chance of lymph node involvement than other breast cancer subtypes [138, 152].
BRCA1 is a DNA repair enzyme and mutations in this gene result in a high degree of
genomic instability [149]. Moreover, it has been shown that BRCA1 down-regulation
can lead to ER silencing, hence the majority of BRCA1 mutated breast cancers are ER
negative and thus not treatable with endocrine therapy [153]. In fact, the majority of
basal-like cancers are triple negative and consequentially there are few targeted therapies
making prognosis very poor [134, 103].
Despite the aggressive nature of BRCA1 mutated, basal-like breast cancer, the knowledge
of the role of this gene has led to the development of novel therapies. The poor repair
ability of BRCA1 deﬁcient tumours has led to the use of platinum salts as DNA damage
inducing agents, these are cytotoxic to the tumour cells, which cannot tolerate the high
level of DNA damage [138]. Moreover, it is known that inhibition of PARP genes lead
to an increase in the number of single stranded DNA breaks, in the absence of BRCA1
this damage again induces cytotoxicity [154]. This synthetic lethality has led to the use
of PARP inhibitors as successful treatments for BRCA1 mutated breast cancer [153].
1.3.4.5 Claudin-low The claudin-low breast cancer subtype is the most recently
identiﬁed, hence not much is known about these tumours which comprise 12-14% of all
breast cancer cases [138]. Histologically, these cancers are typically high grade IDC-NST
cancers, although medullary and metaplastic features are signiﬁcantly more common than
other breast cancer subtypes [64]. Claudin-low breast cancers are characterised by a low
expression of tight junction and cell adhesion genes such as E-cadherin and claudin 3, 4
and 7. These tumours are also enriched for epithelial to mesenchymal transition (EMT)
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genes and immune system response [64].
Claudin-low breast cancers tend to be triple negative (about 80%) and express low levels
of proliferation genes [138]. Despite the low proliferation rate claudin-low tumours are of
very poor prognosis [64], this is potentially due to the high similarity between claudin-
low breast cancers and CSCs [155]. Indeed it was shown by comparison between the
expression proﬁles of mammary stem cells, luminal progenitors and mature luminal cells,
that the claudin-low subtype is the least diﬀerentiated of all breast cancer subtypes [64].
The possible tumour initiating capacity of claudin-low breast cancer could lead to resid-
ual disease following local and adjuvant therapy, re-establishing the tumour at a rapid
pace. Therapy for claudin-low breast cancer is currently limited to chemotherapy, though
enrichment of BRCA1 inactivation in this subtype may speak to the utility of PARP
inhibitors or platinum salts [156].
1.3.4.6 Deeper molecular subtyping Despite the careful characterisation of the
above described molecular subtypes, it has become recently apparent that even this level
of subdivision may be insuﬃcient. Criticism exists questioning the validity of these clas-
siﬁcations, notably from the histological subtype community, where the above described
subdivisions are considered only applicable to IDC-NST [108]. Moreover, a large study
by the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC)
proﬁled genomic aberrations (single nucleotide polymorphisms (SNPs) and copy number
variations (CNVs)) alongside microarray expression data, for 2000 breast cancer tumour
samples and concluded that there may in fact be 10 distinct molecular subtypes of breast
cancer [157].
1.3.4.7 Gene expression proﬁling for prognostic evaluation It is clear that
molecular subtyping of breast cancer based on gene expression has signiﬁcant prognostic
implications and important clinical relevance in the assignment of an optimal therapeutic
regime. Consequentially molecular proﬁling as a diagnostic tool has made its way into
the clinic. Two platforms for assessing gene expression from tumour biopsies to assign a
molecular subtype are currently in clinical trials: MammaPrint [158] (FDA approved and
mostly utilised in the USA) and OncotypeDX [159] (recently approved by NICE for use in
the UK). Both platforms assess the expression of a large number of genes to classify breast
cancers into prognostic subtypes and inform treatment. MammaPrint uses a microarray
platform to assess a 70 gene signature, mostly of genes involved in proliferation and has
proven a robust predictor of distant metastasis and overall survival [103]. OncotypeDX
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uses the more precise (but less large scale) quantitative reverse transcription polymerase
chain reaction (qPCR) assay to assess the expression of 21 genes (5 controls and 16
breast cancer associated, including ER, PR and HER2 ) to provide a similarly robust
classiﬁcation [103].
Though powerful, these gene expression based prognostic assays are limited, as they ignore
the important contribution of CSCs in prognostic evaluation.
1.3.5 Oncogenesis and cancer stem cells
We have seen above that breast cancer is highly heterogeneous, with various subtypes
characterised by molecular and histological presentation, giving rise to a great diversity in
prognosis and optimal treatment regime. Understanding the origins of this heterogeneity
requires consideration of how the tumour forms and develops and may provide insights
into the prognostic assessment of patients and the investigation of molecular mechanisms
for the proposition of targeted therapies.
1.3.5.1 Tumour origins It is typically accepted that a tumour derives from a single
cell of origin. This cell is believed to acquire a sequence of successive mutations, eventu-
ally culminating in transformation, and subsequently forms the tumour. Several cancers
are characterised by the history of this cell of origin and retain markers of its past life,
either in histological presentation or in gene expression. Due to the fact that the origin
cell must acquire numerous mutations, each in itself a rare event, it is unlikely (but not
impossible) for a cancer cell to arise in the number of divisions required for a diﬀerenti-
ated cell to stop dividing [160]. It is much more likely, therefore, that an oncogenic cell
arises in a cell type that undergoes many divisions during the life of the organism, making
the stem cell a strong candidate [161]. This theory has certainly proved valid for some
malignancies. One such example is teratocarcinomas, which often contain a large number
of highly diverse diﬀerentiated cell types and were shown to originate from germ line cells.
In addition certain leukaemias are capable of generating every cell in the hematopoietic
system, and were found to originate from hematopoietic stem cells [160].
The diversity and heterogeneity of breast cancer, in histological presentation, gene ex-
pression and in pathway mutation, is more in line with the haematological malignancies
than with other common epithelial cancers (such as colon and pancreatic cancers), hint-
ing at a more multipotent stem cell originator for breast tumours [162]. Consequentially,
considerable work has been done to identify possible cells of origin for breast cancers.
This search, though hampered by the fact that the diﬀerentiation hierarchy of human
breast tissue is poorly elucidated, has revealed certain new insights, such as the existence
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of a luminal progenitor cell which expresses the ER and may be a suitable cell of origin
for ER positive breast cancer [163].
Thus it is likely that healthy stem cells are the source of many malignancies, motivating
the work in this thesis on the application of network theoretic tools for measuring cell dif-
ferentiation potential to oncology. Once a cell of origin has formed, it must next develop
into a tumour, understanding of this process is critical to the development of therapies
aimed at reversing it.
1.3.5.2 Tumour development There are two key hypotheses regarding tumour de-
velopment: clonal evolution and the CSC hypothesis [63, 164] (Fig 1.6).
Clonal evolution is a model of cancer development in which tumour heterogeneity is
achieved through successive genetic mutation and microenvironmental stimuli. The tu-
morigenic potential of each cell is thus determined solely by environment and by whether
the given cell has acquired permissive mutations in proliferation genes [63]. In the treat-
ment of such cancers, the eradication of every cell must be the goal.
The CSC hypothesis postulates that tumours are organised hierarchically, with a small
subset of CSCs endowed with tumorigenic potential whilst the remaining tumour bulk
is non-tumorigenic, having diﬀerentiated from the CSCs [63]. Under this hypothesis, tu-
mour heterogeneity is a consequence of epigenetic rather than genetic diﬀerences among
cells [160]. As the cancer cells diﬀerentiate they are posited lose their tumorigenic poten-
tial, analogous to stem cells during healthy development. Consequentially, therapy under
the CSC hypothesis should focus on targeting the small population of CSCs capable of
reseeding the tumour rather than the tumour as a whole [165]. It is thus important to
consider the deﬁning features of CSCs. A CSC is typically characterised by three criteria:
the ability to form tumours in immunocompromised mice, the ability to self-renew and
therefore form tumours in secondary mice and the ability to diﬀerentiate into cells with
non-stem cell characteristics [166].
It is likely that both clonal evolution and CSCs play some role in tumour development
and establishing heterogeneity within the tumour, with clonal evolution possibly taking
place in the long living CSCs [164]. As explored in earlier sections of this introduction,
we wish to develop a network theoretic quantiﬁer of cell diﬀerentiation potential, which
can provide insights in a cancerous setting. It is clear that a signiﬁcant point of overlap
between the dynamics of healthy development and of oncogenesis lies in the CSC hypoth-
esis. We thus here examine the validity of this postulate in breast cancer in detail.
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Figure 1.6: The CSC hypothesis and clonal evolution. Under the CSC hypothesis,
a small CSC pool is capable of self renewal, tumour growth and diversity is driven by
the diﬀerentiation of the CSC pool into epigenetically distinct cell types, which cannot
self renew. In this model, intra-tumour heterogeneity is primarily epigeneitic. Under
the clonal evolution model, all tumour cells are capable of self renewal and intra-tumour
heterogeneity is driven by mutation. The two models can be combined by considering
clonal evolution occurring within the small CSC pool. Page 64
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1.3.5.3 Evidence for breast CSCs Recently, strong evidence has begun to emerge
that breast cancer may adhere to the CSC hypothesis [167]. It was demonstrated by
Al-Hajj et al. that a small population of breast tumour cells displaying high surface
expression of CD44 and low/no expression of CD24 (CD44+/CD24 -) were capable of
generating a tumour in immunocompromised mice. In contrast very large populations of
breast tumour cells not displaying these markers were incapable of reconstituting a tumour
[167]. Interestingly, no morphological phenotype was noted in the breast CSCs, implying
that the epigenetic modiﬁcations as the tumour diﬀerentiated are likely very subtle [164].
Elegantly the CSC population was found to be very rare in the tumour, indicative of a
true hierarchical organisation and not simply the loss of proliferation capacity by a small
subset of tumour cells via clonal evolution [164].
Breast CSCs were subsequently highly studied and found to display treatment resistance
to chemotherapy, hormone therapy and radiotherapy [155, 165, 166, 168]. This intriguing
discovery suggested the worrying concept that current treatments were focusing on the
wrong cells, attacking the well diﬀerentiated, non-tumorigenic tumour bulk and ignoring
the dangerous CSCs, which were capable of reseeding the tumour following treatment.
A push therefore began to understand the mechanisms of treatment resistance in breast
CSCs and many pathways are now being investigated [166]. Of these pathways, those
involved in EMT have shown promise in conveying the therapeutic resistance of CSCs.
For example, it was demonstrated that increased expression of certain EMT transcription
factors (e.g. Snail1 in breast cancer cells endowed resistance to various chemotherapeutics
[165].
Despite this evidence, there are still issues regarding the CSC hypothesis in breast cancer.
Notable concerns refer to the immunocompromised mouse assay utilised to demonstrate
the tumour initiating capacity of transplanted cells. The mouse generally used is the
NOD/SCID mouse [167], which as a result of being immunocompromised is unable to
provide the microenvironment of cytokines and immune cells conventionally utilised by a
growing tumour. Thus it is diﬃcult to infer whether the cells identiﬁed as non-tumorigenic
would truly be classed as such were a microenvironment present [164]. It should also be
noted that these mice while lacking T cells and B cells do retain natural killer cells, which
can reject transplanted human cells and thus under-estimate the proportion of CSCs [169].
Thus more rigorous assays are required to identify whether the tumorigenic population
identiﬁed is indeed a minority of the tumour, indicative of hierarchical organisation. In
addition, given the diversity of breast cancer it is reasonable to ask: do CSCs in all
breast cancer subtypes have the same CD44+/CD24 - signature? Several studies have
suggested that this is likely the case for basal breast cancer and possibly HER2 positive
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breast cancer, but is unlikely for ER positive breast cancer [170]. This could be due to
diﬀerent cells of origin for these distinct breast cancer subtypes and raises the need for
less biomarker speciﬁc, more general systems level markers of CSCs. A more conceptual
concern is the recent notion of cancer cell plasticity [63], in which non-CSCs can switch
to become CSCs under certain conditions. Evidence for such transitions in breast cancer
have been found, and it was recently demonstrated that the chromatin state of the ZEB1
promoter can control this plasticity [171]. Cancer cell plasticity undermines the treatment
strategy of the CSC hypothesis, i.e., targeting the small number of tumorigenic cells to
eliminate the tumour. If it is possible for a non-CSC to become a CSC, then all of the
tumour must be considered tumorigenic, unless the mechanism underlying plasticity can
be understood and targeted [63].
Thus it is clear that healthy development, via stem cells, likely plays an important role
in the birth and growth of a tumour. It is thus logical that a network theoretic tool
developed to understand cell diﬀerentiation will also generate important insights into the
molecular mechanisms of oncogensis.
1.3.6 Perspectives: Relevance for our research
The aim of our work in reference to breast cancer is to develop and apply methodologies
which might postulate novel therapeutics. In this review we have examined the highly
heterogeneous nature of breast cancer pathology and how optimal treatment strategy
is critically dependent upon tumour subtype. Consequentially the application of any
methodology aimed at elucidating useful therapeutics must consider these highly diverse
subtypes separately.
We saw in the ﬁrst review on network methodologies, how network theory has been applied
to cancer, revealing the importance of hub gene mutations in initiating transformation
and revealing pathway dysregulation. However, we also saw that very few methodologies
focus on understanding general principles surrounding the network rewiring in cancer
progression.
We believe that cell diﬀerentiation is a very important process in cancer, which may be
amenable to investigation via network theoretic tools. In the penultimate section of this
review we explored the CSC hypothesis of tumour organisation and discussed the evidence
for its validity in breast cancer. We saw how breast CSCs are resistant to conventional
therapeutics, and thus appear important candidates for investigation by methodologies
aimed at identifying new therapies. We also explored the emerging concept of cancer
cell plasticity and saw that it is possible for certain epigenetic modiﬁcations to convert
non-tumorigenic cells to CSCs.
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It seems likely that as in normal development, the diﬀerentiation of CSCs into non-
tumorigenic cells and indeed the reversion of this process by plasticity, involves some
global coordinated biological network rewiring. Characterisation of this rewiring may be
achieved by the consideration of cell potency in healthy development. As we explored in
the second introductory section on the mathematics of stem cell biology, network entropy
may prove a powerful tool in the quantiﬁcation of cell potency and the development of
measures to compute drivers of cell diﬀerentiation. If tumour development indeed rep-
resents a caricature of healthy development, one would expect network entropy to prove
similarly powerful in discriminating the critical drivers of CSC diﬀerentiation and cancer
cell plasticity. These drivers could represent important drug targets, capable of prevent-
ing tumours replenishing their stem cell pool by plasticity and simultaneously blocking
tumour diﬀerentiation. Moreover network entropy may provide an unbiased classiﬁer for
CSCs, not reliant on the expression of certain markers selected on an ad hoc basis.
In addition to approaches centred around the CSC hypothesis, the analysis of tumour
cell potency may prove informative in understanding pathway activation diﬀerences and
treatment responses between the various phenotypes of breast cancer. Breast carcinomas
display a wide diversity in their level of diﬀerentiation. Currently this level is assessed
by histological grade as discussed above which is a strong prognostic indicator. This
qualitative scoring based on a number of morphological features, however, is both labo-
rious to measure and sheds no light on the molecular mechanisms driving the associated
disease severity. If entropic measures are capable of accurately recapitulating tumour
grade, however, they provide an unbiased assessment of tumour diﬀerentiation and have
the potential to identify molecular drivers of tumour stemness, permitting one to posit
therapeutics for arresting tumour development. Consequentially, we will focus on the
application of entropy based network rewiring methodologies to human breast cancer and
related malignancies.
1.4 The pathophysiology of FSHD
In this thesis we aim to utilise network theoretic tools to investigate the pathomechanisms
of complex disorders involving diﬀerentiation. In the previous introductory subsection we
considered human breast cancer, a malicious caricature of healthy development, in which
the power of cellular diﬀerentiation is usurped and utilised to the detriment of the or-
ganism. The task of the cancer investigator is to ﬁnd therapies which can inhibit the
development of pathological tissue. On the other side of the pathology coin are disorders
in which healthy diﬀerentiation is impaired, and the role of the investigator is to ﬁnd ther-
apies to restore the normal development of healthy tissue. Of such disorders, arguably
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the most well known are the muscular dystrophies.
The muscular dystrophies are group of inherited myopathies, which show considerable
heterogeneity in clinical presentation [172]. Though diﬀerent muscular dystrophies aﬀect
distinct muscle groups, with varying severity, all are characterised by a progressive skele-
tal muscle atrophy, resulting in a state of continual skeletal muscle breakdown. Skeletal
muscle comprises of many bundles of multi-nucleated myoﬁbres, which are heterogeneous
in type, permitting a wide array of movements [173]. Myoﬁbres contain sarcomeres which
are the functional units of skeletal muscle, comprising of two classes of myoﬁbrillar pro-
teins: myosins and actins. The interactions between actins and myosins provide the force
required for muscle contraction. Each individual myoﬁbre is contained within a thin layer
of connective tissue, referred to as the endomysium, whilst myoﬁbre bundles (fascicles)
are bound within another connective tissue layer, the perimysium. An entire skeletal
muscle in bound by a ﬁnal layer of connective tissue the epimysium, which maintains the
shape of the muscle. These connective tissue layers fuse at the muscle terminus, forming
tendons which typically anchor the muscle to bone (Fig 1.7).
The state of continual skeletal muscle breakdown in muscular dystrophy demands con-
stant repair of myoﬁbers by diﬀerentiation, a process known as myogenesis. The main
skeletal muscle stem cell is the muscle satellite cell, which occupies a niche beneath the
basal lamina [174] (Fig 1.7). Quiescent muscle satellite cells express the transcription
factor PAX7, however, upon activation by muscle damage, the cells migrate from the
basal lamina and undergo asymmetric division, with a proportion of cells expressing the
basic helix loop helix, myogenic regulatory factor MYOD. The cells expressing MYOD
(known as myoblasts) proliferate and lose PAX7 expression, eventually expressing a later
myogenic regulatory factor Myogenin, which terminates myoblast proliferation and initi-
ates alignment and fusion into multi-nucleated myoﬁbres, which express myosins, such as
myosin heavy chain (MyHC ). In certain muscular dystropies, continual damage is thought
to put strain on the satellite cell pool, whilst in others the entire process of myogenesis
is believed to be disrupted. It is to a prominent member of the latter class which we now
turn.
Facioscapulohumeral muscular dystrophy (FSHD) is the third most common muscular
dystrophy with an incidence of around 1/20000 [175], however, the relative longevity of
patients ensures that this condition is in fact the most prevalent form of muscular dys-
trophy, with a prevalence of 4-12/100000 [176]. Despite such prevalence no treatment
currently exists for this complex and multifaceted disorder, (though several have been
suggested [177, 178, 179, 180, 181]). One of the current greatest barriers to the discovery
of a viable treatment is the elucidation of the enigmatic genotype to phenotype link.
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Figure 1.7: The structure of skeletal muscle. Figure adapted from [174].
FSHD is an autosomal dominant inheritable disorder typically diagnosed by the second
decade of life. The condition is progressive and approximately 20% of patients eventually
require the use of a wheelchair [182]. The condition manifests most notably via an asym-
metric, highly tissue speciﬁc skeletal muscle atrophy, initially eﬀecting the facial muscles,
then extending to the limb girdle and upper arm muscles [183] with occasional lower limb
involvement [184]. However, FSHD is also associated with a number of extra-muscular
features, pointing to a more global dysregulation of signalling pathways in the pathology.
The best documented of these unusual features are a retinal vasculopathy very similar in
presentation to Coat's disease [185, 186, 187], and a high frequency, sensorineural hear-
ing loss, believed to be cochlear [188, 189, 190], both of which have been associated with
early onset or severe FSHD. Perhaps less well studied are subclinical cardiac arrhythmias,
which have also been found to associated with the pathology [191]. It was noted that
any unifying hypothesis of FSHD pathomechanisms must explain both the characteristic
muscle wastage and these less common symptoms, and must therefore consider a systems
perspective [186]. It is clear, therefore that FSHD is a prime candidate pathology for the
application of network theoretic tools.
In understanding a complex developmental pathology, it is critical to ﬁrst consider the
clinical presentation in detail. This phenotypic manifestation may provide critical clues to
pathway dysregulation. Further, when considering the molecular mechanisms of an inher-
itable condition, insights from genetics often prove invaluable. In what follows, therefore,
we ﬁrst explore the history of FSHD research, from its clinical presentation, through to
the identiﬁcation of its genetic basis. Subsequently we explore the primary candidate
FSHD gene DUX4, elucidated from the genetic basis of FSHD, and examine endeavours
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to understand how very low expression of this gene may cause the pathology. We then
examine the results of a more general probing of FSHD molecular mechanisms via muscle
biopsy genome wide gene expression. We close as usual with perspectives relating the
ﬁndings of this literature review to the work undertaken in this thesis. In particular we
note that network based approaches have been distinctly absent in FSHD research and
we argue that they are essential to unravelling the molecular mechanisms of this highly
systemic and heterogeneous pathology. Moreover, we note that an entropic approach may
determine the impact of DUX4 expression on muscle diﬀerentiation dynamics.
1.4.1 History of clinical presentation and heredity
Early understanding of muscle disease was hampered by the belief up until the mid 1800s
that the basis of all pathological muscle wastage was neurological. Thus, as a myopathy,
with no aﬀectation of the spinal muscles, nor signs of myelopathy in biopsied samples,
FSHD was not identiﬁed until the latter half of the 19th century. The ﬁrst clinical report
of a patient with FSHD is believed to be due to Cruveilheirs in 1848 and describes an
18 year old male, who died of smallpox, and presented with severe weakening of the fa-
cioscapulohumeral regions, with no spinal involvement [184]. Though this report is likely
the ﬁrst description of the pathology, it received little attention at the time of publication
and it was not until 36 years later in 1884 that Landouzy and Dejerine, published the
ﬁrst complete description of FSHD in a single family [192]. Landouzy-Dejerine disease,
as FSHD was initially known, was described in the original family as a myopathy without
nervous system involvement that began in the face and extended over life to the upper
limbs. Over time more detailed descriptions of patients arose and a more robust picture
of clinical pathology was gained. Facial weakness was generally observed earliest, with a
notable weakening in the orbicularis oris and orbicularis oculi manifesting in an inability
to fully close the eyes, and a weakness in the muscles around the mouth often resulting in
the inability to whistle [184]. Subsequent upper limb involvement derives from aﬀectation
of the latissimus dorsi, serratus anterior, pectoralis, subscapularis, rhomboids and latterly
the trapezius [184, 193]. Lower limb involvement typically presents as foot drop and in-
volvement of the pelvic girdle muscles [184], the rare and heterogeneous involvement of
the lower limbs led some physicians to suggest a separate classiﬁcation from FSHD [194].
It should be emphasised that all muscle atrophy in FSHD often presents asymmetrically,
without a consensus severity bias for left or right [184] (Fig 1.8).
In addition to muscle involvement, it has been demonstrated that FSHD is signiﬁcantly
associated with an exudative retinal vasculopathy similar in presentation to both Coat's
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Figure 1.8: FSHD aﬀected muscle groups. This ﬁgure was produced by Francoise
Helmbacher and was adapted with kind permission.
disease and Norrie Disease [185, 186, 187, 195, 196]. Coat's disease only eﬀects males and
typically presents unilaterally as a retinal telangiectasia consequential of a breakdown
of the endothelial cell wall of blood vessels in the retina, though asymmetric cases have
been reported [197]. It is progressive and can lead to blindness through retinal detach-
ment [186]. Norrie Disease is similarly X linked and presents as a failure of vascularisation
of the retinal periphery, alongside telangiectatic blood vessels and again can lead to blind-
ness via retinal detachment [186]. Interestingly, Norrie disease is also associated with an
asymmetric, high frequency, sensorineural hearing loss, believed to be cochlear on the
basis of mouse models [198]. Whilst about half of FSHD patients display some sort of
retinal vasculature abnormality as detected by ﬂorescence angiography [196], these tend
to be subclinical in the vast majority of patients. Indeed, a recent meta-analysis of Coat's
disease in FSHD demonstrated that it was a rare symptom associated with severe pre-
sentations of FSHD [196]. Moreover, in 70 reported cases of Coat's Disease in FSHD,
only a single patient reported visual loss [196]. In addition, retinal symptoms in FSHD
can be bilateral and equally eﬀect women and men, suggesting a deviation from Coat's
disease and Norrie Disease [199]. Thus whilst some similarities exist between the clinical
presentation of FSHD and these retinal conditions, suggesting an overlap in their molec-
ular mechanisms, their presentation is clearly less severe in FSHD.
Sensorineural hearing loss is also associated with severe cases of FSHD which present
early in childhood [189], however, there is controversial literature on the association with
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typical onset FSHD [188, 190]. When observed, hearing loss tends to be bilateral and
progressive, in a manner similar to noise induced hearing loss, though asymmetric pre-
sentations have been documented [196]. As in Norrie disease, hearing loss in FSHD is
believed to be cochlear [186].
There have also been reports of cardiac abnormalities in FSHD, including presentations
of hypertrophic cardiomyopathy [200]. The only signiﬁcant cardiac defect associated with
FSHD, however, appears to be an arrhythmic alteration [191]. This alteration is often
reported as subclinical, though it has been suggested to be progressive with FSHD in a
manner that may increase the risk of a cardiac event [201, 202].
In addition to a report of clinical presentation, Landouzy and Dejerine, the authors of
the initial study on FSHD, also noted that the condition appeared to show an autosomal
dominant inheritance pattern in their family of study. This observation was subsequently
conﬁrmed in 1950 in a study of 4 families exhibiting 18 cases of FSHD [193], and again
in 1982 by a study of a further 19 families by Padberg [183], in which it was concluded
that a recessive pattern of inheritance was of negligible likelihood.
The next challenge of FSHD research became the hunt for the susceptibility locus, how-
ever, this was not as straightforward as expected. Initial studies by Padburg on 120
individuals from 10 families using early genetic linkage techniques failed to identify any
signiﬁcant loci. Following the development of markers for microsatellite regions is was
eventually demonstrated that FSHD was signiﬁcantly associated with a locus at 4q35 a
sub-telomeric region of chromosome 4q [203]. It was subsequently demonstrated in 1993
that FSHD was associated with a contraction of a macrosatellite repeat sequence termed
D4Z4 at the 4q35 locus [204]. Between 1 and 10 D4Z4 repeats were required to convey
susceptibility to FSHD, with healthy individuals having up to 100. Interestingly, although
repeat length was negatively correlated with disease severity [205], at least one repeat ap-
peared essential for FSHD, with complete loss of the D4Z4 region not associated with
the pathology [206]. Critically, it was also shown that each D4Z4 repeat encoded two
homeoboxes, which displayed the same sequence in pathological and control individuals
and early studies were unable to report any expression of the region in either healthy or
FSHD samples [204]. The fact that FSHD was a disease of copy number variation rather
than a mutation in a functional gene represented a great barrier to the understanding of
the pathomechanisms of the pathology. The D4Z4 region was considered junk DNA with
no role in healthy function, thus contractions in this region could not be eﬀecting normal
development in a trivial manner. Moreover, there was a small subset of FSHD patients
(about 5%), who presented with the clinical phenotype but without D4Z4 contraction,
indicating multiple mechanisms of pathogenesis [207]; this subgroup is generally referred
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Figure 1.9: The Genetics of FSHD. FSHD arises via hypomethylation of the D4Z4
region on chromosome 4q35, given a permissive haplotype (4A161PAS) encoding a
polyadenylation signal. Hypomethylation can occur either via truncation of the D4Z4
region (FSHD1), or via other mechanisms, such as mutation in SCHMD1 (FSHD2).
to as FSHD2 (OMIM158901), with the D4Z4 contraction associated group referred to
as FSHD1 (OMIM158900). FSHD2 was associated with hypomethylation of the D4Z4
region implying that mis-regulation of this region may be the basis of the clinical presen-
tation of FSHD [208, 209, 210] (Fig 1.9). However, as we will see, it was many years until
suﬃciently large FSHD2 patient cohorts permitted the identiﬁcation of the genetic basis
of this rare subtype. The complex genetic nature of FSHD represented an ominous stum-
bling block to the identiﬁcation of candidate genes to target to mitigate the pathology.
Page 73
Network Theoretic Tools in the Analysis of Complex Diseases C. R. S. Banerji
1.4.2 The identiﬁcation of FSHD candidate genes and the rise of DUX4
For many years it was believed that the D4Z4 repeat region was non-coding and the
general hypothesis of FSHD1 pathogenesis was that D4Z4 truncation conveyed pathology
through a chromatin destabilisation, leading to the aberrant expression of chromosome
4q35 neighbouring genes, such as FSHD region gene 1 (FRG1 ) [211, 212]. Investigations
along these lines were initially promising, and it was shown that mice over expressing
FRG1 displayed a muscle phenotype [211]. Expression results were not always consistent
with this hypothesis of D4Z4 regional dysregulation, however, and it was called into doubt
strongly in an early microarray study [213]. It was discovered in 1999 that each 3.3kb
D4Z4 repeat encoded a copy of a novel transcription factor, double homeobox 4 (DUX4 )
[214]. Structurally DUX4 's N-terminus contains two homeodomains with high similarity
to the homeodomains of the transcription factors PAX7 and PAX3, (important in muscle
satellite cell speciﬁcation), and the C-terminus is an activator of transcription [175, 215].
DUX4 admits two stable (polyadenylated) splice variants, a full length transcript, DUX4,
a shorter transcript, limited only to the homeodomains, DUX4s, in addition, there exists
a homologous sequence mapping 42kb centromeric of the D4Z4 repeats termed DUX4c.
Only the full length transcript is diﬀerentially expressed in FSHD, with the other two
variants expressed in both FSHD and control samples [216]. Interestingly DUX4c ap-
pears to be induced speciﬁcally during FSHD myogenesis, moreover it has been shown
to regulate myogenic factors, suggesting a role in pathology [217, 218]. Phylogenetic
studies revealed that DUX4 was evolutionary conserved in primates [219] and a mouse
homologue, mDUX, has recently been shown to induce a myopathic phenotype when over
expressed in mice [220]. However, the 4q35 D4Z4 region is primate speciﬁc and there
exists no syntenic region in the mouse [221].
These ﬁndings initiated a new hypothesis of aberrant expression of DUX4 leading to
broad transcriptional dysregulation culminating in the FSHD phenotype. Subsequent
studies investigated targets of DUX4 and it was demonstrated that pituitary homeobox
1, (PITX1 ) was a direct target [222]. It was later revealed that PITX1 causes skeletal
muscle dystrophy in mice when over-expressed [222, 223]. Issues with the DUX4 hy-
pothesis of FSHD1 pathogenesis also arose from the fact that DUX4 expression was not
observed consistently in FSHD1 myoblasts. It was not until 2010 that it was demonstrated
by the use of qPCR, with high quantities of cDNA template, that DUX4 was expressed in
FSHD1 myoblasts (albeit in very small quantities), though not in healthy controls [224].
It was also revealed that DUX4 expression required a permissive haplotype (4A161PAS),
which was demonstrated to present in both FSHD1 and FSHD2 patients. The haplotype
consists of a polyadenylation signal adjacent and distal to the subtelomeric D4Z4 repeat
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region [224]. This chromosomal background is essential to ensure the stability of DUX4
mRNA transcripts expressed from the most distal D4Z4 unit, a ﬁnding that provided
strong evidence for DUX4 as an FSHD1 candidate gene.
Given the potentially important role of DUX4 in FSHD1, much work was subsequently
undertaken to identify the genetics of FSHD2 with the hope of reconciling this condi-
tion with FSHD1 via the DUX4 hypothesis. It was recently demonstrated that FSHD2
was signiﬁcantly associated with a mutation in SMCHD1 a putative epigenetic modiﬁer,
which was shown to induce D4Z4 contraction independent DUX4 expression [225]. This
ﬁnding provided strong evidence for the involvement of DUX4 in both FSHD subtypes,
reconciling the similar clinical phenotypes with disparate genetics.
Many studies began to investigate the mechanisms by which DUX4 may induce FSHD,
generally by cell culture experiments, documenting the DUX4 over-expression phenotype.
These revealed that DUX4 was highly toxic in murine myoblasts, and that this toxicity
was p53 dependant [181]. Oxidative stress sensitivity was also shown to be induced by
DUX4 by the generation of a doxycycline inducible DUX4 expressing C2C12 myoblast
cell line [175]. This study further demonstrated that DUX4 expression caused oxidative
stress sensitivity (at least in part) by repression of the glutathione redox pathway. DUX4
expression also induced a myogenesis defect and this was shown to be related to the over
expression of MyoD [175]. Moreover, DUX4 expression in ES cells was found to push
cells down the neuronal lineage [226].
Whilst encouraging a complication to the understanding of FSHD pathogenesis through
the study of DUX4 centres around the fact that the gene is only expressed at very low
levels in FSHD muscle [227]. Moreover, it was demonstrated that this low abundance is
attributable to high expression of DUX4 by a small proportion (as low as 1/10000) of
FSHD myoblasts [216]. It is therefore natural to ask how this low concentration of DUX4
can lead to the symptoms FSHD. Two theories currently stand on this issue: the minority
rules hypothesis and the majority rules hypothesis [228]. In the minority rules hypothesis
FSHD is driven by the high expression of DUX4 in a small number of myoblasts and
myotubes. DUX4 is posited to cause such a widespread phenotype by diﬀusing out of
single nuclei into the cytoplasm of multinucleated myoﬁbers, where it can enter adjacent
nuclei and spread its transcriptional dysregulation throughout the ﬁbre. Evidence for
this hypothesis stems from the clustering of DUX4 positive nuclei in cultured FSHD my-
oblasts. Moreover, it was recently demonstrated that DUX4 expression in a single nucleus
of a multinucleated myotube leads to a gradient of expression of DUX4 and PITX1 in
neighbouring nuclei [227].
Conversely, the majority rules hypothesis posits that transient high expression of DUX4
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occurring in all cells in the myogeneic lineage before the myoblast stage leads to FSHD,
and that this expression is ineﬃciently silenced in a small proportion of cells [228]. The
majority rules hypothesis draws credit from the short half life of DUX4, regulated by the
ubiquitin proteasome pathway [228], which makes long range diﬀusion of DUX4 unlikely.
Moreover, the involvement of DUX4 in myogenesis, would lead one to believe that its
pathogenic eﬀects are upstream of the myoﬁbre stage, at which point the minority rules
hypothesis is invalid.
Investigation of the role of DUX4 in muscle diﬀerentiation may prove critical in informing
which of these postulates are correct, and hence providing a stronger basis for the devel-
opment of therapies. A transcriptomic measure of cell potency, similar to that explored
in previous sections, may be able to determine whether DUX4 over expression retards or
accelerates the diﬀerentiation process in FSHD muscle.
1.4.3 DUX4, necessary but not suﬃcient? An emerging role for telomeres
We have above presented evidence for the critical role of DUX4 in FSHD pathogenesis.
Recently evidence has begun to accumulate, however, demonstrating that though DUX4
may be necessary to cause FSHD, other factors may also be at play. Evidence for this
theory came from a recent study of Italian families, in which the truncated D4Z4 regions
with the permissive FSHD allele were found at a prevalence of 1.2%, one hundred times
higher than the prevalence of FSHD [229]. In addition, DUX4 expression was found in the
muscle cells of both FSHD patients and their unaﬀected ﬁrst degree relatives, indicative
of DUX4 modiﬁers determining disease progression [230].
A new hypothesis has emerged to reconcile these observations, centred around the con-
cept of telomere position eﬀect (TPE) [231]. TPE is an epigenetic silencing mechanism
in eukaryotes, in which repressive heterochromatin spreads from the telomeres over the
sub-telomeric region causing gene silencing, as the telomere shortens, this repressive eﬀect
diminishes as the heterochromatin shrinks [232]. As DUX4 is located sub-telomerically
on chromosome 4q it was postulated that telomere length variability and truncation,
with numerous cell divisions, may contribute to the heterogeneous nature (even among
monozygotic twins) and progression of FSHD [231]. In fact it was demonstrated that
telomere length was signiﬁcantly negatively correlated with DUX4 expression in immor-
talised FSHD myoblasts, marking FSHD out as the ﬁrst condition in which TPE has been
demonstrated as inﬂuential to pathology.
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1.4.4 FSHD transcriptional dysregulation
Given that DUX4 expression may not be the complete story, many investigators have
considered expression proﬁling of FSHD muscle biopsies, to provide information on tran-
scriptional dysregulation unbiased by the DUX4 hypothesis [52, 187, 213, 233, 234]. In
line with DUX4 cell culture studies, the majority of these gene expression analyses on
FSHD muslce biopsies implicated the transcription factor MyoD. Moreover, FSHD my-
oblasts also demonstrated a diﬀerentiation defect with myotubes from FSHD patients
exhibiting two distinct phenotypes in diﬀerent proportions, an atrophic phenotype and a
disorganised phenotype [235, 236]. It was also revealed that as with DUX4 expressing my-
oblasts, FSHD myoblasts displayed a sensitivity to oxidative stress [235]. Several muscle
biopsy gene expression studies have also implicated members of the JNK signalling path-
way as signiﬁcantly diﬀerentially expressed in FSHD muscle, such as JUND [187], JUNB
[52] and JUN [213]. Immune system pathway dysregulation is also observed in FSHD
[187, 234] and two studies [177, 180] have reported the over-expression of TNFα. Genes
involved in RNA processing and the ubiquitin pathway have also been reported as dif-
ferentially expressed in FSHD [234], while several studies have implicated genes involved
with the cell cycle and apoptosis particularly via p53 [52, 181, 187]. Sensitivity to oxida-
tive stress is a well-studied phenotype of FSHD muscle cells, and there has been several
eﬀorts made to investigate the dysregulation of the hypoxic response in FSHD [180, 235].
Notably the abnormal over-expression of many anti-oxidant enzymes was demonstrated in
FSHD (although notably not MnSOD), as well as mitochondrial dysfunction potentially
attributable to cytochrome c oxidase (COX) activity decrease [52, 180]. In addition the
diﬀerential expression of a number of genes associated with hypoxia inducible factor 1
α (HIF1α) signalling and the NRF-2 mediated oxidative stress response in FSHD was
observed [52].
Given the great diversity of pathway perturbations reported in FSHD, the elucidation of a
unifying theory of pathogenesis has remained enigmatic. Most attempts at such a theory
have been largely hypothesis driven, rather than data driven and include dysregulation of
Wnt/β-catenin signalling [186], Ca2+ signalling [177], epigenetic regulation [210], pertur-
bation of the nuclear envelope [213], disruption of p53 activity [181] and RAGE-NF-κB
signalling [237]. An understanding of which molecular mechanisms may prove the most
therapeutically viable is also currently lacking.
Clearly the dysregulation of such a large number of distinct genes and pathways, yet the
positing of a causal aberration arising from mis-expression of a single gene, suggests that
there may a systems property of network rewiring that can trace the diverse molecular
pheonotype of FSHD from its causal genotype. Clearly diﬀerentiation is also perturbed
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in FSHD yet it is unclear what targets may be the best placed to understand this. The
description of molecular networks which are perturbed to convey FSHD pathology in a
manner related to DUX4 has thus been regularly set as a key priority of FSHD research.
1.4.5 Perspectives: Relevance for our research
The aim of our work in reference to FSHD is to develop and apply methodologies which
might postulate novel therapeutics, as well as validate these experimentally. In this sec-
tion we have examined the highly diverse nature of the clinical presentation of FSHD,
indicating that it is a condition aﬀecting a variety of tissues in diﬀerent qualitative ways.
We have also seen how the complexity of this condition both genetically and mechanisti-
cally has hampered the development of viable therapeutics.
Though a candidate gene has been identiﬁed in the transcription factor DUX4, research
into the eﬀect of this protein on muscle cells has not yet been approached from a global
network theoretic perspective. Moreover, though there is a clear muscle diﬀerentiation
defect in FSHD, precisely how this defect causes muscle weakness in patients and the
role of DUX4 therein, is poorly understood. The application of an entropic measure of
diﬀerentiation potential discussed in earlier sections, may prove critical in understanding
the eﬀect of DUX4 overexpression on myogenesis. Whilst careful examination of FSHD
myoblast diﬀerentiation may provide insights into the FSHD myogenesis defect.
Understanding the role of DUX4 in FSHD pathology is complicated by the fact that,
though present in FSHD muscle, the DUX4 protein and transcript are only found at
very low levels [227]. Such a result presents a problem for biochemical assays as it of-
ten makes non-primary cell culture models focused on DUX4 over-expression somewhat
unrealistic. Hence muscle biopsy gene expression data presents a picture of FSHD path-
omechanisms unhindered by non-physiological DUX4 levels. Considerable such data has
been produced, revealing a number of disjoint pathways involved in FSHD, however, an
integration of these pathways and the role of DUX4 is lacking. There is thus scope for the
application of network theoretic tools, aimed at elucidating a unifying picture of FSHD
pathomechansims, and understanding DUX4 's role in FSHD pathogenesis.
Though progress has been made towards generating FSHD animal models, the current
most viable candidate (a mouse model) lacks a muscle phenotype [238]. Thus without
a suitable proxy, the most sensible way to analyse and understand FSHD pathomecha-
nisms is through the consideration of primary muscle biopsies, or from patient derived
cell lines. In such a rare condition the acquisition of a suﬃcient number of primary sam-
ples from patients for reliable inference is an unappealing task. Scapular fusion surgery,
an intervention to address scapular winging in FSHD involving ﬁxation of the scapular
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to the ribcage, is a low risk procedure associated with improved mobility and reduced
shoulder pain and fatigue [239, 240]. The precise procedure varies, but always requires
the clearing of the subscapularis prior to ﬁxation [178, 239]. The resulting large primary
muscle sample is generally disposed of, eliminating a rare and valuable research resource.
Moreover, the surgery is routinely performed twice on the same patient, once on either
shoulder, thus samples obtained from these procedures represent an elegant opportunity
to investigate asymmetry in FSHD. Obtaining such such samples was sadly beyond the
scope of this thesis. However, in lieu of these, we believe the best model available for
interrogating FSHD myogenesis are the immortalised mosaic myoblast cell lines isolated
from a single patient, which are isogenic with the exception of D4Z4 repeat contraction
[241]. It is important to note that these cells require more thorough characterisation
before use.
Thus our work on FSHD will focus ﬁrst on the application of entropic network measures
to gene expression data induced by DUX4 over-expression in muscle cell precursors, to
ascertain whether this gene increases or decreases the stemness of a myoblast, thus in-
hibiting or accelerating myogenesis to cause the FSHD phenotype. Subsequently, we will
characterise the mosaic cellular model of FSHD, conﬁrming DUX4 over-expression and
examining experientially, whether muscle regeneration is indeed slowed or accelerated as
predicted by network theoretic measures. Finally, we will utilise entropy based network
theoretic tools to perform a meta-analysis of FSHD muscle biopsy gene expression data,
we will aim to construct a unifying model of FSHD pathomechanisms and posit and vali-
date therapeutic targets, as well as comparing our model to the genes perturbed by DUX4
expression.
1.5 Overview of introductory sections
In this quite extensive introduction we have covered, what on the surface may appear 4
seemingly disjoint topics. However, we hope that by providing this extensive background,
the reader can appreciate that our journey through these distinct subjects is actually very
natural.
We began with network theory and its application to complex pathology. We revealed
that though clear evidence exists that biological networks rewire in some ordered manner
in response to internal and external perturbation, little attempt has been made to char-
acterise a systems property of this rewiring and exploit it to better understand network
biology, with the possible exception of the under-developed network entropy.
We next moved on to study development and cell diﬀerentiation, processes ubiquitous to
multi-cellular life and central to many complex pathologies. We saw that experimental
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evidence hinted at a systems property that changed systematically during cellular diﬀer-
entiation, the randomness of gene expression. From these ﬁrst two sections we formed
an initial plan: develop the network entropy methodology and validate it as a way to
measure a systems property of network rewiring that alters predictably during cellular
diﬀerentiation.
Given that our primary aim is to apply network theoretic tools to complex disease, and
that the most logical choice of network theoretic measure correlates with diﬀerentiation
potential, it is only natural to consider disorders of development as pathologies of inter-
est. In the ﬁnal two sections of our introduction, therefore, we explored two ends of the
developmental pathology spectrum. Firstly we considered cancer, in which the power of
cell diﬀerentiation is hijacked, to develop a malicious new tissue. Secondly, we considered
muscular dystrophy, in which cell diﬀerentiation is inhibited, resulting in the poor devel-
opment of muscle tissue.
We explored in detail what is known and what is unknown, about a key pathology from
each class: breast cancer and FSHD. We indicated where our diﬀerentiation based network
theoretic tools may prove most useful and outlined approaches to improve understanding
of areas that require elucidation.
In what follows we execute the plan of action detailed in this introduction, ﬁrst develop-
ing entropy based network theoretic tools, then validating the most viable candidate as a
measure of cellular diﬀerentiation and ﬁnally applying our methods to understand breast
cancer and FSHD pathomechansisms. We hope that we have been able to describe many
novel ﬁndings and have laid some foundations from which we can advance the ﬁeld.
2 Entropic Network Theoretic Tools: Concept and The-
ory
In the introduction we motivated the need to develop entropy based network rewiring
methodologies, for improving the understanding of systems properties of biological in-
teractions in developmental disorders. We concluded that a protein interaction network
(PIN) compiled from experimental data, but reﬁned to remove interactions between or-
ganelle separated proteins, would serve as the most suitable model of signal transduction
architecture. We also promoted the use of an edge weighting, derived from genome wide
gene expression data as a means to introduce sample and phenotype speciﬁcity to our
interaction model. Finally, we emphasised the need to develop tools which were scalable,
in the sense that they could elucidate global principles of biological network rewiring,
whilst also identifying critical genes and pathways.
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To this end, in this chapter we ﬁrst motivate and introduce a simple random walk model
of traﬃc on a data weighted PIN, which can be represented as a stochastic matrix. We
then explore 3 distinct entropy based network theoretic tools for the interrogation of
biological network rewiring, namely:
1. Network Transfer Entropy (NTE): A Jensen-Shannon Divergence based mea-
sure for detecting the amount of information transferred between two vertices on a
weighted PIN.
2. Signalling Entropy: A measure for quantifying global signalling promiscuity in a
weighted PIN based on the entropy rate of a random walk process.
3. Interactome Sparsiﬁcation and Rewiring (InSpiRe): A network rewiring
algorithm which utilises vertex speciﬁc entropy and Kullback-Leibler divergence to
detect network rewiring between biological phenotypes described by a weighted PIN.
Following introduction of the weighted random walk model of network traﬃc, we ﬁrst
explain the development of NTE from the consideration of metric spaces of weighted
PINs and random walk walker distributions. We prove a theorem relating to convergence
in these two metric spaces, before explaining how the metric from the space of walker
distributions can be used to construct NTE. We subsequently validate the NTE measure
on some simple synthetic networks and on a small biological data weighted PIN.
We next consider a separate entropy measure of our network traﬃc model, namely the
entropy rate of a random walk on a weighted PIN, which we call signalling entropy. We
brieﬂy explain the history of this measure in a network theoretic context, noting that it
has been demonstrated to be correlated with oncogenic status. We then explore two the-
oretical hypotheses regarding why signalling entropy may have this biological relevance.
Firstly we demonstrate that under our model of network traﬃc, signalling entropy is
most sensitive to the data values of highly connected vertices, in line with mutations in
hub proteins driving high signalling entropy in cancer. Secondly, we show that signalling
entropy, on average, is higher if computed over data samples which correspond to hetero-
geneous mixtures of diﬀerent cell types rather than homogeneous cell types, in line with
cancerous tissue being more heterogeneous than healthy tissue.
Finally we introduce the InSpiRe algorithm (based on a local vertex speciﬁc entropy)
designed to compare two weighted PINs describing diﬀerent biological phenotypes, in a
manner which extracts a subset of proteins and interactions which is signiﬁcantly rewiring
across the phenotypes.
We close with a discussion motivating the development and application of these network
theoretic tools performed in subsequent chapters.
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2.1 A Random Walk Model of Network Traﬃc
The choice of a general dynamic model for a weighted network requires consideration of
the literature. One must be careful to ensure the model makes minimal assumptions yet
has suﬃcient descriptive power to portray complex systems. Much work has focused on
interaction models known as ﬂow networks (see for example [242]), in which transport
from source vertices to sink vertices is subject to edge weight dependant constraints.
These models are useful in optimisation problems where one wants to ﬁnd paths through
a network that maximise or minimise some function associated with path traversal, and
thus tend to be used in systems where traﬃc can be manipulated, such as supply man-
agement [243].
Flow networks are less useful in the interrogation of network dynamics where constraints
on traﬃc are unknown, and sink and source vertices and not readily deﬁned. Moreover,
when network dynamics are stochastic and bursty rather than continuous ﬂows, such as
in social communication systems [244] and gene regulatory networks [245], adaptations
of ﬂow networks are required. Such adaptations include discrete ﬂow networks [246] and
stochastic ﬂow networks [247], in which the interactions of a vertex with its neighbours
is given by a probability distribution proportional to the edge weight distribution. The
elegance of these discrete models is that they may approximate continuous models (such
as ﬂow networks) in the large time limit. Such models are generalised, for example by
the inclusion of holding rates in queuing theory [248], which with detailed information for
parameter estimation can be used to describe and simulate a large variety of real world
systems.
Given this literature we take our dynamic model for weighted networks as a balance
between the descriptive power of the stochastic networks of queuing theory and the sim-
plicity of the stochastic ﬂow networks, namely a weighted random walk. The notion of
random walks on graphs has a rich history [43, 249, 13], hence the novelty of our work
does not derive from the nature of the model, but rather from its biological application
and theoretical investigations. In what follows we introduce our model of biological net-
work traﬃc.
Let G = (V,E) be an undirected graph, where V = {v1, . . . , vn} is a set of vertices and
E = {(i, j)|i, j ∈ V } a set of edges; we denote the adjacency matrix of G by A = (aij)ij∈V .
In our analysis G represents the undirected topology of the PIN, whence aij = aji.
For each biological sample considered we assign to each vertex i ∈ V a variable xi ∈ R>0,
and denote the vector containing all such variables by x = (xi)
n
i=1 ∈ Ω ⊂ (R>0)n, where
Ω is some bounded domain. In our analysis x will represent a vector of gene/protein
expression values, for a single sample.
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We consider a random walk, on the graph G; with transition probability matrix P =
(pij)ij∈V deﬁned at either a phenotype level or a single sample level. In deﬁning P we
aim to model the interaction probabilities between connected proteins in the PIN.
At the single sample level, for each sample x we deﬁne
pij := pij(x) =
aijxj∑
k∈V aikxk
.
This choice of P is motivated by appealing to a simpliﬁed version of the mass action
principle, namely that the rate of a reaction is proportional to the product of the active
masses of the reagents involved. In this model we assume that normalised gene/protein
expression is a rough proxy for protein concentration [23]. We stress that at the single
sample level, pij is independent of xi and that the only contribution of vertex i to the
value of pij derives from the neighbourhood of i in the normalisation of pij .
At the phenotype level, given a set of samples corresponding to a phenotypeX := {xr}lr=1
we deﬁne the stochastic matrix pij := p
pheno
ij either by
pphenoij =
aij(1 + cor(Xi, Xj))∑
k∈V aik(1 + cor(Xi, Xk))
,
or
pphenoij =
aij |cor(Xi, Xj)|∑
k∈V aik|cor(Xi, Xk)|
.
Where Xi := {xri }lr=1 and
cor(Xi, Xj) =
∑l
r=1(x
r
i − 1l
∑l
r=1 x
r
i )(x
r
j − 1l
∑l
r=1 x
r
j)√∑l
r=1(x
r
i − 1l
∑l
r=1 x
r
i )
2
√∑l
r=1(x
r
j − 1l
∑l
r=1 x
r
j)
2
,
is the Pearson correlation between Xi and Xj . This choice of model is motivated by
the assumption that signal transduction ﬂows preferably along paths of proteins with
correlated gene expression proﬁles.
The ﬁrst version of this model, which favours positive correlations
pphenoij =
aij(1 + cor(Xi, Xj))∑
k∈V aik(1 + cor(Xi, Xk))
has been employed previously [23, 13]. It was noted, however, that this was only an
approximation [23], and there is mounting evidence that negative correlations in gene
expression play an important role in signal transduction [250], consequentially the model
pphenoij =
aij |cor(Xi, Xj)|∑
k∈V aik|cor(Xi, Xk)|
,
which assigns both strong positive and strong negative correlations a high weight may be
considered more realistic. We note that unlike the single sample stochastic matrix, the
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(i, j)th entry of the phenotype level matrix pphenoij , is dependent on both Xi and Xj .
In the case of NTE the theoretical results derived in this chapter apply equally to any
choice of stochastic matrix. For signalling entropy, we only consider the single sample
stochastic matrix as this is the most analytically tractable for our purposes. For the
phenotype level InSpiRe algorithm, we will explore the implications of using each of
the two phenotype level stochastic matrices in Chapter 5 in the context of FSHD gene
expression data.
2.2 Network Transfer Entropy and Metric Space
2.2.1 Introduction
In this section we will ﬁrst investigate our probabilistic model of network traﬃc from the
perspective of metric spaces. We will then utilise this global perspective to construct our
local NTE measure.
We will consider an arbitrary edge weighted network, represented as a stochastic matrix
as described above, equipped with a further vector of vertex weights or initial signal dis-
tribution (ISD). By examining the evolution of the ISD on the network according to a
random walk determined by the edge weights, we will derive a closed form expression for
the probability distribution of vertex weights after an arbitrary number of walker evolu-
tions.
We will subsequently consider a metric space of signal dynamics, corresponding to the
space of such probability distributions derived from weighted networks with the same ISD
and topology, equipped with the square root Jensen-Shannon Divergence (JSD) metric.
We prove a convergence principle, demonstrating that a form of convergence of weighted
networks onN vertices (represented by stochastic matrices) in the metric space Lp(MN×N )
implies convergence in the constructed metric space of signal dynamics. This result shows
that in our general framework, deformation of network structure inﬂuences network dy-
namics in an intuitive way. This result has real world implications in, for example, network
drug design, where one wishes to modify the chemical aﬃnities of interacting proteins in
a pathological signalling network (i.e. modify the edge weights) to restore a healthy sig-
nalling regime (i.e. modify the dynamics).
Following this global theoretical investigation we consider an application of our metric
space framework to derive a local measure of information transfer between two vertices in
a weighted network (analogous to the transfer entropy measure for time series introduced
by Schreiber [251]) which we name NTE. After constructing this measure we demonstrate
its validity with some simple examples before applying our it to the quantiﬁcation of in-
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formation transfer between proteins in a phosphorylation network. Finally, we motivate
potential further work in this area by explaining how theoretical problems in network
evolution and network perturbation can be approached within our framework.
2.2.2 Information transfer on weighted networks and metric space
We here consider the above described Markovian model for signal dynamic evolution on
a weighted network, in which each vertex is assigned a value quantifying a signal that the
given vertex is capable of forwarding to one its neighbours. The vector containing these
values for every vertex is the ISD of the network. In real world applications this distri-
bution can be qualitatively diverse. For example, in biological networks, where vertices
represent genes, the ISD may quantify the diﬀerential expression of genes in pathologi-
cal versus healthy samples, or correlation between gene expression and clinical outcome.
There are no restrictions on the ISD other than it being a vector in RN , where N is the
number of vertices.
We evolve this signal over a network G with N vertices according to a stochastic matrix
P = (pij)
N
ij=1 ∈MN×N , which may be derived from experimental and interaction data as
described in Section 2.1. The ISD is propagated over the network in multiple discrete time
steps. At each time step the signal at each vertex i is independently forwarded to vertex
j ∈ Ni with probability pij (we emphasise that self-edges can be added to the network
and the weights on such edges would determine the probability that a vertex maintains
its signal over a single time step). Thus the number of time steps directly corresponds
to the maximal path length the ISD has traversed. Given an ISD, ~X0, and path length,
n, for every vertex i in the network we can compute the probability distribution of the
signal at vertex i given that the ISD has been forwarded along paths of length n (i.e.,
over n time steps), denoted P [Xin| ~X0].
In this section we ﬁrst derive a closed form expression for P [Xin| ~X0]. We then show how
a metric space over such distributions for a given ISD and network topology can be con-
structed. Finally, we prove a convergence criterion relating this space to the metric space
Lp(MN×N ).
2.2.2.1 A closed form expression of P [Xin| ~X0] To derive a closed form expression
for P [Xin| ~X0], we ﬁrst note that
P [Xin = y| ~X0] =
∑
~x
P [ ~Xn = ~x| ~X0]δyxi , (1)
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Where δji denotes the Kronecker delta of i and j.
In addition by the Markovian nature of our dynamic model
P [ ~Xn = ~x| ~X0] =
∑
~X1,..., ~Xn−1
P [ ~Xn = ~x| ~Xn−1] . . . P [ ~X1| ~X0], (2)
Reducing our problem to the calculation of the transition probabilities P [ ~Xk+1| ~Xk], be-
tween states and the states themselves which must be summed over. These are not,
however, immediate.
Let us ﬁrst consider the following: given we know the full signal distribution at time-point
k ∈ N i.e. ~Xk = ~xk, then all possible states of signal distribution at time-point k+1 have
the form
~Xk+1 = A
T~xk. (3)
Here A = (Aij)
N
i,j=1, Aij ∈ {0, 1} is a binary matrix with a single non-zero entry in every
row; the column index j of the non-zero entry in row i corresponds to the unique vertex
j that i has sent its signal to during the time-step k → k + 1. We note that in addition
Aij = 0 if j 6∈ Ni and that A is independent of ~xk.
Thus every realisation of a single signal transfer event in a given weighted network can
be represented as a matrix operation A, independently of ISD. We denote the set of such
matrices by A, and emphasise that it depends only upon the topology (i.e., zero pattern)
of the weighted network.
It is clear that for N < ∞ the set A must be countable, and its cardinality must be
|A| = ∏Ni=1 ki, where ki = |Ni|. Moreover, it is clear that we can construct every element
in A given ∪Ni=1Ni.
Following this, it is clear that given any ISD ~X0 the signal distribution at time point
k > 0 must have the (possibly non-unique) form
~Xk = A
T
k . . . A
T
1
~X0, (4)
where Ai ∈ A for i = 1, . . . , k. Whence Eq. (2) can be expressed as
P [ ~Xn = ~x| ~X0] =
∑
A1,...,An−1∈A
P [ ~Xn = ~x| ~Xn−1 = ATn−1 . . . AT1 ~X0] . . . P [ ~X1 = AT1 ~X0| ~X0]. (5)
Thus to compute P [Xin| ~X0], it suﬃces to compute
P [ ~Xk+1 = A
T
k+1 . . . A
T
1
~X0| ~Xk = ATk . . . AT1 ~X0],
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which is simply the probability of the signal dynamic Ak+1 being selected from A. By
model construction this can be expressed as
N∏
i=1
N∑
j=1
pijAij .
Whence combining this with (1) and (5) we derive the closed form expression
P [Xin = y| ~X0] =
∑
A1,...,An∈A
δy
(AT1 ...A
T
n
~X0)i
n∏
r=1
N∏
k=1
N∑
j=1
pkj(Ar)kj . (6)
2.2.2.2 Metric Space We demonstrated above how, for a speciﬁc network G, and
ISD ~X0 we can calculate a set of matrices describing possible signal dynamics over a
single time-step of our model, as well as a probability distribution describing the signal
on the entire network after n time steps. We will denote these constructs for the weighted
network G by AG and PG [ ~Xn| ~X0], respectively and stress that the former only depends
on the topology of G and not the edge weights, we will denote the topology of G by t(G)
(as noted before, topology in this context refers to the zero pattern of the network and is
independent of the edge weights). The probability distribution PG [ ~Xn| ~X0] is a measure
over the ﬁnite set
{AT1 . . . ATn ~X0 : (Ai)ni=1 ⊂ AG},
which we will denote Ωn~X0
(t(G)). If we denote the space of probability measures over
Ωn~X0
(t(G)) by M+1 (Ωn~X0(t(G))), then it is clear that for any two weighted networks G1 and
G2 with the same topology, T , the probability distributions PG1 [ ~Xn| ~X0] and PG2 [ ~Xn| ~X0]
are elements of M+1 (Ω
n
~X0
(T )).
It has been shown that for any measurable space Ω, the square root of the JSD induces
a metric on the space M+1 (Ω) [252]. The JSD is deﬁned by
DJS(p, q) =
1
2
(∑
x∈X
(
p(x) log
p(x)
m(x)
+ q(x) log
q(x)
m(x)
))
(7)
where p, q : X → [0, 1] are probability distributions (with no restrictions placed on their
kernels) and m = (p+ q)/2. Thus the quantity√
DJS(PG1 [ ~Xn| ~X0], PG2 [ ~Xn| ~X0])
computes a metric distance between the probability distributions describing the dynamics
on G1 and G2.
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Thus our network traﬃc framework results in a mapping from the space of weighted
networks to a family of metric spaces in which elements of the metric space represent
possible signal dynamics.
2.2.2.3 Convergence Principle We have above constructed a family of mappings
from the space of weighted networks to a family of metric spaces, in which elements of
the metric spaces correspond to signal dynamics on the networks. The mappings and
structure of the metric spaces are parametrised by the path length parameter n, the ISD
~X0 and the topology (i.e., the zero pattern, but not the edge weights) of the network.
This formalism allows a more theoretical treatment of dynamics on networks from the
perspective of metric spaces, and permits a coupling between weighted network structure
and dynamics. In certain ﬁelds, understanding the reaction of network dynamics to
perturbations of edge weights is of great importance. This is particularly true of network
drug design [253], in which one is interested in sequentially deforming the quantitative
strengths of interactions in a pathological signalling network (via drugs) into those of
a healthy network, with the aim of establishing a healthy gene expression dynamic and
mitigating the pathology. If this notion of treatment is logical within our framework, then
one would postulate that convergence in weight distribution of a sequence of networks to a
limit distribution (in a matrix metric space) would imply convergence of the corresponding
sequence of dynamics to the dynamics of the limit network (in the network dynamic metric
space). We thus consider the following theorem
Theorem 1 (Convergence Principle) Let (Wn)n∈N be a sequence of weighted net-
works on N vertices of ﬁxed topology, T , and let (Pm)m∈N ⊂ [0, 1]N×N be the corre-
sponding row normalised stochastic matrices for the sequence. Let P ⊂ [0, 1]N×N be a
stochastic matrix of topology T . If Pm → P in Lp(MN×N ), p ≥ 1, as m → ∞, then for
ﬁxed ISD ~X0 and path length parameter n, the signal distributions
PPm [ ~Xn| ~X0]→ PP [ ~Xn| ~X0]
as m→∞ in the metric space(
M+1 (Ω
n
~X0
(T )),
√
DJS(·, ·)
)
.
Proof: Firstly we deﬁne the Lp norm of a matrix A ∈MN×N
||A||p :=

(∑N
i,j=1 |aij |p
)1/p
if p <∞
maxi,j |Aij | if p =∞
. (8)
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A well-known and easy to derive bound on Lp spaces, which holds for any A ∈MN×N is
||A||∞ ≤ ||A||p.
Fix  > 0. As Pm → P in Lp(MN×N ), there exists M ∈ N such that for all m ≥M ,
||Pm − P ||p < .
Let us deﬁne the matrix ∆P ∈ (−1, 1)N×N via
∆P := PM − P,
it is clear that ||∆P ||∞ < .
We now consider for a ﬁxed ISD ~X0 and path length parameter n the distributions
PP [ ~Xn = ~x| ~X0] and PPM [ ~Xn = ~x| ~X0], which we will hereafter refer to as PP (~x) and
PPM (~x). It was shown above that
PP (~x) =
∑
A1,...,An∈A
δ~x
(AT1 ...A
T
n
~X0)
n∏
r=1
N∏
i=1
N∑
j=1
Pij(Ar)ij . (9)
The set of possible signal dynamics A for a given weighted network was also explicitly
constructed above and was shown to depend only on the network topology and not on the
edge weights of the network. Consequentially as the sequence (Pn)n∈N and the network
P have the same topology T , the set of possible signal dynamics A is the same for every
element of the sequence and the network P .
Consider expanding the product
n∏
r=1
N∏
i=1
N∑
j=1
Pij(Ar)ij =
n∏
r=1
N∏
i=1
N∑
j=1
(PMij −∆Pij)(Ar)ij (10)
=
[( N∑
j=1
(PM1j (A1)1j −
N∑
j=1
∆P1j)(A1)1j
)
. . .
( N∑
j=1
(PMNj(A1)Nj −
N∑
j=1
∆PNj)(A1)Nj
)]
. . .
[( N∑
j=1
(PM1j (An)1j −
N∑
j=1
∆P1j)(An)1j
)
. . .
( N∑
j=1
(PMNj(An)Nj −
N∑
j=1
∆PNj)(An)Nj
)]
.
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Grouping together terms we can express the product as
n∏
r=1
N∏
i=1
N∑
j=1
Pij(Ar)ij =
n∏
r=1
N∏
i=1
N∑
j=1
PMij (Ar)ij
−
[
N∑
i=1
n∑
r=1
( N∑
j=1
∆Pij(Ar)ij
) n∏
l 6=r
N∏
s6=i
( N∑
j=1
PMsj (Al)sj
)]
+o(). (11)
We will denote the second term in the above expression by
H(Ai)ni=1(∆P ) :=
[
N∑
i=1
n∑
r=1
( N∑
j=1
∆Pij(Ar)ij
) n∏
l 6=r
N∏
s6=i
( N∑
j=1
PMsj (Al)sj
)]
(12)
Substitution of (11) into (9) yields
PP (x) =
∑
A1,...,An∈A
δ~x
(AT1 ...A
T
n
~X0)
[
n∏
r=1
N∏
i=1
N∑
j=1
PMij (Ar)ij −H(Ai)ni=1(∆P ) + o()
]
. (13)
Clearly from (9) the ﬁrst term can be expressed∑
A1,...,An∈A
δ~x
(AT1 ...A
T
n
~X0)
n∏
r=1
N∏
i=1
N∑
j=1
PMij (Ar)ij = PPM (x). (14)
For the second term, notice that∣∣∣∣∣∣
∑
A1,...,An∈A
δ~x
(AT1 ...A
T
n
~X0)
H(Ai)ni=1(∆P )
∣∣∣∣∣∣ ≤
∑
A1,...,An∈A
δ~x
(AT1 ...A
T
n
~X0)
N∑
i=1
n∑
r=1( N∑
j=1
||∆P ||∞(Ar)ij
) n∏
l 6=r
N∏
s6=i
( N∑
j=1
PMsj (Al)sj
)
< 
∑
A1,...,An∈A
δx
(AT1 ...A
T
n
~X0)
N∑
i=1
n∑
r=1
n∏
l 6=r
N∏
s6=i
( N∑
j=1
PMsj (Al)sj
)
≤
(
N∏
i=1
ki
)n
nN (15)
where the second inequality follows from ||∆P ||∞ <  and
∑N
j=1(Ar)ij = 1 by construction
of the set A. The ﬁnal inequality follows from the facts that ∑Nj=1 PMsj (Al)sj ≤ 1 and
|A| = ∏Ni=1 ki. Given these bounds and Eq. (13) it follows that
PP (x) < PPM (x) +
(
N∏
i=1
ki
)n
nN+ o(). (16)
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An identical argument can be used exchanging PM and P , in which case the sign of
H(Ai)ni=1(∆P ) in (13) changes to positive, however the bound established in (15) bounds
the modulus of H(Ai)ni=1(∆P ) and thus will always be greatest than the largest negative
or largest positive value of H(Ai)ni=1(∆P ). Thus we obtain the symmetric bound
PPM (x) < PP (x) +
(
N∏
i=1
ki
)n
nN+ o(). (17)
Let us deﬁne
m(x) :=
1
2
(PP (x) + PPM (x)) ,
it follows from (16) and (17) that
PP (x)
m(x)
<
2PP (x)
2PP (x)−
(∏N
i=1 ki
)n
nN+ o()
(18)
and
PPM (x)
m(x)
<
2PPM (x)
2PPM (x)−
(∏N
i=1 ki
)n
nN+ o()
. (19)
Thus it follows that
DJS(PP ,PPM ) =
1
2
(∑
x
PP (x) log
PP (x)
m(x)
+ PPM (x) log
PPM (x)
m(x)
)
<
1
2
(∑
x
log
 2PP (x)
2PP (x)−
(∏N
i=1 ki
)n
nN+ o()

+ log
 2PPM (x)
2PPM (x)−
(∏N
i=1 ki
)n
nN+ o()
). (20)
By algebra of limits, it is clear that as → 0
2PP (x)
2PP (x)−
(∏N
i=1 ki
)n
nN+ o()
→ 1
and
2PPM (x)
2PPM (x)−
(∏N
i=1 ki
)n
nN+ o()
→ 1.
Whence it follows that
DJS(PP ,PPm)→ 0
as m→∞ and the theorem is true.
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
We note that the theorem also holds if the topologies of the sequence of weighted
networks and limit network are diﬀerent from one another, the proof of this statement
follows precisely as above, the only diﬀerence being the set A utilised is that induced by
the complete graph topology.
2.2.3 Network Transfer Entropy
In the previous section we demonstrated how our random walk model of network traﬃc
ﬁnds a natural interpretation in the concepts of metric space. We further demonstrated
that in this framework global network dynamics are inﬂuenced by global network struc-
ture in a natural way. In this section we consider our random walk model in a more local
setting to construct an information theoretic measure, NTE, quantifying the directed
amount of information transferred between any two vertices in a weighted network. Fol-
lowing construction, we demonstrate our measure on simple synthetic networks and a
biological signalling network.
Transfer entropy was a measure introduced by Schreiber, to quantify the directed amount
of information transferred between two mutually dependent time series [251] and is an
important starting point when considering the construction of our own measure of in-
formation transfer. In what follows we employ an approach analogous to Schreiber's to
construct NTE.
The deﬁnition of Schreiber's transfer entropy required a model in which it was possible to
express whether two time series inﬂuenced each other. For transfer entropy to be widely
applicable, this model needed to be suﬃciently general to portray a wide array of diverse
systems. It was thus intuitive to describe time series as realisations of (approximately)
Markov processes of order k. For such a process I the conditional probability of ﬁnding
the process in state in+1 at time n+ 1 satisﬁes
p(in+1|in, . . . , in−k+1) = p(in+1|in, . . . , in−k). (21)
These generalised Markov process are not all encompassing in their descriptive power; for
example, they are in general not-applicable to studying subsystems of Markov processes
[254]. However for a broad range of datasets including heart and breathing rate data
[251], magnetoencephalography data [255] and ﬁnancial time series [256], the approxi-
mate Markov process model can be justiﬁed, making Schreiber's transfer entropy widely
applicable.
It is clear that our Markovian model of signal transfer can be analogised to that of
Schrieber and hence is suitable for construction of a network transfer entropy. For our
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purposes we wish to identify the directed amount of information transferred between any
two pairs of network vertices during a period of system evolution. In the derivation of
Schreiber's transfer entropy the directed amount of information transferred from a pro-
cess J to a process I is formulated as the incorrectness of the assumption that I is not
conditional on J . This quantity can be expressed as the Kullback-Leibler divergence [257]
∑
p(in+1n−k+1, j
n
l ) log
p(in+1|inn−k+1, jnl )
p(in+1|inn−k+1)
, (22)
where inm = (in, . . . , im) for m < n. Thus to quantify the amount of information vertex j
in our network transfers to vertex i over paths of length n we must derive a distribution
for Xin (the signal at vertex i after n signal transfer events) in which vertex j sends
no information to vertex i. We must then compute the informational distance between
this distribution and the above considered distribution P [Xin| ~X0] in which j is able to
communicate with i. Clearly if we set the jth row in the stochastic matrix P to ~ej (i.e.,
make j an absorbing state; ~ej denotes the j
th element of the standard basis of RN ), then
it is impossible for vertex j to communicate with any vertex i 6= j under our model. Given
this modiﬁed matrix we can compute the probability distribution of Xin given the ISD
and that j cannot communicate with i. We denote this distribution P [Xin| ~X0, j]. Here
we diverge from Schreiber, however, as the Kullback-Leibler divergence
∑
P [Xin| ~X0] log
P [Xin| ~X0]
P [Xin| ~X0, j]
is only well deﬁned provided
{x : P [Xin = x| ~X0, j] = 0} ⊂ {x : P [Xin = x| ~X0] = 0},
which is an assumption that does not hold in general. Consider, for example, a directed
graph on two vertices 1 and 2, with a single directed edge oriented from 1 to 2; if we assign
the ISD as ~X0 = ~e1, then it is trivial that P [X
2
1 = x| ~X0] = δ1x and P [X21 = x| ~X0, 1] = δ0x.
Thus to quantify the directed amount of information transferred from vertex j to i we
must employ a diﬀerent measure of statistical distance. There are several possible choices
available, among the most promising are the previously considered JSD, which is a linear
combination of Kullback-Leibler divergences, and the statistical distance introduced by
Wootters [258]. Both measures are theoretically rich; Wootters' measure was designed
as a distinguishably distance between pure quantum states after a ﬁnite number of ob-
servations, and applies equally well to distinguishing two probability distributions. The
measure also has a geometric interpretation in the context of Hilbert space. The JSD of
two distributions, quantiﬁes the total Kullback-Leibler divergence from each distribution
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to the average of the two, and thus is a measure of distributional similarity. As explored
above, however, the JSD is also the square of a metric over the space of probability dis-
tributions on a measurable set [252] and it is worth mentioning also that the JSD and
Wootters' measure have been shown to agree to second order in a quantum mechanical
framework [259].
Given the relationship to our theoretical work in metric spaces, it is natural to use the
JSD. Whence we deﬁne the network transfer entropy (NTE) from j to i over path length
n and given an ISD ~X0 by
τn~X0
(j||i) := DJS(P [Xin| ~X0], P [Xin| ~X0, j]) (23)
Note that τn~X0
(j||i) ∈ [0, log 2] is inherently asymmetric, and thus quantiﬁes information
transfer through a network in a directed sense, permitting the inference of causality.
2.2.4 Simple examples
In order to demonstrate the use of NTE we ﬁrst consider two simple synthetic networks as
examples. To evaluate NTE in these examples, we estimated the probability distributions
P [Xin| ~X0] and P [Xin| ~X0, j] for all j, using simulation, as described in the Materials and
Methods, Chapter 2.
The ﬁrst and most simple example we consider is a directed path of length 5 with equal
edge weights (Fig 2.1). This induces the stochastic matrix
P =

0 1 0 0 0
0 0 1 0 0
0 0 0 1 0
0 0 0 0 1
0 0 0 0 1

. (24)
The structure of this network provides a completely predictable path for signal transfer
and thus is ideal for proving the capability of our measure to detect information transfer.
We consider two ISDs on this network, ﬁrstly ~X0 = ~e1, where the ﬁrst vertex in the path
is given an initial signal and all other vertices have no signal to transfer. If we number
the vertices 1 to 5 from the start of the path to the end, then it is clear that for this
ISD, over paths of length n = 1, vertex 1 sends information to vertex 2, and no other
vertices communicate, for n = 2 vertex 1 sends information to vertex 3 and vertex 2 sends
information to vertex 3 and no other vertices communicate, and similarly we can compute
all pairwise information transfer events up to n = 4 beyond which all signal is absorbed
at vertex 5 and cannot be transmitted through the network. This pattern is precisely
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signal present
signal absent
Sending vertex
ISD 1
2
3
4
5
1 2 3 4 5
Receiving vertex
n=1
n=2
n=3
n=4
n=5
1234 5
12 34 5
12 34 5
12 34 5
12 34 5
Sending vertex
ISD 1
2
3
4
5
1 2 3 4 5
Receiving vertex
n=1
n=2
n=3
n=4
n=5
1234 5
12 34 5
12 34 5
12 34 5
12 34 5
0 0.2 0.4 0.6
NTE
A)
B)
Figure 2.1: NTE Example 1: Deterministic Path. Matrices showing NTE be-
tween all vertex pairs in a deterministic path over path lengths n = 1 − 5 for ISDs (A)
(1, 0, 0, 0, 0)T and (B) (1, 1, 1, 1, 1)T .
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what is seen if we calculate the NTE between all vertex pairs over diﬀerent path lengths
n (Fig 2.1A).
We next consider the ISD ~X0 = (1, 1, 1, 1, 1)
T , on the same network, in order to demon-
strate the ability of the NTE measure to discern between situations where networks with
identical edge weights have diﬀerent starting signal states. One would expect that with
this ISD, for n = 1, rather than just vertex 1 forwarding information to vertex 2, we have
vertex j forwarding information to vertex j + 1 for j = 1, . . . , 4, and similar extensions
for longer path lengths. We ﬁnd that the NTE measure can detect these diﬀerences due
to ISD (Fig 2.1B).
The next network we consider is a slight extension to the deterministic path which con-
stitutes a directed feedback from vertex 2 to vertex 4 weighted w = x/(1− x) (Fig 2.2).
This induces the stochastic matrix
P =

0 1 0 0 0
0 0 1 0 0
0 0 0 1 0
0 x 0 0 1− x
0 0 0 0 1

. (25)
The network introduces some indeterminism in that if vertex 4 holds signal, it can either
forward it to vertex 5 with probability 1−x or feedback the signal to vertex 2 with prob-
ability x. This essentially sets up a feedback loop which dampens the signal received at
node 5 over a given path length, by a factor dependant on x. We calculated the NTE for
all vertex pairs in this altered path for x = 0.1, 0.5, 0.9, corresponding to w = 1/9, 1, 9,
and found that as x is increased the NTE to vertex 5 from all other vertices falls, as
expected (Fig 2.2). Thus in the context of these very simple synthetic networks, the use
of NTE as a tool for detecting information transfer is clear.
2.2.5 NTE on a biological network
We next consider NTE in the context of a real world biological network, speciﬁcally the
human primary naive CD4+ T cell intracellular signalling network analysed by Sachs et
al. [260], consisting of 11 vertices (Fig 2.3). In this network vertices are proteins which
can be phosphorylated and directed edges connect kinases (capable of phosphorylating
proteins) with their targets. The kinases must be in an active state before they can phos-
phorylate a target; activity can be achieved by either phosphorylation by an upstream
kinase or activation by a reagent. Sachs et al. generated data accompanying this network
consisting of quantiﬁcation (by ﬂow cytometry) of the amount of phosphorylated protein
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0 0.2 0.4 0.6
NTE
signal present
signal absent
1
1
1
1
w
ISD 1
2
3
4
5
Sending vertex
w=1/9
1 2 3 4 5
Receiving vertex
n=1
n=2
n=3
n=4
n=5
1234 5
12 34 5
12 34 5
12 34 5
12 34 5
Sending vertex
w=1
1 2 3 4 5
Receiving vertex
n=1
n=2
n=3
n=4
n=5
1234 5
12 34 5
12 34 5
12 34 5
12 34 5
Sending vertex
w=9
1 2 3 4 5
Receiving vertex
n=1
n=2
n=3
n=4
n=5
1234 5
12 34 5
12 34 5
12 34 5
12 34 5
Figure 2.2: NTE example 2: Directed Feedback. Matrices showing NTE between
all vertex pairs in the modiﬁed, weighted path with feedback from vertex 4 to vertex 2,
over path lengths n = 1 − 5, for a range of feedback strengths. Note that as the weight
on the edge (4, 2) rises the NTE from vertices 1-4 to 5 falls.
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for each vertex in the network, following ten independent perturbations. The network
perturbations consisted of the administration of reagents which could either activate or
inhibit the kinase activity of particular vertices.
To apply NTE we considered two of these perturbations, ﬁrstly treatment with anti-CD3
and anti-CD28 to activate the T-cells and induce ﬂux through the network, secondly
treatment with anti-CD3, anti-CD28 and psitectorigenin, a reagent which speciﬁcally in-
activates PIP2. The computation of NTEs on the perturbation of the biological network
requires the assignment of network edge weights and an ISD for each perturbation, this
requires careful consideration. The assigned weightings are presented in Fig 2.3A-B and
are described in detail in the Materials and Methods, Chapter 2.
Following the assignment of ISDs and edge-weights to the two perturbations of the bio-
logical network, we computed matrices of NTEs between all vertex pairs for path lengths
n = 1 . . . 5 in each perturbation (Fig 2.3C-D).
To compare information transfer under the two perturbations we next considered the
diﬀerential NTE evaluated from subtracting the PIP2 inhibited (psitectorigenin treated)
NTEs from the uninhibited NTEs (Fig 2.4). We found that in the psitectorigenin treated
network, information transfer from PIP2 to the rest of the network was reduced over all
path lengths (Fig 2.4). Speciﬁcally, information transfer from PIP2 to PIP3 was greatly
reduced and information transfer from PIP2 to Plcg was reduced over paths of maximal
length greater than one (implying PIP3 received less information from Plcg via PIP2 un-
der psitectorigenin treatment). At longer path lengths we also see a reduced information
transfer from PIP2 to Akt and p38 in the psitectorigenin treated network. This indicates
that speciﬁc inhibition of PIP2 can lead to decreased Akt and p38 activation downstream
of PIP2 signalling.
Interestingly, we also notice that in the PIP2 inhibited network, there is increased infor-
mation transfer from PKA to Akt and from PKC to p38. This points at a compensatory
mechanism, in which inhibition of PIP2 leading to reduced Akt and p38 activation is
compensated for by PKC dependant p38 activation and PKA dependant Akt activation.
Thus our NTE measure is capable of providing novel insights into signalling mechanisms
in biological networks.
2.2.6 Conclusions and Possible Further Work
In this subsection on NTE and metric space, we ﬁrst constructed a general metric space
framework for dynamics on weighted networks and proved a convergence principle re-
lating global weighted network structure to dynamics. We next derived a general, local
information theoretic measure, NTE, for quantifying the amount of information trans-
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Figure 2.3: ISDs, edge-weights and NTE computations on the biological net-
work. The top half of the ﬁgure shows the ISD and edge weights for (A) the anti-CD3
and anti-CD28 treated network and for (B) the anti-CD3, anti-CD28 and psitectorigenin
treated network. The bottom half displays matrices of NTEs computed between every
vertex pair over path lengths n = 1 − 5, in (C) the anti-CD3 and anti CD28 treated
network and (D) the anti-CD3, anti-CD28 and psitectorigenin treated network.
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Figure 2.4: NTE computed over two perturbations of a biological network.
Matrix displaying diﬀerential NTEs computed for every vertex pair over the displayed
network, positive values (green) correspond to NTEs higher in the network perturbed
with anti-CD3 and anti-CD28, whilst negative values (red dashed) are higher in the
network also perturbed by psitectorigenin, a PIP2 inhibitor.
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ferred between any two vertices of a weighted network over paths of varying length. We
demonstrated our measure on simple synthetic weighted networks before applying it to
biological signal transduction, revealing insights into the robustness of kinase signalling.
Hence, we have considered a framework which can elucidate both global properties of
network rewiring and local information on perturbed genes and pathways. We note that
whilst useful for understanding information transfer on a network, there are limitations to
NTE, most notably it is computationally expensive, even with estimation by simulation.
Asides from application of the measure to other phenotype comparisons of network dy-
namics and reﬁnement of the algorithms for NTE estimation, there is scope for further
investigation of our NTE framework along theoretical lines.
Further theoretical questions may consider which ISDs are maintained under diﬀerent
networks, these represent persistent (attractor) states of the network information distri-
bution. To identify such states we note that every graph (if we permit self edges at every
vertex to represent a non-zero probability of signal maintenance) admits a disjoint vertex
cycle decomposition [261]. Thus there is always a way of sending signal around the net-
work, without combining signal from two vertices at any one vertex. This implies that
for every weighted network G, with self edges, there must exist a permutation matrix φ,
which admits at least one vector ~x satisfying φ~x = ~x (e.g., the vector (1, . . . , 1)T ), such
that P [X1 = φ~x| ~X0 = ~x] > 0. The state ~x thus has a non-zero probability of being a
persistent information state of the network.
Questions concerning the evolution of self-assembling networks can also be considered
in our framework via an application of dynamic programming. To see this we consider
the space A (constructed above) containing matrix representations of all possible single
path length signal forwarding choices, induced by the complete graph on K vertices. We
note that for every weighted network, G, on N vertices, where N < K, the correspond-
ing stochastic matrix P can be expressed as a convex combination of elements in A,
P =
∑KN
j=1 ρjAj where {Aj}K
N
j=1 = A,
∑
j ρj = 1, ρj ≤ 1 for all j. If one interprets the
space A as a state space of possible choices of signal dynamics through the network and
considers ~ρ = {ρj}KNj=1 as a policy, giving a probability distribution of selecting a given
global signal dynamic from the state space, that has been obtained by some optimality
criterion, then one has a dynamic programming framework for network dynamic evolu-
tion. We note that one can calculate the policy selected by a given weighted network
explicitly, as ρi = P [ ~X1 = Ai ~X0| ~X0]. Thus we have information to guide to construction
of an optimality criterion describing network evolution. Forms of such a criterion can
be posited and parametrised for diﬀerent systems and suitable parameter regimes can be
reverse engineered from the policy solution ~ρ.
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2.3 Signalling Entropy: Theoretical Investigations
2.3.1 Introduction
In the previous section we introduced and robustly examined a theoretical framework for
traﬃc on a weighted network. We also introduced and explored NTE, demonstrating its
applicability to analysing biological signal transduction. Whilst useful, there are limita-
tions to NTE, however, and it is worth examining other entropy based network theoretic
tools derived from our model of network traﬃc. In this section we thus consider the
entropy rate of the Markov chain described by our data derived stochastic matrix model
of network traﬃc. We will focus on the single sample derived stochastic matrix as this is
more analytically tractable and has a history of use in a biological context [262]. To avoid
ambiguity, we will refer to the entropy rate of such a single sample stochastic matrix as
the `signalling entropy' of the sample.
Formally, we consider a random walk, on an undirected graph G = (V,E), where V =
{v1, . . . , vn} is a set of vertices and E = {(i, j)|i, j ∈ V } a set of edges, with adjacency
matrix A = (aij)ij∈V . To each vertex i ∈ V we assign a variable xi ∈ R>0, and denote the
vector containing all such variables by x = (xi)
n
i=1 ∈ Ω ⊂ (R>0)n, where Ω is a bounded
domain, for which there exists φ, ω ∈ R>0 such that for x ∈ Ω, xk ∈ [φ, ω],∀k ∈ V .
We consider a Markov Chain on G with transition probability matrix P (x) = (pij(x))ij∈V
deﬁned via
pij(x) =
aijxj∑
k∈V aikxk
and deﬁne the following measures
1. The degree of vertex i ∈ V in the interactome, deﬁned by
deg(i) :=
∑
k
aik. (26)
2. The local entropy of vertex i ∈ V , deﬁned by
Si(x) := −
∑
j∈V
pij(x) log pij(x). (27)
3. The entropy rate of P (x), deﬁned by
SR(x) :=
∑
i∈V
µi(x)Si(x). (28)
where µi denotes the stationary distribution of P (x) and satisﬁes
µj(x) =
∑
i∈V
pij(x)µi(x). (29)
We refer to SR(x) as the signalling entropy of x.
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We note that we will only be considering this single sample construction, where G repre-
sents a PIN describing proteins which correspond to genes, and x represents a vector of
gene or protein expression. Hence to emphasise biological relevance, we will interchange-
ably use protein/gene to refer to a vertex of G, and use the expression of gene/protein i
to refer to xi.
Theoretical investigations of the entropy rate of a random walk on a complex network
have been considered extensively previously. The concept was introduced in [249] as a
measure of the minimal amount of information required to describe a diﬀusion process on
a complex network. The measure was considered for degree biased random walks on scale
free and real world networks, and was shown to diverge for synthetic scale free networks
as the degree exponent tends to 2. Interestingly, it was demonstrated that diﬀerent real
world networks displayed either a consistently higher or lower entropy rate than their syn-
thetic counterparts, with social networks and internet router networks displaying higher
entropy rates and airport and hyperlink networks lower. This diﬀerence was attributed
to degree-degree correlations.
Previous work from our group focused on the idea that oncogenic signal transduction was
more disordered compared to its healthy counterpart [23, 17]. This work considered the
phenotype level stochastic matrix
pphenoij (x) =
aij(1 + cor(Xi, Xj))∑
k∈V aik(1 + cor(Xi, Xk))
,
and demonstrated that `ﬂux entropy', deﬁned as a weighted sum of local entropies
S :=
∑
i
1
deg(i)
Si(x),
was elevated in the cancerous as opposed to healthy phenotype [23] and in metastatic as
opposed to non-metastatic breast cancer [17]. It was subsequently demonstrated on the
single sample level, using the stochastic matrix described above, that cancerous samples
displayed a signiﬁcantly higher signalling entropy than healthy samples [262].
These results are encouraging and merit further investigation. In particular we wish to
attribute clearer biological relevance to the ﬁnding that signalling entropy is elevated in
cancerous samples, so that the result may ﬁnd a more solid basis for experimental and
clinical investigation. In this section we thus consider theoretical properties of signalling
entropy, which may predispose our measure to be an indicator of oncogenic status.
We ﬁrst demonstrate that the expression of high degree vertices contribute the most to
changes in signalling entropy, a ﬁnding we validate using proteomic and transcriptomic
data describing cancerous tissue. This result suggests that signalling entropy may be
detecting the mutations in, and over-expression of, hub genes which drive oncogenesis.
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Moreover, the result indicates that signalling entropy may be most easily controlled ex-
perimentally by modiﬁcation of the expression of hub genes.
We subsequently consider intra-sample heterogeneity, and derive a suﬃcient condition
for a sample consisting of two mixed cell types to, on average, have a higher signalling
entropy than a homogeneous sample. We validate that this condition holds on transcrip-
tomic data describing 33 distinct tissue types corresponding to 528 pairwise mixtures.
This second ﬁnding suggests that signalling entropy may be detecting the increased cell
type heterogeneity found in cancerous tissue. As such heterogeneity varies between pa-
tients and is considered a diﬃcult to measure prognostic factor, this ﬁnding motivates
the use of our measure as a correlate of clinical outcome, independent of other current
measures.
We close with a discussion of further biological implications of these theoretical results.
Notably we mention a possible use for signalling entropy as a quantiﬁer of the diﬀeren-
tiation potential of a sample, and motivate the data driven investigations of subsequent
chapters.
2.3.2 Signalling entropy and high degree vertices
2.3.2.1 Motivation Previous work has demonstrated that signalling entropy is a
quantiﬁer of malignant status [262]. It has also been observed that genes which are
diﬀerentially expressed and mutated in cancer appear to correspond to proteins of higher
degree in the PIN [2]. Given this association we wished to investigate whether the diﬀeren-
tial expression of high degree vertices could be driving the association between signalling
entropy and oncogenic status.
We hypothesised that the sensitivity of signalling entropy to changes in the expression of a
given gene, may be bounded by an increasing function of the degree of the corresponding
protein in the PIN. This hypothesis amounts to the following proposition:
Proposition 1 Let x ∈ Ω and f : N→ R+ be a strictly increasing function, then
|∂kSR(x)| ≤ f(deg(k)). (30)
Where ∂k :=
∂
∂xk
.
Clearly, if the above proposition is correct, then changes in the expression of genes corre-
sponding to high degree proteins, will have greater potential to alter the signalling entropy
of a cellular sample. Whence our hypothesis that the diﬀerential expression of high de-
gree vertices is a potential driver of signalling entropy's association with malignancy is
theoretically sound.
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In what follows we prove that this proposition is indeed correct and that the function f
can be expressed simply as a multiple of deg(k).
Subsequently we consider the METABRIC transcriptomic data set of 1980 breast can-
cers [157] and proteomic data from the Human Protein Atlas [263] corresponding to 20
cancerous tissue types to provide empirical validation of our hypothesis. We demonstrate
that genes whose expression variations are most correlated with signalling entropy varia-
tions are more likely to be of higher degree. These results provide strong evidence that
the association of signalling entropy with malignancy is likely related to the diﬀerential
expression of genes corresponding to highly connected proteins, and suggest the targeting
of such proteins as a strategy to control signalling entropy experimentally.
2.3.2.2 Proof of Proposition 1 In this section we prove the following version of
Proposition 1
Theorem 2 Let x ∈ Ω, such that xk ∈ [φ, ω],∀k ∈ V , then
|∂kSR(x)| ≤
ω
∣∣∣2SR(x)− log ω2|V |2φ2 ∣∣∣
W (x)
deg(k). (31)
Proof: We ﬁrst note that the a closed form expression for signalling entropy can easily
be derived as described in [264]. To demonstrate this let us deﬁne the following quantities
Wij(x) := aijxixj
Wi(x) :=
∑
j
Wij(x)
W (x) :=
∑
i
Wi(x).
By multiplying pij(x) by 1 = xi/xi, we see that
pij =
Wij(x)
Wi(x)
.
Thus P (x) describes a weighted random walk on an undirected graph and it thus follows
that
µi(x) = Wi(x)/W (x). (32)
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The proof of (32) follows from simple substitution into (29):
LHS =
∑
i
pij(x)µi(x)
=
∑
i
Wij(x)
Wi(x)
Wi(x)
W (x)
=
Wj(x)
W (x)
= RHS.
From this result it follows that
SR(x) = − 1
W (x)
∑
ij
Wij(x) log
Wij(x)
Wi(x)
. (33)
By diﬀerentiation of (33) with respect to xk we obtain
∂kSR(x) = ∂k
− 1
W (x)
∑
ij
Wij(x) log
Wij(x)
Wi(x)

=
∂kW (x)
W (x)2
∑
ij
Wij(x) log
Wij(x)
Wi(x)
−
1
W (x)
∑
ij
[
∂kWij(x) log
Wij(x)
Wi(x)
+Wij(x)
(
∂kWij(x)
Wij(x)
− ∂kWi(x)
Wi(x)
)]
= −∂kW (x)
W (x)
SR(x)− 1
W (x)
∑
ij
[
∂kWij
(
1 + log
Wij(x)
Wi(x)
)
−
∂kWi(x)
Wij(x)
Wi(x)
]
. (34)
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It is sensible to next evaluate the partial derivatives of Wij(x),Wi(x) and W (x).
∂kWij(x) = ∂k(aijxixj)
= aij(xjδik + xiδjk). (35)
∂kWi(x) =
∑
j
∂kWij(x)
=
∑
j
aij(xjδik + xiδjk)
= xiaik + δik
∑
j
aijxj . (36)
∂kW (x) =
∑
i
∂kWi(x)
=
∑
i
xiaik + δik∑
j
aijxj

=
∑
i
xiaik +
∑
j
akjxj
= 2
∑
i
xiaik. (37)
Where the last line was obtained by appealing to the undirected nature of the interactome
which ensures aij = aji. Substituting these expressions into (34) we obtain:
∂kSR(x) = −2
∑
i xiaik
W (x)
SR(x)−
1
W (x)
∑
ij
[
aij(xjδik + xiδjk)
(
1 + log
Wij(x)
Wi(x)
)
−(
xiaik + δik
∑
l
ailxl
)
Wij(x)
Wi(x)
]
. (38)
Considering just the second term in the above expression we see
− 1
W (x)
∑
ij
[
aij(xjδik + xiδjk)
(
1 + log
Wij(x)
Wi(x)
)
−
(
xiaik + δik
∑
l
ailxl
)
Wij(x)
Wi(x)
]
= − 1
W (x)
[∑
j
akjxj
(
1 + log
Wkj(x)
Wk(x)
)
+
∑
i
aikxi
(
1 + log
Wik(x)
Wi(x)
)
−
∑
ij
xiaik
Wij(x)
Wi(x)
−
∑
jl
aklxl
Wkj(x)
Wk(x)
]
.
(39)
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We again appeal to aij = aji, which implies that Wij(x) = Wji(x), to obtain:
− 1
W (x)
[∑
j
akjxj
(
1 + log
Wkj(x)
Wk(x)
)
+
∑
i
aikxi
(
1 + log
Wik(x)
Wi(x)
)
−
∑
ij
xiaik
Wij(x)
Wi(x)
−
∑
jl
aklxl
Wkj(x)
Wk(x)
]
= − 1
W (x)
[∑
i
xiaik
(
2 + log
Wik(x)
2
Wk(x)Wi(x)
)
−
∑
ij
xiaik
(
Wij(x)
Wi(x)
+
Wkj(x)
Wk
)]
= − 1
W (x)
[∑
i
xiaik
(
2 + log
Wik(x)
2
Wk(x)Wi(x)
)
−
∑
i
xiaik
(∑
jWij(x)
Wi(x)
+
∑
jWkj(x)
Wk(x)
)]
= − 1
W (x)
∑
i
xiaik log
Wik(x)
2
Wk(x)Wi(x)
.
(40)
Substitution of this term into (38) we obtain
∂kSR(x) = − 1
W (x)
∑
i
xiaik
(
2SR(x) + log
Wik(x)
2
Wk(x)Wi(x)
)
. (41)
Given that
Wik(x)
2
Wk(x)Wi(x)
≥ φ
2
ω2|V |2 , (42)
it is a simple deduction that
|∂kSR(x)| ≤
ω
∣∣∣2SR(x)− log ω2|V |2φ2 ∣∣∣
W (x)
deg(k). (43)
Hence the theorem is proven.

It has been demonstrated that the maximal entropy rate of a random walk on an adjacency
matrix (aij)ij∈V , with largest eigen value λ and corresponding eigen vector ν = (νi)i∈V
is log λ and is achieved when pij =
aijνj
λνi
[274]. We note that this corresponds in our
framework to SR(ν) = log λ. It is easily proven by substitution that (41) evaluates
to zero when x = ν, in line the maximal entropy rate being achieved when the gene
expression proﬁle matches the eigen vector centrality of the PIN.
2.3.2.3 Empirical Validation In the above section we demonstrated that the sen-
sitivity of signalling entropy to changes in the expression of a gene is bounded by a
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multiple of the degree of the corresponding protein. This result suggests that expres-
sion diﬀerences between cancerous and healthy tissue, which are dominantly in genes
corresponding to high degree proteins, strongly inﬂuence our measure. Here we further
validate this hypothesis by consideration of the METABRIC transcriptomic data set of
1980 breast cancers divided into discovery and validation data sets of equal proportion,
and the Human Protein Atlas dataset describing proteomic data for 20 healthy and can-
cerous tissues.
To ascertain which gene expression patterns are most associated with signalling entropy,
we ﬁrst computed the signalling entropy of each sample in both the discovery and val-
idation data sets of METABRIC and for the cancerous samples in the Human Protein
Atlas (Materials and Methods, Chapter 2). We then evaluated the Pearson correlation
between gene expression and signalling entropy for each gene corresponding to a protein
in our PIN, across all samples in the discovery and validation data sets of METABRIC
and all cancers in the Human Protein Atlas separately.
As expected, we found that there was a highly signiﬁcant correlation between the a
gene's association with signalling entropy, and its corresponding degree in the PIN (p <
2.2× 10−16, Fig 2.5). This conﬁrms our theoretical result that higher degree proteins are
more associated to changes in (and hence are more correlated with) signalling entropy.
2.3.2.4 Summary In this section we have demonstrated that the sensitivity of sig-
nalling entropy to changes in the expression of a given gene is bounded by a multiple
of the degree of the corresponding protein in the PIN. Whence it is to be anticipated
that expression changes in genes corresponding to high degree proteins are more likely
to drive changes in signalling entropy. By considering transcriptomic and proteomic data
from primary tumour samples, we empirically conﬁrmed this postulate, demonstrating
that genes whose expression was most strongly correlated with signalling entropy across
tumour samples were more likely to be of high degree.
The results in this section thus make the case that elevated signalling entropy in cancer-
ous tissue, may be driven by mutation or over-expression of high degree genes and marks
out such genes as the organisers of order in interactome signalling. Experimental and
therapeutic studies aimed at reducing signalling entropy in cancer may thus beneﬁt from
a focus on the modiﬁcation of expression of high degree proteins.
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Figure 2.5: Signalling entropy is driven by the expression of high degree
vertices. Correlation between degree in the PIN and Pearson correlation between
gene expression and signalling entropy in the MEATABRIC discovery dataset (A), the
METABRIC validation dataset (B) and the Human Protein Atlas cancer samples (C).
We see that high degree vertices have gene expression variances more closely associated
to signalling entropy.
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2.3.3 Signalling Entropy and heterogeneity
2.3.3.1 Motivation Intra-sample heterogeneity, the diversity of cell types within a
cellular sample has long been observed as higher in tumours than healthy tissue, and we
therefore postulated that an elevated signalling entropy in cancerous tissue may be driven
by a more diverse cell population.
To investigate whether signalling entropy does associate with intra-sample heterogeneity,
we consider our measure evaluated for three theoretical samples: namely two homoge-
neous samples consisting only of cell type x or y respectively, and a third heterogeneous
sample consisting of a 50:50 mixture of cell types x and y. It is clear that if cell type x
has an expression proﬁle that maximises signalling entropy and cell type y does not, then
the signalling entropy of the mixture will be lower than the signalling entropy of x, thus
signalling entropy is not a point-wise measure of heterogeneity. However, most biologi-
cally realistic cell types have distinct expression proﬁles, corresponding to the existence
of non-overlapping active pathways between cell type pairs [265]. We therefore posited
that the signalling entropy of a mixed sample may be higher than that of a homogeneous
sample on average.
In what follows, we ﬁrst show that it is a consequence of simple algebra that if signalling
entropy is super-additive over the set of biologically admissible expression proﬁles (i.e.,
Signalling Entropy
(
x+y
2
)
> 12 Signalling Entropy(x) +
1
2 Signalling Entropy(y)) then sig-
nalling entropy will on average be elevated in mixed samples as opposed to homogeneous
samples. We thus derive a condition for point-wise super-additivity of our measure, which
we show is typically valid for biologically realistic data sets. Following the derivation of
this condition we consider data corresponding to gene expression proﬁles for 33 distinct
adult tissues, representing 528 possible pairwise homogeneous mixtures [265]. We demon-
strate that our condition for super-additivity and hence for elevated signalling entropy
in heterogeneous samples holds for all 528 mixtures, before demonstrating that signalling
entropy is indeed elevated in the mixed samples on average compared to the homogeneous
tissue samples.
These results provide strong evidence that signalling entropy associates with intra-sample
heterogeneity on average. Hence elevated signalling entropy in cancer may be a conse-
quence of increased heterogeneity in cancerous tissue.
2.3.3.2 Super-additivity implies signalling entropy is elevated in a mixed
sample on average We hypothesised that the signalling entropy of a heterogeneous
sample generated from a 50:50 mixture of two homogeneous cell types will be greater,
on average, than the signalling entropy of a homogeneous sample. Here we show that if
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signalling entropy is super-additive then the hypothesis is correct. Let us ﬁrst deﬁne some
preliminaries: Let xi ∈ R>0 be the expression of gene i in cell type X, and denote the
vector containing all such variables by x = (xi)
n
i=1 ∈ Ω ⊂ R>0, where Ω is some bounded
domain. In our analysis x will represent the vector of normalised gene expression values
for a homogeneous sample.
Our hypothesis that signalling entropy is elevated in heterogeneous samples on average
amounts to proving the following proposition:
Proposition 2 Let x, y ∈ Ω, then∫
Ω
∫
Ω
(
SR
(
x+ y
2
)
− SR(x)
)
dxdy > 0. (44)
Let us consider the following claim:
Claim 3 (Super-additivity) Let x, y ∈ Ω then
SR
(
x+ y
2
)
>
SR(x)
2
+
SR(y)
2
. (45)
It is clear that if the claim is true then the proposition must be true. Notice ﬁrst that if the
claim is true then as it is a strict bound ∃ > 0 such that SR (x+y2 ) > SR(x)2 + SR(y)2 + .
Whence∫
Ω
∫
Ω
(
SR
(
x+ y
2
)
− SR(x)
)
dxdy >
∫
Ω
∫
Ω
(
SR(y)
2
− SR(x)
2
+ 
)
dxdy (46)
= |Ω|2 (47)
> 0, (48)
and thus the proposition is true.
Thus if signalling entropy is super-additive over homogeneous cell types, this implies that
signalling entropy will on average be elevated in heterogeneous mixtures of cell types.
2.3.3.3 A suﬃcient condition for signalling entropy to be super-additive
Here we will prove the following theorem
Theorem 4 Let x, y ∈ Ω, let a = maxi
(
xi
yi
)
, and let b = mini
(
xi
yi
)
. A suﬃcient
condition for Claim 3 to be true is
sign(1− 1/b+ 2/a) + sign(1− a+ 2b) = 2 (49)
Proof: From (33)
SR((x+ y)/2) = − 1
W ((x+ y)/2)
∑
ij
Wij((x+ y)/2) log
Wij((x+ y)/2)
Wi((x+ y)/2)
, (50)
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it is prudent to ﬁrst consider Wij((x+ y)/2):
Wij((x+ y)/2) =
aij
4
(xi + yi)(xj + yj) (51)
=
1
4
(Wij(x) +Wij(y) + aij(xiyj + xjyi)). (52)
We will deﬁne
Wˆij(x, y) = aij(xiyj + xjyi) (53)
Wˆi(x, y) =
∑
j
Wˆij(x, y) (54)
Wˆ (x, y) =
∑
j
Wˆi(x, y) (55)
for notational ease. Note that as y, x > 0
Wˆij(x, y) =
xi
yi
Wij(y) +
yi
xi
Wij(x). (56)
Wˆi(x, y) =
xi
yi
Wi(y) +
yi
xi
Wi(x). (57)
It thus follows that:
SR((x+ y)/2) =
−1
W (x) +W (y) + Wˆ (x, y)
∑
ij
(Wij(x) +Wij(y) +
Wˆij(x, y)) log
Wij(x) +Wij(y) + Wˆij(x, y)
Wi(x) +Wi(y) + Wˆi(x, y)
. (58)
We will now appeal to the log sum inequality:
Theorem 5 (Log-sum inequality) Let a1, ..., an, b1, ..., bn be non-negative numbers then
n∑
i=1
ai log
ai
bi
≥
(
n∑
i=1
ai
)
log
∑n
i=1 ai∑n
i=1 bi
. (59)
If we denote a1 = Wij(x), a2 = Wij(y), a3 = Wˆij(x, y) and b1 = Wi(x), b2 = Wi(y), b3 =
Wˆi(x, y), and apply the log-sum inequality to the summand of (58) we obtain:
SR((x+ y)/2) ≥ −1
W (x) +W (y) + Wˆ (x, y)
∑
ij
Wij(x) log
Wij(x)
Wi(x)
+ (60)
Wij(y) log
Wij(y)
Wi(y)
+ Wˆij(x, y) log
Wˆij(x, y)
Wˆi(x, y)
(61)
=
W (x)SR(x) +W (y)SR(y)−∑ij Wˆij(x, y) log Wˆij(x,y)Wˆi(x,y)
W (x) +W (y) + Wˆ (x, y)
. (62)
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Now consider the term−∑ij Wˆij(x, y) log Wˆij(x,y)Wˆi(x,y) and apply the log sum inequality again:
−
∑
ij
Wˆij(x, y) log
Wˆij(x, y)
Wˆi(x, y)
= −
∑
ij
(
xi
yi
Wij(y) +
yi
xi
Wij(x)
)
log
xi
yi
Wij(y) +
yi
xi
Wij(x)
xi
yi
Wi(y) +
yi
xi
Wi(x)
≥ −
∑
ij
xi
yi
Wij(y) log
Wij(y)
Wi(y)
+
yi
xi
Wij(x) log
Wij(x)
Wi(x)
. (63)
Returning to (60), it now follows that
SR
(
x+ y
2
)
− SR(x)− SR(y)
2
≥
1
2(W (x) +W (y) + Wˆ (x, y))
(
SR(x)(W (x)−W (y)− Wˆ (xy)) +
SR(x)(W (y)−W (x)− Wˆ (xy))−
2
∑
ij
xi
yi
Wij(y) log
Wij(y)
Wi(y)
+
yi
xi
Wij(x) log
Wij(x)
Wi(x)
)
. (64)
So Claim 3 is true if the LHS of the above equation is positive, i.e.,
0 <
1
2(W (x) +W (y) + Wˆ (x, y))
(
SR(x)(W (x)−W (y)− Wˆ (xy)) +
SR(x)(W (y)−W (x)− Wˆ (xy))−
2
∑
ij
xi
yi
Wij(y) log
Wij(y)
Wi(y)
+
yi
xi
Wij(x) log
Wij(x)
Wi(x)
)
. (65)
We note that if (65) holds then
2
W (x)SR(x) +W (y)SR(y)−∑
ij
xi
yi
Wij(y) log
Wij(y)
Wi(y)
+
yi
xi
Wij(x) log
Wij(x)
Wi(x)
 >
(SR(x) + SR(y))(W (x) +W (y) + Wˆ (xy)) (66)
We note that the RHS of (66) satisﬁes
2(W (x)SR(x) +W (y)SR(y)−
∑
ij
xi
yi
Wij(y) log
Wij(y)
Wi(y)
+
yi
xi
Wij(x) log
Wij(x)
Wi(x)
> 2W (x)SR(x)(1 + min
i
yi
xi
) + 2W (y)SR(y)(1 + min
i
xi
yi
). (67)
We further notice that
Wˆ (xy) =
∑
i
xi
yi
Wi(y) +
yi
xi
Wi(x) (68)
< max
i
xi
yi
W (y) + max
i
yi
xi
W (x) (69)
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whence the LHS of (66) satisﬁes
(SR(x) + SR(y))(W (x) +W (y) + Wˆ (xy)) <
SR(x)W (x)(1 + max
i
yi
xi
) + SR(y)W (y)(1 + max
i
xi
yi
). (70)
Thus it follows that if
SR(x)W (x)(1 + max
i
yi
xi
) + SR(y)W (y)(1 + max
i
xi
yi
) <
2W (x)SR(x)(1 + min
i
yi
xi
) + 2W (y)SR(y)(1 + min
i
xi
yi
), (71)
and consequentially
SR(x)W (x)(1−max
i
yi
xi
+ 2 min
i
yi
xi
) + SR(y)W (y)(1−max
i
xi
yi
+ 2 min
i
xi
yi
) > 0
SR(x)W (x)(1− 1/b+ 2/a) + SR(y)W (y)(1− a+ 2b) > 0 (72)
then LHS<RHS. Where a = maxi
(
xi
yi
)
, and b = mini
(
xi
yi
)
, as in the claim. We note
that as SR(x)W (x) > 0 and SR(y)W (y) > 0 that the condition will always hold provided
sign(1− 1/b+ 2/a) + sign(1− a+ 2b) = 2.
Hence the theorem is correct.

We note that the condition can be computed numerically for a range of values and is
valid for the majority of biologically plausible ranges, with the exception of samples with
extremely low expression value ratios (Fig 2.6).
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2.3.3.4 Empirical validation of super-additivity of signalling entropy on Ω If
the bound derived above holds in Ω, the space of biologically admissible homogeneous
sample expression regimes, then Claim 3 and hence Proposition 2 are true and we have
proven our postulate that signalling entropy is elevated on average in mixed biological
samples.
Though we have shown that most biologically realistic expression values adhere to this
bound, for very low maximum expression ratio values the bound can fail. Such low
expression ratio values are unlikely to be biologically realistic, however for rigour we
here consider the validity of the bound in a biological context, via a data set described in
GSE2361 [265] (Materials and Methods, Chapter 2). The data set proﬁles 33 distinct adult
tissues and 3 foetal tissues. We will disregard the foetal tissues as the tissue types overlap
with the adult tissues and thus cannot be considered distinct homogeneous samples.
We ﬁrst computed the value of sign(1− 1/b+ 2/a) + sign(1− a+ 2b) for every pairwise
combination of the 33 tissue types (528 pairwise combinations). We found that for every
combination of heterogeneous samples the condition described in Theorem 4 was satisﬁed
and thus Claim 3 (super-additivity of signalling entropy) was correct for this data set
(Fig 2.7).
We next computed signalling entropy for the 33 homogeneous tissue types and the 528
pairwise mixtures of samples. As explained above signalling entropy cannot be expected
to be a point-wise measure of heterogeneity, and it is certainly true that not every tissue,
when mixed with another, displays an increased signalling entropy. We do, however, see
a trend towards this happening, with the reproductive tissues (testes, uterus, ovaries,
breast) providing the most signiﬁcant increases (Fig 2.8).
Whence, as expected, Proposition 2 is indeed correct for this data set, and the signalling
entropy of the mixed samples is higher than the homogeneous samples on average (paired
Wilcoxon test p = 0.012, Fig 2.9).
2.3.3.5 Summary In this section we have derived a condition which if satisﬁed by
homogeneous samples guarantees that signalling entropy will be higher in heterogeneous
50:50 mixtures of two homogeneous samples, as compared to the unmixed samples, on
average. We then veriﬁed that for a large number of homogeneous adult tissues the
condition was indeed satisﬁed and signalling entropy was higher in 50:50 mixtures of
homogeneous tissues on average.
These results suggest that signalling entropy represents a quantiﬁer of intra-sample sample
heterogeneity, being correlated with heterogeneity at the population level. Hence elevated
signalling entropy in cancer may be driven by an increased heterogeneity of tumours as
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A) B)
b
Figure 2.6: Analysis of the expression sign(1 − 1/b + 2/a) + sign(1 − a + 2b) for a
range of biologically plausible values: a, b ∈ [0.01, 20]. (A) Histogram of values of
the sign(1−1/b+ 2/a) + sign(1−a+ 2b) evaluated over 2000 equally incremented values
of a and b over the range a, b ∈ [0.01, 20]. We see that the majority of the values satisfy
the condition sign(1−1/b+2/a)+sign(1−a+2b) = 2. (B) Plot of sign(1−1/b+2/a)+
sign(1 − a + 2b) for a, b ∈ [0.01, 20], values of a are plotted on the x axis whilst colors
from red to green to blue denote increasing values of b, we see that as a and b increase
the condition very quickly becomes true, suggesting that the condition only fails for very
low maximal expression value ratios, unlikely to be observed in reality.
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Figure 2.7: Demonstration that the claim of super-additivity
SR
(
x+y
2
)
> SR(x)2 +
SR(y)
2 is correct for all pairwise combinations of samples
in GSE2361. Signalling entropy (denoted SR/max SR) is computed for 528 distinct
pairwise mixtures of 33 homogeneous tissue samples demonstrating that our measure
is super-additive and hence will be raised, on average, in mixed samples compared to
homogeneous samples.
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Figure 2.8: Signalling entropy of homogeneous and mixed tissues. The ﬁrst box
represents the signalling entropy distribution of unmixed tissues, whilst each subsequent
labelled box represents the signalling entropy distribution of the labelled tissue with each
of the remaining 32 tissues. The red line represents the median of the unmixed samples.
We see that for 20/33 tissue types, the median of the mixture is greater than the median
of the pure samples, suggesting that on average the signalling entropy of the mixture is
greater than the signalling entropy of the pure sample.
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p=0.012
n=33 distinct tissues, 
528 mixtures
Figure 2.9: Demonstration that the proposition∫
Ω
∫
Ω
(
SR
(
x+y
2
)− SR(x)) dxdy > 0 is correct for samples in GSE2361. Signalling
entropy is raised on average in mixed samples as compared to homogeneous samples,
considering 528 mixtures of 33 homogeneous tissue samples. The p-value corresponds
to a two tailed paired Wilcoxon signed rank test, and reveals that signalling entropy is
signiﬁcantly elevated in the admixed cell populations on average.
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compared to healthy tissue.
2.3.4 Conclusions and Future Directions
Here we have considered signalling entropy, deﬁned as the entropy rate of the Markov
chain described by a sample speciﬁc stochastic matrix. This measure has been demon-
strated as elevated in cancerous tissue and we here investigated two key properties of
signalling entropy, which may provide biological insight into this ﬁnding, analytically and
with empirical validation.
Firstly we proved that the sensitivity of signalling entropy to changes in the expression
of a given protein is bounded by a multiple of the degree of that protein in the PIN.
Suggesting that signalling entropy may be elevated in cancer as a consequence of over-
expression/mutation of hub genes and that such genes may represent targets for the
experimental control of signalling entropy.
Secondly we derived and validated a condition for signalling entropy to be raised in het-
erogeneous 50:50 mixtures of two homogeneous samples, as compared to the unmixed
samples on average. Suggesting that signalling entropy may be elevated in cancer, as a
consequence of the heterogeneity of tumours compared to healthy tissues.
Both these results thus have clear implications in a cancerous setting. Given that intra-
tumour heterogeneity has long been considered a diﬃcult to measure prognostic indicator
in oncology [266], the latter result motivates the investigation of signalling entropy in a
prognostic context. If signalling entropy is indeed prognostic, lowering it may represent a
novel therapeutic strategy. Hence the result that our measure is most strongly inﬂuenced
by hub genes may become important in therapeutic development.
In the introduction we also discussed employing a network entropy such as signalling en-
tropy as a correlate of a sample's diﬀerentiation potential. Given that pluripotent stem
cell populations have been characterised by an increased heterogeneity at the population
level, the results in this section suggests that our measure is a good candidate quantiﬁer
of cell potency.
These theoretical results thus strongly motivate further data driven work on establishing
the biological validity of signalling entropy in the context of cellular diﬀerentiation and
cancer. Whence in Chapter 3, by considering over 1000 genome wide gene expression sam-
ples of healthy tissue, we will demonstrate that signalling entropy is elevated stem cells as
opposed to diﬀerentiated tissue, and deceases systematically during diﬀerentiation. We
also reveal that signalling entropy is elevated in CSCs as opposed to the tumour bulk. In
Chapter 4 we further demonstrate that our measure is strongly prognostic in epithelial
cancer, through the consideration of over 5000 primary tumour samples. Finally in Chap-
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ter 5, we consider signalling entropy in the context of muscular dystrophy, demonstrating
that it is elevated as a consequence of over-expression of the FSHD candidate gene DUX4.
2.4 Interactome Sparsiﬁcation and Rewiring
2.4.1 Introduction
In the previous two subsections of this chapter we have introduced two network theoretic
tools: NTE and signalling entropy. Our aim of this chapter, as outlined in the intro-
duction, is the development of entropy based network rewiring methodologies, which can
provide local information about gene and pathway rewiring between phenotypes, as well
as elucidation of some general, global principles of network rewiring.
We have seen that NTE is powerful for tracing local paths of diﬀerential network infor-
mation ﬂow between two biological phenotypes and that the measure can be derived from
a metric space framework which can provide general insights into network rewiring in
response to drug perturbation. Thus the NTE measure does indeed satisfy our criteria.
However, the algorithm to compute NTE is computationally expensive and does not per-
form well on large networks.
We have also seen how signalling entropy may represent a global measure of signalling
disorder and intra-sample heterogeneity, which can discriminate between cancerous and
healthy tissue and may provide insights into cell potency and prognosis in developmental
pathology.
Given the global power of signalling entropy and our goal to develop scalable methodolo-
gies, we here propose an algorithm based on a local analogue of signalling entropy, which
we name Interactome Sparsiﬁcation and Rewiring (InSpiRe).
The algorithm is designed to extract a subset of the human PIN, describing genes and
interactions which are signiﬁcantly rewired between two biological phenotypes described
by gene expression data. In contrast to NTE the algorithm is easy to evaluate on large
networks.
As the InSpiRe algorithm is intended to extract critical genes and interactions which are
rewiring between two biological phenotypes, a full evaluation of its validity requires a
biological context. In such a setting pathways which are expected to be detected as a
consequence of previous literature can be outlined in detail, and InSpiRe detected path-
ways which are unexpected can be validated as providing novel insight via experimental
models. Such an evaluation is hence a detailed undertaking, requiring experimental biol-
ogy and thus is not best positioned in this subsection on mathematical analysis of network
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theoretic tools. Rather we present here simply an outline of the application of InSpiRe,
noting how it can be considered a local analogue of signalling entropy. A full validation
of the algorithm in a biological context (that of FSHD), including the experimental val-
idation of novel pathways and the comparison of the algorithm to other methodologies
can be found in Chapter 5.
2.4.2 The three steps of the InSpiRe algorithm
InSpiRe is a diﬀerential network methodology, consisting of three main steps displayed in
Fig 2.10 and described below.
2.4.2.1 Step 1: Integration of mRNA expression data with the PIN The
ﬁrst step of InSpiRe is the integration of expression data with a PIN to create a phe-
notype level stochastic matrix describing network traﬃc as explained above (Fig 2.10A).
Brieﬂy, for each phenotype we integrate expression data with the PIN by assigning each
interaction connecting two proteins, i and j, with a transformed Pearson correlation in
the gene expression proﬁles of proteins i and j across the samples corresponding to the
given phenotype r (denoted Crij). This results in a weighted network w
r
ij which is then
transformed into a stochastic matrix prij where
prij =
wrij∑
k∈N (i) w
r
ik
, (73)
where N (i) denotes the set of neighbours of protein i in the PIN.
We interpret row k in the matrix prij as a probability distribution describing the interaction
preferences of protein k in phenotype r. Note that
∑
j∈N (i) p
r
ij = 1 and p
r
ij = 0 whenever
i and j are not connected in the PIN. For (prij)j∈N (i) to be a probability distribution we
require that prij ≥ 0, which is guaranteed if wrij ≥ 0. The choice of the transformation
of the Pearson correlation wij must be made carefully to ensure non-negativity and that
interpretation of a high edge weight, indicative of an increased likelihood of interaction
between connected proteins, is valid.
As explored in Section 2.1, we consider two possible phenotype level stochastic matrices,
corresponding to transformations
wrij = |Crij |
and
wrij = (1 + C
r
ij).
The former deﬁnition biases information ﬂow along paths of highly positively or negatively
correlated proteins, whereas the latter biases only positively correlated protein paths,
Page 123
Network Theoretic Tools in the Analysis of Complex Diseases C. R. S. Banerji
Primary Muscle Biopsies
Healthy and Pathological
Genome-wide gene
expression assays
Database of muscle gene
exression
Protein A Protein B
Protein interaction assays
Database of protein-
protein interactions
Protein Interaction
Network
Interrogate Public Databases
Protein A Protein B
Interaction data
Expression data
Expression of Protein A in
phenotypeEx
pre
ssi
on
 of
 Pr
ote
in 
B i
n
ph
en
oty
pe
Protein A Protein B
Pearsons Correlation
Coefficient: r = 0.8
Modulus of Pearsons r
Interaction Weight
|r|=0.8
Weighted Interaction
Weighted Protein Interaction
Network
Step 2: Rewiring with Information Theoretic Measures
<0
>0
>0
>0
=0
>0
Apply to all proteins in weighted protein 
interaction network
Set of proteins rewiring across phenotypes
Step 3: Sparsify network of rewiring proteins and their neighbours
Differential Correlation
between phenotypes:
p-value<0.05
Protein A
Protein B
Interaction data Example 1: Keep Interaction Example 2: Remove Interaction
Step 1: Integrate Expression and Interaction Databases for a given phenotype
Interactome Sparsification and Rewiring (InSpiRe): 3 steps
Interaction 
distribution of 
central protein: 
phenotype x
Interaction 
distributions of 
central protein: 
phenotype y
Expression of Protein A
Differential 
Entropy(x-y)
KL 
Divergence(x,y)
Phenotype x
Phenotype y
Ex
pre
ssi
on
 of
 Pr
ote
in 
B
Expression of Protein AEx
pre
ssi
on
 of
 Pr
ote
in 
B
Differential Correlation
between phenotypes:
p-value>0.05
Key
Maintain 
Interaction
Remove 
Interaction
A
B
A
B
Apply to all rewiring protein 
interaction distrbutions
5962
1808
60625
27175
5196
10401
9223
8655
10211
23348
383
4097
23534
55201
10928
6239
4616
2290
7972470104049
8899
6778
51517 51160
23047
10286
9328
4005 4745
9276
9391
55775
863
6654
85458
3977
3866
1108
595
2022
6337
6885
9587
3560
10713
6925
6938 4066
862
2230
7410
10750
2189
8328 8935
25842
4057
998
79441
3280
10465
5488111017
51690
5581
988
23378
4886
2571
7447
7106
1839
3679
50618
51691
928
930
27258
333
55274
405 10332
91887283
4296
11100
2348
9815
6777
873563931
5422
2033
92140
307
79728
55723
6602
80347
58
5885
11273
5558
79751
6146
3188
8653
22826
8812 2997
51021
60488
79068
10148
4809
6432
1398
29766
64848
3716
9092
3310
27349
3843
7082
1890
63893
2533
55119 5621
65993
10728
54865
6741
54433
5128
10643
10165
4927
5268
51444
8471
29924
25804
741
9716
4088
334
9410
24144
8890
3694
284
2274
10980
98979410163
81875
5297
56897
10726
5927
9103
9448
9402
80228
23186
112950
3726 5934
29842
466
3800
23621
6388
10010
148022
60492
2166
4798
808910900
4190
79913
5050
54477
55193
3054
51773
81624
7407
7970511335
50717
3890
80227
2965
55147
79016
1051
4855
9989
2113
60561
6880
6462
695
51191
4486
2209
8347
10467
26009
9684
4254
355
23133
3929
23396
8665
221061
4709
11033
3883
54819
79447
50619
8900
8287
8738
51133
4323
23650
7458
10301
8613
219333
9656
940
10915
8886
4137
6794
10664
490510579 4089
5560711056
1642
7416
51592
324
4926 55466
230355903 517478607
5437
25793 2293879871
23410
7428
7277
7168
4188
2688
9577
3065
526
8289
4331
5104
51616
5914
358
8911
116138
25820
9979867
10116
3097
627
23588
2873
4090 2119
8974 5214
43167980
84861
2948
83700975
1277
7704
5654
1514 1294
1161
9047
5774
23363
55914
10868
6871
1954
285
64375
11059
3146
1791
79797
27332
2150
60684
5716
4778
1436
1399
25814
26263
51138
26057
6883
6878
8837
1647
488
7409
1991
5324
26128
4602
348
23197
10426
710
23064
23460 9456
6261
51433
8996
3482
27185
8772 6404
22861
1278
7818
10425
23062
2662 4430
4478
52
960
871
51495
7412
6262
335
5646
1120
79568
7786
29108
5599
2909
6789
80012
1500
26994
7185
4723
54539
5473
5097
58477
4995
57165
712
80279716
5764
9638
1511
8321
874
321
6282
4035
868
1947
7328
51599
10055
81570
6049
1871
409
3172
9451 7080 4208
6241
9378 5519
96664085
6927
2244
558
991
2195
10112
5606
930610857
8604
11030
8743
3135 6477
51337
596
9640
1106
5530
10945
284403
8689
5110
4649
64761 8766
154
2731
6522
162
1315
29123 82378723
256364
64397
10193
23122
51307
3356
35536596
9351
6944
6396
28232
7112
93973
93664
3543
25909
4233
26227
51230
208
84148
5450
7444
190
8473
9874
7388
8535
54474 97297135
105427301
7358
4583
11007
26150
8227
7004
114876
773
9757
1053
604
2623
6597
3849
9320
5170 6182
51154
3799
568653788239
6721
8417210794
1111
79003
575
7169
831
950
8330
4116
1385
55367
9479
5295
9500
2353
2309
11260
25865
5582
2806
10949
9748
6117 20509919
5744
3636
2006
23612
4722
51207
84612
8697
1010
56478
8651
10125
5970
9021 29978
79902
1069
4301649710015
38574216657 55970
8490
10269
90
5318
1439
2047
23235
6949
8021
6714
51564
29761
306954205
5588
284119
8649
9470
6278
5894
3960
23373
673
357
818
999
1847
8673
5902
10687
23111
4145
427
57706
7014852185021
652209529
6018
57506
23136
7422
7879
9699
9107
2886 19
11116
4008
6240
11016
98599342
23043
5529
9020
4139
688
5269
51384
57761
3299
57337
1659 23203
55813
23613
1060
23429 9685
57405
23303
650
7528 10403
1870
51096
93
7555
1022423299
25833
25936
9134
25847
80254
943
3032
23275
10629
10755
153
23645
6456
6185
643314
54919
10393
112869
9667
107461356
11130
2690
8835
6612
57082
468
2316
51068
1649
51043 1207
9322
8301
1854
7456
5467
23198
372
3312
5709
5602
2049
10075
5705
1021
5707
71
1780
3850
55291
3725
2961
3895
3017
3690
6850
6257
896
57645 10499
78990
10043
3798
84669
84516
5870
30849
79023
51181
51341
6688
10656
813
11004
29127
5868
55339
8841
64858
3596
8312
3665
1025
7027
60681
55729
23162
6310
29844
4615
7045
25852
6598
9761
27330
832
51514
5782
3689
867392
231
51203
23523
11140
8480
2969
7536
9139
8570
54472
117178
2643
2193
332
1103
63925 567
6670 7189
29087
4741
5449
5876
5930
8411
4204
6305
54954
6839
51552
26060
79801
5878
10040
7430 2241
9146
2107
10294
2213 4253
79980
5563
515208848
5796
10254
5595
2670
7047
11321
9212
57091
8202
7436
8712
2171
10607
3500
2207
6840
79837
56997
22915
52261969
23095
92
472
3932
23367
10287
10389
27076
23309 7533
824310482
3014
2242
3297
2010
4067
30851
815
8290
51193
6748
5584
1455
9669
84075564
27101 1743
1457
7086
36431974
9240
908810768
682
62944904
11103
9401
10423
54994676
5223
5905
238
6709 4173
79590
29997
640
5250
3852 8295
46569282
61759793
51504
3646
8550
1717
10921
5300
851761939588
213387082
2023
26135
8878
10576
5204
652026292
1000129968
9969226
23411
1917 10128
23193 873
6464 105896203
5296
1973
23405 302
2058 10992
23239
85476 191
3006
1152
4544
10575
2923
4627
10087
8662
5496
3183
73529701
8148 7317
8717
6187
10627
10527
6122
1933
29966
808
8634
6129
206716
6421
5432
6431
7248
55294
840
53637
3611
8945
1837
867
5142
7133
7024 4619
10969
4622
5954
9126
6625
81892
647081665
7072
7531 5211
55027
51362
25937
80306
80232
5469790
798334155
51082 6894
22936
602
3308 8091
9584
83443
10989
10454
509
85723389
6232
6134
2597 4340
22818
81857
203068
4628 27252 6158
10274
3098
7554
5140026056
53339
2910210202
4313
4092
648
5213
5644
10944
5127
22909
9136
55969
54989
292
6950
9978
55651 3336
83660
5034
8520
5058
2957
11052 4621
1107
58525
80344
9987149510342
55037
309688826
5725
1163
3185
3619
10605
10236
3868
7184
10749
1499
5479
51366
9590
6059
7153
9063
91754
1018
9782
10606
3493
10130
79084
26986
9775
3921
10644
1813 9045
5111
2312
6197
55740
8669
1017
51466
2931
79075
5165
3717
7791
7053
23244
27
11183
9183
8711
7128
9655 5883 3240
5763
2044
26073
7297
1041 1453
9414
1786
27102
9688
28299
8436
8650
54906
23279
114885
7535
54900
1234
1982
309
10926
79659
114883
6990
3856
920
9869
5836
2317
51729
27165
10208
6010
5294 5451
23741
51186
3488
10273
187710524
50943702
1781
9513
8557
5908
54978
900
7158
28227
53347 5494
3043
1000
6875
2064
6416
23360
1508
2243
367
22933
1212
5770
57664 51755
6723
55660
5747
64122
4193
53305515
54915
9520
6125
1652
752
9338
5518
6996
10808
9879
3875 9202
30008
1024323031145929088
22827
10491 26586
220988 99436801 8453
5201
90432821
7251 8850
27229
26525
1629
23658
1843
4792
9648
1844
55183106152962
5029
4282
5464
11698555149
23132
8761
2146
7088
55734
26156
9643
79571
2235
3485
3627
1968
23633
7727
3937
9846
3953
3593
9898
10067
9094
23083595
55165
11124
9700
51759
2674
64710
2
6566
4179
10940
1441
26130
9217
1386
6711
408
4705
23028
55720
51150
5610
3688
10084
6774
10210
55757
9112
83989
25949
55505
35721583
51562
49297408
7041
1630
51701
23558
6628
94104
10603
10241
10735
891
55120
9232
55898
3570
23354
4734
5884
100287932
8161
467
2774
79665
2178
64963
2040
79876
1601
9931
9100
8861
2151
10557
250
8156511319
6311
6830
8971
27238
3161
4353
9101
6223
5824109239221
26271
55327
57819
23451
10528
95259541
641759531 9551
25840
10471
5781
9416
890
9733 11157
25493791
521
4698
8115433 23085
4771
1095110856
6133
1828
7284
10212
79184
2079
158
2483
9774
3191
4691
8803
50628
1762
10970 54788
10580
10667
5052
4318
9368
57470
4801
1020
114791
575994720
391
22981
10006
10094
605023246
51347
8379
1191
11315
308
29074 8576
9254 1028
7018
79691
3091 5340
3945
3881
57634
1984
1600
2960
11336
23530
2813
27043
23327
6304
55851
3059 56829
8661
10092
2516 81628
56159
23291
11215 8986
91807 3514
3075
10285
7775
27037
7324
60487 1407
4635
31052778
55034
2767 11141
7295
5580
760
7083
5493
29882
6238
2677
6198
995
23234
64682
339622806
51421
260243414131
23071
11224
543010845
1674
27125
23172
236031950
5571
126353
996 7417 10421
983
9412
10533 23382
1123
57418
157680 3182
4638
51065
271836206
580 400
103672665
11045786
5984
8406
5923
25980
11277 3667
6046
224
10432
8178
8894 7150
51386
51720 54962
54532
55217
5933
9578
56257
8548
27250
4898
9833
10635
3635
6742
23635
55100
56827936
3880
2776
4034
1052
1756
1608
11155
7709
10174
6510
81552
55512
2661 9467
8575
84433853
3861
1326
79139
659 55143
272
79726
228204719
6655
7276
1460
5931
344 654
10451
26092
3842
5660 5339
9040
10289
8365856252
6118
60496
23328
23255
4288
6494310594
2647
23020 378
7525
8425
11243
55718
2963
4311
64759
3053 5465
7257
7094
64464710
10146354 6470
3855
5197 5198
23223
83955
689
3437
8648
5981 1675 231925803
655
2280
345
10481
2959
5912
46257402
3858
3419
10240
6780483964799
26019
55226
11331
2550
27316
80658924
2747
8658
22948
23352
9295
6498
11190
26121
79009
54726
10159
4851
5663
9967
107877037
8976
27044
26747
1266
1022 1855
54606
79026 8464 8522
8666
5272
6897
845011235
51512
7448
54800
1822 1105
4738
5867
8614
4640
2041
642236879
9098
54499
1615
865
5925
27335
5130
2634
1643
5290 6696
7336
8615
25843
140890
7572 3010
23524
10765
2569
3680
55062
1148848751
5578
51780
3163
84271
56949
10036
29927
6176
23126
4686
9372
9861
54927
4214
4172
1175
118
1965
1783
3718
2668
2346 22822
515
5160
10464
10672
1003
6331
4942
9319
919
23130
24148
9646
9639
5825
9682
2318
768110207
3891
5093
9784
973
2175
7462
2335
5335
3778
1031
3479
10567
11214
7052
197
79183
9612
29347376
55589 2185
4436
11021 1956
23294
9778 1482
147
23636
347240
5069
22941
22994
1471
57180
10293263
6767
387
55139
7813
629
337
22848 7259
5562
55652
3815
2065
1050 1736
85315514255234
34
1909 9133
3832
51574
9181
26052
5062
10309
2155
54468
810
9882
2570
1408
9475
51663
219426999
54948
23196
79155
10548
10238
7520
1119326993 3848
24624354187
64852
4670
1660
387265005
27292
3184
373530053189
7419 192670
5879
1653
4659
779 2017
23770
51035
10413
26064
9318
1432
336
8626
5175
1981
10382
1936
3187
6526
235211654
11171
3615 220134
3178
5591
8106
4149
1655 5230 3181
8175
9049
1213
319
22907
2246
2091
10985
4841
10514
10694
51184
7874
1062
615981545
10492
64866
265234678
4040
10912
23513
6872
11136
10458
27161
64576500
3608
6502
498
6165
1915 6141
10291
7398
6188 3192
331555112
463410988
3012
615757062
8554
5347
10466
9411
9129
10298
51471
2771
8305800
55958
545
23640
2648
7465
51202 1759 56945
6576
1373
55794
6144
57551
151
10096
2525994
5216
1778
973055379
142
5358
4356
9218
1027
96764
6886 10436
130223607
330
8452
7319
8451 2803
151987 3685 51185
3339
506494690
23345
23019 4692
6275 5036
403 6874
6722
8825
3301
8883
3008
23315
6426
1454
6136
841
373156
10179
47357846
1796
322
4925
1063
8241 8428
1468 25845873
7167 26278
10443
6128
9443
7347
26354
55791 9610
88912147
704010188 5921
80204
59
3486
3693
3164 2720
3055
3148
847
10111
2059
81929
1964039734
36
23189
81855
83444
5983
556834205
80781
827
4528
5361
55176
8218 10397
5208
4072
3682
1997
3337
27132
1875
7025
10477
58500
5685
10002
7474
11338
4968
83478
23493
55024
8793
1602
6280
9099
9124
51143
7322
921
6517
2887
114
8859 84617 56616
4361
4522
54700
39
10014 3854
166 55743
92335
1211
2002
2181
5427
2932
6015
8525
10445
27134
10975
55968
5955 10276
81027
6256
6605
304
3561
3487
1179
228743985
6667
23435
5829
732910954
8266291
6452
25778
5091
4646
3309
7514
8533
506
6892
25667157
27709440
1487
5129
4747
57038
22913
81
10419
8864
10982
347
7159
207
10297
4130
5257
5536
55161
4543
7170
6181
79813
9555
23001
3925
231917334
1994
5228 9994
26037
55827
10213
4435
9611935223170
6923
4289
1080
6891
99396924
8349
79818
5784
7124
9759
79921 1656
10494 3983
23380 10847
47
7026
637
1948 4140
55905
2889
2060
29888
11172
23216 79595
70685306
20456720
6881
2101
8467
25920
10420
23118
7385
3276
1154
2099
2736
3654 549693675 55049
331
4086
5687
836
678
23051
267
86090379
9135
3383
5316
171023
4782
10290
55164
9972
35071937
4350413479858 5286
1616
3710
55833
10645
49674613
5261
11228
701
22870
3480
56893
1068
51474
53944
356
53371
476
8881
9908
3624
990
3605
313
2048 7508
5537
23592
823
3831
51268
230601540 8844
7046
598
7164 64864
50855
2534
80223 10973
1856
4637
552123677
6184
6895
1070
6745
5605
5906
62272872
5304
10469
816
9260
53635
1452 5594
286 1975
22841
5531
8668
10849
5481
8767
10260
8500
140597
4076
3376
10885
64837
2896 26031
81618
6921
23243
55832
4794
708
3836
6929
10048 51428
4082
8660
23332
23710
858
3066
72495971
79869
64794
4791
62796601
57602
1147 23077
51806 60
4175
3984 6472
29081431
8664 428646416790 369
24140
5805 6277
2631
7030
3839
55844
5982 3030
892
5440
7431
2072
2182
5901
4215
481
58472
5315 9036210920
3609
5886
6626
560411337
3313
7132
72033329
1829
4548
9131
3851
9044
943910971
9862
2307854677
23160
5691 11198 55699
1650
10245
7916
1072
10383
4673
7414
5317 83734
54386
539
5241
9114
5693
23517
6387
5702
724191
7374
5516
5438
6139
29117
6124
80267
57172931785
11073
29562547
5684
5603
7529
10963 5478
821
2289 6418 423765055
55705
3837
31338667
6732
9641
10480
301
908 9692
699 277352457074 7006
8508
5511
9601
10155
9052
2737
4171
1869
29894
8030
23038
79269
5291
3516
8536
10987
5528
55257
50813
6837
23648
9693
8454
518074697
23350
8412
4790
1434
7273
74114087
7015
3305
5526
4701
55717
1173
79718
105238079
5759651019
1019727339
3551
6259
328
11176 7057
4830
89
6430
8204
64750 4642
51586
9532 1019 9533
4609
1445
7337 20373281
10025
54868
2319255090
2494
7534
56075587 29110
2011
51067 5434
83638
1314
6137
1024
1978
445
58715265
6318
3320
70
51727
22824
65109
1823
1938
84790
23511
10541
55215
7343 10772
83737
4001
2580
1509
233104069
5618
3326
23450
10131
5966
3306
23683
8819
4170
1977
2810
23139
412
55038
9493
4292
7756
7186
64431
5566
51493
26146
6204 5711
2108
7989610038
51018
3107
1280
29046737
10452 7023 5101
5692
5700
5520
7280
672
55135
5788
1456
9321
10946
22992
9575 3840
829
5719
10121
1476
51003
3394
64422
4163
23304
2104
55658
55178
5431
9802
9785
4437 6749
5928
90395690
11098
9097
79753
55860
7029
3476 8863
30367360
7443
21096595
5701 5689 3106 36925049
7802
5708
3728
7020 5710
5688
9817
5439
88
9141
2063
5714
5683
2232
28965
10762
9184
29079 5718
5694
9968
7342
11047
10891
5695
5704
64425
577129086
9238
1368
5887 5590
56667
10049 26058
1059
23165
5713
5586
23054
51377
4928 3838
1387
5706 5310
7415
4217
4629
9477
10574
9442
3959
3275
5696 3149
904
Sparse network of 
differential interactions
Apply to entire database
A)
B)
C)
Isolation of myoblasts/
Differentiation into myotubes
Figure 2.10: An overview of the InSpiRe algorithm. Public databases are inter-
rogated for expression and interaction data. (A) Step 1: integration of expression and
interaction data, via Pearson correlations, results in a weighted network for each pheno-
type. (B) Step 2: information theoretic measures detect proteins rewiring between the
phenotypes, which are reconnected to their neighbours in the PIN (C) Step 3: sparsiﬁ-
cation of the rewired network, via diﬀerential correlations, results in a sparse network of
proteins and interactions which are signiﬁcantly rewiring. Page 124
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with negatively correlated being selected against. We explore these two weightings in
the context of FSHD and control muscle gene expression in Chapter 5 and ﬁnd that the
weighting based on absolute correlations provides the basis of a more robust discriminator
of network rewiring.
2.4.2.2 Step 2: Detecting Rewiring Hotspots - Local Entropy and Kullback-
Leibler divergence The second stage of InSpiRe appeals to a local analogue of sig-
nalling entropy, namely local entropy (deﬁned earlier) to detect rewiring between two
phenotypes described by the stochastic matrices constructed by Step 1 of InSpiRe. In
addition to local entropy, we also employ a symmetrised Kullback-Leibler divergence to
detect a wider class of network rewiring events (Fig 2.10B).
Local entropy quantiﬁes the disorder of a protein interaction distribution in a given phe-
notype and is based on Shannon entropy.
Given a stochastic matrix corresponding to a phenotype r, prij , the local entropy of protein
i is deﬁned as
Sri := −
1
log ki
∑
j∈N (i)
prij log p
r
ij (74)
where ki is the degree of protein i in the PIN. S
r
i ∈ [0, 1] is a measure of how close a
protein's interaction distribution is to uniform. Values close to 0 imply protein i has a
deterministic interaction distribution and values close to 1 suggest a uniform proﬁle.
We compute vectors describing the local entropy of each protein in the interactome for
two phenotypes. These are statistically analysed using the jackknife technique (below) to
identify proteins with signiﬁcantly diﬀerent local entropies between phenotypes (signiﬁ-
cance assessed at the 5% level). Such proteins can be considered as altering heterogeneity
in their interaction distributions.
Previous studies into cancer have revealed that proteins with lower local entropy in a
given phenotype can be interpreted as being more active in that phenotype [17, 23]. Ex-
amples of interaction distribution changes which lead to either an increase or a decrease
in local entropy are displayed in Fig 2.10B.
It is possible, however, for a protein interaction distribution to be rewired without chang-
ing uniformity and hence without altering local entropy (Fig 2.10B). Consequentially, we
introduce another measure based upon Kullback-Leibler divergence, which though lacking
the functional interpretation of local entropy is sensitive to such rewiring.
The Kullback-Leibler divergence was introduced earlier and is deﬁned as follows:
Given two probability distributions P : X → [0, 1] and Q : X → [0, 1], provided
{x ∈ X : Q(x) > 0} ⊂ {x ∈ X : P (x) > 0} the Kullback-Leibler divergence between
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P and Q is given by:
DKL(P ||Q) :=
∑
x∈X
P (x) log
P (x)
Q(x)
. (75)
Note that DKL(P ||Q) 6= DKL(Q||P ) as DKL(P ||Q) quantiﬁes the expected number of
bits required to describe a sample from the probability distribution P given one incorrectly
assumes the sample follows the distribution Q. To compare distributions describing the
interactions of proteins in control and pathological samples, the choice of the direction of
Kullback-Leibler divergence is ambiguous. Arguably both orientations are informative.
The quantity DKL(pathological||control) may describe the amount of information the
causal genetic insult of the pathology bestows to the interaction distribution of a protein.
Conversely DKL(control||pathological) may quantify the amount of information required
as input to the pathological protein interaction distribution (say by a drug) to restore a
healthy phenotype. We will therefore use the symmetrised Kullback-Leibler divergence
deﬁned by:
DS(P,Q) := DKL(P ||Q) +DKL(Q||P ). (76)
Given two phenotypes r and s described by stochastic matrices prij , p
s
ij , the local sym-
metrised Kullback-Leibler divergence of protein i between phenotypes is given by
Ki(r, s) := DS((p
r
ij)j∈N (i), (p
s
ij)j∈N (i)) (77)
=
∑
j∈N (i)
(prij − psij) log
prij
psij
. (78)
We note that Ki(r, s) ∈ [0,∞) and values near 0 indicate that the interaction distribution
of protein i is similar across the phenotypes, large values imply rewiring of protein i
between the phenotypes.
We again employ the jackknife technique (below) to determine which proteins have a
signiﬁcantly non-zero Kullback-Leibler divergence (and therefore are rewiring) between
two phenotypes (signiﬁcance assessed at the 5% level).
To create a relevant subset of the PIN proteins identiﬁed as signiﬁcantly rewiring between
two phenotypes, are connected to their neighbours in the interactome.
2.4.2.3 Step 3: Sparsiﬁcation of Relevant Subset of PIN The ﬁnal step of
InSpiRe is the sparsiﬁcation of the relevant subset of the PIN constructed in Step 2 on
InSpiRe, to delete interactions which are not driving the detection of proteins by informa-
tion theoretic measures (Fig 2.10C). Interactions in this sub-network connecting proteins
whose expression is not signiﬁcantly diﬀerently correlated between the two phenotypes
(assessed again at the 5% level, via the jackknife) are deleted, sparsifying the network to
leave only rewired interactions.
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2.4.2.4 Statistical signiﬁcance determined via the jackknife The jackknife re-
sampling procedure has been employed previously to analyse diﬀerential local entropies
[23], and is considered superior to the bootstrap estimation (for our purposes) which is
known to artiﬁcially inﬂate correlations [23, 267].
Jackknife estimation is performed as follows: given a quantity X (e.g. a diﬀerential local
entropy), we ﬁrst estimate X from our entire data set, consisting of n samples, denoting
this estimate by Xˆ. We next compute n subsequent estimators (Xi)
n
i=1, from the data
set, by removing each sample, one at a time, and re-estimating X. We then compute an
estimate for the mean Xµ and the variance Xσ of X via:
Xµ := nXˆ − (n− 1)
n
n∑
i=1
Xi (79)
Xσ =
V ar[nXˆ − (n− 1)Xi]
n− 1 . (80)
Utilising these estimates we construct a Z statistic
Z =
Xµ√
Xσ
∼ N (µ, 1). (81)
which can be used to test the hypotheses on the mean of the quantity X. In the In-
SpiRe algorithm X will either be a diﬀerential local entropy a diﬀerential correlation or
a Kullback-Leibler divergence, hence the null hypothesis will always be that the mean of
the quantity if 0. Statistical signiﬁcance is assessed at the 5% level.
2.4.3 Summary
In this short section we have outlined InSpiRe a local algorithm, which employs an ana-
logue of signalling entropy alongside Kullback-Leibler divergence and statistical sparsiﬁ-
cation to investigate network rewiring between two phenotypes described by expression
data. This algorithm scales the global power of signalling entropy to identify genes and
proteins driving changes in this global measure. Moreover, unlike NTE, the InSpiRe al-
gorithm does not require extensive simulation and thus is computationally inexpensive to
implement on large networks.
We note that a robust validation of InSpiRe requires a biological context, wherein exper-
imental validation can take place, hence we postpone our validation to Chapter 5, where
we explore InSpiRe in detail in the context of FSHD.
2.5 Discussion
The aim of this chapter was to construct and develop entropy based network theoretic
tools, which could provide insight into the global and local basis of network rewiring. To
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this end we have introduced three such tools and motivated further work.
The ﬁrst was NTE, a local transfer entropy measure capable of detecting the directed
amount of information transferred between any two vertices in a weighted biochemical
network. We demonstrated the validity of the NTE measure to detecting diﬀerential
pathway activation in a phosphorylation network. In addition to being a powerful local
measure, we also explored how the theoretical framework behind NTE can be interpreted
in the context of a metric space, which can permit the elucidation of global network
rewiring properties. In particular, we demonstrated that deformation of network edge
weights is followed by a congruent deformation of network dynamics as assessed by a
weighted random walk. This global property indicates that a network drug strategy is
coherent within the NTE framework.
We next introduced signalling entropy, as a global measure of disorder in protein inter-
action signalling, computable from a single sample of genome wide gene expression data.
We noted that this measure has been previously employed as a discriminator of oncogenic
status and here motivated and validated two possible reasons behind this. Firstly, genes
which correspond to highly connected vertices in the PIN have been shown to be over-
expressed and mutated in cancer [2]. We thus demonstrated theoretically that signalling
entropy is more sensitive to the expression of such genes. Subsequently we considered two
independent data sets describing gene and protein expression for a number of cancers,
empirically conﬁrming that high degree gene expression was a more dominant driver of
signalling entropy variation than low degree gene expression. Secondly, tumours are typi-
cally more cellularly heterogeneous than healthy tissues. We thus derived a condition for
signalling entropy to be elevated on average in samples corresponding to heterogeneous
mixtures of cell types. By considering an expression data set describing 33 homogeneous
tissue types we conﬁrmed that the condition was valid for all 528 pairwise mixtures, thus
providing evidence that signalling entropy is a correlate of intra-sample heterogeneity at
the population level. The ﬁnal network theoretic tool introduced in this chapter was the
InSpiRe algorithm, derived from consideration of a local analogue of signalling entropy.
This algorithm is intended to extract a subset of the human interactome which is rewiring
across two phenotypes, and is more computationally tractable than NTE.
These three network theoretic tools can beneﬁt from further development. In the case of
NTE, there is considerable scope for the investigation of high level theoretical properties
of network rewiring, such as persistent network states and network dynamic evolution.
However, a primary goal of this thesis is the understanding of complex pathology, through
the characterisation of cell diﬀerentiation and the positing of therapeutics. It is not im-
mediate that further theoretical investigations of the NTE framework will progress these
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goals.
The theoretical results regarding signalling entropy, however motivate further investiga-
tion to achieve the goals of this thesis. The fact that signalling entropy correlates with
intra-sample heterogeneity suggests that the measure may associated with the increased
population level diversity of pluripotent stem cells and thus may represent a powerful
correlate of cell potency. We will investigate this notion in detail in the next chapter. In
addition, intra-tumour heterogeneity is a diﬃcult to measure prognostic factor in epithe-
lial cancer and thus signalling entropy may prove important in survival studies. We will
therefore investigate our measure as a prognostic indicator in Chapter 4.
This InSpiRe algorithm is a local analogue of the potentially powerful signalling entropy,
designed to provide detailed information about genes and pathways perturbed in pathol-
ogy, in an easily computable manner. Establishing the validity of this algorithm requires
further work and is best performed in a biological context, where it can be compared with
other algorithms and where experimental techniques can be employed to validate poten-
tially novel ﬁndings. Our algorithm will likely provide greatest insight in a pathology
where network analysis is lacking and we thus apply and validate InSpiRe in Chapter 5
in the context of FSHD.
2.6 Materials and Methods, Chapter 2
2.6.1 Estimating NTE
NTE is formulated as the JSD between two probability distributions, for which we can
derive closed form expressions. The evaluation of these closed form expressions can be
computationally expensive, however, especially if there are multiple vertices of large de-
gree. This is because a main step in the evaluation of the expressions is constructing
the set A of possible signal dynamics over a single time step, which for a network on N
vertices is of dimension
∏N
i=1 ki, where ki is the degree of vertex i. Moreover, the time
complexity of evaluation scales exponentially with the path length parameter n.
For most networks, however, estimation of the probability distributions involved in the
NTE expression can be done eﬃciently. As the model underlying these distributions is a
discrete time Markov chain, with a discrete state space, we can employ Monte Carlo sim-
ulation for any ISD to provide realisations of the signal distribution on the entire network,
for any path length parameter n. From these realisations the probability of a speciﬁed
signal level at vertex i, given an ISD and path length parameter n, can be estimated as
the proportion of simulations in which the speciﬁed level is achieved.
Page 129
Network Theoretic Tools in the Analysis of Complex Diseases C. R. S. Banerji
Two major considerations need to be addressed to ensure accurate estimation from this
procedure. Firstly, it is clear that the more simulations of the model performed, the more
accurate the estimate of the probability distribution, moreover the estimate computed
from K simulations will converge to the true distribution as K →∞. Thus it is essential
to select K suﬃciently large to ensure that the estimated distribution is suﬃciently near
the true distribution with high probability. Secondly, given a speciﬁed K it is important
to establish how the error in estimating the probability distributions translates to error
in estimating the NTE.
To address the ﬁrst issue, we consider only the full network i.e., without any vertices
set to absorbing state, as the stochastic matrix for the full network will have the fewest
deterministic vertices, and thus will be the hardest to estimate probability distributions
for. For each probability to be estimated we construct a trace plot describing the change
of the estimate with the number of simulations K. This plot allows us to assess conver-
gence of the estimate as K is increased. We select the number of simulations K for each
network as the maximal K such that, the shape of the trace plots indicates convergence
and the estimates (for every vertex signal probability) at K and K − 100 diﬀer by no
more than 0.01. The selected value of K is highly dependent on network size, however
we found that a value of 500 is suﬃcient even for very large networks (> 8000 vertices).
To address the second issue of error in the NTE after selecting K, we computed multiple
(R) estimations of the signal probability distributions for the full network from K simula-
tions. We then computed, for every
(
R
2
)
estimate pair of the signal probability distribution
at a given vertex i, the JSD between the two estimates of the signal distributions. This
JSD, computed for vertex i, can be interpreted as the NTE from an arbitrary vertex j
to i, when j sends no information to i, if the estimation is perfect, this quantity should
be zero. As the estimation is imperfect we obtain
(
R
2
)
estimates of the error in the NTE,
deriving from error in the estimation of the probability distributions from simulation, for
each receiving vertex. From these estimates we can approximate the ﬁrst two moments of
the error distribution, a NTE for a given receiving vertex is considered not attributable to
error, provided it lies at least two standard deviations above the maximal error observed
for the vertex.
A program for implementation of the above described algorithm for estimating NTE was
written in R and is included as supplementary material to our publication [268].
2.6.2 Assigning an ISD to the biological network
To compute the NTEs over the two perturbations of the biological signalling network we
must ﬁrst deﬁne an ISD and edge weights for each perturbation, from the data. As the
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kinases in the network must be phosphorylated to phosphorylate their direct targets, two
connected proteins with highly positively correlated phosphorylation levels across single
cell observations under a given perturbation, are likely interacting. Thus a suitable edge
weight which captures the strength of a phosphorylation interaction represented by an
edge (i, j) under a given perturbation k is 1 + Ckij , where C
k
ij is the Pearson correlation
of phosphorylated protein levels across single cell measurements under perturbation k.
Deﬁning the ISD is less trivial and requires consideration of the question we wish to answer
and some technicalities. To determine the diﬀerences in information transfer between the
two perturbations, it makes sense to consider an ISD which quantiﬁes the diﬀerence in
phosphorylated protein levels between the two treatments. A technical issue to consider
is how diﬀerent signal distributions on the same network lead to diﬀerent NTE values
between vertices. It is clear that weighting a vertex with a non-zero signal leads to a
higher NTE value between that vertex and its downstream interaction partners (depend-
ing on the value of n) than weighting the vertex with zero signal. Thus vertices with
an information deﬁcit in one perturbation versus another should be weighted with zero
signal in that perturbation and a non-zero signal in the other.
A more subtle issue concerns the number of unique signal values attainable at each ver-
tex for a given ISD and how this relates to the NTE. It is somewhat intuitive that if the
inputs to a given vertex each have a unique initial signal value, then the range of values
attainable by the receiving vertex will be more diverse than if all the inputs had the same
initial signal value. Thus one may hypothesise that the NTE from one vertex to another
vertex, with multiple inputs, will be larger if the input vertices have unique initial signal
values than if they have identical signal values.
To explain this concept, consider the network shown in Fig 2.11, consisting of one central
vertex with 3 possible inputs, which are each as likely to forward signal to the central
vertex as they are to forward signal to a separate independent neighbour. We consider
the eﬀect of the ISD on the NTE from the circled vertex to the central vertex for path
length parameter n = 1 via two cases. In the ﬁrst scenario the initial signal at every input
vertex is identical (Fig 2.11A, in this example this signal value is one), while the signal at
every other vertex starts at zero. In the second case every input vertex is given a unique
value (Fig 2.11B, in this example these values are 1, 2 and 3), while the other vertices
are again given initial signals of 0. Consider the probability distribution of signal at the
central vertex after a single signal transfer event. For the ﬁrst ISD, this distribution can
take 4 unique values (namely 0, 1, 2 and 3), however for the second ISD, with unique
signal values at the inputs, the distribution can take 7 values (integers 0 through 6). Now
consider the signal distribution at the central vertex given that we prevent the circled
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Figure 2.11: NTE dependence on the ISD. Comparing the NTE from source vertices
to a target vertex when the ISD at source vertices are (A) non-unique and (B) unique,
note that a unique ISD at input vertices results in a higher NTE from source to target.
vertex from sending information. For the ﬁrst ISD, this distribution now admits only
3 possible values (0, 1 and 2), while for the second ISD only 4 possible values are now
attainable (0, 2, 3 and 5). Thus the size of the coding alphabet at the central vertex
after removal of input from the circled vertex has shrunk from 4 to 3 under the ﬁrst ISD
but from 7 to 4 under the second ISD (a much greater fall). Consequentially, we notice
that the NTE from the circled vertex to the central vertex is lower for the ﬁrst ISD than
the second ISD.
If we follow this concept that inputs with unique initial signal send more information to
their outputs, it is logical that vertices with signiﬁcantly higher signal in one perturba-
tion versus another should be given a unique initial signal value in the ﬁrst perturbation,
reﬂecting their capacity to send more information about the network.
All that remains now is to consider how to assign initial signal to vertices which do not
display a great diﬀerence in signal distribution across the two perturbations of our bio-
logical network. One solution to this problem is to assign all these vertices an identical
initial signal, in this way they can transfer more information than vertices with a signal
deﬁcit in one perturbation versus another but less information than vertices with a signal
surplus.
Guided by these concepts we constructed the ISD for each perturbation of the phospho-
rylation network as follows. We utilised the limma package in R [269] to compute t-values
testing, for each vertex in the network, the hypothesis that the phosphorylated protein
level of the vertex was signiﬁcantly diﬀerent in the two treatments. If for a given vertex
the phosphorylated protein levels were signiﬁcantly lower (p < 0.05) in one perturbation
versus another it was assigned an initial value of zero in that perturbation and a unique
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initial value (here chosen as the absolute t-statistic of the test) in the other perturbation.
All vertices which did not display signiﬁcant changes between the two perturbations were
assigned the same non-unique initial value of 1 in both perturbations.
The ISDs and edge weights for the two perturbations of the biological network are pro-
vided in Fig 2.3A-B.
2.6.3 mRNA Expression data
The analysis in this chapter required the use of two microarray gene expression data
sets. For the analysis of signalling entropy's association with high degree vertices, we
considered data from 1980 primary breast cancer patients by the Molecular Taxonomy of
Breast Cancer International Consortium (METABRIC) project [157]. The data consists
of microarrays proﬁled on the Illumina HT 12v3 platform and log normalised as described
in [157]. This expression data is accompanied by extensive clinical annotation describing
tumour grade, size, stage, cellularity, histological subtype, lymph node status, hormone
receptor status, Pfam50 subtype and p53 mutation status, as well as patient age at
diagnosis, menopausal status, treatment and survival data. As described in [157] the
expression data was divided into a discovery set of 997 samples and a validation set of
983 samples, each representing a distribution of clinical variables and molecular subtypes
observed in the full data set.
For the analysis of signalling entropy's association with intra-sample heterogeneity we
downloaded from the GEO database [270], normalised data corresponding to accession
number GSE2361 [265]. This data set proﬁled 33 distinct healthy human tissues and 3
foetal tissues on the Aﬀymetrix Human Genome U133A Array platform. Data was inter
array normalised.
2.6.4 Protein Expression data
Data describing protein expression via immunohistochemistry for 15805 proteins across
multiple samples describing 20 cancerous tissues was downloaded from the Human Protein
Atlas data base [263]. The expression of each protein in each cancer sample was scored on
an integer scale from 1-4, where 1 indicated no expression, 2 low expression, 3 moderate
expression and 4 high expression. For each protein we computed the average expression
score across samples corresponding to a given cancerous tissue, resulting in a protein
expression vector for each of the 20 cancerous tissues.
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2.6.5 Protein Interaction Network
The PIN utilised in the signalling entropy analysis was downloaded Pathway Commons
(http://www.pathwaycommons.org) [8] (date stamp 13th June 2012). Using this com-
prehensive resource, we built an integrated network including the Human Protein Refer-
ence Database [271], the National Cancer Institute Nature Pathway Interaction Database
(NCI-PID) (pid.nci.nih.gov), the Interactome (Intact) (http:/www.ebi.ac.uk/intact/)
and the Molecular Interaction Database (MINT) (http://mint.bio.uniroma2.it/mint/).
Protein interactions in this network include physical stable interactions such as those
deﬁning protein complexes, as well as transient interactions such as post-translational
modiﬁcations and enzymatic reactions found in signal transduction pathways, includ-
ing 20 highly curated immune and cancer signaling pathways from NetPath (http:
//www.netpath.org) [272]. Redundant interactions were removed and only genes with
an EntrezGene ID annotation were retained.
Interactions derived from publicly available interaction databases have been criticised, for
false positives introduced by the lack of cellular organisation constraints in Y2H assays.
To remove network edges which may likely represent false positives, a sparsiﬁcation proce-
dure based on imposing a (bi-directional) signalling hierarchy on the network. This spar-
siﬁcation was kindly performed by Andrew E. Teschendorﬀ (supervisor for this project).
Brieﬂy, the procedure removed edges between proteins whose main cellular localisations
are not adjacent in the context of the signalling hierarchy by utilising GO annotations
[26]. Genes may be annotated to multiple domains, and thus mutually exclusive sets were
constructed by favouring the more external domain, so that a gene annotated to both
extracellular and transmembrane domains was allocated to the extracellular domain only,
and a gene annotated to both transmembrane and intracellular domains was assigned to
the transmembrane domain only. Thus, all EntrezGene identiﬁers were annotated to one
of the extracellular (EC), transmembrane receptor (MR) or intracellular (IC) domains.
Nodes in the PIN which could not be assigned to one of these domains were removed
and the resulting network was pruned by removing edges (interactions) inconsistent with
the signalling hierarchy structure. Thus, only edges with corresponding end nodes in the
following combinations were allowed: EC-EC, EC-MR (or MR-EC), MR-IC (or IC-MR)
and IC-IC. This resulted in a maximally connected PIN of 8,434 nodes and over 300,000
interactions.
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2.6.6 Integration of the PIN with gene expression data
To integrate expression data with the PIN, expression proﬁles of probesets/proteins map-
ping to the same EntrezGene identiﬁer in the PIN were averaged. Proteins in the PIN
without probesets/proteins representing their coding genes on the array, were removed.
The resulting maximally connected component of the PIN deﬁned an interaction network
for each data set.
2.6.7 Signalling Entropy
Signalling entropy for a given sample in a data set is computed as described above in
Section 2.3, where it is theoretically analysed. We note, however, that as the PIN for
each data set can vary due to the genes described by each experimental technology, it
is important to consider the normalisation of signalling entropy, so that it is comparable
across data sets.
Brieﬂy, for the computation of signalling entropy each sample is ﬁrst integrated with the
PIN to create a sample speciﬁc stochastic matrix, P = (pij), via the mass action principle
as described above (Section 2.1).
For each protein i we then deﬁne the local entropy of its interaction distribution, Si,
which quantiﬁes the promiscuity of its signalling within the sample:
Si = −
∑
j∈N (i)
pij log pij . (82)
Signalling entropy is then computed from the entire stochastic matrix pij as the entropy
rate, S˜R, of the stochastic process described by pij :
S˜R =
∑
i
µiSi, (83)
where µi denotes the stationary distribution of the stochastic matrix, satisfying
∑
i µipij =
µj . We note that µi is therefore the non-degenerate eigenvector of P corresponding to
the eigenvalue 1 and that by the Perron Frobenius theorem, the existence of µi requires
that the matrix P be irreducible; this is guaranteed by the fact that the PIN considered
is connected and non-bipartite [273].
The maximum entropy rate of a weighted network, MR, depends solely upon its adja-
cency matrix, A = (Aij), and can be calculated as the entropy rate of the stochastic
matrix pij = Aijνj/λνi, where λ and ν are the dominant eigenvalue and corresponding
eigenvector of A, respectively [274]. In order to ensure the signalling entropy values are
comparable across data sets, we present our data driven ﬁndings in terms of normalised
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signalling entropy:
SR = S˜R/MR. (84)
R-scripts for the computation of signalling entropy are freely available for download at
www.sourceforge.net/projects/signalentropy.
3 Signalling Entropy as the energy potential of Wadding-
ton's Landscape
3.1 Introduction
In our introductory chapter we motivated the need for network theoretic tools which can
elucidate global principles of biological network rewiring. Furthermore, we posited that
there likely exists an organisation to such network rewiring during complex biological
processes, which manifests via the predictable change of a global measure of biological
signalling as the process evolves. The development of such a measure, however, requires
the selection of a biological process to investigate and we subsequently motivated cellular
diﬀerentiation as a clear candidate.
We explained how organisms develop from the diﬀerentiation of a single pluripotent ES
cell, whilst adult tissues are maintained by a tissue speciﬁc stem cell pool, ready to expand
and diﬀerentiate to restore what is lost. We also revealed the incredible sophistication of
the orchestrated gene expression regimes required for cellular diﬀerentiation, making it
hardly surprising that aberrant diﬀerentiation underpins the most complex and malicious
pathologies. We examined two antithetical such pathologies in detail, namely breast can-
cer and FSHD. We saw how considerable evidence has arisen suggesting that tumours
may possess a small population of CSCs from which the tumour bulk diﬀerentiates [167],
and how such cells are posited to be responsible for the growth and repair of the tumour
in the same way that healthy stem cells contribute to the growth and maintenance of the
organism. Further we saw how in FSHD mis-expression of a transcription factor, DUX4,
is believed to produce a subtle perturbation to the muscle diﬀerentiation programme re-
sulting in atrophic or disorganised muscle ﬁbres in patients.
In our examination of the mathematics of cellular diﬀerentiation we saw how recently,
it has been proposed that pluripotency, is an emergent statistical property of cell pop-
ulations [54, 98, 80], not well-deﬁned at the single-cell level. Speciﬁcally, it has been
argued that high cellular heterogeneity underpins the pluripotent or multipotent capacity
of stem cell populations, with diﬀerentiated cell populations representing a more homo-
geneous synchronised state [54].
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In Chapter 2, we developed a number of network theoretic tools. In particular, we exam-
ined signalling entropy, the entropy rate of a single sample, mass-action principle derived
stochastic matrix, describing a random walk model of network traﬃc. Signalling entropy
is a sample speciﬁc measure of disorder in interactome signalling, however, we further
revealed, by theoretical investigation that our measure also correlates with intra-sample
heterogeneity at the population level.
Motivated by this, we here investigate signalling entropy in the context of cellular diﬀer-
entiation. We ﬁrst explain the rationale of using signalling entropy in this context, before
demonstrating by the consideration of genome wide gene expression data that the measure
is elevated in pluripotent and multipotent cells as opposed to diﬀerentiated tissue, across
multiple cell fates. We subsequently consider time course gene expression proﬁling of dif-
ferentiation across multiple lineages, demonstrating that signalling entropy systematically
decreases throughout such time courses. We next consider CSCs and demonstrate that
signalling entropy is elevated in these cells as compared to the tumour bulk. Finally we
consider local entropy and demonstrate this measure capable of detecting the key drivers
of the diﬀerentiation process. We also ﬁnd that signalling entropy is a more robust in-
dicator of diﬀerentiation potential than other gene expression based indicators. These
results mark out signalling entropy as a powerful measure of the diﬀerentiation potential
of a single sample and motivates the use of our measure in a pathological context. We
note in particular that signalling entropy can be considered as a proxy for the energy
potential in Waddington's diﬀerentiation landscape.
3.2 Results
3.2.1 Rationale of signalling entropy as a measure of diﬀerentiation potential
The rationale behind signalling entropy as a correlate of diﬀerentiation potential is based
on the proposition that our measure captures the average level of signalling pathway
promiscuity in a given sample, in a manner related to intra-cellular pathway activation
diversity and inter-cellular heterogeneity. Undiﬀerentiated and plastic cells, such as stem
cells, which must maintain diverse pathway activation and heterogeneous populations,
would thus be characterised by a state of high signalling entropy. Similarly, since diﬀer-
entiation results in the activation of a restricted set of molecular signalling pathways and
a homogenisation of cell populations, one would expect a reduction in signalling entropy
as this process progresses. As explored in Chapter 1, a commonly used model for cell
diﬀerentiation potential is Waddington's landscape, in which stem cells are considered to
occupy states of high potential energy, which decreases throughout cellular diﬀerentiation.
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If our model is correct then signalling entropy represents a proxy for the energy potential
in Waddington's landscape (Fig 3.1A).
We have demonstrated analytically in Chapter 2 that signalling entropy is an average
measure of inter-cellular heterogeneity. By its nature as an entropy rate, signalling en-
tropy can also be expected to measure the level of intra-cellular pathway diversity, in
homogeneous cell populations. To conﬁrm this we devised a simulation model in which
the signalling entropy of an unbiased random walk on our PIN (i.e. pij = 1/ki where
ki is the degree of node i) representing a promiscuous, poised, intra-cellular signalling
state, is compared to the signalling entropy obtained by randomly activating individual
genes and speciﬁc pathways (Fig 3.1B, Materials and Methods, Chapter 3). In the case
where individual genes were activated, this led, in approximately 70% of perturbations,
to a reduction in signalling entropy (Binomial p < 0.001, Fig 3.1B). However, in the
case where whole signalling pathways were activated, a reduction signalling entropy was
observed in 85% of cases (Binomial p < 10−10, Fig 3.1B). These results conﬁrm that
signalling entropy is a measure of intra-cellular pathway diversity, which decreases on the
deterministic activation of genes and pathways.
Thus by approximating intra-cellular and inter-cellular heterogeneity in pathway acti-
vation, signalling entropy can be considered an appropriate quantiﬁer of the changes in
signal transduction that occur during cellular diﬀerentiation.
3.2.2 Signalling entropy is raised in pluripotent stem cells
Given our theoretical results we next sought to determine if our measure could discrim-
inate pluripotent samples from more diﬀerentiated ones in a data driven manner. We
evaluated the signalling entropy of all 219 samples in the stem cell matrix (SCM), 59 of
which were deemed pluripotent, and the remaining 160 non-pluripotent [79] (Materials
and Methods, Chapter 3). We observed that signalling entropy was signiﬁcantly higher
in the pluripotent cell lines (p < 10−10, Fig 3.2A).
To provide an independent benchmark for signalling entropy we considered a transcrip-
tomic measure of pluripotency, derived by Mikkelsen et al. [275] (Materials and Meth-
ods, Chapter 3). This pluripotency score was also found to be signiﬁcantly higher in the
pluripotent cell lines, and was signiﬁcantly correlated, with signalling entropy across sam-
ples in the SCM, conﬁrming that our measure associates with other correlates of stemness
(Fig 3.2B).
To further validate signalling entropy we considered an independent data set proﬁling
107 human ES cell and 52 iPSC lines, as well as 32 diﬀerentiated tissue samples (SCM2)
[276]. Our measure achieved 100% accuracy in discriminating pluripotent from diﬀerenti-
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Figure 3.1: Signalling entropy as the height in Waddington's Landscape. (A)
The z-axis represents the signalling entropy of a cellular sample. The plane spanned by
the x-and-y axes represents gene expression phase space. In accordance with Wadding-
ton's landscape, an undiﬀerentiated cell occupies a region of phase space with increased
potential energy, signalling entropy is considered to be a proxy for this potential. (B)
Simulation of pathway activation in a realistic PIN decreases signalling entropy. The
boxplot compares the signalling entropy (SR/maxSR) of the unbiased random walk state
(diamond), to the signalling entropies obtained by separately activating each individual
gene in the network (> 1000 perturbations), and those obtained by activating whole signal
transduction pathways (100 pathways). Binomial test p-values are given.
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Figure 3.2: Signalling entropy correlates with the diﬀerentiation potential of
a sample. (A) Signalling entropy (SR/maxSR, y-axis) is elevated in the 59 pluripotent
compared to the 160 non-pluripotent cell-lines from the SCM compendium, the p-value is
from a Wilcoxon rank sum test. (B) Signalling entropy correlates with the pluripotency
score of Mikkelsen et al., (values for replicates of each cell type have been averaged).
Linear regression p-value and R2 value are given. (C) Signalling entropy (SR/maxSR, y-
axis) is elevated in the 159 pluripotent samples compared to the 32 diﬀerentiated samples
from the SCM2, the p-value is from a Wilcoxon rank sum test. (D) Corresponding ROC
curve plus AUC of signalling entropy discriminating pluripotent from diﬀerentiated cells
in SCM2.
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Figure 3.3: Signalling entropy is similar in ES cells and iPSCs. Signalling entropy
displays similar values for ES cells and iPSCs, signiﬁcantly higher than the values corre-
sponding to embroid bodies (EB) and iPSC parental ﬁbroblasts. This is in line with the
similar diﬀerentiation potential of these pluripotent cell types.
ated samples in this data set (Fig 3.2C-D). We also observed that iPSC samples exhibited
high signalling entropy values, similar to those of ES cells, and signiﬁcantly higher than
those of their parental diﬀerentiated cells (p < 0.0001, Fig 3.3).
We note that cell cycle gene expression has previously been associated with ES cells [277].
To determine if the expression of these genes was driving signalling entropy's discrimi-
natory power, we removed cell proliferation and cycling genes from our PIN [277] and
recomputed signalling entropy over the remaining maximally connected component. We
found that our measure remained a signiﬁcant discriminator of pluripotent cells and hence
is not determined purely by cell proliferation (Fig 3.4).
3.2.3 Signalling entropy is raised in adult stem cells
Following the ﬁnding that signalling entropy is raised in pluripotent stem cells, we next
considered our measure evaluated over multipotent adult stem cell types, including neural
stem cells (NSCs), hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs).
We found that all these adult stem cell types exhibited higher signalling entropy values
than their diﬀerentiated progeny but lower values than pluripotent ES cells (Fig 3.5).
Thus, signalling entropy is capable of discriminating cells within a lineage according to
their diﬀerentiation hierarchy.
To test this ﬁnding further in the context of a single lineage, we considered a haemato-
logical data set [278], encompassing a number of diﬀerent blood cells, including diﬀeren-
tiated (e.g. monocytes), and less diﬀerentiated types (e.g. CD34+ HSCs and erythrob-
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Figure 3.4: Signalling entropy is not driven by cell cycle genes. (A) Signalling
entropy shows near identical variations between samples in the SCM after removal of
cell cycle genes. Linear regression R2 and p-values are provided. (B) Signalling entropy
computed without cell cycle genes is still a powerful discriminator of pluripotency in the
SCM, the p-value corresponds to a Wilcoxon rank sum test.
lasts/megakaryocytes). We found that signalling entropy recapitulated the hematopoietic
diﬀerentiation hierarchy consistent with prior knowledge [279, 280] (Fig 3.6).
3.2.4 Signalling entropy dynamically decreases during diﬀerentiation time
courses
We have demonstrated that signalling entropy is elevated in pluripotent cells as compared
to multipotent cells and in multipotent cells as compared to diﬀerentiated cells, across
multiple cell fates. However, these cell types represent discrete positions in a lineage and
we wonder whether signalling entropy dynamically decreases during cell fate transition.
To investigate this we ﬁrst considered time course expression data of diﬀerentiated retinal
pigment epithelium (RPE) cells, which were induced to de-diﬀerentiate, for expansion,
and then were re-diﬀerentiated back in to RPE (Materials and Methods, Chapter 3).
Elegantly, signalling entropy increased dynamically upon de-diﬀerentiation, reaching a
maximum at the point the cells were induced to re-diﬀerentiate, after which it systemat-
ically decreased as the cells reverted to RPE (Fig 3.7A).
As another example, we considered a time course data set consisting of human promye-
locytic leukaemia progenitor (HL60) cells, diﬀerentiating into neutrophils [83] via two
independent stimuli (ATRA and DMSO). In both cases, signalling entropy was signiﬁ-
cantly reduced over the diﬀerentiation time course (ATRA stimulus, R2 = 0.96, p < 10−8,
Fig 3.7B).
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Figure 3.5: Signalling entropy associates with the diﬀerentiation hierarchy
within multiple lineages. (A) Signalling entropy associates with the diﬀerentiation
hierarchy in the hematopoetic lineage, being highest in ES cells, then adult HSCs and
lowest in diﬀerentiated T & B-cell lymphocytes plus natural killer cells (LYMPH/NKC),
and monocytes plus neutrophils (MC/PMN). (B) Signalling entropy associates with the
diﬀerentiation hierarchy in the mesenchymal lineage being highest in ES cells, then adult
MSCs and lowest in diﬀerentiated osteoblasts (OST) and chondrocytes (CHO). (C) Sig-
nalling entropy associates with the diﬀerentiation hierarchy in the neural lineage being
highest in ES cells, then adult NSCs and foetal neural stem cells (FNSC) and lowest in
diﬀerentiated primary astrocytes (AC). Wilcoxon rank sum test p-values.
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Figure 3.6: Comparison of signalling entropy across major blood cell types
in the hematopoietic system. Blood cell types have been arranged with lymphoid
cells to the left, and myeloid (monocytes & granulocytes) cells to the right, with the
pluripotent HSCs and less diﬀerentiated erythroblasts/megakaryocytes in the middle.
Signalling entropy is lower for the more diﬀerentiated lymphoid and myeloid lineages.
The HSCs and PMNs (polymorpho neutrophils) were proﬁled with the Aﬀymetrix U133
Plus 2 platform, while the rest of samples were proﬁled with Illumina Human WG6v2
arrays. The similarity of signalling entropy for PMNs and ganulocytes conﬁrms the cross
platform validity of our measure.
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As yet further conﬁrmation we considered a data set describing ES cell diﬀerentiation
into pancreatic β-cells at 5 time points, in sextuplicate [70]. Once again, we found that
signalling entropy systematically decreased as the cells diﬀerentiated (mean of sextupli-
cates: R2 = 0.68, p = 0.04 Fig 3.7C).
Thus signalling entropy dynamically decreases as cells diﬀerentiate into diverse cell fates.
It is worth noting that these dynamic changes were independent of cell-proliferation (i.e.
the results held when cell-cycle genes were removed from the network).
3.2.5 Signalling entropy discriminates cancer stem cells from the tumour
bulk
As discussed in Chapter 1, cancer is a disorder of development and there are several
hypotheses surrounding oncogenesis. One hypothesis is that cancerous tissue arises via
de-diﬀerentiation of healthy tissue into a more proliferative, heterogeneous state. In line
with this theory, it has previously been demonstrated that signalling entropy, computed
over transcriptomic data, is elevated in cancerous tissue compared to its normal counter-
part [262]. Here we further validate this ﬁnding using proteomic data from the Human
Protein Atlas describing 20 diﬀerent malignancies and healthy tissues [263]. We ﬁnd that
signalling entropy is still elevated at the protein level in cancerous as opposed to healthy
tissue (p < 0.003 Fig 3.8A).
Recently, considerable evidence has arisen suggesting that CSCs may drive malignancy,
given signalling entropy's power as a discriminator of stem cells in a healthy context,
we analysed an expression data set proﬁling putative CSCs and their parental tumours,
across a number of diﬀerent tissues [281]. This revealed that CSCs exhibited a marginally
higher signalling entropy than their non-stem like counterparts (Fig 3.8B).
3.2.6 Dynamic changes in local entropy identiﬁes key diﬀerentiation genes
and pathways
Given the power of signalling entropy as a measure of a sample's diﬀerentiation potential
we next investigated whether we could identify critical mediators of the diﬀerentiation
process through the consideration of local entropy. As an entropy rate, signalling entropy
is deﬁned as a weighted sum of local entropies, corresponding to given proteins in the
PIN. A low local entropy of a protein indicates a deterministic interaction distribution,
which can be attributed to involvement of the protein in an active pathway. We thus
hypothesised that decreases in the local entropy of certain genes during diﬀerentiation
may indicate their activation during this process.
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Figure 3.7: Signalling entropy exhibits dynamic changes during the diﬀerentia-
tion process. (A) Signalling entropy (SR/maxSR, y-axis) ﬁrst increases then decreases
in a time course de-diﬀerentiation followed by re-diﬀerentiation of RPE plated at two
diﬀerent densities. (B) Signalling entropy systematically decreases during HL60 leukemic
progenitor cell diﬀerentiation into neutrophils, stimulated by two independent initial stim-
uli: ATRA and DMSO. (C) Signalling entropy systematically decreases during ES cell
diﬀerentiation into pancreatic β-cells (points displayed are the average of sextuplicates).
For (B) and (C) we provide the R2 values and associated p-values for a linear regression
of signalling entropy against diﬀerentiation time.
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Figure 3.8: Signalling entropy is higher in cancerous tissue and in CSCs. (A)
Signalling entropy computed over proteomic data describing 20 cancerous and matched
healthy tissues is signiﬁcantly higher in cancerous tissue, p-value is from a paired Wilcoxon
test. (B) Comparison of signalling entropy between putative CSCs and their parental
tumour cell lines (PTC) for ﬁve diﬀerent tissue types shows signalling entropy is higher
in CSCs. The combined Fisher t-test p-value is given.
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We considered, as a proof of principle, the case of Notch-signalling. Notch signalling
is inactive yet inducible in the pluripotent state, with activation normally associated
with diﬀerentiation [282, 283, 284, 285, 286, 287]. We thus anticipated that essential
components of the Notch signalling pathway would exhibit a higher local entropy in the
pluripotent, compared to the diﬀerentiated state. Considering data from the SCM [79],
we were able to conﬁrm a decreased local entropy for 10 Notch pathway genes in our
PIN, in non-pluripotent samples (Figs 3.9 & 3.10). To conﬁrm the statistical signiﬁcance
of this, in none of 10000 random selections of 10 genes from the PIN did we observe
the same level of consistency and statistical signiﬁcance as for the Notch pathway genes
(p < 0.0001). This result indicates that reduced local entropy of the Notch pathway is a
key feature of the non-pluripotent state, conﬁrming that our measure can detect pathway
activation during diﬀerentiation.
To further test the added value of local entropy, we revisited the HL60 diﬀerentiation
time course data [83]. Using linear regression we identiﬁed the genes showing the most
signiﬁcant decreases in local entropy during the diﬀerentiation process. Ranking genes
according to those showing the largest reductions in signalling entropy and performing a
subsequent Gene Set Enrichment Analysis (GSEA), we identiﬁed JAK -STAT signalling
as one of the key pathways (Fig 3.11 & 3.12). The involvement of this pathway in neu-
trophil diﬀerentiation is heavily supported by previous studies [288, 289, 290, 291].
To conﬁrm the statistical signiﬁcance of the JAK -STAT pathway ﬁnding and the biolog-
ical relevance of the structure of the PIN, we computed local entropies after randomly
permuting the gene expression proﬁles over the vertices of our network. This led to no
signiﬁcantly enriched biological terms (adjusted p-values > 0.05), emphasising the criti-
cality of the network structure to our results. Finally, we note that other non-network
based approaches fail to identify the JAK -STAT pathway (Fig 3.11).
3.3 Discussion
The aim of this chapter was to propose and test the hypothesis that signalling entropy, a
network theoretic measure of intra-cellular signalling promiscuity and inter-cellular het-
erogeneity, is correlated with the cell potency of a sample.
We computed the signalling entropy of over 1000 samples, describing gene expression in
healthy cell types from many diverse lineages and diﬀerentiation stages, as well cancerous
tissues and CSCs, proﬁled using a variety of diﬀerent technologies. Through this analysis
we have demonstrated that signalling entropy provides a near absolute quantiﬁcation of
the diﬀerentiation potential of any given sample.
In the context of normal physiology, ES cells and other pluripotent cell types were cor-
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Figure 3.9: Local entropy identiﬁes rewiring of Notch pathway mediators in
non-plutipotent cells. Graphical rewiring diagram of alterations in the interaction
preferences in the main Notch pathway components after transition from pluripotency.
The main increased and decreased probability interactions are depicted as arrows. Most
of the Notch pathway components have reduced local entropies, highlighting the fact that
the interaction distributions become more focused (mostly increased interactions between
Notch pathway members).
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Figure 3.10: Local entropy decreases in critical Notch pathway mediators in
non-plutipotent cells. Boxplots showing the signiﬁcant reduction in local entropy in
10 critical Notch pathway components after transition from pluripotency. p-values are
from a Wilcoxon test.
Page 150
Network Theoretic Tools in the Analysis of Complex Diseases C. R. S. Banerji
Negatively Correlated Local Entropy Methodology
GO ID GO Term P Value Adjusted P
value
GO:0042517 positive regulation of tyrosine phosphory-
lation of Stat3 protein
6.72E-07 0.0010
GO:0050731 positive regulation of peptidyl-tyrosine
phosphorylation
1.65E-06 0.0013
GO:0004896 cytokine receptor activity 4.70E-06 0.0013
GO:0042516 regulation of tyrosine phosphorylation of
Stat3 protein
5.20E-06 0.0026
GO:0042531 positive regulation of tyrosine phosphory-
lation of STAT protein
6.68E-06 0.0025
GO:0019838 growth factor binding 1.16E-05 0.0016
GO:0046427 positive regulation of JAK-STAT cascade 1.28E-05 0.0039
GO:0042509 regulation of tyrosine phosphorylation of
STAT protein
2.97E-05 0.0075
GO:0002673 regulation of acute inﬂammatory response 3.10E-05 0.0067
Mar and Quackenbush Regression Methodology; Core gene set
GO ID GO Term P Value Adjusted P
value
GO:0003676 nucleic acid binding 1.08E-06 0.00833
GO:0016070 RNA metabolic process 5.52E-06 0.0129
GO:0044446 intracellular organelle part 7.10E-06 0.0129
GO:0044422 organelle part 7.24E-06 0.0129
GO:0044428 Nuclear part 8.41E-06 0.0129
GO:0006350 transcription 3.18E-06 0.0407
GO:0032774 RNAb iosynthetic process 5.46E-06 0.046
GO:0032991 macromolecular complex 5.60E-06 0.046
GO:0006694 steroid biosynthetic process 5.74E-06 0.046
Positively Correlated Expression Methodology
GO ID GO Term P Value Adjusted P
value
GO:0005773 vacuole 1.67E-06 2.30E-04
GO:0005764 lysosome 9.66E-07 2.66E-04
GO:0000323 lytic vacuole 9.66E-07 2.66E-04
GO:0044437 vacuolar part 5.78E-04 0.052
GO:0006952 defense response 5.59E-05 0.089
GO:0006955 immune response 2.47E-04 0.19
GO:0005886 plasma membrane 0.0035 0.21
GO:0043020 NADPH oxidase complex 0.011 0.38
GO:0015629 actin cytoskeleton 0.0089 0.39
GO:0005774 vacuolar membrane 0.013 0.41
Figure 3.11: JAK -STAT signalling is signiﬁcantly enriched among genes which
decrease their local entropy during HL60 diﬀerentiation into neutrophils.
GSEA results for genes which showed a signiﬁcant reduction in local entropy over the
two stimulations of HL60 diﬀerentiation into neutrophils, reveals an enrichment of JAK -
STAT signalling. In contrast the non-network based regression analysis of Mar and
Quackenbush, and the consideration of gene expression correlation with diﬀerentiation,
identiﬁes only high level processes.
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Figure 3.12: Local entropy detects the rewiring of JAK2 's interaction distribu-
tion into an active state during neutrophil diﬀerentiation. (A) The local entropy
of JAK2 systematically decreases during neutrophil diﬀerentiation (here shown is DMSO
stimulated diﬀerentiation, the result is similar for ATRA stimulated). Pearson's r and
corresponding p-value for linear regression are displayed. (B) We see that the reduction
in local entropy is due to the interaction proﬁle of JAK2 rewiring into a more active state
during diﬀerentiation.
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rectly predicted to exhibit the highest signalling entropy, followed by multipotent stem
cells (e.g. NSC/HSC/MSC), with terminally diﬀerentiated cells exhibiting signiﬁcantly
lower signalling entropy. In the context of cancer, CSCs exhibited higher signalling en-
tropy than the tumour bulk, although this diﬀerence appears substantially less than
between normal stem cells and their diﬀerentiated progeny. We also demonstrated that
the local entropy of proteins whose activation is critical to diﬀerentiation decreased as
the process progressed.
As demonstrated in Chapter 2, signalling entropy is a measure of intra-sample heterogene-
ity. Our results thus support the view that the pluripotent state is a statistical property
of a diverse cell population [97, 54]. It will be important to assess, when single cell data
becomes available, whether the increased signalling entropy in pluripotent cells requires a
population level assessment, or whether the pluripotent state is achieved via an inherent
intra-cellular stochasticity. [97, 54].
Our measure thus provides a very general system's level correlate of the undiﬀerentiated
state of a sample. This is in contrast to pluripotency gene expression signatures [275, 292],
which lack a systems level interpretation and understanding. We also note that such sig-
natures could only consistently discriminate pluripotent from non-pluripotent cell types,
but generally failed to discriminate cell types located further down the diﬀerentiation
hierarchy ([293] analysis performed by project supervisor: Andrew E. Teschendorﬀ, data
not shown). Thus, signalling entropy provides a more reﬁned classiﬁcation of distinct cell
types across the global diﬀerentiation hierarchy than previous transcriptomic measures.
Moreover, though we observed some variation in signalling entropy between studies pro-
ﬁling the same cell types, we note that these variations were in general very small. Thus
signalling entropy provided a relatively robust measure of cell potency across studies
and technologies, with ES cells always demonstrating the highest levels. This robust-
ness stems from two key features. Firstly, signalling entropy is self-calibrating, as it is
constructed from ratios of gene expression intensity values, making it a dimensionless
quantity, fairly insensitive to experimental technology or normalisation method. This is
in contrast to pluripotency gene expression signatures, which showed signiﬁcant variations
between studies. Secondly, unlike pluripotency expression signatures signalling entropy
does not depend on feature selection, thus it is not subject to over-ﬁtting and independent
of tunable parameters.
In summary, we have here demonstrated that signalling entropy, correlates with the dif-
ferentiation potential of a cellular sample and can be considered a proxy for the energy
potential in Waddington's landscape. To this end we have achieved one of the main goals
of the thesis, namely the development of an entropic network theoretic tool, which can
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approximate the diﬀerentiation level of a single sample and hence form the basis of a
methodology designed to investigate developmental pathology. In the next two chapters
we will thus investigate signalling entropy in the context of cancer prognostics and FSHD
pathomechanisms.
3.4 Materials and Methods, Chapter 3
3.4.1 Signalling Entropy
Signalling entropy was computed as described in the Materials and Methods, Chapter 2.
3.4.2 Simulation analysis of signalling entropy as a measure of pathway
promiscuity
Our simulation study was intended to investigate the eﬀect of perturbations to the stochas-
tic matrix pij on signalling entropy, to ascertain whether gene and pathway activation
can lower our measure as postulated.
Our perturbations alter the stochastic matrix in such a way as to prevent the validity of
the closed form expression derived in Chapter 2. Consequentially, signalling entropy for
a perturbed stochastic matrix must be computed by numerical approximation of the left
eigenvector of the stochastic matrix, a computationally expensive procedure. Without
loss of generality, we therefore randomly sampled 2000 genes from the PIN, resulting in a
maximally connected component consisting of ∼ 1500 genes. This reduced network size
allowed for swift numerical computation of signalling entropy under a large number of
perturbations.
To simulate a pluripotent poised state, in which all pathways can be activated with equal
likelihood, a stochastic matrix was deﬁned as an unbiased random walk: pij = 1/ki,
whenever j ∈ N (i), 0 otherwise. We considered two types of perturbation to this state,
the activation of genes and the activation of pathways. In the ﬁrst case, we considered
all vertices of degree ≥ 2 in the PIN, for each such vertex, a randomly picked edge was
assigned a large weight (in the range 0.8− 0.95), with the remaining edges assigned a low
weight (∼ 0.1), ensuring that the sum of weights equals 1, as required for a stochastic
matrix. This was done for each vertex in the network separately, resulting in > 1000
perturbations and associated signalling entropies. In the second scenario, pathway acti-
vation, we randomly selected sequences of connected vertices (paths) and assigned edges
connecting vertices in a path a high weight as above. Path lengths were chosen to be
of maximum length 9, corresponding to the diameter of the network, and cycles were
not permitted. We simulated 100 distinct active pathways and computed the resulting
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signalling entropies.
3.4.3 Gene expression data
We compiled a transcriptomic expression database, consisting of ∼ 1000 samples, from
the sources described below. The choice of data sets was guided by our desire to perform
speciﬁc comparisons between certain cell types, thus requiring that these speciﬁc cell
types were proﬁled as part of the same study, in order to minimise potential confounding
by batch eﬀects. In the case of Aﬀymetrix data, if RMA normalised data was publicly
available, this was used. If normalised data was not provided, or if this was unspeciﬁed,
raw data was downloaded and RMA normalised using the Bioconductor aﬀy package. In
the case of Illumina data sets, the normalised data provided by the respective studies was
used. In all cases, quantile normalisation was performed to normalise across all arrays
within a study. Finally, for later integration with the PIN, expression proﬁles of probes
mapping to the same EntrezGene identiﬁer were averaged. Probes mapping to multiple
genes were excluded.
3.4.3.1 The stem cell matrix (SCM and SCM2) compendia We obtained the
normalised gene expression data of the SCM compendium, consisting of 219 samples (59
pluripotent, 160 non-pluripotent) [79]. The pluripotent samples consisted of 48 ES cells,
5 teratocarcinomas, 3 iPSCs and 3 germ tumour cell samples. All the SCM data were
generated using Illumina Human Reference8 arrays.
In addition, we also obtained the normalised gene expression data (Illumina HT12v3
expression arrays, GSE30652) describing a subset of the samples used in the SCM2 com-
pendium, consisting of 107 ES cell lines, 52 iPSC samples and 32 samples from diﬀeren-
tiated tissue [276].
3.4.3.2 Further ES cell, MSC and iPSC data sets We obtained normalised data
from GEO [270] for two studies proﬁling human ES cell lines and derived MSCs. One
study [294] proﬁled an ES cell line (H1) at 3 diﬀerent passages, giving 3 replicates, as well
as two MSC precursors and a bone marrow derived MSC population. These 6 samples
were proﬁled on Aﬀymetrix HG-U133A arrays. The other study [295] proﬁled two ES
cell lines and derived MSCs, all 4 samples were performed in triplicate resulting in 12
samples, proﬁled Aﬀymetrix HG-U133 Plus 2 arrays.
We also downloaded the normalised data for three additional, independent studies proﬁl-
ing bone-marrow derived MSCs (MSC-BM), all proﬁled on Aﬀymetrix HG-U133 Plus 2
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arrays [296, 297, 298]. Samples however varied in terms of donor, donor age and passage
numbers. GSE7888 [296] consisted of a total of 23 MSC-BM samples, GSE9593 [297] of
13 MSC-BM samples, and GSE9520 [298] of 6 MSC-BM samples.
In addition, we downloaded the normalised data for three further independent, stud-
ies proﬁling ES cell samples [299, 300, 301], on the Aﬀymetrix HG-U133 Plus 2 array:
GSE7896 (5 samples) [299], GSE13828 (5 samples) [300], and GSE15148 (10 samples)
[301]. GSE13828 also proﬁled iPSCs from skin ﬁbroblast samples taken from a child
with spinal muscular atrophy [300]. Speciﬁcally, in addition to the 5 ES cell samples,
there were 3 iPSC samples and 2 skin ﬁbroblast samples. GSE15148 contained 16 iPSCs
derived using episomal vectors from 2 foreskin samples [301]. Another fourth data set
comparing iPSCs (n = 12) to parental ﬁbroblasts (n = 6), including ES cells (n = 20) was
obtained from [302]. The raw data, generated with Aﬀymetrix HG HT U133A arrays,
was quality checked and RMA normalised. Thus, all these data sets allowed a three-way
comparison between adult diﬀerentiated cells, the iPSCs derived from them, and ES cells.
3.4.3.3 Expression data describing the diﬀerentiation of MSCs into osteoblasts
and chondrocytes We downloaded the normalised data for two studies [303, 304] pro-
ﬁling MSC samples and diﬀerentiated osteoblasts and chondrocytes, proﬁled on Aﬀymetrix
HG-U133 Plus 2 arrays.
3.4.3.4 Combined haematological data set We obtained the normalised data
from GEO for three haematological studies. One study proﬁled ﬁve CD34+ HSC samples
and ﬁve diﬀerentiated neutrophil samples using the Aﬀymetrix Human Genome U133A
Plus 2 array [305]. The remaining two studies proﬁled 3 and 4 CD34+ HSC cell samples
respectively using the same Aﬀymetrix platform [306, 307]. We also obtained normalised
data from the HaemAtlas [278]. The array for this study was the Illumina Human WG-6
v2 Expression beadchip. However, both array platforms led to integrated networks of
similar size encompassing eﬀectively the same genes, permitting direct comparison.
3.4.3.5 Time course de-diﬀerentiation and re-diﬀerentiation experiment of
RPE cells The RPE de-diﬀerentiation and re-diﬀerentiation normalised data set was
obtained from ArrayExpress (E-MTAB-854), where a detailed experimental protocol can
be found. Brieﬂy, a single cell suspension of RPE was derived from ES cells and plated
in 96 well plates at two densities in triplicate, a high density (100,000 cells/cm2) and a
low density (8000 cells/cm2), and cultured for 5 weeks. RNA was extracted from the
starting RPE cell suspension and from the plated cells at 8 subsequent time points (1,
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2, 3, 7, 15, 19, 29 and 35 days after plating). In the high density plates, cells proliferate
and de-diﬀerentiate (acquiring a mesenchymal morphology) during the ﬁrst 5 days before
re-diﬀerentiating to RPE by the end of the 5 weeks. In the low density plates cells pro-
liferate and de-diﬀerentiate for the ﬁrst 7 days before re-diﬀerentiating to RPE by end of
the 5 weeks. RNA was proﬁled on Illumina HumanHT12v4 arrays.
3.4.3.6 Time course HL60 neutrophil expression data We obtained from GEO,
the raw CEL ﬁles for the microarray (Aﬀymetrix Human Genome U95 Version 2 Array)
dataset collected by Huang et al. [83] describing HL60 progenitor cells diﬀerentiating into
neutrophils. The dataset consists of 25 samples; the ﬁrst sample is of HL60 progenitor cells
during proliferation and the remaining 24 samples correspond to two time courses, each
of 12 time points (2 hrs, 4 hrs, 8 hrs, 12 hrs, 18 hrs, 1 day, 2 days, 3 days, 4 days, 5 days, 6
days, 7 days), describing diﬀerentiation of HL60 progenitors into neutrophils. Each time
course corresponds to diﬀerentiation initiated via stimulation with a given medium; either
DMSO or ATRA supplementation. The dataset underwent quality control assessment via
the arrayQualityMetrics package in R, and was normalised using RMA.
3.4.3.7 Time course pancreatic β-cell diﬀerentiation The pancreatic β-cell dif-
ferentiation data set was obtained from ArrayExpress (E-MTAB-817), where a detailed
experimental protocol can be found. Brieﬂy ES cells were plated in sextuplicate, (dupli-
cates of 3 thawed batches) and induced to diﬀerentiate into pancreatic β-cells, RNA was
isolated at 5 time points (0, 1, 2, 5, 8 and 11 days) and proﬁlled on Illumina HumanHT-12
v3.0 Expression BeadChip arrays.
3.4.3.8 Cancer stem cell and parental cancer cell data set In order to compare
putative CSC to their parental tumour cell PTC lines we used the normalised data (GEO)
from [281]. Speciﬁcally, we focused on ﬁve tissues: breast with 2 CSCs and 3 PTCs, brain
with 5 CSCs and 4 PTCs, lung with 5 CSCs and 3 PTCs, oral cavity with 8 CSCs and
5 PTCs and colon with 7 CSCs and 4 PTCs. In the case of colon we used positivity of
CD133, a colon stem cell marker to assign CSC/PTC status (samples on GEO are likely to
have been mis-labelled). Reported results across all tissue types is however independent
of inclusion or exclusion of the colon subset. All samples were proﬁled on Aﬀymetrix
HG-U133 Plus2 arrays.
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3.4.4 Protein Expression data
Data describing protein expression via immunohistochemistry for 15805 proteins across
multiple samples describing 20 cancerous and matched healthy tissues was downloaded
from the Human Protein Atlas data base [263]. The expression of each protein in each
sample was scored on an integer scale from 1-4, where 1 indicated no expression, 2 low
expression, 3 moderate expression and 4 high expression. For each protein we computed
the average expression score across samples corresponding to a given tissue, resulting in
a protein expression vector for each of the 40 tissues.
3.4.5 Gene expression based pluripotency signatures
We considered two pluripotency gene expression signatures: A 19 gene pluripotency sig-
nature, consisting of 11 up and 8 down regulated genes in pluripotent cells described
by Mikkelsen et al., [275] and a 189 gene pluripotency expression signature derived by
Palmer et al. [292].
For the Mikkelsen et al. signature, the pluripotency score of a given sample was derived
as the t-statistic comparing the expression levels of the 11 up-regulated genes to the 9
down-regulated ones.
For the Palmer et al. signature a score was derived from the 189 genes following the princi-
pal component analysis (PCA) procedure outlined in [292]. We performed a focused PCA
on the SCM compendium, utilising the genes from the Palmer signature represented in
the array platform as a feature space (a total of 157 genes). The top principal compo-
nent from the PCA correlated with pluripotency status (Wilcoxon rank sum, p < 10−10),
validating the signature in the SCM data. The sign of the loadings in the top principal
component was then utilised to assign the 157 genes into up and down-regulated cate-
gories. A pluripotency score of an independent sample was then obtained as the t-statistic
of the test comparing the expression levels of the up and down regulated genes.
3.4.6 Protein Interaction Network
The PIN utilised in this Chapter was constructed as described in the Materials and
Methods, Chapter 2.
3.4.7 Integration of PIN with gene expression data
To integrate the gene expression data with the PIN, expression proﬁles of probesets and
proteins mapping to the same EntrezGene identiﬁer in the PIN were averaged. Proteins
in the PIN without probesets representing their coding genes on the array, were removed.
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The resulting maximally connected component of the PIN deﬁned an interaction network
for each array platform. In the case of Aﬀymetrix U133 Plus 2 arrays (the most widely
used array in this work), the resulting maximally connected integrated PIN consisted of
8290 nodes and 299459 edges. For the Aﬀymetrix Human Genome U95 v2 arrays, the in-
tegrated PIN consisted of 5555 nodes and 175640 interactions. For the Aﬀymetric U133A
arrays, the PIN was of size 7027 nodes and 246005 edges. Finally, for the Illumina Human
WG-6 v2 expression beadchip, the integrated maximally connected PIN consisted of 8135
nodes and 290360 edges, i.e., very similar in size to the Aﬀymetrix U133 Plus 2 arrays.
3.4.8 GSEA
Functional annotation and GSEA was performed using the DAVID Bioinformatics Re-
sources 6.7 [308]. The proteins in the PIN were used as a background gene set and p-value
estimated using Fisher's exact test. Adjusted p-values used the Benjamini-Hochberg cor-
rection as implemented in DAVID.
4 Signalling Entropy Correlates with Clinical Outcome
in Epithelial Cancer
4.1 Introduction
In the introductory chapter we explored the molecular diversity of breast cancer in detail.
We revealed the considerable heterogeneity of this epithelial cancer and how it leads to
a multitude of subtypes, each with diﬀering prognosis and treatment options. We also
saw how this diversity has led to the rise of gene expression based prognostic assays,
which may be employed to stratify patients into diﬀerent clinical classes. Furthermore,
we examined the clonal evolution and CSC hypotheses of tumour development, explain-
ing how acquired mutations and epigenetic alterations can lead to heterogeneity within
individual tumours. We motivated the development of network theoretic measures aimed
at the understanding of CSCs and how they drive intra-tumour heterogeneity, positing
that entropic approaches may prove fruitful.
In Chapter 2 we demonstrated that signalling entropy is a correlate of intra-sample het-
erogeneity, and hence may prove useful in understanding intra-tumour heterogeneity.
Moreover, in Chapter 3 we demonstrated that signalling entropy is a powerful measure
of the diﬀerentiation potential of a single sample in a healthy context, and is capable
of discriminating CSCs from the tumour bulk. Here we investigate signalling entropy in
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more detail in the context of a prognostic measure of intra-tumour heterogeneity.
The observation that epithelial cancers display intra-tumour heterogeneity in cell mor-
phology and that this may impact on clinical outcome was made over 40 years ago
[309, 310, 266]. It was only recently, however, that intra-tumour heterogeneity was demon-
strated at the molecular level [311, 312, 313, 314]. Not only has this revealed considerable
diversity in the mutational landscapes of single tumours [312, 314], but also that gene
expression based prognostic scores diﬀer in outcome on multiple biopsies from the same
tumour [311], raising signiﬁcant challenges for their clinical application. Other recent
studies have shown that cellular heterogeneity may promote progression to neoplasia and
dictate response to treatment [311, 315, 316].
The clinical assessment of intra-tumour heterogeneity is currently an open problem,
with a number of proposed solutions [313]. Arguably the major clinical concern from
intra-tumour heterogeneity is its contribution to therapeutic resistance [317], thus the
most relevant measures must consider this carefully. Treatment resistance of heteroge-
neous tumours likely stems from the ability of the cancer cell population to activate a
diverse array of pathways permitting subversion of the intended therapeutic response
[318, 318, 314, 317]. Thus it is reasonable that a clinically relevant measure of intra-
tumour heterogeneity will quantify the signalling promiscuity of a tumour and infer its
phenotypic plasticity, making signalling entropy a strong candidate.
Intra-tumour heterogeneity will have several sources, however as mentioned earlier an im-
portant contribution is likely to come from epigenetic diversity, driven by CSCs [314, 161,
162]. Putative breast and lung CSCs have been identiﬁed by surface marker expression,
isolated, and demonstrated to be chemotherapeutic resistant [167, 165, 155, 319, 320].
However, the measurement of the stemness of a tumour in a manner related to CSCs
remains a signiﬁcant challenge. Although ES cell gene expression signatures have been
constructed and shown to be prognostic in breast cancer [277, 64, 321], their overall
prognostic signiﬁcance seems limited and they are unable to distinguish CSCs from the
tumour bulk [277]. Given that signalling entropy is a measure of stemness in a healthy
context, and is elevated in CSCs, it is not unlikely that our measure may also prove a
robust correlate of tumour stemness in a manner related to CSC abundance and hence
potential intra-tumour heterogeneity.
Motivated by these results of previous chapters, we here propose and investigate signalling
entropy as a prognostic measure of tumour stemness and intra-tumour heterogeneity.
We demonstrate that our measure strongly associates with both histological and tran-
scriptomic measures of tumour anaplasia across a wide variety of malignancies (breast,
lung, prostate, glioma), validating our measure as a correlate of tumour stemness.
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We next investigate signalling entropy as a prognostic variable in the context of the two
leading causes of cancer death world wide: breast cancer and non-small cell lung cancer
(NSCLC). We ﬁnd that signalling entropy associates with diﬀerent clinical subtypes in
both malignancies, providing novel hypotheses on pathogenesis.
In NSCLC, we discover that signalling entropy is elevated in patients with strong smoking
history. We also ﬁnd that signalling entropy is higher and less variable in lung squamous
cell carcinoma (SCC) as compared to lung adenocarcinoma. Our results suggest this dif-
ference may be driven by the smoking of high tar, unﬁltered cigarettes which is associated
with SCC [322].
In breast cancer we ﬁnd that the luminal B subtype displays a a high signalling entropy,
despite a low tumour stemness (judged by the expression of ES cell genes). This suggests
that increased intra-tumour heterogeneity may be driving high signalling entropy in lu-
minal B breast cancer.
By performing a meta-analysis over 2000 primary lung adenocarcinoma and 3500 primary
breast cancer samples we further demonstrate that signalling entropy is signiﬁcantly prog-
nostic in both cancers, independently of other clinical variables. Importantly, our measure
is prognostic within the stage I stratum of lung adenocarcinoma and within ER positive
and ER negative breast cancer subsets, in contrast to other transcriptomic prognostic
indicators.
Finally, we consider proteomic data from the Human Protein Atlas describing healthy
and cancerous tissue from numerous tissue types. We demonstrate that the signalling
entropy increase in cancerous tissue correlates with tissue speciﬁc cancer mortality rates.
Thus we here reveal that signalling entropy is a powerful prognostic factor in epithelial
cancer capable of providing novel insights into pathomechanisms.
4.2 Results
4.2.1 Rationale of signalling entropy as a prognostic measure
As shown in Chapter 3, a cellular sample with a high signalling entropy will possess a
robust intra-cellular signalling regime, capable of activating a number of diverse path-
ways. Such a sample will likely be resistant to perturbation by pharmacological agents.
Hence a tumour with a high signalling entropy may be expected to possess an innate resis-
tance to therapeutic intervention and thus a poor prognosis. We also demonstrated that
signalling entropy is elevated in treatment resistant CSCs as compared to the tumour
bulk (Chapter 3), suggesting that a high signalling entropy tumour will likely possess
a greater proportion of such cells. As CSCs are considered capable of driving tumour
Page 161
Network Theoretic Tools in the Analysis of Complex Diseases C. R. S. Banerji
Sig
na
llin
g P
rom
isc
uit
y
Ce
llu
lar
 He
ter
og
en
eit
y
Tumour cell population
Small circles represent 
cells. Different colours 
represent different 
signalling regimes.
Intra-cellular signalling 
regime
Small circles represent 
proteins. Thickness and 
brightness of connections 
represent interaction 
strength.
SIG
NA
LL
ING
 EN
TR
OP
Y
Patient Prognosis
Mo
rta
lity
 Ra
te
High network entropy 
tumours have plastic 
phenotypes and are likely 
treatment resistant. Brown 
cells denote those killed 
by treatment.
Figure 4.1: Rationale behind signalling entropy as a prognostic factor in cancer.
A high signalling entropy of a tumour sample indicates a promiscuous, intra-cellular
signalling regime and a heterogeneous cancer cell population. The consequence of a high
signalling entropy is thus a tumour with a plastic phenotype, capable of activating diverse
pathways in response to treatment. High signalling entropy tumours are thus likely to
result in higher patient mortality.
growth and heterogeneity, one can therefore expect a high signalling entropy tumour to
be of poor prognosis. In addition we saw in Chapter 2, that signalling entropy is elevated
in heterogeneous as opposed to homogeneous samples, whence a high signalling entropy
tumour can be expected to possess a diverse population of cell types, some of which may
be resistant to therapeutic response.
Thus, in contrast to other prognostic measures, signalling entropy can be expected to
associate with tumour stemness in a manner related to CSC abundance, intra-cellular
signalling promiscuity and intra-tumour heterogeneity, making it good candidate for an
improved prognostic indicator (Fig 4.1).
4.2.2 Signalling entropy correlates with tumour stemness
We demonstrated in Chapter 3 that signalling entropy correlated with diﬀerentiation
potential in healthy tissue. We therefore hypothesised that our measure would correlate
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with transcriptomic and histological measures of tumour diﬀerentiation across multiple
cancer types. To investigate this we considered 4 malignancies: breast cancer, NSCLC,
prostate cancer and glioma. We found a strong correlation between signalling entropy
and conventional measures of tumour stemness.
4.2.2.1 Signalling entropy correlates with measures of tumour stemness in
breast cancer We ﬁrst considered the METABRIC breast cancer data sets. For this
malignancy two appropriate transcriptomic measures of tumour diﬀerentiation are the
Ben-Porath et al. 100 gene ES cell signature [277, 323] and the 97 gene Sotiriou et al.
grade signature [324].
As expected, we found that both signatures were strongly correlated with signalling
entropy in the METABRIC data sets (Ben-Porath: p < 2.2 × 10−16, Sortiriou: p <
2.2 × 10−16, (Fig 4.2A & B) indicating that signalling entropy is indeed associated with
external, transcriptomic measures of the stemness of a tumour.
As anticipated, signalling entropy also strongly correlated with histological tumour grade
in breast cancer, being signiﬁcantly higher in grade 3 tumours compared with grade 2
and signiﬁcantly higher in grade 2 tumours as compared with grade 1 (p < 7.3 × 10−15
and p < 2.6 × 10−4 respectively, Fig 4.2C). Importantly, we found that unlike signalling
entropy the Ben-Porath et al. signature was unable to distinguish between grade 1 and
grade 2 tumours in the discovery set of METABRIC (Ben-Porath et al. signature: p = 0.4,
signalling entropy: p < 2.6 × 10−4, Fig 4.2D). This result indicates that our measure is
more sensitive to tumour stemness than ES cell transcriptomic signatures.
We further note that tumours with a high signalling entropy display a bi-modality of
enrichment for the Ben-Portah et al. ES cell signature. High ES cell enriched, high sig-
nalling entropy tumours are generally grade 3, whereas the low ES cell enriched, high
signalling entropy tumours can be of lower grade (Fig 4.2A). This indicates that a high
signalling entropy is related to but not solely determined by the level of diﬀerentiation
of a tumour, and that other factors, such as inter-cellular heterogeneity may cause high
signalling entropy in certain samples.
We also found that signalling entropy correlated with tumour cellularity and was high-
est in those samples with the greatest proportion of cancerous cells (p < 7.7 × 10−15).
This result is consistent with our previous ﬁnding that cancerous tissue displays a higher
signalling entropy its healthy counterparts [23, 293].
4.2.2.2 Signalling Entropy correlates with levels of tumour stemness in lung
adenocarinoma, and is elevated in squamous-cell carcinoma We next consid-
ered three NSCLC microarray data sets: The Director's Challenge dataset proﬁling 398
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Figure 4.2: Signalling entropy is correlated with measures of tumour stemness
in breast cancer. Signalling entropy correlates with the (A) Ben-Porath et al. ES cell
and (B) Sotiriou et al. tumour grade signatures. The p-values are for linear regression.
We note a bi-modality in signalling entropy for tumours with high ES cell gene expression.
(C) Signalling entropy is associated with histological tumour grade. (D) The Ben-Porath
et al. signature cannot discriminate between grade 1 and grade 2 breast cancers in the
METABRIC discovery data set, p-values are from Wilcoxon tests.
Page 164
Network Theoretic Tools in the Analysis of Complex Diseases C. R. S. Banerji
primary lung adenocarcinomas [325], GSE4573 proﬁling 130 SCCs [326] and GSE41271
proﬁling 183 adenocarcinomas, 80 SCCs and 12 lung tumours of diﬀerent histology [327].
In addition, we considered RNA-seq data-sets downloaded from The Cancer Genome
Atlas (TCGA) data base (http://cancergenome.nih.gov/) consisting of 455 lung ade-
nocarcinomas and 409 SCC samples.
The molecular tumour grade signature derived by Ben-Porath et al. [277], has also pre-
viously been applied to measuring tumour stemness in NSCLC [323]. The signature was
investigated by Hassan et al. and found to show association with histological grade and
clinical outcome in lung adenocarcinoma but not in SCC [323].
We thus evaluated the relationship between signalling entropy and histological and molec-
ular measures of tumour stemness, as well as the relationship between signalling entropy
and histological subtype in NSCLC. We found that, as in breast cancer, signalling entropy
correlated strongly with the Ben-Porath et al. signature in both lung adenocarcinoma and
SCC (p < 2.2× 10−16, Fig 4.3A). Moreover, we found that signalling entropy correlated
strongly with histological assessments of tumour diﬀerentiation in lung adenocarcinoma,
being highest in poorly diﬀerentiated tumours, then moderately diﬀerentiated tumours
(p < 1.4 × 10−4 poorly vs. moderately diﬀerentiated) and lowest in well diﬀerentiated
tumours (p < 2.5 × 10−5 moderately vs. well diﬀerentiated, Fig 4.3B). In line with the
ﬁndings of Hassan et al., however, we found that signalling entropy, like the Ben Porath et
al. signature, showed no association with histological grade assessments in SCC (p = 0.17
poorly vs. well/moderately diﬀerentiated).
To understand this diﬀerence we investigated the eﬀect of histological subtype on both
signalling entropy and the Ben-Porath et al. signature, in data sets which proﬁled a large
number of both adenocarcinomas and SCCs. Intriguingly, we found that both signalling
entropy and the Ben-Porath et al. signature were signiﬁcantly higher in SCC as compared
to adenocarcinoma (p < 1.3× 10−10, Fig 4.3C). This elevation of both signalling entropy
and the expression of stem cell genes in SCC, suggests that these factors may be driv-
ing the treatment resistance and heterogeneous expression of prognostic markers in this
subtype [328, 329]. The fact that neither the Ben-Porath et al. signature nor signalling
entropy correlate with histological grade in SCC may be reﬂective a considerable intra-
tumour heterogeneity, endemic of this subtype, which imposes a lower bound on these
measures and limits their variability and thus capacity to associate with histological grade
assessments. Indeed, in the large TCGA data set the variance of signalling entropy was
signiﬁcantly higher among lung adenocarcinomas as compared to SCCs (p = 7.6× 10−6).
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Figure 4.3: Signalling entropy is correlated with measures of tumour stemness
in lung adenocarcinoma. (A) Signalling entropy correlates with the Ben-Porath et
al. signature in both lung adenocarcinoma and SCC. The p-value is for linear regression.
(B) Signalling entropy is only associated with histological tumour grade in lung adeno-
carcinoma not SCC. (C) Both signalling entropy and the Ben-Porath et al. signature
are elevated in SCC as compared with adenocarcinoma. p-values for (B) and (C) are for
Wilcoxon tests.
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4.2.2.3 Signalling Entropy associates with measures of tumour stemness in
prostate cancer and glioma Breast and lung cancer are our main malignancies of
interest in this study. However, as a ﬁnal validation that signalling entropy correlates
with measures of tumour stemness across multiple malignancies, we investigated cancers
arising from two more tissues of origin, namely prostate cancer and glioma.
We ﬁrst considered a microarray data set (GSE6606) proﬁling 65 primary prostate tu-
mours annotated with Gleason grade. A suitable molecular signature for tumour stem-
ness in prostate cancer was derived by Penney et al. [330] and we found that signalling
entropy signiﬁcantly correlated with this signature across all prostate cancer samples
(p = 1.3 × 10−4, Fig 4.4A). Moreover, we found that signalling entropy was elevated in
high Gleason grade (≥ 8) as compared to low Gleason grade (≤ 6) tumours (p < 0.037,
Fig 4.4B).
We next considered a microarray data set proﬁling 180 primary glioma tumours of diﬀer-
ing histological grade (GSE4290). As with other malignancies we found that signalling
entropy was signiﬁcantly elevated in grade 3 as opposed grade 2 oligodendrogliomas and
astrocytomas (p < 0.022, Fig 4.4C) and was signiﬁcantly higher in grade 4 glioblastomas
as opposed to lower grade gliomas (p < 0.003 Fig 4.4D).
4.2.3 Signalling Entropy associates with key clinical variables in breast and
lung cancer: novel insights into pathology
Signalling entropy is thus a correlate of tumour stemness in many malignancies, though
not in lung SCC, where it displays very high values. We thus postulated that other cancer
clinical features may drive our measure, most likely through an association with cell
potency independent intra-tumour heterogeneity. Given the extensive clinical annotation
of the breast and lung cancer data sets considered, we investigated this postulate in the
context of these two malignancies.
4.2.3.1 Luminal B breast cancer displays the highest signalling entropy, yet
a low tumour stemness, suggesting high intra-tumour heterogeneity We ﬁrst
examined whether signalling entropy was associated with breast cancer subtypes.
We found that signalling entropy strongly associated with the Pfam50 intrinsic subtype
classiﬁcations [136] in the METABRIC discovery and validation data sets. Normal tu-
mours displayed the lowest signalling entropy, followed by luminal A tumours (lumi-
nal A vs normal p < 2.5 × 10−8), then HER2 positive tumours (HER2 vs luminal A
p < 1.9× 10−12), and lastly luminal B and basal tumours (luminal B vs HER2 p < 0.02,
basal vs luminal B p = 0.3), which displayed statistically equivalent signalling entropies.
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Figure 4.4: Signalling entropy is correlated with measures of tumour stemness
in prostate cancer and glioma. (A) Signalling entropy correlates with the Penney et
al. Gleason grade signature in prostate cancer. (B) Signalling entropy is elevated in high
as opposed to low Gleason grade tumours. (C) Signalling entropy is elevated in grade
3 compared to grade 2 oligodendrogliomas and astrocytomas. (D) Signalling entropy
is higher in grade 4 glioblastoma as compared to lower grade gliomas. p-values are for
Wilcoxon tests and linear regression.
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This result is in concordance with the report by Ben-Porath et al. [277], that basal breast
cancers displayed a stronger enrichment of an ES cell transcriptomic signature than lu-
minal A breast cancer (Fig 4.5).
To more fully compare the Ben-Porath et al. signature with signalling entropy, we ex-
amined its ability to discriminate between the intrinsic subtypes of breast cancer. As
reported in the presenting paper, the signature is most enriched in the basal breast can-
cer subtype and least in luminal A. However the overall ordering of the intrinsic subtypes
by Ben-Porath et al. signature enrichment is quite dissimilar from the ordering by sig-
nalling entropy. Notably luminal B breast cancers are signiﬁcantly less enriched for the
Ben-Porath et al. signature than basal (p < 2.2× 10−16), despite these subtypes sharing
the highest signalling entropy values.
This result is intriguing as it implies that the severity of luminal B breast cancer may be
linked to a plastic signalling regime, rather than the enrichment of genes typically over-
expressed in ES cells. One may conclude from this that the high signalling entropy of the
luminal B subtype may be driven by intra-tumour heterogeneity rather than stemness.
Criticism of molecular subtyping has derived from the lack of diversity in the histological
subtype of tumours used to deﬁne the classiﬁcations [108]. Consequently, we also exam-
ined the association between signalling entropy and histological subtype. This revealed
that medullary carcinoma has the highest signalling entropy, consistent with this cancer
generally being of higher grade and displaying a basal phenotype [331]. Invasive ductal
carcinoma of no special type (IDC-NST) displayed the second highest signalling entropy,
signiﬁcantly higher than invasive lobular carcinoma (p < 2.3 × 10−5) mixed ductal and
lobular carcinoma (p < 1×10−3) and tubular carcinoma, which all displayed a statistically
equivalent signalling entropy (Fig 4.6). This result suggests that the better prognosis of
tubular carcinomas compared to IDC-NST may be related to a less heterogeneous sig-
nalling regime.
We also found that signalling entropy could discriminate grade matched ER positive
tumours from ER negative tumours (p < 0.01). Given the ﬁnding by Ben-Porath et al.
that ER negative tumours were enriched for an ES cell signature [277], this result sug-
gests that a stem cell-like signalling regime is more prevalent in ER negative tumours,
regardless of histological grade.
Tumours carrying a mutation in p53 have also been demonstrated to be enriched for
an ES cell gene expression signature [332]. In line with this result we found that grade
matched p53 mutated tumours displayed a higher signalling entropy as compared their
wild type counterparts (p = 0.005). This result is consistent with the hypothesis that p53
mutations in breast cancer can facilitate de-diﬀerentiation [332].
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Figure 4.5: Association between signalling entropy and the Ben-Porath et al.
ES cell signature and intrinsic subtypes in the METABRIC dataset. (A) Sig-
nalling Entropy is highest in the luminal B and basal subtypes. (B) Expression of the
Ben-Porath et al. ES cell signature is highest in the basal subtype, but low in luminal B.
We note that the results shown are for the METABRIC discovery data set, the results in
the validation set are near identical. p-values denote Wilcoxon tests.
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Figure 4.6: Association between signalling entropy and histological subtypes
in the discovery and validation sets of METABRIC. IDC denotes invasive ductal
carcinoma of no special type, ILC, denotes invasive lobular carcinoma, IDC-MED denotes
medullary carcinoma, IDC-MUC denotes mucinous carcinoma, IDC-TUB denotes tubular
carcinoma and IDC+ILC denotes mixed ductal and lobular carcinoma. p-values are for
Wilcoxon tests comparing IDC with the other histological types.
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4.2.3.2 Signalling Entropy associates with smoking history in NSCLC We
next examined whether signalling entropy associated with diﬀerent clinical variables in
NSCLC.
We demonstrated earlier that SCC has a higher signalling entropy than lung adenocar-
cinoma and it is important to investigate why this may be. In addition to contrasting
treatment resistance and prognostic gene expression proﬁles, the epidemiological diﬀer-
ences between these two NSCLC histological subtypes is well studied [322, 333]. Though
genetic risk factors have been identiﬁed [334], the primary cause of NSCLC is smoking.
Over the last 20 years, smoking habits have changed from favouring high tar, unﬁltered
cigarettes towards a preference for lower tar, ﬁltered cigarettes [333]. Concurrent with
this habitual change, SCC has reduced in prevalence relative to lung adenocarcinoma and
it is widely accepted that the former change caused the latter [322, 333]. In addition,
patients with SCC generally have a greater exposure to cigarette smoking than those with
lung adenocarcinoma. We thus postulated that signalling entropy may associate with a
positive smoking history.
Hassan et al., previously reported that lung adenocarcinoma patients with a positive
smoking history displayed an increased expression of stem cell genes, but no association
between smoking history and stem cell gene expression in SCC could be demonstrated
[323]. We found, however, a strong association between signalling entropy and smoking
history in both lung adenocarcinoma and SCC, manifesting by patients with a positive
smoking history displaying a signiﬁcantly higher signalling entropy (p < 0.03, Fig 4.7A-
B). Moreover, unlike signalling entropy, the Ben-Porath et al. stem cell signature was
unable to discriminate between SCC patients who were current smokers and those who
were reformed smokers (p > 0.2, Fig 4.7C).
After conﬁrming that signalling entropy was elevated in patients with a positive smoking
history in an independent data set of mixed histologies (p < 10−4, Fig 4.7D), we next
investigated whether smoking increased signalling entropy in a dose dependent manner.
We found a signiﬁcant positive correlation between signalling entropy and the number
of packs of cigarettes smoked by a patient per year (Pearson's r = 0.11, p = 0.003, Fig
4.7E), conﬁrming this postulate.
These results suggest that cigarette smoking induces an increased molecular hetero-
geneity in NSCLC tumours, regardless of histological subtype. Moreover, this change
is accompanied by the increased expression of stem cell genes in lung adenocarcinoma,
but not in SCC. Consequently, one may deduce from these results that cigarette smoking
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Figure 4.7: Signalling entropy is elevated in NSCLC patients with a history
of smoking. (A) Signalling entropy correlates with smoking history in lung adenocar-
cinoma. (B) Signalling entropy correlates with smoking history in SCC. (C) The Ben-
Porath signature doesn't correlate with smoking history in SCC. (D) Signalling entropy
correlates with a positive smoking history in a data set of mixed histologies. (E) Sig-
nalling entropy positively correlates with number of packs smoked per year. p-values are
for Wilcoxon tests and linear regression.
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increases heterogeneity in pathway activation in lung adenocarcinoma via increasing the
stemness of a the tumour, whilst in SCC where tumour stemness is high to begin with,
smoking may increase signalling entropy by promoting intra-tumour heterogeneity.
In addition to the associations between signalling entropy, smoking history and stemness,
we note that our measure also correlated with tumour stage in NSCLC (p < 5 × 10−5),
was elevated in males (who typically have poorer survival) (p < 0.042), and was higher
in patients lacking an EGFR mutation (p < 4.2× 10−3).
4.2.4 Signalling Entropy correlates with clinical outcome in breast cancer
and lung adenocarcinoma
Given the association between signalling entropy and prognostic factors, we next inves-
tigated the potential of our measure as a prognostic indicator, in a meta-analysis over a
large number of breast and lung adenocarcinoma datasets.
4.2.4.1 Signalling entropy is prognostic in the major subtypes of breast can-
cer In order to assess the prognostic signiﬁcance of signalling entropy in breast cancer,
we ﬁrst considered the METABRIC dataset [157]. Using outcome as a binary phenotype,
we observed that patients who died of breast cancer had a higher signalling entropy than
patients who were alive at last follow up; a result which was seen in both METABRIC
subsets (p < 1 × 10−7). Using a Cox proportional hazards model, on 5 year censored
survival data, we ascertained that high signalling entropy is associated with increased
risk of death in breast cancer (c-index= 0.6, p < 1.1 × 10−6). Stratifying patients into
3 groups, representing the 3 tertiles of the signalling entropy distribution, revealed that
tumours with a high signalling entropy exhibited a doubling of the hazard rate compared
to low signalling entropy tumours.
As mentioned earlier signalling entropy is associated with tumour grade and ER status,
however, its prognostic power is independent of these variables, as well as of stage, p53
status, tumour size and lymph node status. In addition, signalling entropy was also found
to be independent of the prognostic Ben-Porath et al. signature [277] and the prognostic
Sotiriou et al. grade signature [324]. Importantly, signalling entropy was signiﬁcantly
prognostic within each tumour grade strata; notably it was prognostic within the grade
2 stratum in both METABRIC data sets (p < 0.036), an important result given the diﬃ-
culty in deciding treatment courses in this intermediate prognosis group [324]. The fact
that signalling entropy is prognostic independently of all other measures of cell anaplasia,
suggests that our measure may be capturing more than just the stemness of a tumour
sample, and that intra-tumour heterogeneity may be contributing to its prognostic power.
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A recent study by Venet et al. described prognostic associations for a number of ran-
dom gene expression signatures in breast cancer [335]. To ascertain whether random
eﬀects may be driving our ﬁndings, we evaluated the prognostic associations of the three
random gene expression signatures described by Venet et al.. We found that only one
was prognostic in both discovery and validation data sets of METABRIC and that its
prognostic power was determined entirely by ER status. To further assess the impact of
random eﬀects and the importance of our network, we randomised the gene expression
proﬁles of the METABRIC data sets over the network. Performing 5 randomisations and
recomputing signalling entropy for all 1980 samples in both METABRIC data sets, re-
vealed that randomised signalling entropy did not display robust prognostic associations
independently of ER status. We are therefore conﬁdent that the prognostic power of
signalling entropy is not driven by random eﬀects.
To validate the prognostic impact of signalling entropy we considered eight further in-
dependent breast cancer data sets. All these datasets described both ER positive and
negative tumours with accompanying clinical outcome, proﬁled on either Aﬀymetrix or
Illummina platforms and totalling 1688 samples [336, 337, 338, 339, 340, 341, 342, 343],
(Table 1). Meta-analysis revealed that signalling entropy is prognostic across both ER
positive and ER negative samples (ER positive: c-index=0.63, 95% CI=(0.604, 0.657),
p = 8.5× 10−15, ER negative: c-index=0.57, 95% CI=(0.538, 0.602), p = 0.032, Fig 4.8).
Five of the additional eight data sets also described histological tumour grade for each
sample, allowing us to further conﬁrm that signalling entropy is prognostic within the
grade 2 stratum (c-index=0.63, 95% CI=(0.581, 0.675), p = 1.05× 10−6, Fig 4.8).
These results are in contrast to the performance of MammaPrint, a microarray based
breast cancer prognostic signature currently being assessed in the MINDACT trial [344].
In a meta-analysis over the 10 breast cancer data sets we found that unlike signalling en-
tropy MammaPrint was not signiﬁcantly prognostic over ER negative samples (Fig 4.9).
Another popular breast cancer prognostic assay in clinical trials is OncotypeDX, which
uses qPCR to quantify the expression of genes associated with survival [158]. Due to dif-
ferences in the normalisation of qPCR and microarrays, a direct comparison between our
measure and OncotypeDX is diﬃcult to perform. Moreover, not all the genes required for
computing the OncotypeDX recurrence score were present in all the array platforms con-
sidered. However, using a microarray version of OncotypeDX, we found that it performed
comparably to signalling entropy across both ER positive and ER negative samples (On-
cotypeDX vs. signalling entropy p > 0.13, Fig 4.10).
Thus signalling entropy is prognostic in the major clinical subtypes of breast cancer and
hence is a more robust prognostic indicator than MammaPrint.
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Figure 4.8: Meta-analysis of prognostic implications of signalling entropy in
breast cancer The plots display the concordance index for signalling entropy in each
data set alongside its 95% conﬁdence interval. The overall concordance index was derived
via meta-analysis using a random eﬀects model. The vertical line denotes concordance
index= 0.5, data sets where the conﬁdence interval for the concordance index crosses this
line did not reach signiﬁcance. Meta-analysis of signalling entropy across 10 breast cancer
data sets reveal that our measure is signiﬁcantly prognostic across both ER positive and
ER negative subtypes. Meta-analysis across 7 breast cancer data sets reveal that our
measure is also signiﬁcantly prognostic within the grade 2 stratum.
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Figure 4.9: Signalling entropy out-performs MammaPrint over ER negative
samples The plots display the negative of the log10 of the p-value for a survival analysis
using Cox-regression on 5-year censored data, evaluating the prognostic signiﬁcance of
signalling entropy and MammaPrint in each data set. The overall p-value was produced
by a Fisher's combined test. The vertical red line on each plot denotes p = 0.05; data
sets in which the bar crosses this line reached signiﬁcance for the corresponding score.
Meta-analysis comparison of signalling entropy with MammaPrint across 10 breast cancer
data sets, demonstrates that only signalling entropy is signiﬁcantly prognostic across ER
negative samples.
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Figure 4.10: Meta-analysis comparison of signalling entropy with OncotypeDX.
The plots display the concordance indices for signalling entropy and a microarray based
approximation of OncotypeDX in each data set alongside 95% conﬁdence intervals. The
overall concordance indices were derived via meta-analysis using a random eﬀects model.
The vertical line denotes concordance index= 0.5, data sets where the conﬁdence interval
for the concordance index crosses this line did not reach signiﬁcance. Meta-analysis across
10 data sets reveal that signalling entropy performs comparably to OncotypeDX across
(A) ER positive samples and (B) ER negative samples.
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Data Set No. Samples No. ER+
Samples
No. ER-
Samples
No. Grade 2
Samples
METABRIC Discovery Set 997 801 196 415
METABRIC Validation Set 983 697 243 355
GSE20685 327 181 146 NA
GSE7390 198 134 64 83
GSE1456 159 85 75 NA
GSE3494 251 213 34 128
E-TABM-158 130 84 46 46
GSE2034 286 209 77 NA
GSE11121 200 162 38 136
GSE6532 137 86 40 51
Total 3668 2652 959 1214
Table 1: Breast cancer data sets. GEO and ArrayExpress accession numbers for
the breast cancer data sets. Sample counts are provided for ER segregated and grade 2
samples.
4.2.4.2 Signalling entropy is prognostic in stage I lung adenocarcinoma We
next investigated the prognostic power of our measure in lung adenocarcinoma. We ﬁrst
considered The Director's Challenge dataset proﬁling 398 tumours [325], and the 455 lung
adenocarcinoma RNA-seq tumour samples downloaded TCGA. We found that signalling
entropy was signiﬁcantly lower in lung adenocarcinoma patients who were alive at last
follow up as opposed to those who had died (p < 0.03). Fitting Cox proportional hazard
models to 3 year censored data revealed that an increased signalling entropy implied a
worse prognosis in lung adenocarcinoma (c-index=0.6, p < 0.007). We again separated
patients into tertiles of the signalling entropy distribution and found that high signalling
entropy conferred almost a doubling of the hazard rate, as assessed over the ﬁrst 3 years
following diagnosis.
As reported earlier, signalling entropy associates with tumour stage, grade and smoking
status in NSCLC, importantly, however, the prognostic power of signalling entropy was
independent of these clinical variables.
It is of particular note that signalling entropy is signiﬁcantly prognostic if computed from
either microarray or RNA-seq data sets, this result attests to the biological relevance of
our measure, which is not masked by experimental technique.
Page 179
Network Theoretic Tools in the Analysis of Complex Diseases C. R. S. Banerji
To validate the prognostic power of signalling entropy in lung adenocarcinoma, we per-
formed a meta-analysis across 4 further independent data sets consisting of a total of 522
lung adenocarcinomas (Table 2) [345, 346, 347, 327]. This revealed that signalling entropy
is prognostic across all samples and across stage I samples (all samples: c-index=0.58, 95%
CI=(0.55, 0.60), p = 1.9e× 10−6, stage I : c-index=0.56, 95% CI=(0.52, 0.60), p = 0.037,
Fig 4.11 & 4.12).
Early stage lung adenocarcinoma suﬀers from a high relapse rate and it is important to
Data Set No. Samples No. stage I
Samples
TCGA 455 243
Directors' Challenge 398 232
GSE31210 246 168
GSE37745 196 130
GSE50081 127 92
GSE41271 270 132
Total 1692 997
Table 2: Lung cancer data sets. GEO and ArrayExpress accession numbers for the
lung cancer data sets. Sample counts are provided for stage I samples.
establish more robust prognostic assessments in the stage I subgroup for chemotherapeu-
tic treatment stratiﬁcation [348]. Sub-staging by size is currently the standard clinical
approach to stratify stage I tumours, however, on meta-analysis we found that this strati-
ﬁcation, unlike signalling entropy was not signiﬁcantly prognostic over the stage I stratum
(Fig 4.12).
We note that whilst no lung adnenocarcinoma gene expression based prognostic indicators
are currently in clinical trials, two scores are considered viable candidates: the expression
of CADM1 [346] and a qPCR based score derived recently by Kratz et al. [348]. We found
that both prognostic scores performed similarly to signalling entropy in a meta-analysis
setting. Though we note that as with OncotypeDX, a direct comparison with the qPCR
based Kratz et al. score is not conclusive in a microarray/RNA-seq setting.
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Figure 4.11: Meta-analysis of prognostic implications of signalling entropy in
lung adenocarcinoma. The plots display the concordance index for signalling entropy
in each data set alongside its 95% conﬁdence interval. The overall concordance index
was derived via meta-analysis using a random eﬀects model. The vertical line denotes
concordance index= 0.5, data sets where the conﬁdence interval for the concordance index
crosses this line did not reach signiﬁcance. Meta-analysis of signalling entropy across 7
lung adenocarcinoma data sets reveal that our measure is signiﬁcantly prognostic across
all samples and within the stage I stratum.
Page 181
Network Theoretic Tools in the Analysis of Complex Diseases C. R. S. Banerji
Overall
GSE37745
TCGA
GSE31210
GSE41271
Director's Challenge
GSE50081
−log(p)
Signalling Entropy
Stage
Overall
GSE41271
Director's Challenge
TCGA
GSE31210
GSE37745
GSE50081
p=0.05 p=0.05
All Samples Stage I Samples
Signalling Entropy outperforms tumour size within the  Stage I stratum
n=246
n=196
n=127
n=270
n=455
n=398
n=1692
n=168
n=130
n=92
n=132
n=243
n=232
n=997
0 2 4 6 8 10
−log(p)0
.0 0.5 1.0 1.5 2.0 2.5
Figure 4.12: Signalling entropy outperforms tumour size staging expression
across stage I samples. The plots display the negative of the log10 of the p-value for a
survival analysis using Cox-regression on 3-year censored data, evaluating the prognostic
signiﬁcance of signalling entropy and tumour stage in each data set. The overall p-value
was produced by a Fisher's combined test. The vertical red line on each plot denotes p =
0.05; data sets in which the bar crosses this line reached signiﬁcance for the corresponding
score. Meta-analysis comparison of signalling entropy with pathological tumour stage
across 7 lung adenocarcinoma data sets, demonstrates that signalling entropy outperforms
the stage Ia/b sub staging across stage I samples.
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4.2.5 Signalling entropy's prognostic power in breast cancer can be repre-
sented by a small number of genes
Signalling entropy is a clear prognostic indicator in breast cancer, yet its computation
requires the expression of many thousands of genes, something which is currently cum-
bersome and expensive for clinical application. Moreover, our measure associates with
tumour grade and ER status in breast cancer and thus the factors driving its prognostic
power independently of these variables is unclear. We posited that the prognostic power
of our measure, independent of ER status and grade may be captured by the expression
of a small number of genes.
We thus utilised correlations and prognostic associations to identify a small set of 81 genes
from the METABRIC discovery data set, associated with signalling entropy's prognostic
power independently of ER status and grade (Materials and Methods, Chapter 4). A
Signalling Entropy prognostic score (SE score) was then deﬁned from the expression of
these 81 genes to ascertain whether our hypothesis was correct (Materials and Methods,
Chapter 4).
Meta-analysis across the remaining 9 independent breast cancer data sets revealed that
like signalling entropy, the SE score is prognostic across both ER positive and ER negative
samples (ER positive: c-index=0.63, 95% CI=(0.59, 0.67), p = 4.6× 10−15, ER negative:
c-index=0.62, 95% CI=(0.58, 0.66), p = 8.1× 10−8, (Fig 4.13A).
Moreover, meta-analysis further demonstrated that the SE score performed comparably
to MammaPrint over ER positive samples (p = 0.18, Fig 4.13B), and out-performed
MammaPrint over ER negative samples (p = 0.04, Fig 4.13C). Whence the prognostic
power of signalling entropy is well captured by the expression of this small set of genes.
4.2.6 A signalling entropy based prognostic score for lung adenocarcinoma
outperforms CADM1 expression
We next investigated whether a similar SE score is capable of capturing the prognostic
power of our measure via the expression of a small number of genes, in lung adenocar-
cinoma. Signalling entropy is correlated with, yet prognostically independent of tumour
stage in lung adenocarcinoma, we therefore derived a set of 29 genes from the Director's
Challenge data set, which captured the prognostic power of our measure independently of
tumour stage and utilised these genes as the basis of an SE score (Materials and Methods,
Chapter 4).
Meta-analysis across 5 independent validation data sets revealed that the SE score is
prognostic across all samples and across stage I samples (all samples: c-index=0.62,
95% CI=(0.59, 0.66), p = 1.9 × 10−11, stage I : c-index=0.66, 95% CI=(0.60, 0.71), p =
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Figure 4.13: Meta-analysis comparison of the breast cancer SE score with
MammaPrint. (A) Survival analysis statistics for the SE score and MammaPrint over
ER positive samples and ER negative samples separately, c-index denotes concordance
index and p denotes p-value. (B) & (C) The plots display the concordance index for
the SE score and MammaPrint in each data set alongside 95% conﬁdence intervals. The
overall concordance indices were derived and compared via meta-analysis using a random
eﬀects model. The vertical line denotes concordance index= 0.5, data sets where the
conﬁdence interval for the concordance index crosses this line did not reach signiﬁcance.
Meta-analysis reveals that the SE score (B) performs comparably to MammaPrint in ER
positive samples and (C) outperforms MammaPrint across ER negative samples. p-values
are from a Fisher's combined test across all data sets.
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3.35× 10−5, Fig 4.14).
We next compared the SE score to the leading microarray gene expression based prog-
nostic indicator for lung adenocarcinoma, mentioned earlier, the expression of CADM1.
CADM1 expression was outperformed by pathological tumour stage (p = 0.03) in a meta-
analysis. In contrast the SE score performed comparably to tumour stage (p = 0.13, Fig
4.14B). We note that this is in contrast to signalling entropy which performed identically
to CADM1 expression, indicating that in the generation of the SE score we have improved
on signalling entropy's prognostic power.
As mentioned earlier conventional tumour sub-staging by size within the stage I stratum,
is established clinical practice, it has thus been suggested that prognostic scores should
aim to provide information which complements this staging, rather than seeks to replace
it [349]. We therefore evaluated whether prognostic models which combined either the
SE score or CADM1 expression with stage Ia/b status within the stage I sub group, out-
performed stage Ia/b status alone. We found that the SE score improved over stage Ia/b
alone in a meta-analysis across 765 stage I lung adenocarcinomas (p = 0.025), whereas
CADM1 expression made no improvement over stage Ia/b (p = 0.13, Fig 4.14C). Whence
the SE score provides a stronger candidate prognostic tool than CADM1 expression for
clinical application in lung adenocarcinoma.
4.2.7 The prognostic impact of signalling entropy is associated with genes
involved in CSCs and treatment resistance
Given the power of signalling entropy as a prognostic factor in both breast and lung
cancer can be reduced to the expression of a small set of genes we next investigated which
pathways and processes these genes were involved in.
We performed GSEA on the genes utilised to derive the SE scores (Materials and Methods,
Chapter 4). The strongest enrichment was for genes associated with poor survival in lung
cancer, histological grade in breast cancer and cell proliferation. In addition, considerable
enrichment was found for genes down regulated by the therapeutic agent salirasib and by
EGFR inhibitors, as well as for genes up regulated in cell lines resistant to the doxorubicin,
supporting the hypothesis that signalling entropy associates with therapeutic resistance.
Enrichment was also found for gene sets associated with stem cells and certain CSC
pathways. Examples include, genes down-regulated by EZH2, a well known stem cell
gene involved in the pathogenesis of several cancers and which plays a documented role
in both breast and lung CSCs [350, 351, 352, 353]. The set of genes down regulated by
CTNNB1 knock-out, a critical component of the Wnt signalling pathway, posited to be
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Figure 4.14: Meta-analysis comparison of the lung cancer SE score with the
expression of CADM1. (A) Survival analysis statistics for the SE score and CADM1
expression over all samples and stage I samples, statistics across stage I samples are
provided for the 2 scores combined with stage Ia/b status, c-index denotes concordance
index and p denotes p-value. (B) The plots display the concordance index for the SE
score, CADM1 expression and pathological tumour stage in each data set alongside 95%
conﬁdence intervals. The overall concordance indices were derived and compared via
meta-analysis using a random eﬀects model. The vertical line denotes concordance index=
0.5, data sets where the conﬁdence interval for the concordance index crosses this line
did not reach signiﬁcance. Meta-analysis across 5 validation data sets reveal that the SE
score performs comparably to tumour stage, whilst CADM1 expression is outperformed
by tumour stage. (C) The plots display the concordance index for the SE score and
CADM1 expression combined with stage Ia/b status, as well as stage Ia/b status alone,
for stage I samples in each data set alongside 95% conﬁdence intervals. Meta-analysis
across 5 validation data sets reveal that only the SE score adds prognostic value to stage
Ia/b status.
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important in CSCs and their therapeutic resistance [354]. Targets of BMP2 were also
among the most enriched gene sets in breast but not lung cancer, which is intriguing
given the role of this gene speciﬁcally in breast CSCs [355]. Enrichment was also found
for many gene sets associated with immune system processes.
Thus signalling entropy is prognostically related to genes associated with both CSCs and
treatment resistance, across multiple malignancies and independently of clinical variables.
This result conﬁrms our initial postulate that signalling entropy is a powerful prognostic
measure, related to tumour stemness and CSCs as well as treatment resistance.
4.2.8 Signalling entropy diﬀerences between healthy and cancerous tissue
correlates with tissue speciﬁc cancer mortality
As a ﬁnal investigation of the prognostic power of signalling entropy across multiple
malignancies, we return the Human Protein Atlas dataset considered in Chapters 2 and
3. In Chapter 3, we demonstrated that signalling entropy was elevated in the 20 cancerous
tissues as compared to their 20 healthy counterparts, implying that oncogenesis induces
an elevation of our measure. Moreover, diﬀerent healthy and cancerous tissues display a
range of signalling entropy values, and the diﬀerence between the signalling entropy of a
tumour and its healthy counterpart varies across tissue types. This is indicative of some
tissues generating tumours via a larger increase in signalling entropy than others.
Cancers arising in diﬀerent tissues suﬀer from diﬀering mortality rates, and many diverse
factors are believed to underlie this [356]. Given the prognostic power of signalling entropy
across multiple malignancies, however, we hypothesised that tissues forming tumours with
much higher signalling entropy than their healthy counterparts, may be intrinsically more
aggressive.
We obtained mortality rate data for 16 of the 20 cancerous tissues described in the Human
Protein Atlas data set [356] and found that the diﬀerence in signalling entropy between
cancerous and healthy tissue was signiﬁcantly correlated with tissue speciﬁc mortality
rate (Pearson's r = 0.51, p < 0.05, Fig 4.15).
Thus the signalling entropy increase induced by oncogenesis in a given tissue, correlates
with overall tissue speciﬁc cancer mortality.
4.3 Discussion
The aim of this chapter was to investigate signalling entropy as a prognostic measure in
epithelial cancer.
We previously demonstrated that signalling entropy is elevated in CSCs compared to the
tumour bulk (Chapter 3) and associates with intra-sample heterogeneity (Chapter 2).
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Figure 4.15: Signalling entropy increase during oncogenesis correlates with tis-
sue speciﬁc cancer mortality. The signalling entropy diﬀerence between cancerous
and healthy tissues is plotted against tissue speciﬁc cancer mortality rate for 16 diﬀerent
tissue types described by the Human Protein Atlas. We see that there is a signiﬁcant
positive correlation between the two variables. A p-value and Pearson's r is given for a
linear regression.
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As explored in Chapter 1, the discovery that CSCs are resistant to conventional ther-
apy necessitates an evaluation of their prognostic value, and the development of targeted
therapies [165, 155]. Recent observations have also demonstrated the importance of char-
acterising intra-tumour heterogeneity in the prognostic assessment of epithelial cancers
[311]. The measurement of both CSC abundance and intra-tumour heterogeneity in a
clinically relevant manner, however, has presented a considerable challenge [313]. More-
over, the majority of suggested approaches are limited in sample size, and require the
time consuming collection of large new data sets (such as multiple biopsies from single
tumours) for validation and proof of concept.
Signalling entropy, computable from genome wide gene expression data is not so encum-
bered. We here considered over 5000 primary tumour samples, demonstrating robustly
that our measure of tumour stemness, related to CSC abundance and intra-tumour het-
erogeneity correlates with clinical outcome in breast cancer and lung adenocarcinoma.
As explored in Chapter 1 breast cancer is the most common cancer among women and a
foremost cause of cancer death worldwide. Recently, advances in breast cancer stratiﬁca-
tion for prognostic evaluation and treatment, have been achieved by the consideration of
gene expression assays such as OncotypeDX and MammaPrint [357, 158]. The power of
these indicators in ER positive breast cancer has been demonstrated [358, 359], however,
they ignore intra-tumour heterogeneity and CSCs and thus likely under-perform [311].
We found that signalling entropy performed comparably to these indicators across ER
positive breast cancers and outperformed MammaPrint over ER negative samples (a di-
rect comparison to OncotypeDX is diﬃcult due to non-comparability of data types).
NSCLC is the leading cause of cancer death worldwide [356] and the response of the
condition to therapy is often limited [360]. Moreover, survival beneﬁt from adjuvant
chemotherapy has only been demonstrated for stage II-III patients [348]. These cir-
cumstances motivate the development of more sophisticated staging assays in NSCLC,
particularly within the stage I stratum. Two key candidates for such an assay are the
Kratz et al. signature [348] and the expression of CADM1 [346]. Both scores, however,
have been considered limited due to lack of consideration of micro-environmental and
CSC inﬂuences on prognosis [361]. We found that signalling entropy performed compara-
bly to these indicators but that a SE score derived from the expression of a small number
of signalling entropy related genes outperformed CADM1 expression even across stage I
samples (a direct comparison to the Kratz et al. score is diﬃcult due to non-comparability
of data types).
We note that there exist many other sophisticated prognostic signatures for breast can-
cer, derived from within the DREAM challenge consortium, and several of these, like
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signalling entropy, have demonstrated improvement over MammaPrint or OncotypeDX
[362, 363, 364, 365]. The aim of our work was to introduce a new prognostic measure of
signalling promiscuity, which by approximating CSC abundance and intra-tumour hetero-
geneity may prove a basis by which to improve the construction of prognostic models for
epithelial cancers. A direct comparison of signalling entropy to the prognostic indicators
from the DREAM challenge, is thus inappropriate. However, we believe that incorpora-
tion of our measure into the construction of such indicators may yield improved results
and this is a topic for further work.
We note that in addition to prognostic implications, signalling entropy also provides in-
sight into the eﬀect of clinical variables on tumour composition. Most notably, our results
are compatible with luminal B breast cancer displaying a considerable intra-tumour het-
erogeneity, and with cigarette smoking inducing increased heterogeneity in lung SCC.
Finally we demonstrated that the diﬀerence between cancerous and healthy signalling
entropy is correlated with tissue speciﬁc cancer mortality. Suggesting that our measure
captures an intrinsic property associated with cancer aggression.
We thus propose signalling entropy as a powerful and readily applicable tool for assessing
the prognostic impact of intra-tumour heterogeneity, and CSC abundance. In doing so
we acheive a major goal of the thesis: the application of an entropic network theoretic
tools to the understanding of malignancy.
4.4 Materials and Methods, Chapter 4
4.4.1 Expression Data
For our initial survival studies in breast cancer and for identiﬁcation of signalling entropy
associations with clinical variables we considered the METABRIC dataset [157] described
in Chapter 2.
Eight further independent breast cancer data sets were located via Oncomine, the GEO
database and ArrayExpress [366, 270, 367]. All studies considered both ER positive and
ER negative breast cancers and were proﬁled on either Aﬀymetrix or Illumina platforms
[336, 337, 338, 339, 340, 341, 342, 343]. With the exception of two, all studies were
annotated with overall survival data, in the two remaining cases, relapse and distant
metastasis were used as proxies for survival. Two studies also lacked ER immunohisto-
chemistry, in these cases, a dip test was utilised to conﬁrm that the distribution of ESR1
expression was signiﬁcantly bimodal, before partitioning around medoids was utilised on
ESR1 expression to generate two clusters dividing samples into ER positive and ER neg-
ative subgroups. The sample counts, stratiﬁed by ER status for all data sets used are
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provided in Table 1, alongside GEO and ArrayExpress accession numbers. Normalised
data from each study was downloaded from the GEO database or ArrayExpress. Quantile
normalisation was subsequently performed across all samples within each study.
For our investigation into NSCLC we ﬁrst considered the TCGA data set of RNAseqv2
data proﬁling 455 lung adenocarcinomas and 401 SCCs tumours and the Director's Chal-
lenge microarray data set proﬁling 398 lung adenocarcinoma tumours, with accompanying
clinical annotation. Processed data from both studies was quantile normalised and log
transformed.
Four further independent NSCLC data sets with survival data were located via Oncomine,
and the GEO database [366, 270, 347, 327, 326, 325]. The sample counts, stratiﬁed spec-
iﬁed for stage I samples, for all data sets used are provided in Table 2 Normalised data
was downloaded from the GEO database and quantile normalised within each study.
For each study separately probes in the microarrays and sequences in the RNAseqv2 data
were matched to unique EntrezGene identiﬁers; probes or sequences mapping to the same
identiﬁer were averaged over.
4.4.2 Protein Expression data
The protein expression data considered was as described in the Materials and Methods,
Chapter 3.
4.4.3 Construction of the PIN
The PIN used in this study was described in Chapter 2.
4.4.4 Signalling Entropy
Signalling entropy was computed as described in Chapter 2.
4.4.5 GSEA
GSEA was implemented using a Fisher's exact test to compare gene lists associated
with signalling entropy's prognostic power against the gene sets deﬁned by the Molecular
Signatures Database [368, 369]. Computations were performed via software downloaded
from the Molecular Signatures Data Base (www.broadinstitute.org/msigdb) [369, 368].
4.4.6 Transcriptomic tumour stemness signatures
We consider three transcriptomic tumour stemness signatures, namely the ES cell based
100 gene signature of Ben-Porath et al., the 97 gene breast cancer grade signature of
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Sotiriou et al and the 157 gene prostate cancer grade signature of Penney et al. [330].
These signatures were selected due to their similarity to signalling entropy in their clinical
variable association. Like signalling entropy all signatures are prognostic and correlate
with tumour stemness. The Ben-Porath et al. signature also correlates with pluripotency
in healthy tissue and associates with ER status and molecular subtype.
All genes in the Ben-Porath et al. signature are positively correlated with tumour grade,
and thus we compute a score for this signature as the mean expression of these genes in
a sample.
The Sotiriou et al. and Penney et al. signatures contains genes both up-regulated and
down-regulated in higher grade cancers compared to lower grade. We therefore compute
a score for these signatures as the statistic of a t-test evaluating the hypothesis that the
expression of the up-regulated genes is higher than that of the down-regulated genes in
each sample.
4.4.7 The SE Score in Breast Cancer
The breast cancer SE score was computed from the METABRIC discovery data set from
prognostic genes, which were correlated or anti-correlated with signalling entropy inde-
pendently of grade and ER status, and whose prognostic power was also independent of
grade and ER status. This gene set of 320 genes was reﬁned by ﬁtting a Cox proportional
hazards model on 5 year censored data, using all the identiﬁed genes as covariates and
deleting genes which were not signiﬁcantly prognostic, independently of others in the gene
set. This resulted in a small set of 81 genes, 10 of which were negatively correlated with
signalling entropy and 71 of which were positively correlated. These genes are provided
in a supplementary table to our publication [370]. An SE score was then deﬁned as the
t-statistic evaluating the hypothesis that the 71 positively correlated genes are expressed
more highly than the 10 negatively correlated genes (after z-score normalising the data
for each gene, across samples).
Before survival analysis the SE score was normalised by its standard deviation within
each study.
We note that by using signalling entropy to reﬁne a set of prognostic genes identiﬁed by
Cox regression, our approach reﬁnes the feature selection approach based on correlation
with outcome [357]. Consequently, the genes utilised to construct our SE score are both
correlated with outcome and with signalling entropy and thus should provide a prognos-
tic indicator representative of signalling promiscuity. Criticism of feature selection for
prognostic classiﬁers based on gene sets ranked by correlation with outcome has stemmed
from the considerable discordance of such features between data sets [371, 372]. By using
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signalling entropy to reﬁne the prognostic gene set we found that this gene set instability
was reduced. The genes which were both prognostic and correlated with signalling en-
tropy showed more concordance between discovery and validation sets of METABRIC as
compared to the genes which were only prognostic. Moreover, this increase in overlap was
signiﬁcantly higher than would be expected by chance (p < 10−5, based on re-sampling
size matched sets of prognostic genes and assessing overlap).
To further conﬁrm this increased robustness, we derived a set of genes for constructing an
SE score from the METABRIC validation set, using an identical procedure to that per-
formed on the discovery set. This gene list was slightly shorter than for the discovery set
(55 genes, 34 positively correlated and 13 negatively correlated with signalling entropy)
but had an overlap of 4 genes, signiﬁcantly more than would be expected by chance
(p = 0.012, based on re-sampling size matched sets of prognostic genes and assessing
overlap).
4.4.8 The SE Score in Lung Adenocarcinoma
For the lung adenocarcinoma data the SE score was computed analogously to the compu-
tation of the breast cancer SE score, using the Director's Challenge data set as a discovery
set. The only diﬀerences were that that adjustment was made for tumour stage rather
than grade and ER status and survival analysis was performed on 3 year censored data
rather than 5 year. The basis of the score was a small set of 27 genes, 8 of which were
negatively correlated with signalling entropy and 19 of which were positively correlated.
These genes are provided in a supplementary table to our publication [370]. The SE score
was then computed as the statistic of the t-test evaluating the hypothesis that the genes
negatively correlated with signalling entropy were less expressed than those positively
correlated (after z-score normalising each gene, across samples).
Before survival analysis the SE score was normalised by its standard deviation within
each study.
4.4.9 MammaPrint and CADM1 expression
A MammaPrint score was assigned to each sample in the 10 breast cancer datasets and
was evaluated from the expression of the 70 genes required to deﬁne the signature as the
t-statistic comparing the genes found to positively correlate with survival against those
negatively correlated with survival in the study of [357].
Before survival analysis the MammaPrint score was normalised by its standard deviation
within each study.
CADM1 expression was found in all 6 lung adenocarcinoma data sets and was similarly
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normalised by its standard deviation within each data set before survival analysis.
4.4.10 OncotypeDX and Kratz et al. score approximations
OncotypeDX and the Kratz et al. score are both derived from qPCR rather than from
microarrays like MammaPrint and CADM1 expression. Consequentially, the comparison
of signalling entropy and SE score to these indicators is not conclusive. This is because
we only consider microarray and RNA-seq data, which though correlated, is normalised
diﬀerently to qPCR data. Moreover some of the array platforms considered lack the
expression of certain genes required to compute the OncotypeDX and Kratz et al. scores.
We therefore approximate these scores from our data to allow a rough comparison. In
the case of OncotypeDX, a score was computed from the expression of 21 genes (or as
many as were represented in the data set) in each breast cancer microarray sample using
the formula deﬁned by reference [159]. In the case of the Kratz et al. score, this was
similarly approximated from the expression of 14 genes (or as many as were represented
in the data set) in each lung adenocarcinoma microarray or RNA-seq sample, using the
formula deﬁned by reference [348].
4.4.11 Meta-analysis of prognostic scores
Meta-analysis was performed to combine survival statistics for signalling entropy, the SE
score, MammaPrint, CADM1 expression and the approximations of OncotypeDX and the
Kratz et al. score. Concordance indices were computed for each prognostic measure in
each data set considered and combined using a random eﬀects model. The p-values were
combined using Fisher's combined test. Forest plots were generated using the survcomp
package in R [373].
4.4.12 Evaluation of random gene expression signatures
The 3 random gene expression signatures described by Venet et al. were obtained from the
supplementary information provided in reference [335]. Following the analysis described
by Venet et al., probes in the METABRIC data sets mapping to genes in each random
gene set were extracted, genes which were associated with cell cycling as described by
Ben-Porath et al. [277] were removed. The expression values were then median polished
and a principal component analysis was performed. Samples were then partitioned into
two groups, for each score via the median PC1 value. A Cox regression on 5 year censored
data was then performed to evaluate the prognostic power of each random gene expression
signature in each METABRIC data set. Only KRISHNAN2007DEFEAT was signiﬁcantly
Page 194
Network Theoretic Tools in the Analysis of Complex Diseases C. R. S. Banerji
prognostic in both METABRIC data sets, however partition of the datasets by ER status
mitigated this prognostic association.
4.4.13 Mortality rate data
Tissue speciﬁc cancer mortality rate data for 16 of the 20 cancerous tissue types described
by the Human Protein Atlas were obtained from reference [356].
5 Network Rewiring in Facioscapulohumeral Muscular
Dystrophy
5.1 Introduction
In our work so far we have motivated the use of signalling entropy for the investigation
of complex biological phenotypes, from both analytical and data driven perspectives. It
is clear that signalling entropy associates with the diﬀerentiation potential of a sample
in both healthy and pathological contexts. Our measure has also has proven power-
fully prognostic in epithelial cancer (a pathology epitomised as a `caricature of healthy
development'[374]), where its relationship to intra-sample heterogeneity has provided use-
ful insights. Given this association between signalling entropy and development it is only
natural to consider our measure in the context of other developmental disorders.
Arguably a highly suitable such disorder is FSHD. As explored in Chapter 1, FSHD is
the most prevalent muscular dystrophy [176], yet no treatment currently exists. The
condition is characterised by asymmetric, skeletal muscle atrophy aﬀecting speciﬁc mus-
cle groups, often associated with features including retinal vasculature abnormalities and
sensorineural hearing loss [188, 186, 187].
Genetic investigations have proposed aberrant expression of a transcription factor DUX4
as a unifying driver of FSHD pathogenesis. High levels of DUX4 expression result in
apoptosis and oxidative stress sensitivity, whilst low levels have been shown to decrease
expression of the myogenic regulatory factor MyoD and aﬀect myoblast diﬀerentiation
and function. Moreover, myotube formation is compromised in FSHD, with myotubes
possessing either atrophic or disorganised phenotypes [235]. Whilst some studies have
posited that DUX4 inhibits diﬀerentiation [375], others have suggested that an accelera-
tion of myogenesis in FSHD drives the aberrant myotube phenotypes [241]. Given that
signalling entropy is an unbiased transcriptomic measure of cell potency, it is important
to assess the eﬀect of DUX4 and related genes on our measure.
We here reveal that DUX4 over-expression results in an elevated signalling entropy, sug-
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gesting it prevents diﬀerentiation rather than accelerates it.
We next investigate the myogenesis programme in FSHD patient derived myoblasts in
detail, to experimentally conﬁrm inhibition of diﬀerentiation, as suggested by signalling
entropy. As explored in Chapter 1, FSHD is a highly heterogeneous condition, with
variable penetrance even among monozygotic twins [376]. Hence the validation of well
controlled cellular models for the pathology is of value. Here we consider a human model
of FSHD consisting of two immortalised cell lines isolated from a mosaic patient [241].
One cell line is healthy (54-6) and possesses 13 D4Z4 repeats, whilst the other is patho-
logical (54-12) and possesses only 3. The lines are otherwise isogenic and thus represent
a perfectly controlled model of FSHD.
This model has not previously been characterised, with respect to DUX4 phenotypes
and given the relevance of DUX4 expression to our investigation such characterisation is
important. We demonstrate that the model adheres well to results found previously in
primary culture: 54-12 displays a proliferation defect, a sensitivity to oxidative stress and
an atrophic myotube morphology. We also demonstrate that DUX4 is over-expressed in
54-12, albeit at very low levels.
Following this characterisation, we next perform high throughput imaging of myogenic
diﬀerentiation in the two cell lines. Morphological analysis using image processing soft-
ware reveals that the DUX4 expressing pathological line shows considerable defects at
both the alignment and fusion phases of myotube formation, resulting in an overall re-
tardation of muscle diﬀerentiation, as predicted by signalling entropy.
As mentioned earlier we found that myoblasts derived from FSHD patient muscle display
very low levels of DUX4. Moreover, many genes and pathways have been implicated as
perturbed in FSHD and by DUX4 expression, however, the overlap between such gene
sets has not been rigorously assessed by network theoretic techniques. Consequently, at-
tribution of the FSHD phenotype to DUX4 expression remains a challenge.
FSHD is thus a pathology which can beneﬁt from the application of local network theoretic
tools, to elucidate the relationship between genes and pathways driving the pathology and
provide the basis for a prioritisation of therapeutic targets. Given the value of signalling
entropy in the understanding of DUX4 expression, we employ its local analogue InSpiRe
(introduced in Chapter 2), to understand genes and pathways perturbed in FSHD.
We performed a meta-analysis with InSpiRe on multiple FSHD and healthy human con-
trol sample data sets to identify pathological network rewiring. Rewiring associated with
ageing, disuse atrophy, inﬂammation and muscle wasting was then subtracted to con-
struct a uniﬁed FSHD-speciﬁc disease network. We further revealed by consideration of
transcriptomic data describing DUX4 over-expression, that the expression of genes in our
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FSHD network can be directly attributed to DUX4.
Our network conﬁrms previous ﬁndings on FSHD molecular mechanisms such as the
role of perturbed myogenesis, oxidative stress sensitivity, actin cytoskeletal signalling and
p53-mediated apoptosis [186, 377, 181, 213]. Importantly, we also describe novel FSHD
molecular mechanisms. Notably, local network measures revealed β-catenin at the cen-
tre of our network, as the main coordinator of FSHD signalling. To determine whether
DUX4 activates β-catenin signalling, we investigated downstream β-catenin targets in
DUX4 expressing myoblasts. This conﬁrmed signiﬁcant DUX4 -mediated perturbation of
β-catenin signalling.
Thus we here reveal that DUX4 expression increases signalling entropy, suggesting a
retardation rather than acceleration of myogenesis in FSHD. We conﬁrm this ﬁnding
experimentally by high throughput time course imaging of FSHD cellular models. We
next apply the InSpiRe algorithm to a meta-analysis of FSHD, deriving a detailed map
of molecular mechanisms, which we attribute directly to DUX4 expression. Finally we
experimentally conﬁrm β-catenin signalling is perturbed in FSHD, validating the capacity
of InSpiRe to detect novel pathomechanisms.
5.2 Results
5.2.1 Over-expression of DUX4 increases signalling entropy
5.2.1.1 Overview As explored above and in Chapter 1, DUX4 is the primary FSHD
candidate gene, yet very little is known about how DUX4 expression may lead to FSHD
pathogenesis. Two models of DUX4 expression have previously been investigated. The
ﬁrst is the inducible iDUX4 C2C12 murine myoblast cell line, in which cre-mediated
recombination was utilised to place the DUX4 gene under the control of a doxycycline
inducible promoter [175]. The second model is the introduction of a vector containing
the DUX4 gene into a cell of interest, resulting in high levels of expression [234]. The
latter has the advantage or permitting the investigator to modify the DUX4 gene and
investigate how its sequence pertains to function.
Precisely such a strategy was employed by a previous PhD student, Paul Knopp, who
generated a panel of DUX4 constructs in the pMSCV-IRES-eGFP retroviral backbone.
In addition to full length DUX4 and the homologous DUX4c located centromeric to
DUX4 but lacking the C-terminal domains [218], several modiﬁed DUX4 constructs were
investigated to further probe the role of the C-terminus. These included tMALDUX4
[216], a putative DUX4 splice variant initiating with the amino acids MAL and lacking
the C-terminal domains. In addition, the tMALDUX4 construct was fused to a VP16
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A) B)
Figure 5.1: The DUX4 retroviral constructs introduced to murine myoblasts
before transcriptomic analysis. (A) Schematic representation of DUX4 coding se-
quences: full length DUX4, DUX4c a truncated DUX4 variant (tMALDUX4 ) and
tMALDUX4 C-terminal VP16 and ERD fusions, cloned into the pMSCV-IRES-eGFP
retroviral expression vector. (B) Retroviral expression of DUX4 constructs in C2C12 my-
oblasts immuno-stained for eGFP (green), actin (red), DAPI (blue) and with the 9A12
DUX4 monoclonal antibody (white, in inset panel). (immunocytochemistry performed
by Paul Knopp., ﬁgure adapted from Knopp et al., 2015, in preparation).
trans-activation domain from the human herpes simplex virus 1 VP16 protein, to generate
tMALDUX4 -VP16 a transcriptional activator of DUX4 targets. Conversely, to repress
transcriptional targets of DUX4 via recruitment of a repressive complex, tMALDUX4
was fused to the N-terminus of Drosophila melanogaster engrailed (residues 2-298) to
create tMALDUX4 -ERD (Fig 5.1A).
To determine the expression landscape induced by DUX4 expression, a microarray of
transcriptional changes induced by the DUX4 constructs was performed (by Paul Knopp).
Primary mouse satellite cells from three adult C57BL10 male mice were expanded, split
and infected in parallel. RNA was prepared 20 hours later to assay early gene expression
changes caused by DUX4, before more non-speciﬁc changes associated with cell death.
Gene expression was analysed using Aﬀymetrix GeneChip Mouse Gene 1.0 ST Arrays.
Here we investigate this data to ascertain the genes and pathways perturbed by DUX4
expression and to determine the impact of DUX4 expression on signalling entropy.
5.2.1.2 DUX4 is a transcriptional activator The DUX4 construct transcriptomic
data was log-normalised using RMA, batch eﬀects were detected by clustering analysis
and corrected for using the ComBat function in R [378]. Hierarchical clustering and PCA
on the 1000 most variable probes demonstrated that the diﬀerent constructs clustered
as expected. Full length DUX4 clustered with the transcriptionally active tMALDUX4 -
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VP16, while DUX4c and tMALDUX4 displayed similar transcriptional proﬁles, distinct
from those obtained for DUX4 and tMALDUX4 -VP16 (Fig 5.2). tMALDUX4 -ERD,
designed to negatively regulate DUX4 transcriptional targets, did not cluster with the
other DUX4 constructs.
We next performed a diﬀerential expression analysis. Using an empirical Bayes ap-
proach [269], we compared each DUX4 construct to control retrovirus. By consider-
ing, t-values, corresponding to expression diﬀerences from control for each microarray
probeset, we evaluated the concordance in transcription caused by each DUX4 con-
struct (Fig 5.3). We found that the DUX4 and tMALDUX4 -VP16 constructs displayed a
strong positive correlation in their transcriptional perturbations from control (Pearson's
r = 0.835, p < 2.2 × 10−16), conﬁrming that DUX4 is a transcriptional activator. In
contrast, DUX4 and tMALDUX4 -ERD displayed no signiﬁcant correlation in transcrip-
tional perturbation from control (Pearson's r = 0.007, p = 0.15). The tMALDUX4 -VP16
and tMALDUX4 -ERD constructs did display signiﬁcantly anti-correlated transcriptional
perturbations from control, however, conﬁrming the fact that the ERD and VP16 do-
mains mediate inverse transcriptional responses. However, the anti-correlation between
tMALDUX4 -VP16 and tMALDUX4 -ERD mediated transcription, though signiﬁcant is
weak in magnitude (Pearson's r = −0.087, p < 2.2 × 10−16). Coupled with the fact
that the transcriptional changes induced by DUX4 are not mirrored by the repressive
tMALDUX4 -ERD, this suggests that DUX4 is a transcriptional activator of genes not
normally expressed in murine muscle satellite cells. Were this not the case one would
expect the ERD construct to repress these genes and hence display a negative correlation
with the DUX4 construct.
The transcriptional changes caused by DUX4c were signiﬁcantly positively correlated
with those caused by DUX4 (Pearson's r = 0.41, p < 2.2× 10−16). Interestingly, we also
found that DUX4c induced transcriptional changes which were signiﬁcantly positively
correlated with both tMALDUX4 -VP16 and tMALDUX4 -ERD (Pearson's r = 0.55,
p < 2.2×10−16 and Pearson's r = 0.04, p = 3.5×10−12 respectively). This result suggests
that whilst DUX4c transcriptionally activates some DUX4 target genes, it may also re-
press others. This result is indicative of a possible antagonistic function for DUX4c on the
DUX4 phenotype. We also note that the transcriptional changes caused by tMALDUX4
and DUX4c are highly correlated (Pearson's r = 0.817, p < 2.2 × 10−16), as anticipated
from the high sequence similarity of these two constructs and our clustering analysis.
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Figure 5.2: Clustering of the DUX4 construct infected myoblast samples. (A)
PCA and (B) hierarchical clustering on the 1000 most variable probes across the 5 DUX4
retroviral constructs show the clustering of technical replicates, demonstrating repro-
ducibility. Note the clustering of tMALDUX4 -VP16 infected samples with full length
DUX4 infected samples, and DUX4c infected samples with tMALDUX4 infected sam-
ples.
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Figure 5.3: Relationship between transcriptional perturbations induced by the
DUX4 constructs. The plot shows correlations between diﬀerential expression t-values
comparing each DUX4 construct to control. Plots are coloured red to green according to
correlation, grey plots did not display signiﬁcant correlations. Of note is the negative cor-
relation between tMALDUX4 -VP16 and tMALDUX4 -ERD and the positive correlations
between DUX4 and DUX4c.
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5.2.1.3 DUX4, but not DUX4c, induces genes associated with apoptosis and
reduced cell proliferation DUX4 and DUX4c expression in murine satellite cells re-
sult in some similar phenotypes (inhibition of diﬀerentiation [218]) and some opposite
phenotypes (apoptosis, proliferation [217]). Moreover, both the transcriptionally active
tMALDUX4 -VP16 and the transcriptionally repressive tMALDUX4 -ERD result in tran-
scriptomic proﬁles which are positively correlated with those induced by DUX4c expres-
sion, suggesting that DUX4c, acts both synergistically and antagonistically with DUX4.
We thus investigated the pathways which are co-regulated and diﬀerentially regulated, by
these two similar genes.
To identify these gene sets robustly we ﬁltered genes sequentially, utilising information
from all the 5 DUX4 constructs. We employed a relaxed signiﬁcance threshold for dif-
ferential expression (p < 0.05) and considered for each of the 5 DUX4 constructs com-
pared to control independently. Taking advantage of construct similarity demonstrated
above, a microarray probeset was considered signiﬁcantly up-regulated by DUX4 if it
was up-regulated by both DUX4 and tMALDUX4 -VP16 constructs. A probeset was
considered signiﬁcantly up-regulated by DUX4c if it was up-regulated by both DUX4c
and tMALDUX4 (Fig 5.4 summarises the ﬁltering process). After mapping probesets to
unique RefSeq identiﬁers, we found 211 genes were co-up-regulated by DUX4 and DUX4c
whilst 245 genes were co-down-regulated.
We next performed a GSEA using a Fisher's exact test, to evaluate whether the genes
commonly and diﬀerentially regulated by DUX4 and DUX4c are signiﬁcantly associated
with particular functional classes (Materials and Methods, Chapter 5 [308, 368]). After
correcting for multiple testing we found that gene sets down-regulated by both DUX4 and
DUX4c were signiﬁcantly enriched for axonal guidance and muscle proteins, of interest,
given that DUX4 expression induces a neuronal phenotype in ES cells [226]. Conversely
genes up-regulated by both DUX4 and DUX4c were signiﬁcantly enriched for urogenital,
gland and vasculature development. The association with genital formation is intriguing
given that DUX4 is found to be expressed at high levels in the testes [216], and that
FSHD has been found to show less severity in females than males [379]. Moreover, the
association with blood vessel development, is of note given the association between FSHD
and the presentation of a Coat's disease like retinal vasculopathy [186].
Genes down-regulated by DUX4 but not DUX4c were signiﬁcantly enriched for regulation
of cell proliferation and apoptosis, in concordance with previous ﬁndings that DUX4 but
not DUX4c inhibits proliferation and increases cell death [217]. Moreover, considerable
enrichment was found among these genes for nitrogen compound metabolic processes,
indicating a role for nitric oxide in DUX4 mediated oxidative stress sensitivity.
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Figure 5.4: Flowchart describing the selection of DUX4 and DUX4c expressed
genes. A probeset is considered signiﬁcantly up-regulated by DUX4 if it is up-regulated
by both DUX4 and tMALDUX4 -VP16 constructs. A probeset is considered signiﬁcantly
up-regulated by DUX4c if it is up-regulated by both DUX4c and tMALDUX4.
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We note that genes up-regulated by DUX4 and not DUX4c as well as genes regulated
only by DUX4c showed no signiﬁcantly enriched gene sets after correction for multiple
testing.
5.2.1.4 A DUX4 expression signature validates in multiple data sets Other
groups have investigated the transcriptional perturbation induced by DUX4 expression
[235, 234]. However, the results of these investigations diﬀer in regard to the main path-
ways perturbed and a comparison of published DUX4 microarrays has not yet been
performed. Moreover a robust marker of DUX4 expression valid in diﬀerent cell lines is
currently lacking.
We derived a signature of DUX4 expression from our multiple construct dataset. By con-
sidering genes regulated by DUX4 (as described in Fig 5.4), we deﬁned a sample speciﬁc
DUX4 expression score, as the statistic of the t-test evaluating whether the expression of
the genes up-regulated by DUX4 is higher than those down-regulated.
We considered our DUX4 expression score on three further microarray datasets, one de-
scribing iDUX4 C2C12 cells exposed to diﬀerent levels of doxycyline, another describing
DUX4 over-expression in C2C12 cells by retrovial infection and yet another describing
DUX4 over-expression in human myoblasts by lentiviral infection. This revealed that
the DUX4 expression score was signiﬁcantly elevated in samples over-expressing DUX4
regardless of cell type and mode of over-expression (Fig 5.5), validating our score as a
robust indicator of DUX4 expression.
5.2.1.5 DUX4 expression increases signalling entropy Given that DUX4 ex-
pression has been shown to inhibit satellite cell diﬀerentiation [380], we next investigated
whether the DUX4 constructs induced a stem cell like transcriptomic proﬁle. We previ-
ously demonstrated in Chapter 3 that signalling entropy (a measure of signalling pathway
promiscuity, derived from the integration of gene expression data with a PIN) is a powerful
measure of cell diﬀerentiation potential, valid across multiple lineages. Here we compute
signalling entropy for each microarray sample describing gene expression induced by the
5 DUX4 constructs and control retrovirus.
We found that expression proﬁles induced by DUX4 and tMALDUX4 -VP16 displayed
signiﬁcantly higher signalling entropy than control retrovirus and DUX4c (p < 0.005 and
p < 0.0006 respectively Fig 5.6), suggesting that DUX4 expression results in a more stem-
cell like transcriptomic proﬁle. In contrast tMALDUX4 -ERD displayed a signiﬁcantly
lower signalling entropy than control retrovirus (p < 0.04), suggesting that repression
of DUX4 target genes results in a more diﬀerentiated expression regime. Interestingly
tMALDUX4 and DUX4c displayed similar signalling entropy to control retrovirus, sug-
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Figure 5.5: A DUX4 expression signature validates in multiple datasets. We
derived a signature of DUX4 expression from our multiple construct data sets and demon-
strated it capable of discriminating DUX4 expressing samples from non-DUX4 expressing
samples in 3 independent micorarray datasets: (A) A data set produced by Geng et al.,
of DUX4 and a putative non-pathogenic splice variant DUX4-s over expression by lenti-
virus in human myoblasts. Control cells were infected with GFP. (B) A data set produced
by Bosnakovski et al., of iDUX4 C2C12 murine myoblasts expressing DUX4 in response
to doxycycline exposure (4 hours (4h dox) and 12 hours (12h dox) exposure are shown,
the longer exposure induces higher DUX4 ). (C) A data set produced by Sharma et al. of
DUX4 retroviral mediated over-expression in C2C12 murine myoblasts. p-values denote
t-tests.
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gesting that these constructs do not signiﬁcantly alter global transcriptomic measures of
diﬀerentiation potential.
We also computed signalling entropy in two independent DUX4 data sets conﬁrming that
DUX4 expression drives increased signalling entropy.
5.2.2 FSHD cell lines show an inhibition of diﬀerentiation
5.2.2.1 Overview In the previous section we considered over-expression of the pri-
mary FSHD candidate gene, DUX4, at high levels and the corresponding transcriptional
perturbation, demonstrating via signalling entropy that DUX4 induces a stem cell like
phenotype. We also revealed that DUX4 modiﬁes the expression of genes involved in
urogenital development, apoptosis and oxidative stress.
It has been shown in primary cultured myoblasts from FSHD patients that DUX4 is ex-
pressed only at very low levels, though it is absent in myoblasts from healthy individuals
[216]. Thus it is important to conﬁrm our signalling entropy related ﬁnding that muscle
diﬀerentiation is inhibited in FSHD patient derived cells. We could not demonstrate that
signalling entropy is elevated in gene expression data corresponding to patient muscle
biopsies, a ﬁnding which is likely due to the low expression of DUX4 in these sample.
Hence a more detailed experimental investigation is required to conﬁrm that diﬀerentia-
tion is indeed inhibited in FSHD.
FSHD is a highly heterogeneous pathology, however, and there are considerable diﬀer-
ences in clinical presentation and DUX4 expression levels, even between close relatives
and monozygotic twins [376]. Hence it is important to establish models for FSHD which
are as well controlled as possible. Recently such a model was derived by Krom et al.
[241], in which a 54 year old male proband, mosaic for FSHD, displaying classical clinical
presentation, underwent a biceps muscle biopsy. The biopsy contained two myoblast cell
populations completely isogenic except for the D4Z4 repeat region, where one popula-
tion contained a pathogenic truncation (3 D4Z4 repeats, characteristic of FSHD1) and
the other did not (13 D4Z4 repeats). Myoblasts were isolated from the biopsy and im-
mortalised via transduction with retrovirus encoding hTERT and Cdk4. Subsequently
glass cylinders were utilised to isolate and expand single cells into clonal populations.
These clonal populations were then genetically conﬁrmed to contain either the patholog-
ical D4Z4 locus or the healthy.
These cell lines represent an important well controlled FSHD model, for the investigation
of FSHD myogenesis. We thus obtained a healthy (54-6, 13 D4Z4 repeats) and a patholog-
ical (54-12, 3 D4Z4 repeats) cell line from this model. We ﬁrst validate the lines as FSHD
models, conﬁrming that the pathological 54-12 cells over-express DUX4, and demonstrate
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Figure 5.6: DUX4 expression increases signalling entropy. (A) Signalling En-
tropy is elevated in the transcriptional proﬁles induced by DUX4 and tMALDUX4 -VP16
expression, relative to control retrovirus, whilst it is reduced by tMALDUX4 -ERD ex-
pression. The p-values denote Wilcoxon tests (B) Signalling entropy is also correlated
with exposure to DUX4 inducing agent doxycycling in iDUX4 cells, the p-value denotes
linear regression. (C) Signalling entropy is elevated in DUX4 expressing human myoblast
samples. The p-value denotes a Wilcoxon test. These results support the hypothesis that
DUX4 inhibits myogenic diﬀerentiation.
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defects in proliferation and myogenesis as well as a sensitivity to oxidative stress. Finally
we examine the myogenesis defect in detail by high throughput time course imaging. We
demonstrate that the 54-12 cells align and fuse more slowly than the healthy 54-6 cells,
consistent with an inhibited diﬀerentiation driven by DUX4 expression, as indicated by
signalling entropy.
5.2.2.2 Pathological immortalised myoblast cell line 54-12 over expresses
DUX4 In the presenting paper, Krom et al. described DUX4 expression in 5 healthy
and 5 pathological lines isolated from the same mosaic patient, by qPCR. It was demon-
strated that the average DUX4 expression of the pathological lines was higher than the
control, however, a direct comparison of the 54-6 control line and the 54-12 pathological
line was not performed.
We demonstrated that 54-12 cells do express signiﬁcantly more DUX4 than 54-6 cells,
although the expression level in 54-12 is extremely low (1.2× 10−6 the level of the house-
keeping gene RPLPO, Fig 5.7). It is worth noting that detection of DUX4 by qPCR
required the use of 4 times as much cDNA template than is normally used (50ng/20µl
reaction), and cDNA needed to be prepared from high quality RNA (RIN score> 9.5,
A260/A280 = 1.9− 2). We were unable to detect any DUX4 positive cells by immunocy-
tochemistry.
5.2.2.3 FSHD cell lines demonstrate a proliferation defect Diﬀerent studies
have found contrasting results regarding FSHD myoblast proliferation, one study has re-
ported no proliferation defect in FSHD myoblasts [235], whilst others have found that
FSHD myoblasts undergo early cell cycle arrest [381] and that DUX4 expression in-
duces a proliferation defect [175]. To assess proliferation rate in our cell lines, cells were
maintained in proliferation conditions and assessed for 5-Ethynyl-2'-deoxyuridine (EdU)
incorporation (Materials and Methods, Chapter 5). EdU is incorporated by myoblasts
during S-phase of the cell cycle during the EdU incubation period (2 hours) and gives a
measure of rate of proliferation.
There was a signiﬁcantly reduced percentage of EdU nuclear uptake in the FSHD cell line
54-12 as compared to the control cell line 54-6 (Fig 5.8).
5.2.2.4 FSHD cell line 54-12 demonstrates a sensitivity to oxidative stress
Sensitivity of proliferating FSHD myoblasts to oxidative stress is a well-documented phe-
notype [381, 175]. To assess the sensitivity of our cell lines to oxidative stress we incubated
proliferating cells, plated at a density of 5×103 per well in a 96 well plate, with and with-
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Figure 5.7: DUX4 is over expressed in pathological cell line 54-12. qPCR evalu-
ating DUX4 expression in 54-12 and 54-6 immortalised myoblast cell lines, expression was
normalised to housekeeping gene RPLPO. The assay was performed in triplicate, error
bars denote standard error, signiﬁcance was assessed via a two tailed, unpaired t-test, *
denotes p < 0.05.
out 400µM hydrogen peroxide (H2O2) for 24 hours. Similar conditions have previously
been utilised to induce oxidative stress in iDUX4 myoblasts. Immunocytochemistry was
performed to quantify morphological changes (via tubulin expression) and cell number
alterations (4',6-diamidino-2-phenylindole (DAPI) counts) brought about by oxidative
stress (Materials and Methods, Chapter 5).
Fold change in cell number between control and stressed conditions were computed for
each cell line and compared. FSHD line 54-12 showed a signiﬁcantly greater reduction
in cell number under oxidative stress than the control line 54-6, demonstrating a clear
oxidative stress sensitivity phenotype (Fig 5.9A).
Cell morphology was analysed using image analysis software written in R, using the EBIm-
age package for automated cell phenotyping [382]. In particular the average eccentricity
of cells (a measure of how stretched as opposed to circular cells are) was quantiﬁed in
both stressed and unstressed conditions (Materials and Methods, Chapter 5).
The 54-12 cell line also showed a signiﬁcantly greater increase in eccentricity under ox-
idative stress than observed in control (Fig 5.9B).
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Figure 5.8: Pathological cell line 54-12 displays a defect in proliferation. (A) Im-
munocytochemistry: Cells were stained with DAPI, which binds to DNA, (blue), tubulin
(red) and with a ﬂurophore which binds to EdU (green). Note the elongated morphology
of the pathological cells and the low nuclear EdU incorporation. B) Quantiﬁcation of nu-
clear EdU incorporation reveals a defect in proliferation in the 54-12 cells. The assay was
performed in triplicate, at least 500 cells were imaged in 5 distinct ﬁelds per repeat, error
bars denote standard error, signiﬁcance was assessed via a two tailed, unpaired t-test, *
denotes p < 0.05.
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Figure 5.9: Pathological cell line 54-12 displays a sensitivity to oxidative stress.
Immunocytochemistry: Cells were stained with DAPI, which binds to DNA, (blue) and
tubulin (red) to elucidate morphology. (A) 54-12 cells show a signiﬁcantly greater reduc-
tion in cell number following oxidative stress as compared to the healthy cell line 54-6.
(B) 54-12 cell lines undergo a signiﬁcantly greater increase in cell eccentricity following
oxidative stress than the healthy cell line. The assay was performed in triplicate, at least
500 cells were imaged in 5 distinct ﬁelds per repeat, error bars denote standard error,
signiﬁcance was assessed via a two tailed, unpaired t-test, * denotes p < 0.05.
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5.2.2.5 FSHD cell line 54-12 displays an atrophic myotube phenotype My-
otube morphology has been reported as considerably heterogeneous in FSHD, with some
patient derived myoblasts displaying a disorganised myotube phenotype and others an
atrophic phenotype [235, 236, 375]. Moreover, the formation of atrophic myotubes has
been linked directly to DUX4 expression [375]. To assess the myotube phenotype in our
cell lines in a robust dynamic manner, we placed conﬂuent human myoblasts into mitogen
poor media to induce diﬀerentiation and fusion and ﬁxed the cells after 2, 3 and 5 days.
Immunocytochemistry was then performed to evaluate the expression of myosin heavy
chain (MyHC ) using the MF-20 antibody (Materials and Methods, Chapter 5).
Image analysis software was written using the EBImage package in R to evaluate the
fusion index for each cell line as well as the area of image positive for MyHC, to assess
myotube morphology (Materials and Methods, Chapter 5).
In line with the results of Krom et al., fusion index appeared to be higher in the 54-12
cell line as compared to the 54-6. Quantiﬁcation of myotube size by MyHC positive area,
further revealed that the 54-12 cell line, displayed signiﬁcantly smaller myotubes than
54-6 at all time points, indicative of an atrophic phenotype (Fig 5.10).
5.2.2.6 Immortalised cell lines 54-6 and 54-12 fuse at diﬀerent rates To in-
vestigate in detail the diﬀerences between the myogenesis programmes in the pathological
and healthy cell lines, we performed high density, time lapse microscopy imaging, in
triplicate, over 5 days of diﬀerentiation. One 10× magniﬁcation image of the cells was
captured every 5 minutes over the process using an an Eclipse Ti-E Live Cell Imaging
System, generating a total of 8640 images (Materials and Methods, Chapter 5).
We subsequently developed image analysis software to process and analyse the images,
generating a time course of morphological changes (eccentricity/elongation of cells) in
each cell line over the myogenesis programme (Materials and Methods, Chapter 5).
The time course imaging revealed the myogenesis process in great detail, we found that
cells underwent a rapid alignment phase (increasing eccentricity), followed by a cytoplas-
mic expansion during fusion, during which unfused plated cells were pushed oﬀ the plate,
causing them to round up (decreasing eccentricity). Following this rapid phase of cyto-
plasmic expansion, the ﬁrst visible myotubes appeared (increasing eccentricity, Fig 5.11).
Evaluation of diﬀerences between eccentricities at each time point using an empirical
Bayes approach [269] revealed signiﬁcant morphological diﬀerences between cell lines oc-
curred particularly during the early stages of myogenesis. We found that both the align-
ment and cytoplasmic expansion phases took slightly longer and resulted in less extreme
morphological changes in the pathological line, 54-12, as compared to the healthy line,
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Figure 5.10: Pathological cell line 54-12 displays an atrophic myotube pheno-
type. (A) Cells were stained with DAPI, which binds to DNA, (blue) andMyHC (red) to
elucidate morphology. (B) 54-12 cell lines diﬀerentiate into signiﬁcantly smaller myotubes
than the healthy line 54-6. The assay was performed in triplicate, at least 500 cells were
imaged in 5 distinct ﬁelds per repeat, error bars denote standard error, signiﬁcance was
assessed via a two tailed, unpaired t-test, * denotes p < 0.05.
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54-6.
This retardation of myogenic progression in FSHD is coherent with an inhibition of dif-
ferentiation caused by DUX4 expression.
5.2.3 Network Rewiring in FSHD reveals β-catenin as central to DUX4
driven pathomechanisms
5.2.3.1 Overview We have shown that DUX4 expression induces a high signalling
entropy and that FSHD myoblasts have an impaired myogenesis programme. However,
DUX4 is only expressed at very low levels in FSHD myoblasts. A hypothesis surrounding
this is that transient high DUX4 expression, early in development, may pre-programme
FSHD myoblasts to undergo aberrant diﬀerentiation in a hysteretic manner, before being
epigenetically silenced. If this is the case the low DUX4 expression in FSHD myoblasts
may represent ineﬃcient silencing. Such a hypothesis raises the question as to whether
DUX4 is the optimal target for therapeutic intervention, and motivates the investigation
of more downstream targets that may be responsible for perpetuating the adverse eﬀects
of DUX4 expression in FSHD muscle.
In this section we consider gene expression data corresponding to FSHD primary muscle
biopsies from four independent data sets. To elucidate the drivers of FSHD pathome-
chansisms we employ a local network theoretic tool introduced in Chapter 2: InSpiRe.
The InSpiRe algorithm employs a local entropy measure of network rewiring as well as
a symmetrised Kullback-Leibler divergence alongside statistical graph sparsiﬁcation to
extract a subset of the human interactome with is rewired between two phenotypes de-
scribed by expression data.
We apply InSpiRe to a meta-analysis of FSHD and related gene expression data sets,
to extract a network describing protein interactions which are speciﬁcally perturbed in
FSHD muscle and which are not attributable to muscle atrophy, inﬂammation, ageing or
other muscle diseases. Importantly, we demonstrate that the genes in our FSHD network
are signiﬁcantly perturbed by DUX4 expression. Finally we utilise betweenness centrality
to identify β-catenin as a critical bottleneck to FSHD pathological signalling and demon-
strate experimentally that downstream targets of β-catenin signalling are perturbed by
DUX4 expression.
5.2.3.2 Meta-analysis of FSHD data sets using InSpiRe InSpiRe is a diﬀeren-
tial network methodology we designed to extract a subset of the human PIN containing
proteins and interactions that are altered between two phenotypes described by expres-
sion data and is explained in detail in Chapter 2.
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Figure 5.11: Pathological cell line 54-12 aligns and fuses more slowly than con-
trol line 54-6. A plot of average cell eccentricity (elongation) over the myoblast diﬀer-
entiation time course. Thin lines denote time points where the FSHD and control cell
lines signiﬁcantly diﬀer morphologically (p < 0.05) and are coloured red to yellow in or-
der of signiﬁcance. Green lines denote morphologically important time points during the
myogenesis programme.
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We ran the ﬁrst two steps of InSpiRe on each of 4 FSHD data sets obtained from the
GEO Database [270] (GSE3307 and GSE10760 plus GSE26145 combined with GSE26061
but divided into myoblasts and myotubes. Materials and Methods, Chapter 5). ∼ 3500
genes were implicated per set by InSpiRe as rewiring between FSHD and control samples.
Considering all FSHD data, the intersection of rewired sets consisted of a signiﬁcantly
large overlap of 829 genes (p < 10−5, based on randomly selecting genes from each data
set and assessing the size of overlap obtained). Many genes in this intersection have been
implicated in FSHD, e.g. TP53 [181], JUNB [52, 213], HIF1A [52], WNT3 [186], LMO3
[52], ANXA4 [187] and HSPB1 [383]. GSEA [368] on the intersection implicated many
enriched pathways associated with FSHD, including myogenesis [213], p53 signalling [181],
Wnt pathway [186], regulation of actin cytoskeleton [377] and VEGF signalling pathway
[187].
5.2.3.3 Gene expression changes speciﬁc to FSHD Superimposed on network
rewiring due to FSHD molecular mechanisms, are rewiring events due to non-speciﬁc
changes. To identify genes implicated as rewiring speciﬁcally in FSHD, we also ran the
ﬁrst two steps of InSpiRe on two data sets each describing skeletal muscle gene expres-
sion during ageing (GSE5086 and GSE9676), disuse atrophy (GSE5110 and GSE8872)
and other muscle diseases involving inﬂammation and wasting (GSE3307, where Juve-
nile dermatomyositis and limb-girdle muscular dystrophy type 2A data sets were inde-
pendently analysed). Genes rewiring in these non-FSHD data sets were considered as
secondary rewiring. Of the 829 InSpiRe identiﬁed genes, 273 were associated with age-
ing, 364 with disuse atrophy and 394 with other muscle diseases, identifying a set of 164
genes speciﬁcally rewiring in FSHD. For the ﬁnal stage of InSpiRe we considered the 164
high conﬁdence genes and their direct neighbours in the protein interaction network (a
complete network of 2866 genes). Statistical sparsiﬁcation on the largest FSHD data set
(GSE10760) was performed to eliminate interactions that were not signiﬁcantly altered
between FSHD and control phenotypes to generate the FSHD network.
5.2.3.4 The FSHD network Our FSHD network consists of 2616 proteins and
15972 interactions, the majority of which forms a single maximally connected compo-
nent (2603/2616 genes). To evaluate the signiﬁcance of certain properties of the FSHD
network, we computed a distribution of random networks by performing 1000 random
selections of 164 genes and re-running the statistical sparsiﬁcation on GSE10760 each
time. This demonstrated that the FSHD network has signiﬁcantly more interactions and
genes than one would expect by chance (p = 0.04 and p = 0.034 respectively). Such
network density implies that signalling dysregulation underlying FSHD is a coordinated
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perturbation of a large number of intersecting signalling pathways.
The FSHD network is provided in a Cytoscape format as supplementary material to our
publication [384].
5.2.3.5 DUX4 -driven gene expression mirrors FSHD We next determined how
much network rewiring in FSHD is directly due to DUX4, to investigate this we re-
considered the microarray dataset, describing transcriptional perturbations induced by a
panel of DUX4 retroviral constructs. To establish whether genes in the FSHD network are
perturbed as a result of DUX4 expression, we extracted all microarray probes mapping
to genes with direct human orthologs in our FSHD network, creating a network probeset
consisting of 1866 genes. We then performed a re-sampling procedure (see Materials and
Methods, Chapter 5) to determine whether the expression of the network probeset was a
signiﬁcant biomarker of DUX4 expression. This analysis conﬁrmed that mouse orthologs
of genes in our human FSHD network are signiﬁcantly modiﬁed by DUX4 (p < 10−5).
5.2.3.6 Dysregulation of β-catenin signalling is central to rewiring in FSHD
To identify critical genes and pathways in our FSHD network we employed local network
measures. Betweenness centrality measures the number of shortest paths between any
two genes passing through a given gene, and can identify signalling bottlenecks. Genes
in our network demonstrating high betweenness centrality are important for coordina-
tion of signal dysregulation in FSHD: the gene with the highest is CTNNB1 encoding
β-catenin. CTNNB1 is also highly connected in our network, with a degree of 73, sup-
porting a role for this gene in numerous dysregulated interactions. To determine if an
increase in β-catenin activity is occurring in FSHD muscle we considered the neighbour-
hood of CTNNB1 in the FSHD network (Fig 5.12). β-catenin is highly correlated with its
neighbours in the FSHD network across FSHD samples, but not across control samples,
implying an increase in β-catenin activation in FSHD (Fig 5.12).
To determine whether β-catenin is acting via its role in transcription, we queried our
network for downstream targets that mediate β-catenin signalling, i.e. the TCF/LEF
family of transcription factors. Importantly, all members of the TCF/LEF family (TCF7,
TCF7L1 (TCF-3), TCF7L2 (TCF-4) and LEF1 ) as well as PITX2 were involved in net-
work rewiring in FSHD.
To analyse control of β-catenin activity via canonical Wnt signalling, we queried our net-
work for Wnt, dishevelled and frizzled family members [385]. This revealed WNT16, two
dishevelled DVL1 and DVL2 and one frizzled FZD1.
These genes upstream and downstream of β-catenin are connected in the FSHD network
(except WNT16 ), indicating dysregulation of the β-catenin signalling pathway is con-
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tributing to FSHD pathogenesis. There is a signiﬁcantly increased positive correlation
in gene expression along the chain: FZD1 → DVL1 → CTNNB1 → TCF-3 (TCFL1 )
→ c-Myc (MYC ) in FSHD samples, implying an increased activation of this pathway
(Fig 5.13). Increased negative correlation between β-catenin gene expression and that of
PITX2 and increased positive correlation between gene expression of PITX2 and LEF1
also occurred. β-catenin is also involved in numerous other processes including substan-
tially altered correlations with CASP3, CASP8, interactions associated with apoptosis,
and Hypoxia inducible factor 1-α (HIF1-α) (Fig 5.13).
5.2.3.7 HIF1-α Signalling HIF1-α is one of the most rewired of the 164 genes and in-
creases in activity in FSHD (Fig 5.14), with many genes associated with HIF1-α signalling
in the FSHD network, including, VHL, HSP90AA1, RBX1, RRAS, VEGFA, MAPK8,
NCOA1, PIK3R3, SLC2A4, HIF1AN and TCEB2. HIF1-α signalling has recently been
implicated as FSHD associated, due to the identiﬁcation of several downstream compo-
nents of the pathway as diﬀerentially expressed [52].
5.2.3.8 TNF-α over-activation of reactive oxygen species induced JNK cell
death pathways Many genes involved in TNF-α over-activation of Reactive Oxygen
Species (ROS) induced JNK cell death pathways were in our FSHD network. These in-
cluded MAP4K5, PARP2, JUNB (Fig 5.15-5.17) TNFA, JUN, JUND, JNK1 and JNK3.
MAP4K5 is a highly speciﬁc activator of JNK signalling [386], and displays a signiﬁcantly
increased (p = 0.0035) negative expression correlation with TNF-receptor associated fac-
tor 2 (TRAF2 ) in FSHD samples. PARP2 is necessary for activating TNF-α induced
necrosis [387] and displays increased positive expression correlation with BRCA1 across
FSHD samples, in an interaction associated with cell death [154]. JUNB displays sig-
niﬁcantly increased positive expression correlation with FOS (p = 1.5 × 108) and JUN
(p = 0.044). JNK1 and JNK3 display clear shifts from predominantly uncorrelated in
expression with neighbours in control samples, to highly correlated in FSHD samples,
implying their increased activity in FSHD muscle.
5.2.3.9 Perturbed Wnt/β-catenin signalling in DUX4 -infected satellite cell-
derived myoblasts Several Wnt/β-catenin targets were identiﬁed as being altered in
both the human FSHD network and the DUX4 microarray. These included Leucine rich
repeat containing G protein coupled receptors 5 and 6 (Lgr5/6 ), Transcription factors
3 and 4 (Tcf3/4 ), Myogenic factor 5 (Myf5 and Lymphoid enhancer binding factor 1
(Lef1 ). To validate this we performed qPCR on satellite cell-derived myoblasts retrovi-
rally infected with the DUX4 and control retroviral constructs for 24 and 48 hours. Lef1,
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Figure 5.12: The neighbourhood of CTNNB1 in the FSHD network. Interactions
are coloured proportional to the Pearson correlation in gene expression between connected
genes across control samples (A) and FSHD samples (B). Red edges are negatively cor-
related, grey edges uncorrelated and green edges positively correlated. The thickness of
edges is proportional to 1− p, where p ∈ (0, 0.05] is the p-value of the statistical analysis
performed to determine whether the correlation in gene expression between connected
edges is diﬀerent between FSHD and control samples. Large nodes belong to the set of
164 high conﬁdence FSHD speciﬁc rewiring genes. There is a clear shift from predomi-
nantly uncorrelated to highly correlated between FSHD and controls, with an increased
correlation between CTNNB1 and its interaction partners across FSHD samples as com-
pared to controls. This is indicative of increased β-catenin activity. Note the increased
positive correlation between CTNNB1 and HIF1A, CASP3 and CASP8.
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Figure 5.14: The neighbourhood of HIF1A in the FSHD network. Interactions are
coloured proportional to the Pearson correlation in gene expression between connected
genes across control samples (A) and FSHD samples (B). Note the strong increase in
correlation between HIF1A and CTNNB1.
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Page 223
Network Theoretic Tools in the Analysis of Complex Diseases C. R. S. Banerji
JUNB
ATF7
SMAD4 
FOS
IL2
JUNB
ATF7
SMAD4 
FOS
IL2
Gene expression 
correlation between 
connected proteins
1-1
 JUNB in FSHD Muscle
 JUNB in Control MuscleA)
B)
Figure 5.17: The neighbourhood of JUNB in the FSHD network. Interactions are
coloured proportional to the Pearson correlation in gene expression between connected
genes across control samples (A) and FSHD samples (B). The interaction between JUNB
and FOS is signiﬁcantly altered in FSHD muscle.
Page 224
Network Theoretic Tools in the Analysis of Complex Diseases C. R. S. Banerji
q-RT-PCR: DUX4 modifies expression of Wnt/
β-catenin signalling targets
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Figure 5.18: DUX4 perturbs Wnt/β-catenin signalling. qPCR of downstream tar-
gets of Wnt/beta-catenin signalling Lef1, Tcf3, Tcf4, Lgr5, Lgr6 and Myf5 in satellite
cell derived myoblasts, 24 and 48 hours after infection with DUX4 and control retroviral
constructs. Expression is displayed relative to levels in myoblasts infected with control
retrovirus; *p < 0.05.
Tcf4, Lgr5 and Myf5 were all signiﬁcantly increased in DUX4 -infected samples, whereas
Tcf3 and Lgr6 were signiﬁcantly decreased by DUX4 (Fig 5.18), conﬁrming that DUX4
alters this signalling cascade at a transcriptional level.
5.2.3.10 Comparison of InSpiRe to other methodologies We compared InSpiRe
to other commonly used network methodologies NetWalk [16] and GSEA on diﬀerentially
expressed genes (described in detail in Materials and Methods, Chapter 5). NetWalk
also uses a PIN to identify candidate genes via weighted random walks. Both NetWalk
and InSpiRe displayed a signiﬁcant consensus in the features identiﬁed across the four
FSHD data sets (p < 10−5), whereas no diﬀerentially expressed genes were consistently
identiﬁed. This demonstrates the power of network based methodologies over conventional
diﬀerential expression. NetWalk performed similarly to InSpiRe in identifying genes which
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Figure 5.19: Comparing InSpiRe to NetWalk and GSEA on diﬀerentially ex-
pressed genes. Each method is scored with the number of data sets considered in which
it identiﬁes a given pathway. The average score across all pathways is highest for InSpiRe.
proved a signiﬁcant classiﬁer of the DUX4 construct microarray samples (p < 10−5) and
generated a network with more genes and fewer connections than InSpiRe (3363 genes
and 5651 connections). However, both NetWalk and GSEA on diﬀerentially expressed
genes were inferior to InSpiRe in identifying functional annotations previously associated
with FSHD (Fig 5.19).
5.3 Discussion
The aim of this chapter was to understand FSHD pathomechanisms, through the use of
network theoretic tools and experimentation, in a manner related to DUX4 expression.
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We wished to understand the nature of the FSHD myogenesis phenotype through sig-
nalling entropy and to posit novel therapeutic targets for the condition via the use of
local network theoretic algorithms.
Our investigation was two-fold, we ﬁrst considered the transcriptional landscape induced
by high DUX4 expression. We revealed that DUX4 modiﬁed the expression of genes
involved in apoptosis, oxidative stress, proliferation, uritogenital development and vascu-
lature development. We also derived a DUX4 gene expression signature, which validated
in multiple independent data sets. We further demonstrated that DUX4 induces a stem
cell like phenotype characterised by an elevated signalling entropy. We next experimen-
tally characterised then validated this inhibition of diﬀerentiation, in a well controlled
cellular model of FSHD. We revealed by high-throughput time course image analysis that
alignment and fusion of DUX4 expressing, FSHD myoblasts is slower and less complete
than their healthy counterparts.
Though there is a clear relationship between the DUX4 over-expression and FSHD phe-
notypes, the low expression of DUX4 in FSHD primary myoblasts led us to question
whether there may be more useful targets for mitigating the pathology. To investigate
this we applied the local analogue of signalling entropy, InSpiRe, introduced in detail in
Chapter 2.
By applying InSpiRe to a meta-analysis of gene expression data, we constructed the FSHD
network: the ﬁrst uniﬁed, unbiased map of network rewiring underlying FSHD. Moreover,
we revealed that the expression of genes in our FSHD network was signiﬁcantly altered
by DUX4, consistent with the growing consensus that FSHD is caused by aberrant DUX4
expression [225, 388]. Diﬀerential gene expression studies have previously implicated dis-
jointed collections of genes (e.g. myogenesis [213] and vasculature growth factors [187]),
and hypotheses have been proposed on FSHD pathogenesis [186, 177]. However, there has
been no unbiased, data driven insight into how these pathways relate, let alone actually
co-ordinate. Our results emphasise the importance of development and application of
network theoretic tools, such as InSpiRe, to identify pathomechanisms and therapeutics
in complex diseases.
CTNNB1 has the highest betweenness centrality in our FSHD network, identifying β-
catenin as a critical bottleneck of FSHD signalling. Gene expression correlation between
β-catenin and its interaction partners is also signiﬁcantly increased in FSHD, implying
increased activation. Moreover, the TCF family of transcription factors are present in our
network, as well as several upstream components of the canonical Wnt signalling pathway.
Involvement of Wnt signalling in tissue speciﬁc myogenesis and in retinal angiogenesis led
to a recent hypothesis that Wnt/β-catenin signalling was important for FSHD pathome-
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chanisms [186]. A role of Wnt/β-catenin signalling in controlling DUX4 expression and
FSHD muscle cell apoptosis was also recently examined [389]. Moreover, enhancing the
expression of β-catenin, via administration of LiCl2 has recently been shown to reduce
apoptosis in a model of occulopharyngeal muscular dystrophy [390]. Our FSHD network,
compiled algorithmically from multiple independent data-sets, provides the detailed in-
teractions of dysregulated β-catenin signalling. We also validated via qPCR that DUX4
modiﬁes the expression of critical downstream targets of β-catenin signalling.
The interaction partners of β-catenin in our FSHD network reveal mechanisms by which
Wnt/β-catenin signalling is involved in certain hallmark phenotypes of FSHD through
pathway cross-talk. Among these hallmarks is the characteristic oxidative stress sensi-
tivity of FSHD muscle/myoblasts [235, 180]. Our results implicate HIF1-α signalling as
critically perturbed in FSHD and show that HIF1A displays strong positive correlation
with β-catenin in FSHD samples, providing mechanism for previous observations of the
involvement of downstream components of the HIF1-α pathway in FSHD [52]. HIF1-α
binds β-catenin during hypoxia competitively with TCF-4 [391], which may both inhibit
cell proliferation activated by the TCF-4/β-catenin complex, as well as increase transcrip-
tion of hypoxic response genes, including VEGF. We found that in FSHD, correlation in
gene expression between β-catenin, and both HIF1A and TCF-4, signiﬁcantly increases,
resulting in elevated angiogenic genes such as VEGF, providing an explanation for the
hallmark oxidative stress sensitivity in FSHD, as well as retinal vasculature abnormalities
[186, 187].
Actin cytoskeleletal signalling has been implicated in FSHD pathology [377]. Our work
shows perturbed cross-talk between such signalling and HIF1-α may contribute to FSHD.
MAP2 is associated with microtubule stability and rewired in FSHD. In hypoxic car-
diomyocytes, MAP2 is required for stabilisation of the microtubule network, leading
to suppression of pVHL and increased HIF1-α [392]. Interestingly via this mechanism
HIF1-α was up-regulated at the protein level but not the mRNA level (in early stages
of hypoxia) [392], emphasising the power of our method for detecting events invisible to
diﬀerential expression analysis of microarrays.
The role of ROS in FSHD is well reported, and our FSHD network contains many genes in
the ROS-mediated pathway, including TNF-α. DUX4 represses genes of the glutathione
redox pathway, likely causing ROS accumulation in FSHD muscle [175], which may lead
to increased TNF-α as part of a pro-inﬂammatory response [393]. Additionally, levels of
TNF-α are negatively correlated with muscle endurance [180]. FSHD myoblasts undergo
cell death in response to non-pathological levels of hydrogen peroxide [235] and other
oxidative stress inducing factors; while antioxidants inhibit DUX4 -induced toxicity in
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FSHD myoblasts [175]. Thus over-activation of ROS-mediated TNF-α induced cell death
pathways are potentially important pathomechanism in FSHD. TNF-α also stimulates
ROS production via interaction with NADPH-oxidase, in a positive feedback loop [387].
Our results support this occurring in FSHD as RAC1 is a well-connected member of our
FSHD network and a critical component of the NADPH complex, also capable of activat-
ing JNK cell death signalling. RAC1 is also activated by non-canonical Wnt signalling
in a manner dependant on MAP4K5 [394]. Our network uniﬁes TNF-α, Wnt and JNK
signalling in FSHD.
JNK signalling also plays an important role in oxidative stress-induced cell death, and we
found that JNK signalling is more active in FSHD. JNK signalling can be activated in
many ways, including via TNF-α signalling. In this scenario the AP-1 transcription factor
genes JUN, JUNB and FOS are speciﬁcally up-regulated downstream of JNK. All these
genes are present in our FSHD network, moreover, all display a signiﬁcant increase in
positive gene expression correlation with one another in FSHD samples, indicating their
co-regulation. This result is evidence of TNF-α mediated JNK signalling in FSHD.
In the absence of NF-κB activity, prolonged JNK activation by TNF-α leads to apoptosis
[395]. Due to the increased apoptosis of FSHD muscle cells, we postulate that NF-κB
may be less active. In addition to activating JNK cell death pathways in response to
ROS, TNF-α also activates NF-κB survival signalling causing the production of the anti-
oxidant MnSOD to suppress ROS and minimise JNK cell death signalling [387]. MnSOD
is the only anti-oxidant down regulated in FSHD [180], suggesting that NF-κB may be
less active in FSHD muscle. Our results provide evidence for this theory: NFKB1 en-
codes the DNA binding subunit of the NF-κB transcription factor, which though present
in our FSHD network, is relatively uncorrelated with its interaction partners in FSHD
samples. This implies NFKB1 is inactive in FSHD muscle, and thus unable to repress
the increased cell death via over-active JNK. Finally, we ﬁnd crosstalk between JNK sig-
nalling and Wnt, in that all members of the PAR-1 gene family are in our FSHD network.
This family was identiﬁed as dishevelled kinases, capable of simultaneously regulating
Wnt activation of β-catenin signalling and JNK signalling [396].
Overactive JNK signalling has also been implicated in sensorineural hearing loss, an FSHD
clinical phenotype [397]. Inhibitors of JNK signalling could partially mitigate the oxida-
tive stress sensitivity of FSHD muscle cells, and D-JNKI-1 is currently in clinical trials
for treatment of strokes [398].
In conclusion, we have demonstrated via signalling entropy and microscopy that DUX4
expression leads to inhibited myogenesis in FSHD. We have then employed InSpiRe, to
detect network rewiring in FSHD, performing the ﬁrst meta-analysis of the FSHD tran-
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scriptome and creating an integrated FSHD network. We also analysed a microarray
of DUX4 driven transcriptional changes and demonstrated that expression of genes in
our network is signiﬁcantly altered by DUX4. Our FSHD network provides an unbiased,
unifying molecular map of FSHD signalling, elucidating perturbed genes and pathways
critical to pathomechanisms. Importantly, we identify and validate β-catenin as central
to FSHD pathology. Our network provides insight into the crucial steps of dysregulated
signalling in FSHD and so will inform design of well-targeted therapeutics: currently
lacking for FSHD.
5.4 Materials and Methods, Chapter 5
5.4.1 Cell Culture
During proliferation, the immortalised human myoblast cell lines (54-6 and 54-12) were
grown in Skeletal Muscle Cell Growth Medium (Promocel) supplemented with 20% Foetal
Bovine Serum, 50µg/ml Fetuin (bovine), 10ng/ml Epidermal Growth Factor (recombi-
nant human), 1ng/ml Basic Fibroblast Growth Factor (recombinant human), 10µg/ml
Insulin (recombinant human), 0.4µg/ml Dexamethasone and 50µg/ml Gentamycin, at
37oC under 5% CO2.
5.4.2 Immunocytochemistry
Plated myoblast cultures were ﬁxed in 4% paraformaldehyde, permeabilised in 0.5%
triton-X100 (Sigma Aldrich) for 10 minutes, washed thrice with PBS then blocked for
a further 30 minutes at room temperature in 10% swine serum (DAKO) and 10% goat
serum (DAKO) diluted in PBS. The plated cultures were subsequently incubated on a
rocker in primary antibodies diluted in PBS supplemented with 1% goat serum (DAKO)
overnight at 4oC. Samples were then incubated at room temperature with AlexaFluor con-
jugated secondary antibodies (Life technologies) diluted in PBS supplemented with 1%
goat serum, for 30 minutes, to detect primary antibody binding, before incubation with
1:1000 DAPI diluted in PBS for 10 minutes at room temperature. Primary antibodies
used in this study include: mouse anti-Tubulin (1:1000 dilution) and mouse anti-MyHC
(MF20) (1:400 dilution).
Images were acquired on a Zeiss Axiovert 200 M microscope using a Zeiss AxioCam
HRm and AxioVision software version 4.4 (Zeiss). At least 5 ﬁelds were taken at 10×
magniﬁcation for each cell culture well, resulting in quantiﬁcation of over 500 cells per
well.
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5.4.3 5-Ethynyl-2'-deoxyuridine (EdU) incorporation
Proliferating immortalised myoblast cell lines were plated 5×103 in 8-well chamber slides
(nunc). Cells were maintained in proliferation media (see above) overnight and were
then incubated in EdU (Life technologies) as per the manufacturer's instructions, for two
hours duration, before ﬁxation in 4% paraformaldehyde. Fixed myoblast cultures were
immunostained for tubulin (see above) prior to EdU detection with AlexaFluor azide 594
(Life technologies) (as per the manufacturers protocol).
5.4.4 Oxidative Stress Sensitivity
Proliferating immortalised myoblast cell lines were plated 5×103 in 8-well chamber slides
(nunc). Cells were maintained in proliferation media (see above) overnight and were
then switched to either fresh proliferation media or proliferation media containing 400µM
H2O2. Cells were cultured for 24 hours before ﬁxation in 4% paraformaldehyde. Fixed
myoblast cultures were immunostained for Tubulin (described above).
5.4.5 Cell Diﬀerentiation
For diﬀerentiation the lines were plated at conﬂuency (to avoid fusion rates driven by cell
density diﬀerences acquired by diﬀerent proliferation rates between the lines) in serum free
DMEM Glutamax, supplemented with 50µg/ml Gentamycin, 10µg/ml Insulin (bovine)
and 100µg/ml Apotransferin (human) and cultured at 37oC under 5% CO2. For immuno-
cytochemical analysis of fusion cells were plated at 2.5×104 per well in a 96 well plate and
cultured in diﬀerentiation medium for 2, 3 or 5 days ﬁxation in 4% paraformaldehyde.
Fixed myoblast cultures were immunostained for MyHC (described above).
5.4.6 Time course imaging
Immortalised myoblast cell lines 54-6 and 54-12 were plated in triplicate at conﬂuency at
the centre of a 96 well plate (25× 104 cells per well) and induced to diﬀerentiate with a
high volume (350 µl) of diﬀerentiation media (to prevent media evaporation during the 5
day imaging from altering the diﬀerentiation process). All remaining empty wells in the
96 plate were ﬁlled with DMEM Glutamax to provide humidity to the culture chamber
in which they will be incubated.
Immediately after the addition of diﬀerentiation media cells were placed into a Solent Sci-
entiﬁc chamber at 37oC and 5% CO2. Cells were imaged using an Eclipse Ti-E Live Cell
Imaging System by taking a 10× magniﬁcation, phase contrast image every 5 minutes
from each well over a total of 5 days; this generated 1440 images per well per cell line,
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resulting in a total of 8640 images.
5.4.7 Image analysis
Given the high quantity of image based readouts from immunocytochemical assays and
the time consuming nature of manual image analysis, it was important to obtain a high
throughput, unbiased analytic method. We thus wrote a high throughput image analysis
software in the statistical programming language R, using the image processing package
EBImage [382]. The software can autonomously process hundreds of high quality, large
images in the order of minutes, providing readings of cell counts in 3 colour channels as
well as computing the fusion index for diﬀerentiated cell cultures. Figures derived from
the software were conﬁrmed representative of manually derived values. The EBImage
package has extensive options for automated cell phenotyping and thus characterisation
of cell morphology is also possible in a high throughput manner.
Brieﬂy, each image is ﬁrst split into 3 channels, for nuclear counting a low pass ﬁlter is
used the remove noise and binarise the image, the binarised image is then ﬁltered to re-
move objects which are not suﬃcient large and circular enough to be consider cell nuclei,
ﬁnally any holes in the resulting image are ﬁlled. Particles in the binarised image are
then quantiﬁed and output to a csv ﬁle.
For determination of fusion index, a low pass ﬁlter is used on the channel displayingMyHC
to quantify the area positive for MyHC and binarise the image into MyHC positive and
MyHC negative subsets, subsequently the DAPI channel is processed as above for cell
counting and evaluated for total DAPI positive area. Regions in the processed DAPI
image which are classiﬁed are MyHC negative are then set to zero, the DAPI positive
MyHC positive area is then computed and divided by the total DAPI positive area to
give the fusion index.
To perform cell phenotyping on proliferating cells stained with tubulin, a low pass ﬁlter
is used on the tubulin channel, and the DAPI channel is processed for cell counting as
described above. To avoid overlapping cell cytoplasm from skewing the automated cell
phenotyping, cells are segmented using a Voroni based method, where DAPI deﬁned nu-
clei are used as seeds [382]. Fig 5.20 presents a ﬂow chart of the image analysis process.
Image analysis software to interrogate the myogenesis time-course imaging data simply
adapted the immunocytochemistry software. Each image taken in the time course was
passed through a low pass ﬁlter to reduce noise and binarise the image, high intensity
regions were ﬁltered on size and morphology to remove regions not considered likely to
correspond to cells and ﬁnally holes were ﬁlled in. The regions of high intensity follow-
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B) Image analysis: Fusion quantification
Split into MYH 
and DAPI 
channels
Process:
(i) low pass filter
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Integrate processed 
images: 
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quantified
A) Image analysis: Cell Phenotyping
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Tubulin and 
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Process:
(i) low pass filter
(ii) morphological 
     feature selection
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segmentation 
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Figure 5.20: Automated image analysis of immunocytochemistry. (A) For cell
counting and morphology analysis images were separated into colour channels and bina-
rised via a low pass ﬁlter. Morphological ﬁlters were employed to remove background and
a Voronoi segmentation anchored on DAPI positive nuclei was used to segment contacting
cell cytoplasm, for morphological analysis of single cells. (B) To assess myotube positive
area and fusion index, images were split into colour channels and binarised via a low pass
ﬁlter. Areas ofMyHC positive and DAPI positive area were computed and DAPI positive
MyHC positive area was also computed and normalised by total DAPI positive area to
give the fusion index. Page 233
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ing this thresholding typically corresponded to single cells. The eccentricity of each cell
identiﬁed in each image by this thresholding was measured and the average eccentricity
obtained for each 5 minute time point. We thus obtained a time course of eccentricities
in triplicate for each cell line.
Diﬀerential eccentricities between cell lines were assessed by an empirical Bayes approach
and p-value histograms conﬁrmed that diﬀerential eccentricities were detectable. Non-
linear regression was utilised to ﬁt polynomial curves to the mean (over the triplicates)
eccentricity time course, for each cell line, the turning points of the curves were deter-
mined to assess the most extremely eccentric and non-eccentric time points for each cell
line separately.
5.4.8 Harvesting cells for RNA
Immortalised myoblast cell lines 54-6 and 54-12 were plated in triplicate at conﬂuency
in 12 well plates (3.12 × 105 cells per well) and induced to diﬀerentiate with 1ml of
diﬀerentiation media. At each selected time point for transcriptomic analysis cells were
imaged on a light microscope, before being washed with 500µl PBS and incubated with
150µl trypsin at 37oC for 5 minutes. Trypsin was inactivated and cells were suspended in
1ml warm proliferation media, before cells were pelleted by centrifugation at 4,500 rpm
for 5 minutes. The supernatant was carefully removed by pipetting and cells were stored
at −80oC, until all samples were collected and RNA extraction could commence.
5.4.9 Signalling Entropy
Signalling entropy was computed as described in Chapter 1.
5.4.10 Expression Data sets
From the GEO Database [270], two studies were suﬃciently large for reliable inference,
GSE3307 [399] (14 FSHD samples, 14 controls) and GSE10760 [187] (19 FSHD samples
30 controls), both proﬁled on the Aﬀymetrix Human Genome U133A Array platform. An
additional recent large study available at GEO accession number GSE36398, was disre-
garded due to substantial discordance with other studies in terms of signal intensity [377].
Exon array studies of FSHD and control myoblasts and myotubes, GSE26145 [52] and
GSE26061 [233] were also considered. Both studies employed similar experimental con-
ditions, each containing 3 samples of each cell type and were proﬁled on the Aﬀymetrix
Human Exon 1.0 ST Array. Importantly, isolated cell types were the source of mRNA so
Page 234
Network Theoretic Tools in the Analysis of Complex Diseases C. R. S. Banerji
noise from non-muscle speciﬁc gene expression is removed.
We also obtained from the GEO database human skeletal muscle studies into gene ex-
pression in muscle diseases other than FSHD (GSE3307 [399]), age (GSE5086 [400] and
GSE9676 [401]) and atrophy (GSE5110 [402] and GSE8872 [403]).
All expression data sets considered underwent a quality control step using the ArrayQual-
ityMetrics package in R [404]. This step included analysis of RNA degradation and elim-
ination of samples displaying clear signal saturation eﬀects [405]. Data sets were log
normalised using RMA and PCA was performed to determine if the dominant princi-
pal component correlated with condition being compared (e.g. disease status). PCA
performed on the two larger FSHD studies (GSE3307 and GSE10760) revealed that the
dominant principal component correlated with both disease status and age of patients
sampled. For this reason we additionally analysed data sets associated with age depen-
dant gene expression.
PCA on the age dependant study, GSE5086 revealed that the dominant principal compo-
nent correlated with age and seperated the samples into 2 groups corresponding to young
and older samples. We used this clustering to classify the samples in this data set as
either younger or older patients. Non-FSHD muscle diseases analysed were selected from
GSE3307 due to the large number of high quality samples available.
GSE2614 and GSE26061 were suitable for integration by the ComBat function [378] in R
which employs an empirical Bayes approach to eliminate batch eﬀects, and was recently
demonstrated as superior to a wide range of other microarray data integration methods
[406]. The integrated data set contained 6 FSHD myoblasts, 6 FSHD myotubes, 6 control
myobalsts and 6 control myotubes. PCA was performed on the integrated data set and
the dominant principal component correlated with cell type and disease status but not
with batch, implying a successful integration.
We extracted from data sets probes mapping to genes corresponding to proteins in our
interaction network. For probes mapping to the same gene we computed the average
expression across these probes for each sample, assigning the resulting value to the gene.
For each data set, proteins in the interaction network with no corresponding probe in the
microarrays were deleted from the network, proteins with a degree of zero following this
deletion were also removed from the network. This resulted in a reduced PIN for each
data set.
5.4.11 Construction of the PIN
The human PIN utilised in this section was constructed as described in Chapter 2. The
mouse PIN was constructed from the maximal connected component of our human PIN,
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after vertices were mapped from human to mouse by orthololgy relations.
5.4.12 The InSpiRe Algorithm
The InSpiRe algorithm was implemented as described in detail in Chapter 2.
5.4.13 Comparing Possible Transformed Pearson Correlations in Step 1 of
InSpiRe
The choice of the transformation of the Pearson correlations to construct the stochas-
tic matrix required for the InSpiRe algorithm described in Chapter 2 must ensure non-
negativity, and that the interpretation of a high edge weight indicative of an increased
likelihood of interaction between connected proteins is valid. As discussed we considered
two possible transformations:
wij =
1
2
(1 + Cij) (85)
and
wij = |Cij | (86)
where Cij denotes the Pearson correlation in the gene expression proﬁles of protein i
and protein j across samples corresponding to the phenotype considered. Equation (85)
assumes that signal transduction ﬂows preferably along paths of proteins with positively
correlated gene expression proﬁles and has been employed previously [23, 17]. It was
noted, however, that this was only an approximation [23], and there is mounting evidence
that negative correlations play an important role in signal transduction [250], consequen-
tially the transformation described by equation (86), which assigns both strong positive
and strong negative correlations a high weight may be considered more realistic for this
interpretation.
We utilised both transformations independently and upon performing step 2 of InSpiRe
to identify proteins signiﬁcantly rewiring between FSHD and control skeletal muscle, we
found that the transformation (86) provided a substantially better discriminator than
(85) as judged by p-value histograms [407]. In fact, all p-value histograms utilising the
transformation described in (85) were ﬂat, implying that in utilising this transformation
one is unable to reliably determine diﬀerences between the phenotypes. Consequentially
all results described in this chapter were obtained utilising the more realistic transforma-
tion (86).
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5.4.14 Comparing methodologies
To evaluate the performance of InSpiRe relative to other methodologies, we applied In-
SpiRe, NetWalk [16] and GSEA [368] on diﬀerentially expressed genes to each FSHD data
set independently, and evaluated the enrichments of identiﬁed genes.
5.4.14.1 Diﬀerential expression analysis Diﬀerential expression analysis was per-
formed on normalised data sets matched to the protein interaction network using the
limma package in R [269]. GSEA [368] was then performed against the gene sets of the
Molecular Signatures Database [369], using the t-scores output by the limma analysis to
rank the genes. Gene sets identiﬁed by GSEA as displaying p < 0.05 and FDR < 0.25
were considered signiﬁcantly enriched.
5.4.14.2 NetWalk analysis NetWalk is a network based algorithm described in
Chapter 1, which considers the stationary distribution of a weighted random walk on
a network of compiled interactions. Weights on network vertices are data derived and
bias walker visitation in a biologically relevant manner. We implemented NetWalk on
normalised data sets using the NetWalker software [408], and employing the compiled
Knowledgebase provided as the underlying network for implementation; functional anno-
tation of identiﬁed edges was performed using the FunWalk option. The ith element of
the weight ﬂux vector, (w)Ni=1, where N is the number of genes in the network, for a given
data set, was deﬁned as the ratio of the mean expression the ith probe across samples cor-
responding to the phenotype examined (disease, aged, atrophic) to the mean expression
across control samples. This selection is a recommended option [408]. In order to ensure
the ﬁndings of NetWalk were statistically robust, we utilised the jackknife re-sampling
procedure to assess signiﬁcance of edge visitation ratios, and functional annotation ratios.
As with InSpiRe, NetWalk was run independently on each data set to produce a list of
signiﬁcant functional terms, and each FSHD data set identiﬁed around 3000 signiﬁcant
functional terms. The intersection of the signiﬁcant functional terms in the FSHD data
set consisted of 266 terms, and contained several terms associated to oxidative stress,
apoptosis and mitochondrial dysfunction. When terms also associated with age, atrophy
and other diseases were removed from this intersection however, only 19 terms remained,
none of which had a strong justiﬁcation to association with FSHD in the literature.
5.4.14.3 Functional annotation for InSpiRe implicated genes Functional an-
notation of InSpiRe implicated genes was performed on the signiﬁcant genes (p < 0.05)
Page 237
Network Theoretic Tools in the Analysis of Complex Diseases C. R. S. Banerji
implicated by local ﬂux entropy or local symmetrised KL divergence, using the DAVID
Bioinformatics Resources 6.7 [308]. The p-value cut oﬀ for the Fisher's exact test (EASE
score) employed by the DAVID software for implicating enriched pathways was 0.05. The
background gene set utilised consisted of all the genes in the PIN.
5.4.14.4 Comparison To compare the relevance of the results output by the various
methodologies, we considered 14 FSHD associated pathways: Wnt signalling, TNF or
MAPK related signalling, vasculature development, calcium signalling, oxidative stress
response, cell cycle, apoptosis, mitochondrial dysfunction, asymmetrical development,
muscle structure, nuclear envelope, muscle diﬀerentiation, histone modiﬁcation and actin
cytoskeletal signalling. For each pathway we gave each method a score from 0 to 4
corresponding to the number of FSHD data sets it was capable of detecting the pathway
in. Of the three methodologies considered InSpiRe was the most successful, achieving an
average score of 3.5, NetWalk achieved 3.29 and GSEA on diﬀerentially expressed genes
achieved 1.86.
5.4.15 Re-sampling procedure to assess concordance between microarray and
the the FSHD network
To determine whether expression of genes in our FSHD network was signiﬁcantly altered
by DUX4, we ﬁrst identiﬁed a probeset of mouse orthologs to the genes in the FSHD
network consisting of 1866 genes, to permit comparison with our murine satellite cell
microarray of DUX4 construct expression. Our objective was to assess whether the ex-
pression of the genes in the network probeset was able to distinguish between the 5 DUX4
retroviral constructs better than would be expected by chance. If this is the case, then
the clustering of the DUX4 constructs based on the expression of the network probeset
should be signiﬁcantly better than that based on a random probeset of equivalent size.
We therefore performed a re-sampling procedure, evaluating 10000 random probesets of
1866 genes from our microarray. For each random probeset we performed a hierarchical
clustering and enforced a 6 cluster solution, which we then compared to the optimal 6
cluster solution corresponding to the perfect separation of the 6 retroviral constructs. To
compare cluster distributions we used the Rand index, a function which assesses classiﬁ-
cation similarity on a unit scale. In this manner we obtained a null distribution of Rand
indices describing how well a random probeset may be expected to cluster the 6 DUX4
constructs. This null distribution then allowed us to calculate a p-value evaluating the
hypothesis that the expression of the network probeset clustered the DUX4 constructs
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better than could be expected by chance.
5.4.16 qPCR
For quantiﬁcation of DUX4 over expressing murine satellite cell-derived myoblasts, cells
were infected with DUX4 and control retroviral constructs and RNA extracted at 24
hours and 48 hours after infection using Qiagen RNeasy Kit and quantiﬁcation on a Nan-
odrop ND-1000 spectrophotometer (Labtech). For quantiﬁcation of low levels of DUX4
in immortalised human myoblasts, RNA integrity was also quantiﬁed on an Aligent Bio-
analyzer.
RNA was then reverse-transcribed using the Reverse Transcription Kit with genomic DNA
wipeout (Qiagen) and qPCR was performed on an Mx3005P qPCR system (Stratagene)
with MESA Blue qPCR MasterMix Plus and ROX reference dye (Eurogentec). Primers
used were as follows:
Lef1 ; F- TCATCACCTACAGCGACGAG, R-TGATGGGAAAACCTGGACAT. Lgr5 ;
F- CCGCCAGTCTCCTACATCGCC, R- GCATTGTCATCTAGCCACAGGTGCC. Lgr6 ;
F- CACACATCCCGGGACAGGCAT, R- GGGAGGAGAGCCCCTCAAGC. Tcf3 ; F-
TCTCAAGCCGGTTCCCACAC, R- TTTCCGGGCAAGCTCATAGTATTT. Tcf4 ; F-
TGCCGACTACAACAGGGACT, R- TGCTGGACTGTGGGATATGA. Myf5
F- TGAGGGAACAGGTGGAGAAC, R-AGCTGGACACGGAGCTTTTA; DUX4 F- 5'-
CCCAGGTACCAGCAGACC-3' R- 5'-TCCAGGAGATGTAACTCTAATCCA-3'.
6 Overview, Discussion and Philosophy
6.1 On our philosophy of approach
In this thesis we have considered the interplay between mathematics and biology, in an
attempt to elucidate global principles and local mechanisms underlying certain biological
phenomena and complex pathologies. The motivation underlying this work came from
many sources, but fundamentally it derives from the sheer complexity of the biological
system, which results in the generation of data sets whose analysis is inconceivable with-
out the application of mathematical methodologies.
We began this work with an exploration of network theory in biology because it is clear
that a graphical representation of intra-cellular interactions represents a information rich,
minimal parameter description of the system. Given the nature of the broad but shallow
data typically produced in the biological sciences such a representation seems well suited
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to investigating what we can currently observe. Moreover, the description is ﬂexible and
can be readily adapted as the experimenters eyes adjust through new technology.
We saw how the early forays into network biology revealed novel insights into the nature
of intra-cellular interactions. In particular we noted the discovery of network rewiring, in
which the true biological response can only be found in diﬀerential interactions. In our
expose on current network rewiring approaches, however, we presented a concern, which
to my eyes applies to many aspects of high-throughput, data-driven mathematical biol-
ogy. Much work in this ﬁeld focuses on the encapsulation of pathways and genes which
may be attributed a particular process or pathology. For example, some transcriptomic
signatures associate with survival in breast cancer and some genes involved in myogene-
sis are diﬀerentially expressed in FSHD. These ﬁndings are important and they provide
us with information about features we should target in these pathologies. What do we
learn, however, about the nature of pathological development? What do we understand
about the general dynamics of the biological system? To me developing sophisticated ap-
proaches for the listing of these diﬀerences, without interrogating the general principles
behind why they may indeed be diﬀerent, is a suboptimal strategy. It tailors our under-
standing of processes to speciﬁc data sets, given scenarios which may not scale across the
population. Moreover, it gives us little insight into novel processes, which can only be
understood laboriously, by repetition of the same data-driven approach.
To my eyes an important part of a mathematician's role in any applied science is the
positing of global laws governing the behaviour of systems under study. If these laws val-
idate in observation, they tell us something about the nature of the system, rather than
the nature of the data. Our goal in this work was therefore to consider network based
mathematical methodologies, which can form the basis of a hypothesis driven approach
to biological data analysis. Such methodologies must yield a theoretical framework, per-
mitting one to posit and examine certain global principles, as well as being applicable
to current data, permitting validation. Moreover, the methods should be developed in a
scalable manner, and hence, once validated, can generate the list of diﬀerential features
characteristic of other methodologies. In this way we do not lose what can be gained from
the diﬀerential approach, rather we build on it, obtaining an intuitive understanding of
the system.
The positing of global laws underlying biological network rewiring is fundamentally a pos-
tulate of permissible trajectories in a high dimensional space. More precisely, the state
of a biological network at any given moment, can be considered in terms of elements of
one or more metric spaces. The rewiring of a this network from one state to another,
can thus be described as a trajectory through this space. The nature of the network
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and the process undertaken during state transition, necessarily imposes restrictions on
the possible trajectories. It is the clariﬁcation of these restrictions that will elucidate our
global laws of biological network rewiring. If a suitable framework can be constructed, it
provides the basis to evaluate the merits of a given trajectory restriction hypothesis. If
validated these hypotheses can be used to build up contours in our metric spaces, ﬁrming
up the foundations of our theoretical framework.
Such hypotheses are best ﬁrst generated by consideration of observable properties of bio-
logical systems, evolving during processes where network rewiring is known to take place.
In the introduction we consider cellular diﬀerentiation as precisely such a process. This is
a truly systems level process, evolving as a consequence of coordinated rewiring. We saw
that as cells diﬀerentiate, it has been observed that they homogenise their expression pro-
ﬁles, though the individual gene expression patterns show great diversity across lineages.
We hypothesised therefore, that a restriction on the network rewiring trajectory from an
undiﬀerentiated to a diﬀerentiated biological state, will be a reduction in the disorder of
network interactions.
In truth, this hypothesis, its validation and its consequences in pathology has been at the
heart of all the work undertaken in this thesis.
6.2 An overview of our work
We began our work, as seemed natural, with the consideration of metric spaces. Here
we abstracted our notion of a network state to a combination of structure, deﬁned by
a weighted graph, and dynamics, as deﬁned by probability distributions for vertex in-
teractions. We saw how the two notions were coupled and that deformation of network
structure inﬂuenced dynamics naturally within our framework across all possible state
transition trajectories. Moreover, we saw how this framework could be utilised to con-
sider information transfer within a given state via NTE, and hence to compare information
transfer across network states. Thus our framework permits the phenotype comparisons
typical of conventional biological data analyses.
We progressed to provide a theoretical basis for the evaluation of our hypothesis on per-
missible network rewiring trajectories during cellular diﬀerentiation. We considered the
entropy rate of our network dynamics model, dubbed signalling entropy, and demon-
strated that it was a population measure of heterogeneity across biological cells.
Following the generation of theoretical constructs, we considered large amounts of ex-
perimental data as a means to validate our hypothesis that signalling entropy decreased
throughout cellular diﬀerentiation. We found that our hypothesis was indeed correct in
over 1000 samples corresponding to cells at diﬀerent stages of the diﬀerentiation hierarchy.
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Moreover, we found that as diﬀerentiation progressed signalling entropy dropped system-
atically, even reversing when conditions were manipulated to allow de-diﬀerentiation.
We thus elucidated a restriction on biologically permissible network rewiring trajectories
during cellular diﬀerentiation. As this process progresses signalling entropy decreases.
Given such a trajectory restriction in cellular diﬀerentiation, it is only natural to consider
states where this process is faulty, namely pathologies of development. What happens to
signalling entropy in such pathologies? How is it diﬀerent to the healthy case? What can
this tell us about the developmental defect? What are the genes and proteins that are
driving this? These are all important questions which can elucidate therapeutic targets
for disease and crucially describe global properties underlying them.
We therefore considered our measure in two antithetical diseases of development: breast
cancer and FSHD.
For cancer we saw that signalling entropy is elevated in CSCs and is powerfully prog-
nostic regardless of subtype and across multiple malignancies. This is a result worthy
of contemplation. There currently exist both histological and transcriptomic prognostic
indicators for a range of malignancies, moreover, there exist many biomarkers for CSCs
arising in diﬀerent tissues. The features which deﬁne these indicators and biomarkers are,
however, speciﬁc to a given tissue, or even to a single cancer subtype; they do not show
signiﬁcant overlap; they are derived from data sets not global principles. Is it surprising
that their discriminatory power is limited to the setting from which they were derived,
whilst that of signalling entropy is not? To me this is a clear validation of the importance
of global principles in biology. Why waste time developing many tissue speciﬁc cancer
prognostic indicators, when from global considerations rooted in theory, we can develop
a single indicator which is as good as, or better than those derived from data?
For FSHD, we saw that expression of the primary candidate gene DUX4 induces an
elevated signalling entropy in muscle cell precursors. We showed by detailed characteri-
sation of muscle diﬀerentiation that FSHD myoblasts undergo a slower, inhibited muscle
diﬀerentiation in line with this result. However, the network theoretic methods so readily
applied in cancer are lacking in FSHD, with little known about druggable targets and
pathways. We thus considered a local analogue of signalling entropy, the InSpiRe algo-
rithm. Performing a meta-analysis of FSHD muscle biopsy, gene expression data sets,
we uncovered a network describing FSHD pathomechanisms and detailed a multitude of
potential targets for investigation. We found that β-catenin was central to FSHD and
validated its perturbation in cellular models.
We thus, in this thesis, considered a hypothesis regarding a simple restriction on a per-
missible network rewiring trajectory during a single biological process. Yet we have seen
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that the applications to health and pathology are diverse, and we regret that we have
only scratched their surface in this work.
6.3 Future Directions
Much remains to be done. This is not to say that the work of this thesis is incomplete,
rather it is impress a notion of the size of the ﬁeld that can be approached whilst building
on this work.
Firstly, we can continue to develop the notion of signalling entropy as a measure of cell
potency, theoretically there are number of questions which currently spring to mind:
What sort of gene expression regimes are required to increase or decrease signalling en-
tropy? How much do these depend on the starting state of the network? What is the
minimal number of genes we must modify to change signalling entropy in a predictable
way? These questions can all be addressed in the framework of control theory, and can of
course be coupled with experimental validations using set-ups like siRNA mediated gene
knock-down and retroviral mediated gene over-expression. It is important to understand
the controllability of signalling entropy given its relation to cancer prognostics and dis-
ease gene mediated phenotypes. Control theory derived strategies may form the basis of
powerful therapeutic regimes, most likely in cancer.
From a biological point of view, much remains to be investigated regarding signalling
entropy associations with pathological processes. There is a dearth of time course gene
expression data describing pathological cell diﬀerentiation, but such data represents a
powerful resource for investigating signalling entropy as a measure of cell potency in a
pathological context. Though we have seen that signalling entropy correlates with tumour
stemness and is elevated by DUX4 expression, how this elevation comes about from the
healthy state is unclear. Time course data of pathological diﬀerentiation and tumour pro-
gression, therefore may elucidate network rewiring trajectories which are followed during
the descent into pathology, thus providing the means for their reversion.
The nature of signalling entropy as a measure of cell potency in a healthy context is cur-
rently attributed to a mixture of intra-cellular signalling promiscuity and inter-cellular
heterogeneity. However, which of these factors is dominant is unclear. The generation
of single cell, genome wide, gene expression data is thus essential for the investigation of
this concept. Moreover, the application of signalling entropy to the guided diﬀerentiation
of pluripotent stem cells into desired lineages for regenerative medicine and iPSC derived
pathological models, merits a detailed investigation.
We only scratched the surface of signalling entropy's association with tissue speciﬁc cancer
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mortality, and this is something that must be investigated in more detail. Limitations in
our medical technologies, such as targeted therapies and early detection thorough symp-
tom presentation and imaging, are thought to underlie much of the discrepancies in tissue
speciﬁc cancer mortality. The fact that signalling entropy associates with this variable,
however, suggests that there is something deeper at play and if we can address it we may
be able to normalise survival across cancer types.
In FSHD, we uncovered a myriad of pathogenic mechanisms which merit investigation.
Arguably the most promising are β-catenin signalling and HIF1-α mediated oxidative
stress sensitivity. The targeting of these pathways may yield the ﬁrst viable therapeutics
for this highly prevalent pathology.
It is of course clear that in addition to FSHD and cancer, there are a seemingly endless
stream of development related pathologies, many of which may beneﬁt from the applica-
tion of signalling entropy to an understanding of their pathogenesis. Hence the application
of the techniques developed in this thesis to other diseases can be considered an important
topic of future work.
It must further be emphasised that the investigations of signalling entropy in this thesis,
represent the exploration of a single hypothesis on the restriction of a network rewiring
trajectory during a single biological process. There are a huge number of other biological
processes, each with their own associated systems level properties, validation data sets
and related pathologies e.g., proliferation, apoptosis, necrosis, activation (say of T-cells),
migration (chemotaxis), quiescence, phagocytosis, etc.. For each of these processes an-
other thesis can be written, positing and validating a restriction on a network rewiring
trajectory and investigating the impact of that restriction on associated pathology. Such
restrictions can be combined with signalling entropy to further elucidate the landscape of
permissive biological network rewiring.
Finally our metric space framework, which can be considered analogous to network
rewiring state space requires more theoretical development. We outlined in Chapter 1 a
few of the possible avenues this can take, such as the investigation of network evolution by
dynamic programming and the investigation of persistent network states by vertex cycle
decompositions. Arguably many more investigations are possible and must be considered
an important topic of future work.
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7 Abbreviations
Shorthand Longhand
ARACNe Algorithm for the Reconstruction of Accurate Cellular Networks
ATRA all-trans retinoic acid
BANJO Bayesian Network Inference with Java Objects
ChIP chromatin immunoprecipitation
CNV copy number variation
Co-IP co-immunoprecipitation
COX cytochrome c oxidase
CSC cancer stem cell
CTC circulating tumour cell
DAPI 4',6-diamidino-2-phenylindole
DMSO dimethylsulphoxide
DPI Data Processing Inequality
EdU 5-Ethynyl-2'-deoxyuridine
EGF epidermal growth factor
EMT epithelial to mesenchymal transition
eQED Expression Quantitative trait loci Electrical Diagrams
ER oestrogen receptor
ES embryonic stem
FACS ﬂuorescence-activated cell sorting
FSHD facioscapulohumeral muscular dystrophy
GO Gene Ontology
GSEA Gene Set Enrichment Analysis
H&E haematoxylin and eosin
HPV human papilloma virus
HR Hormone receptor
HSC hematopoietic stem cell
IDC-NST invasive ductal carcinomas of no special type
InSpiRe Interactome Sparsiﬁcation and Rewiring
iPSC induced pluripotent stem cell
ISD initial signal distribution
JNK c-Jun N-terminal kinase
JSD Jensen-Shannon divergence
METABRIC Molecular Taxonomy of Breast Cancer International Consortium
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NIR Network Inference by Reverse-engineering
NSC neural stem cell
NSCLC non-small cell lung cancer
NTE Network Transfer Entropy
ODE ordinary diﬀerential equation
PCA principal component analysis
PIN protein interaction network
PR progesterone receptor
qPCR quantitative reverse transcription polymerase chain reaction
RNA-seq RNA-sequencing
ROS reactive oxygen species
RPE retinal pigment epithelium
SCC squamous cell carcinoma
SCM Stem Cell Matrix
SE Score signalling entropy prognostic score
SNP single nucleotide polymorphism
TCGA The Cancer Genome Atlas
TPE telomere position eﬀect
WHO World Health Organisation
Y2H yeast 2 hybrid
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